{"3ba40deeea33744e3cb9b8d80c01af0ad63ec2f6": [["IntroductionVaccines are a cost effective way of decreasing mortality and morbidity due to various childhood infectious diseases.", [["infectious diseases", "DISEASE", 109, 128], ["IntroductionVaccines", "TREATMENT", 0, 20], ["decreasing mortality", "PROBLEM", 49, 69], ["various childhood infectious diseases", "PROBLEM", 91, 128], ["infectious", "OBSERVATION", 109, 119]]], ["The Expanded Programme on Immunization (EPI) was adopted by WHO in 1977 against diphtheria, polio, tuberculosis, pertussis, measles, and tetanus with prime aim of immunization to all children [1] .", [["diphtheria, polio, tuberculosis", "DISEASE", 80, 111], ["pertussis", "DISEASE", 113, 122], ["measles", "DISEASE", 124, 131], ["tetanus", "DISEASE", 137, 144], ["diphtheria", "ORGANISM", 80, 90], ["polio", "ORGANISM", 92, 97], ["children", "ORGANISM", 183, 191], ["children", "SPECIES", 183, 191], ["Immunization (EPI", "TREATMENT", 26, 43], ["diphtheria", "PROBLEM", 80, 90], ["polio", "PROBLEM", 92, 97], ["tuberculosis", "PROBLEM", 99, 111], ["pertussis", "PROBLEM", 113, 122], ["measles", "PROBLEM", 124, 131], ["immunization", "TREATMENT", 163, 175], ["tuberculosis", "OBSERVATION", 99, 111]]], ["It was started in India in 1978 with BCG, DPT (3 doses) and typhoid vaccine.", [["DPT", "CHEMICAL", 42, 45], ["typhoid", "DISEASE", 60, 67], ["BCG", "TREATMENT", 37, 40], ["DPT", "TREATMENT", 42, 45], ["typhoid vaccine", "TREATMENT", 60, 75]]], ["In 1979, OPV and in 1985, measles vaccine was added to the list subsequent to omission of typhoid vaccine [2] .", [["typhoid", "DISEASE", 90, 97], ["measles vaccine", "TREATMENT", 26, 41], ["typhoid vaccine", "TREATMENT", 90, 105]]], ["Later Hepatitis B and Haemophilus influenzae type b (Hib) were included in the same.", [["Hepatitis B", "DISEASE", 6, 17], ["Haemophilus influenzae type b", "DISEASE", 22, 51], ["Hepatitis B", "ORGANISM", 6, 17], ["Haemophilus influenzae type b", "ORGANISM", 22, 51], ["Hib", "ORGANISM", 53, 56], ["Haemophilus influenzae", "SPECIES", 22, 44], ["Hepatitis B", "SPECIES", 6, 17], ["Haemophilus influenzae type b (Hib)", "SPECIES", 22, 57], ["Later Hepatitis B", "TEST", 0, 17], ["Haemophilus influenzae type b (Hib)", "PROBLEM", 22, 57]]], ["So far, vaccination has successfully eradicated small pox, polio and maternal and neonatal tetanus along with decreasing the burden of many other diseases.IntroductionMajority of the vaccines available are injectable preparations.", [["polio", "DISEASE", 59, 64], ["tetanus", "DISEASE", 91, 98], ["vaccination", "TREATMENT", 8, 19], ["small pox", "PROBLEM", 48, 57], ["polio", "PROBLEM", 59, 64], ["maternal and neonatal tetanus", "PROBLEM", 69, 98], ["many other diseases", "PROBLEM", 135, 154], ["the vaccines", "TREATMENT", 179, 191], ["injectable preparations", "TREATMENT", 206, 229], ["small", "OBSERVATION_MODIFIER", 48, 53], ["pox", "OBSERVATION", 54, 57], ["diseases", "OBSERVATION", 146, 154]]], ["A child receives as many as 18-24 shots of vaccination till he/she reaches the age of two according to CDC vaccine schedule [3] .", [["child", "ORGANISM", 2, 7], ["vaccination", "TREATMENT", 43, 54]]], ["Besides the prototype oral Sabin polio vaccine, rotavirus vaccine, cholera vaccine, typhoid vaccine and Shigella flexneri 2a vaccine are available for oral administration.", [["oral", "ANATOMY", 22, 26], ["oral", "ANATOMY", 151, 155], ["cholera", "CHEMICAL", 67, 74], ["typhoid", "DISEASE", 84, 91], ["oral", "ORGANISM_SUBDIVISION", 22, 26], ["Sabin polio", "ORGANISM", 27, 38], ["rotavirus", "ORGANISM", 48, 57], ["cholera vaccine", "ORGANISM", 67, 82], ["Shigella flexneri 2a", "ORGANISM", 104, 124], ["oral", "ORGANISM_SUBDIVISION", 151, 155], ["rotavirus", "SPECIES", 48, 57], ["Shigella flexneri", "SPECIES", 104, 121], ["rotavirus", "SPECIES", 48, 57], ["Shigella flexneri", "SPECIES", 104, 121], ["the prototype oral Sabin polio vaccine", "TREATMENT", 8, 46], ["rotavirus vaccine", "TREATMENT", 48, 65], ["cholera vaccine", "TREATMENT", 67, 82], ["typhoid vaccine", "TREATMENT", 84, 99], ["Shigella flexneri 2a vaccine", "TREATMENT", 104, 132], ["oral administration", "TREATMENT", 151, 170]]], ["Nasal spray for influenza vaccine is also available but CDC advisory committee abandoned its use during 2016-2017 flu season [4] .IntroductionLife saving benefits aside, the very thought of vaccination comes with pain and anxiety associated with that needle prick.", [["Nasal", "ANATOMY", 0, 5], ["influenza", "DISEASE", 16, 25], ["pain", "DISEASE", 213, 217], ["anxiety", "DISEASE", 222, 229], ["Nasal", "ORGAN", 0, 5], ["Nasal spray", "TREATMENT", 0, 11], ["influenza vaccine", "TREATMENT", 16, 33], ["vaccination", "TREATMENT", 190, 201], ["pain", "PROBLEM", 213, 217], ["anxiety", "PROBLEM", 222, 229], ["needle prick", "TEST", 251, 263]]], ["It is difficult for the parents to handover their child to the nurse knowing that the child does not understand why he is being hurt.", [["child", "ORGANISM", 86, 91]]], ["It is a helpless feeling as the parents know that the discomfort and the side-effects far outweigh the morbidity and mortality due to the disease.", [["the discomfort", "PROBLEM", 50, 64], ["the morbidity", "PROBLEM", 99, 112], ["the disease", "PROBLEM", 134, 145], ["disease", "OBSERVATION", 138, 145]]], ["The most common vaccine-related concern the parents have is that injection will be painful to the child.", [["parents", "ORGANISM", 44, 51], ["painful", "PROBLEM", 83, 90]]], ["Study by Kennedy et al. demonstrated that 44.2% of parents are concerned about pain to the child [5] .", [["pain", "DISEASE", 79, 83], ["parents", "ORGANISM", 51, 58], ["pain", "PROBLEM", 79, 83]]], ["Studies suggest nearly 24% of parents and 63% of children have needle fear and it is the primary reason for immunization non-compliance amongst 7% of parents and 8% children [6] .", [["children", "ORGANISM", 49, 57], ["children", "ORGANISM", 165, 173], ["children", "SPECIES", 49, 57], ["children", "SPECIES", 165, 173], ["Studies", "TEST", 0, 7], ["needle fear", "PROBLEM", 63, 74], ["immunization non-compliance", "TREATMENT", 108, 135]]], ["So being a pediatrician we must ensure vaccine delivery in a painless manner.IntroductionThere are guidelines to assist clinicians in managing vaccination-related fear, pain and anxiety among children.", [["pain", "DISEASE", 169, 173], ["anxiety", "DISEASE", 178, 185], ["children", "ORGANISM", 192, 200], ["children", "SPECIES", 192, 200], ["vaccine delivery", "TREATMENT", 39, 55], ["pain", "PROBLEM", 169, 173], ["anxiety", "PROBLEM", 178, 185]]], ["To reduce pain at the time of injection, breastfeeding, administration of a sweet-tasting solution (sucrose), offering to rub or stroke the skin near the injection site with moderate intensity before and during vaccination, parent and clinician-led distraction, and use of topical anesthetics (lidocaine-prilocaine 5% cream or patch, amethocaine 4% gel and liposomal lidocaine 4% cream) all have been tried [7] .", [["skin", "ANATOMY", 140, 144], ["pain", "DISEASE", 10, 14], ["sucrose", "CHEMICAL", 100, 107], ["stroke", "DISEASE", 129, 135], ["lidocaine", "CHEMICAL", 294, 303], ["prilocaine", "CHEMICAL", 304, 314], ["amethocaine", "CHEMICAL", 334, 345], ["lidocaine", "CHEMICAL", 367, 376], ["sucrose", "CHEMICAL", 100, 107], ["lidocaine", "CHEMICAL", 294, 303], ["prilocaine", "CHEMICAL", 304, 314], ["amethocaine", "CHEMICAL", 334, 345], ["lidocaine", "CHEMICAL", 367, 376], ["sucrose", "SIMPLE_CHEMICAL", 100, 107], ["skin", "ORGAN", 140, 144], ["lidocaine", "SIMPLE_CHEMICAL", 294, 303], ["prilocaine", "SIMPLE_CHEMICAL", 304, 314], ["cream", "SIMPLE_CHEMICAL", 318, 323], ["amethocaine", "SIMPLE_CHEMICAL", 334, 345], ["lidocaine", "SIMPLE_CHEMICAL", 367, 376], ["pain", "PROBLEM", 10, 14], ["a sweet-tasting solution (sucrose)", "TREATMENT", 74, 108], ["stroke the skin", "PROBLEM", 129, 144], ["vaccination", "TREATMENT", 211, 222], ["distraction", "TREATMENT", 249, 260], ["topical anesthetics", "TREATMENT", 273, 292], ["lidocaine", "TREATMENT", 294, 303], ["prilocaine", "TREATMENT", 304, 314], ["patch", "TREATMENT", 327, 332], ["amethocaine", "TREATMENT", 334, 345], ["liposomal lidocaine", "TREATMENT", 357, 376], ["pain", "OBSERVATION", 10, 14], ["skin", "ANATOMY", 140, 144], ["moderate", "OBSERVATION_MODIFIER", 174, 182], ["intensity", "OBSERVATION_MODIFIER", 183, 192]]], ["Topical application of lidocaine-prilocaine cream is proven to be effective and does not interfere with immunogenicity of the vaccine.", [["lidocaine", "CHEMICAL", 23, 32], ["prilocaine", "CHEMICAL", 33, 43], ["lidocaine", "CHEMICAL", 23, 32], ["prilocaine", "CHEMICAL", 33, 43], ["lidocaine", "SIMPLE_CHEMICAL", 23, 32], ["prilocaine", "SIMPLE_CHEMICAL", 33, 43], ["Topical application", "TREATMENT", 0, 19], ["lidocaine-prilocaine cream", "TREATMENT", 23, 49], ["the vaccine", "TREATMENT", 122, 133]]], ["Distraction is defined as the use of strategies to take an individual's attention away from the procedure [7] .", [["Distraction", "TREATMENT", 0, 11], ["the procedure", "TREATMENT", 92, 105]]], ["Its efficacy is variable.", [["efficacy", "OBSERVATION_MODIFIER", 4, 12], ["variable", "OBSERVATION_MODIFIER", 16, 24]]], ["Music seems to reduce distress and pain during vaccinations in adolescents but not in younger children [9] .", [["pain", "DISEASE", 35, 39], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102], ["distress", "PROBLEM", 22, 30], ["pain", "PROBLEM", 35, 39]]], ["However, video distraction relieves anxiety before and after vaccinations but not the pain.", [["anxiety", "DISEASE", 36, 43], ["pain", "DISEASE", 86, 90], ["video distraction", "PROBLEM", 9, 26], ["anxiety", "PROBLEM", 36, 43], ["vaccinations", "TREATMENT", 61, 73], ["the pain", "PROBLEM", 82, 90]]], ["Distraction by blowing a party blower and toys reduces vaccination pain in children.", [["pain", "DISEASE", 67, 71], ["children", "ORGANISM", 75, 83], ["children", "SPECIES", 75, 83], ["Distraction", "PROBLEM", 0, 11], ["vaccination pain", "PROBLEM", 55, 71]]], ["Party blower also aids in breathing techniques which also decreases the pain.", [["pain", "DISEASE", 72, 76], ["breathing techniques", "TREATMENT", 26, 46], ["the pain", "PROBLEM", 68, 76]]], ["Breastfeeding relieves the pain by sweet taste, distraction, suckling, and physical contact and the 24% oral sucrose solution too decreases the pain by releasing endogenous opioids and distraction [8] .", [["oral", "ANATOMY", 104, 108], ["pain", "DISEASE", 27, 31], ["sucrose", "CHEMICAL", 109, 116], ["pain", "DISEASE", 144, 148], ["sucrose", "CHEMICAL", 109, 116], ["oral", "ORGANISM_SUBDIVISION", 104, 108], ["the pain", "PROBLEM", 23, 31], ["distraction", "PROBLEM", 48, 59], ["the 24% oral sucrose solution", "TREATMENT", 96, 125], ["the pain", "PROBLEM", 140, 148], ["endogenous opioids", "TREATMENT", 162, 180]]], ["Tactile stimulation in the form of pressure at the site reduces the pain or not, is controversial [7, 9, 10] .IntroductionImmunization procedure matters a lot.", [["pain", "DISEASE", 68, 72], ["Tactile stimulation", "TREATMENT", 0, 19], ["pressure", "TREATMENT", 35, 43], ["the pain", "PROBLEM", 64, 72], ["IntroductionImmunization procedure matters", "TREATMENT", 110, 152]]], ["Parents are advised to hold the infant comfortably and not to place them supine.", [["infant", "ORGANISM", 32, 38], ["infant", "SPECIES", 32, 38]]], ["Injecting the vaccine without aspiration and giving the most painful vaccine (MMR-II and Prevnar) last when administering multiple vaccines at the same visit reduces the pain [7, 8] .", [["pain", "DISEASE", 170, 174], ["the vaccine", "TREATMENT", 10, 21], ["aspiration", "PROBLEM", 30, 40], ["the most painful vaccine", "TREATMENT", 52, 76], ["multiple vaccines", "TREATMENT", 122, 139], ["the pain", "PROBLEM", 166, 174]]], ["Finally, in the era of multiple injections, parents want that multiple injections be given simultaneously, rather than sequentially [10] .", [["multiple injections", "TREATMENT", 23, 42], ["multiple injections", "TREATMENT", 62, 81]]], ["This has insufficient level of evidence in reducing the pain.IntroductionThe said interventions may though decrease the pain but the fear of needles and anxiety associated with procedure of vaccination needs new ways of delivering the vaccines.", [["pain", "DISEASE", 56, 60], ["pain", "DISEASE", 120, 124], ["anxiety", "DISEASE", 153, 160], ["the pain", "PROBLEM", 52, 60], ["The said interventions", "TREATMENT", 73, 95], ["the pain", "PROBLEM", 116, 124], ["the fear of needles", "PROBLEM", 129, 148], ["anxiety", "PROBLEM", 153, 160], ["procedure of vaccination", "TREATMENT", 177, 201], ["the vaccines", "TREATMENT", 231, 243], ["reducing", "OBSERVATION_MODIFIER", 43, 51], ["pain", "OBSERVATION", 56, 60]]], ["The need of the hour is to find out ways of vaccine delivery which do not cause any pain at all.", [["pain", "DISEASE", 84, 88], ["vaccine delivery", "TREATMENT", 44, 60], ["any pain", "PROBLEM", 80, 88]]], ["Various vaccine delivery methods already exist that are painless vis a vis oral and nasal vaccination.IntroductionThe newer non-invasive routes of administering vaccines are the following 1.", [["oral", "ANATOMY", 75, 79], ["nasal", "ANATOMY", 84, 89], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["nasal", "ORGANISM_SUBDIVISION", 84, 89], ["Various vaccine delivery methods", "TREATMENT", 0, 32], ["painless", "PROBLEM", 56, 64], ["a vis oral and nasal vaccination", "TREATMENT", 69, 101], ["administering vaccines", "TREATMENT", 147, 169], ["nasal", "ANATOMY", 84, 89]]], ["Nasal (aerosols and dry powder inhalations) 3.", [["Nasal", "ANATOMY", 0, 5], ["Nasal", "ORGAN", 0, 5], ["Nasal (aerosols", "TREATMENT", 0, 15], ["dry powder inhalations", "TREATMENT", 20, 42]]], ["Transdermal (microneedles and nanopatch)Oral VaccinesThere is a considerable amount of exposure of infectious agents from our gut mucosa.", [["gut mucosa", "ANATOMY", 126, 136], ["gut mucosa", "MULTI-TISSUE_STRUCTURE", 126, 136], ["Transdermal (microneedles and nanopatch)", "TREATMENT", 0, 40], ["Oral Vaccines", "TREATMENT", 40, 53], ["infectious agents", "TREATMENT", 99, 116], ["infectious", "OBSERVATION", 99, 109], ["gut mucosa", "ANATOMY", 126, 136]]], ["Needle vaccination may not be just sufficient to provide protection from the gut infection routes.", [["gut", "ANATOMY", 77, 80], ["infection", "DISEASE", 81, 90], ["gut", "ORGANISM_SUBDIVISION", 77, 80], ["Needle vaccination", "TREATMENT", 0, 18], ["the gut infection routes", "PROBLEM", 73, 97], ["gut", "ANATOMY", 77, 80], ["infection", "OBSERVATION", 81, 90]]], ["Initially the oral vaccines were shunned, considering their digestion into small fragments by the gastric enzymes rendering them ineffective.", [["oral", "ANATOMY", 14, 18], ["fragments", "ANATOMY", 81, 90], ["gastric", "ANATOMY", 98, 105], ["oral", "ORGANISM_SUBDIVISION", 14, 18], ["gastric", "ORGAN", 98, 105], ["gastric enzymes", "PROTEIN", 98, 113], ["the oral vaccines", "TREATMENT", 10, 27], ["their digestion into small fragments", "PROBLEM", 54, 90], ["the gastric enzymes", "TEST", 94, 113], ["small", "OBSERVATION_MODIFIER", 75, 80], ["fragments", "OBSERVATION", 81, 90], ["gastric", "ANATOMY", 98, 105]]], ["However, now oral vaccines are being made using lipids and fats which are not broken down in the stomach and traverse till the intestine where they are absorbed.Oral VaccinesThe well-known oral polio vaccine (OPV) has been used for mass vaccination campaigns due to its ease of administration.", [["oral", "ANATOMY", 13, 17], ["fats", "ANATOMY", 59, 63], ["stomach", "ANATOMY", 97, 104], ["intestine", "ANATOMY", 127, 136], ["Oral", "ANATOMY", 161, 165], ["oral", "ANATOMY", 189, 193], ["oral", "ORGANISM_SUBDIVISION", 13, 17], ["lipids", "SIMPLE_CHEMICAL", 48, 54], ["fats", "SIMPLE_CHEMICAL", 59, 63], ["stomach", "ORGAN", 97, 104], ["intestine", "ORGAN", 127, 136], ["oral", "ORGANISM_SUBDIVISION", 189, 193], ["OPV", "SPECIES", 209, 212], ["oral vaccines", "TREATMENT", 13, 26], ["lipids and fats", "TREATMENT", 48, 63], ["Oral Vaccines", "TREATMENT", 161, 174], ["oral polio vaccine (OPV", "TREATMENT", 189, 212], ["mass vaccination campaigns", "TREATMENT", 232, 258], ["stomach", "ANATOMY", 97, 104], ["intestine", "ANATOMY", 127, 136]]], ["Trivalent OPV consists of a mixture of live attenuated poliovirus strains of each of the three serotypes.", [["Trivalent OPV", "CHEMICAL", 0, 13], ["poliovirus strains", "ORGANISM", 55, 73], ["Trivalent OPV", "TREATMENT", 0, 13], ["live attenuated poliovirus strains", "TREATMENT", 39, 73], ["poliovirus strains", "OBSERVATION", 55, 73]]], ["OPV produces both, local and humoral immune response.", [["OPV", "CHEMICAL", 0, 3], ["OPV", "SPECIES", 0, 3], ["both", "OBSERVATION_MODIFIER", 13, 17], ["humoral immune response", "OBSERVATION", 29, 52]]], ["Antibodies in the blood protect the individual against polio paralysis by preventing the spread of poliovirus to the nervous system.", [["blood", "ANATOMY", 18, 23], ["nervous system", "ANATOMY", 117, 131], ["paralysis", "DISEASE", 61, 70], ["poliovirus to the nervous system", "DISEASE", 99, 131], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["nervous system", "ANATOMICAL_SYSTEM", 117, 131], ["poliovirus", "SPECIES", 99, 109], ["Antibodies", "TREATMENT", 0, 10], ["the blood", "TEST", 14, 23], ["polio paralysis", "PROBLEM", 55, 70], ["poliovirus", "PROBLEM", 99, 109], ["paralysis", "OBSERVATION", 61, 70], ["poliovirus", "OBSERVATION", 99, 109], ["nervous system", "ANATOMY", 117, 131]]], ["The local immune response in the lining ('mucous membrane') of the intestine inhibits the multiplication of subsequent infections of 'wild' (naturally occurring) virus and also stop person-to-person transmission of wild poliovirus [11] .", [["lining", "ANATOMY", 33, 39], ["mucous membrane", "ANATOMY", 42, 57], ["intestine", "ANATOMY", 67, 76], ["infections of 'wild' (naturally occurring) virus", "DISEASE", 119, 167], ["lining", "TISSUE", 33, 39], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 42, 57], ["intestine", "ORGAN", 67, 76], ["poliovirus", "ORGANISM", 220, 230], ["person", "SPECIES", 182, 188], ["person", "SPECIES", 192, 198], ["subsequent infections", "PROBLEM", 108, 129], ["virus", "PROBLEM", 162, 167], ["wild poliovirus", "PROBLEM", 215, 230], ["local", "OBSERVATION_MODIFIER", 4, 9], ["immune response", "OBSERVATION", 10, 25], ["lining", "OBSERVATION_MODIFIER", 33, 39], ["intestine", "ANATOMY", 67, 76], ["infections", "OBSERVATION", 119, 129]]], ["As it has been nearly 5 y that India is free of polio, now bivalent OPV is used.Oral VaccinesSimilar oral vaccine is available for typhoid with 50% to 80% efficacy and it confers protection for at least 5 to 7 y in 62% to 78% of recipients [12] .", [["Oral", "ANATOMY", 80, 84], ["oral", "ANATOMY", 101, 105], ["polio", "DISEASE", 48, 53], ["typhoid", "DISEASE", 131, 138], ["Oral", "ORGANISM_SUBDIVISION", 80, 84], ["oral", "ORGANISM_SUBDIVISION", 101, 105], ["OPV", "SPECIES", 68, 71], ["polio", "PROBLEM", 48, 53], ["bivalent OPV", "TREATMENT", 59, 71], ["Oral VaccinesSimilar oral vaccine", "TREATMENT", 80, 113], ["typhoid", "PROBLEM", 131, 138]]], ["The oral live-attenuated vaccine (manufactured from the Ty21a strain of Salmonella serotype typhi) is known for primary vaccination.", [["oral", "ANATOMY", 4, 8], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["Ty21a strain", "ORGANISM", 56, 68], ["Salmonella serotype typhi", "ORGANISM", 72, 97], ["Salmonella serotype typhi", "SPECIES", 72, 97], ["Salmonella serotype typhi", "SPECIES", 72, 97], ["The oral live-attenuated vaccine", "TREATMENT", 0, 32], ["Salmonella serotype typhi", "PROBLEM", 72, 97], ["primary vaccination", "TREATMENT", 112, 131]]], ["It consists of an enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules [13] .", [["capsule", "ANATOMY", 33, 40], ["capsule", "CANCER", 33, 40], ["an enteric-coated capsule", "TREATMENT", 15, 40], ["enteric", "ANATOMY", 18, 25]]], ["Presently this vaccine is not available for use in India.Oral VaccinesOral cholera vaccines (OCVs): single-dose live oral cholera vaccine and two other oral inactivated, or non-live cholera vaccines have proven to be effective in epidemics and outbreaks [14] .", [["Oral", "ANATOMY", 57, 61], ["oral", "ANATOMY", 117, 121], ["oral", "ANATOMY", 152, 156], ["VaccinesOral cholera", "CHEMICAL", 62, 82], ["cholera", "CHEMICAL", 122, 129], ["oral", "ORGANISM_SUBDIVISION", 117, 121], ["oral", "ORGANISM_SUBDIVISION", 152, 156], ["this vaccine", "TREATMENT", 10, 22], ["Oral VaccinesOral cholera vaccines", "TREATMENT", 57, 91], ["single-dose live oral cholera vaccine", "TREATMENT", 100, 137], ["non-live cholera vaccines", "TREATMENT", 173, 198]]], ["Live oral cholera vaccine strain CVD 103-HgR, which is an attenuated, live vaccine, administered as a single dose has an efficacy of 62% to 100% [12] .", [["oral", "ANATOMY", 5, 9], ["cholera", "CHEMICAL", 10, 17], ["CVD 103-HgR", "CHEMICAL", 33, 44], ["oral", "ORGANISM_SUBDIVISION", 5, 9], ["cholera", "ORGANISM", 10, 17], ["Live oral cholera vaccine", "TREATMENT", 0, 25], ["live vaccine", "TREATMENT", 70, 82]]], ["The establishment of the global OCV stockpile in 2013 has been a major advance in cholera preparedness.", [["cholera preparedness", "TREATMENT", 82, 102], ["global", "OBSERVATION_MODIFIER", 25, 31]]], ["New killed and live-attenuated vaccines are being actively explored as candidate vaccines for endemic settings and/or as a traveller's vaccine.", [["attenuated vaccines", "TREATMENT", 20, 39], ["endemic settings", "TREATMENT", 94, 110], ["a traveller's vaccine", "TREATMENT", 121, 142]]], ["While two doses of the currently available OCVs are recommended by manufacturers, a single dose would be easier to implement.", [["OCVs", "SIMPLE_CHEMICAL", 43, 47], ["OCVs", "TREATMENT", 43, 47]]], ["Qadri et al. proved a single-dose of the current killed oral cholera vaccines, that have been prequalified by the World Health Organization, to be efficacious in epidemics [15] .Oral VaccinesRotavirus is responsible for fever, nausea, vomiting and watery diarrhea in young infants.", [["oral", "ANATOMY", 56, 60], ["Oral", "ANATOMY", 178, 182], ["VaccinesRotavirus", "CHEMICAL", 183, 200], ["fever", "DISEASE", 220, 225], ["nausea", "DISEASE", 227, 233], ["vomiting", "DISEASE", 235, 243], ["watery diarrhea", "DISEASE", 248, 263], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["infants", "ORGANISM", 273, 280], ["infants", "SPECIES", 273, 280], ["the current killed oral cholera vaccines", "TREATMENT", 37, 77], ["Oral VaccinesRotavirus", "TREATMENT", 178, 200], ["fever", "PROBLEM", 220, 225], ["nausea", "PROBLEM", 227, 233], ["vomiting", "PROBLEM", 235, 243], ["watery diarrhea in young infants", "PROBLEM", 248, 280]]], ["Oral vaccines for rotavirus are in use since 2006 and are effective.", [["Oral", "ANATOMY", 0, 4], ["rotavirus", "DISEASE", 18, 27], ["rotavirus", "ORGANISM", 18, 27], ["rotavirus", "SPECIES", 18, 27], ["Oral vaccines", "TREATMENT", 0, 13], ["rotavirus", "PROBLEM", 18, 27]]], ["Both the brands of available vaccines, are administered orally and are only different in the number of doses.", [["available vaccines", "TREATMENT", 19, 37]]], ["With five valent vaccine, three doses are required (2 mo, 4 mo, and 6 mo) and monovalent human strain vaccine requires two doses (2 mo and 4 mo).Oral VaccinesEdible vaccine is an unusual and new concept.", [["Oral", "ANATOMY", 145, 149], ["VaccinesEdible", "CHEMICAL", 150, 164], ["human", "ORGANISM", 89, 94], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["five valent vaccine", "TREATMENT", 5, 24], ["monovalent human strain vaccine", "TREATMENT", 78, 109], ["Oral VaccinesEdible vaccine", "TREATMENT", 145, 172]]], ["Scientists suggest that plants and plant viruses can be genetically engineered to produce vaccines against diseases.", [["plant viruses", "ORGANISM", 35, 48], ["plants and plant viruses", "PROBLEM", 24, 48], ["diseases", "PROBLEM", 107, 115]]], ["These are produced by introducing selected genes encoding bacterial and viral antigens in plants which are used to form immunogenic proteins [16] .", [["bacterial and viral antigens", "PROTEIN", 58, 86], ["immunogenic proteins", "PROTEIN", 120, 140], ["introducing selected genes encoding bacterial and viral antigens in plants", "PROBLEM", 22, 96], ["immunogenic proteins", "PROBLEM", 120, 140], ["bacterial", "OBSERVATION_MODIFIER", 58, 67]]], ["Edible plant vaccines are like conventional subunit vaccines i.e., immunogenic preparations containing antigenic proteins rather than pathogens [17] .", [["antigenic proteins", "PROTEIN", 103, 121], ["Edible plant vaccines", "TREATMENT", 0, 21], ["conventional subunit vaccines", "TREATMENT", 31, 60], ["immunogenic preparations", "TREATMENT", 67, 91], ["antigenic proteins", "PROBLEM", 103, 121]]], ["This process is known as Btransformation^and the altered plants are called Btransgenic plants^.", [["the altered plants", "PROBLEM", 45, 63]]], ["Thus, they are highly safe and cannot cause disease.", [["disease", "PROBLEM", 44, 51]]], ["It will be easy to administer them and they will have a low production cost.", [["a low production cost", "TREATMENT", 54, 75]]], ["It eliminates need of fermentation and purification systems, sterile delivery and being heat stable does not require cold chain maintenance.", [["fermentation", "TREATMENT", 22, 34], ["purification systems", "TREATMENT", 39, 59], ["sterile delivery", "TREATMENT", 61, 77], ["cold chain maintenance", "TREATMENT", 117, 139], ["stable", "OBSERVATION", 93, 99]]], ["It confers both mucosal (IgA) and systemic (IgG) immunity.", [["mucosal", "ANATOMY", 16, 23], ["mucosal", "MULTI-TISSUE_STRUCTURE", 16, 23], ["IgA", "GENE_OR_GENE_PRODUCT", 25, 28], ["IgA", "PROTEIN", 25, 28], ["IgG", "PROTEIN", 44, 47], ["systemic (IgG)", "TREATMENT", 34, 48], ["both", "ANATOMY_MODIFIER", 11, 15], ["mucosal", "ANATOMY", 16, 23]]], ["Over past 5 y significant progress has been made in expressing vaccine antigens in edible leaves (especially lettuce) and processing them to achieve antigen stability and efficacy after prolonged storage at ambient temperatures [18] .", [["leaves", "ANATOMY", 90, 96], ["leaves", "ORGANISM_SUBDIVISION", 90, 96], ["lettuce", "ORGANISM_SUBDIVISION", 109, 116], ["lettuce", "SPECIES", 109, 116], ["prolonged storage at ambient temperatures", "TREATMENT", 186, 227]]], ["And as there is no need of needles, it prevents infection.Oral VaccinesBioencapsulation of antigens in plant cells protects them from the digestive system; the fusion of antigens to transmucosal carriers enhances efficiency of their delivery to the immune system and facilitates successful development of plant vaccines as oral boosters [18] .", [["Oral", "ANATOMY", 58, 62], ["cells", "ANATOMY", 109, 114], ["digestive system", "ANATOMY", 138, 154], ["transmucosal", "ANATOMY", 182, 194], ["immune system", "ANATOMY", 249, 262], ["oral", "ANATOMY", 323, 327], ["infection", "DISEASE", 48, 57], ["plant cells", "CELL", 103, 114], ["digestive system", "ANATOMICAL_SYSTEM", 138, 154], ["transmucosal", "IMMATERIAL_ANATOMICAL_ENTITY", 182, 194], ["oral", "ORGANISM_SUBDIVISION", 323, 327], ["antigens", "PROTEIN", 91, 99], ["plant cells", "CELL_TYPE", 103, 114], ["antigens", "PROTEIN", 170, 178], ["needles", "TREATMENT", 27, 34], ["infection", "PROBLEM", 48, 57], ["Oral VaccinesBioencapsulation of antigens in plant cells", "TREATMENT", 58, 114], ["the fusion of antigens", "TREATMENT", 156, 178], ["transmucosal carriers", "TREATMENT", 182, 203], ["their delivery", "TREATMENT", 227, 241], ["the immune system", "TREATMENT", 245, 262], ["plant vaccines", "TREATMENT", 305, 319], ["oral boosters", "TREATMENT", 323, 336], ["no need", "UNCERTAINTY", 16, 23], ["infection", "OBSERVATION", 48, 57], ["plant cells", "OBSERVATION", 103, 114], ["digestive system", "ANATOMY", 138, 154]]], ["Antigen expression in plants has been successfully shown for LT-B (ETEC) in tobacco and potato; rabies virus-G protein in tomato; HBsAg in tobacco and potato; Norwalk virus in tobacco and potato; CT-B (Vibrio cholerae) in potato [19] .", [["HBsAg", "CHEMICAL", 130, 135], ["CT-B", "CHEMICAL", 196, 200], ["LT-B", "GENE_OR_GENE_PRODUCT", 61, 65], ["ETEC", "ORGANISM", 67, 71], ["tobacco", "ORGANISM", 76, 83], ["potato; rabies virus", "ORGANISM", 88, 108], ["-G protein", "GENE_OR_GENE_PRODUCT", 108, 118], ["tomato", "ORGANISM", 122, 128], ["HBsAg", "GENE_OR_GENE_PRODUCT", 130, 135], ["tobacco", "ORGANISM", 139, 146], ["potato; Norwalk virus", "ORGANISM", 151, 172], ["tobacco", "ORGANISM", 176, 183], ["potato", "ORGANISM_SUBDIVISION", 188, 194], ["CT-B", "ORGANISM", 196, 200], ["Vibrio cholerae", "ORGANISM", 202, 217], ["LT", "PROTEIN", 61, 63], ["rabies virus-G protein", "PROTEIN", 96, 118], ["HBsAg", "PROTEIN", 130, 135], ["tobacco", "SPECIES", 76, 83], ["potato", "SPECIES", 88, 94], ["rabies virus", "SPECIES", 96, 108], ["tomato", "SPECIES", 122, 128], ["tobacco", "SPECIES", 139, 146], ["potato", "SPECIES", 151, 157], ["tobacco", "SPECIES", 176, 183], ["potato", "SPECIES", 188, 194], ["Vibrio cholerae", "SPECIES", 202, 217], ["potato", "SPECIES", 222, 228], ["tobacco", "SPECIES", 76, 83], ["potato", "SPECIES", 88, 94], ["rabies virus", "SPECIES", 96, 108], ["tomato", "SPECIES", 122, 128], ["tobacco", "SPECIES", 139, 146], ["potato", "SPECIES", 151, 157], ["tobacco", "SPECIES", 176, 183], ["potato", "SPECIES", 188, 194], ["Vibrio cholerae", "SPECIES", 202, 217], ["potato", "SPECIES", 222, 228], ["Antigen expression in plants", "PROBLEM", 0, 28], ["LT-B (ETEC", "PROBLEM", 61, 71], ["potato", "TEST", 88, 94], ["rabies virus", "TEST", 96, 108], ["HBsAg", "TEST", 130, 135], ["potato", "TEST", 151, 157], ["Norwalk virus", "PROBLEM", 159, 172], ["potato", "TEST", 188, 194], ["CT", "TEST", 196, 198]]], ["Clinical trials are undergoing for malaria, measles, human papilloma virus (HPV-11), Human Immunodeficiency Virus, Respiratory Synctial Virus and Mycobacterium tuberculosis [19] .", [["malaria", "DISEASE", 35, 42], ["measles", "DISEASE", 44, 51], ["human papilloma virus", "DISEASE", 53, 74], ["Human Immunodeficiency Virus", "DISEASE", 85, 113], ["Respiratory Synctial Virus", "DISEASE", 115, 141], ["Mycobacterium tuberculosis", "DISEASE", 146, 172], ["human papilloma virus", "ORGANISM", 53, 74], ["HPV-11", "ORGANISM", 76, 82], ["Human Immunodeficiency Virus", "ORGANISM", 85, 113], ["Respiratory Synctial Virus", "ORGANISM", 115, 141], ["Mycobacterium tuberculosis", "ORGANISM", 146, 172], ["human papilloma virus", "SPECIES", 53, 74], ["Human", "SPECIES", 85, 90], ["Mycobacterium tuberculosis", "SPECIES", 146, 172], ["human papilloma virus (HPV-11", "SPECIES", 53, 82], ["Human Immunodeficiency Virus", "SPECIES", 85, 113], ["Respiratory Synctial Virus", "SPECIES", 115, 141], ["Mycobacterium tuberculosis", "SPECIES", 146, 172], ["malaria", "PROBLEM", 35, 42], ["measles", "PROBLEM", 44, 51], ["human papilloma virus", "PROBLEM", 53, 74], ["HPV", "TEST", 76, 79], ["Human Immunodeficiency Virus", "PROBLEM", 85, 113], ["Respiratory Synctial Virus", "PROBLEM", 115, 141], ["Mycobacterium tuberculosis", "PROBLEM", 146, 172], ["Mycobacterium tuberculosis", "OBSERVATION", 146, 172]]], ["Human clinical trials using transgenic potatoes having cholera toxin have shown successful seroconversion in volunteers.Oral VaccinesThe sublingual route i.e., via the mucosal surfaces under the tongue and the buccal route have been used for many years to deliver drugs (cardiovascular drugs, steroids, barbiturates, benzodiazepines, opioid analgesics) and small molecules to the bloodstream.", [["Oral", "ANATOMY", 120, 124], ["sublingual", "ANATOMY", 137, 147], ["mucosal", "ANATOMY", 168, 175], ["tongue", "ANATOMY", 195, 201], ["buccal", "ANATOMY", 210, 216], ["cardiovascular", "ANATOMY", 271, 285], ["bloodstream", "ANATOMY", 380, 391], ["cholera toxin", "CHEMICAL", 55, 68], ["steroids", "CHEMICAL", 293, 301], ["barbiturates", "CHEMICAL", 303, 315], ["benzodiazepines", "CHEMICAL", 317, 332], ["steroids", "CHEMICAL", 293, 301], ["barbiturates", "CHEMICAL", 303, 315], ["benzodiazepines", "CHEMICAL", 317, 332], ["Human", "ORGANISM", 0, 5], ["transgenic potatoes", "ORGANISM", 28, 47], ["cholera toxin", "SIMPLE_CHEMICAL", 55, 68], ["volunteers", "ORGANISM", 109, 119], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 168, 184], ["tongue", "ORGAN", 195, 201], ["buccal route", "MULTI-TISSUE_STRUCTURE", 210, 222], ["cardiovascular", "ANATOMICAL_SYSTEM", 271, 285], ["steroids", "SIMPLE_CHEMICAL", 293, 301], ["barbiturates", "SIMPLE_CHEMICAL", 303, 315], ["benzodiazepines", "SIMPLE_CHEMICAL", 317, 332], ["cholera toxin", "PROTEIN", 55, 68], ["Human", "SPECIES", 0, 5], ["potatoes", "SPECIES", 39, 47], ["potatoes", "SPECIES", 39, 47], ["Human clinical trials", "TREATMENT", 0, 21], ["transgenic potatoes", "TREATMENT", 28, 47], ["cholera toxin", "PROBLEM", 55, 68], ["successful seroconversion in volunteers", "PROBLEM", 80, 119], ["Oral Vaccines", "TREATMENT", 120, 133], ["The sublingual route", "TREATMENT", 133, 153], ["the buccal route", "TREATMENT", 206, 222], ["drugs", "TREATMENT", 264, 269], ["cardiovascular drugs", "TREATMENT", 271, 291], ["steroids", "TREATMENT", 293, 301], ["barbiturates", "TREATMENT", 303, 315], ["benzodiazepines", "TREATMENT", 317, 332], ["opioid analgesics", "TREATMENT", 334, 351], ["small molecules to the bloodstream", "PROBLEM", 357, 391], ["seroconversion", "OBSERVATION", 91, 105], ["tongue", "ANATOMY", 195, 201], ["bloodstream", "ANATOMY", 380, 391]]], ["The potential of sublingual and buccal vaccine delivery is largely unexplored.", [["sublingual", "ANATOMY", 17, 27], ["buccal", "ANATOMY", 32, 38], ["sublingual", "MULTI-TISSUE_STRUCTURE", 17, 27], ["buccal", "ORGAN", 32, 38], ["sublingual and buccal vaccine delivery", "TREATMENT", 17, 55], ["buccal", "ANATOMY", 32, 38]]], ["They are superior to oral vaccination method where there is a risk of degradation by gastric enzymes.", [["oral", "ANATOMY", 21, 25], ["gastric", "ANATOMY", 85, 92], ["oral", "ORGANISM_SUBDIVISION", 21, 25], ["gastric enzymes", "GENE_OR_GENE_PRODUCT", 85, 100], ["gastric enzymes", "PROTEIN", 85, 100], ["oral vaccination method", "TREATMENT", 21, 44], ["gastric enzymes", "TEST", 85, 100], ["gastric", "ANATOMY", 85, 92]]], ["Similarly in skin vaccination method, impermeable thick keratinized stratum corneum acts as a physiological barrier and chemical disruption and/or microneedle penetration is required which is not so in sublingual and buccal vaccine delivery.", [["skin", "ANATOMY", 13, 17], ["stratum corneum", "ANATOMY", 68, 83], ["sublingual", "ANATOMY", 202, 212], ["buccal", "ANATOMY", 217, 223], ["skin", "ORGAN", 13, 17], ["keratinized stratum corneum", "TISSUE", 56, 83], ["sublingual", "ORGANISM_SUBDIVISION", 202, 212], ["buccal", "ORGANISM_SUBDIVISION", 217, 223], ["skin vaccination method", "TREATMENT", 13, 36], ["impermeable thick keratinized stratum corneum acts", "TREATMENT", 38, 88], ["a physiological barrier", "TREATMENT", 92, 115], ["chemical disruption", "PROBLEM", 120, 139], ["microneedle penetration", "PROBLEM", 147, 170], ["sublingual and buccal vaccine delivery", "TREATMENT", 202, 240], ["skin", "ANATOMY", 13, 17], ["vaccination", "OBSERVATION", 18, 29], ["chemical disruption", "OBSERVATION", 120, 139], ["buccal", "ANATOMY", 217, 223]]], ["Intranasal immunization also induces mucosal immunity but retrograde transport of antigen and/or adjuvant from vaccine formulations to the brain and other neural tissues, causes serious side-effects.", [["mucosal", "ANATOMY", 37, 44], ["brain", "ANATOMY", 139, 144], ["neural tissues", "ANATOMY", 155, 169], ["mucosal", "MULTI-TISSUE_STRUCTURE", 37, 44], ["brain", "ORGAN", 139, 144], ["neural tissues", "TISSUE", 155, 169], ["Intranasal immunization", "TREATMENT", 0, 23], ["adjuvant from vaccine formulations", "TREATMENT", 97, 131], ["serious side-effects", "PROBLEM", 178, 198], ["brain", "ANATOMY", 139, 144], ["neural tissues", "ANATOMY", 155, 169]]], ["This is in contrast to the sublingual route of delivery wherein no antigenic migration to the central nervous system occurs.", [["central nervous system", "ANATOMY", 94, 116], ["central nervous system", "ANATOMICAL_SYSTEM", 94, 116], ["delivery", "TREATMENT", 47, 55], ["antigenic migration", "PROBLEM", 67, 86], ["antigenic migration", "OBSERVATION", 67, 86], ["central", "ANATOMY_MODIFIER", 94, 101], ["nervous system", "ANATOMY", 102, 116]]], ["Many laboratories have documented the efficacy of sublingual immunization in inducing adequate immune response in experimental animal systems using a variety of antigens, including soluble proteins, inert particulate antigens (killed viruses, virus-like particles, bacterial extracts) as well as live-attenuated viruses [20] .", [["sublingual", "ANATOMY", 50, 60], ["extracts", "ANATOMY", 275, 283], ["sublingual", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 60], ["virus-like particles", "ORGANISM", 243, 263], ["antigens", "PROTEIN", 161, 169], ["soluble proteins", "PROTEIN", 181, 197], ["inert particulate antigens", "PROTEIN", 199, 225], ["Many laboratories", "TEST", 0, 17], ["sublingual immunization", "TREATMENT", 50, 73], ["a variety of antigens", "TREATMENT", 148, 169], ["soluble proteins", "TREATMENT", 181, 197], ["inert particulate antigens", "PROBLEM", 199, 225], ["virus", "PROBLEM", 243, 248], ["bacterial extracts", "PROBLEM", 265, 283]]], ["However in a clinical trial, where HPV vaccine was applied sublingually to humans, antibody titre were 1000-fold lower than in the intramuscular group.", [["intramuscular", "ANATOMY", 131, 144], ["HPV", "ORGANISM", 35, 38], ["humans", "ORGANISM", 75, 81], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 131, 144], ["humans", "SPECIES", 75, 81], ["HPV", "SPECIES", 35, 38], ["humans", "SPECIES", 75, 81], ["HPV vaccine", "TREATMENT", 35, 46], ["antibody titre", "TEST", 83, 97], ["intramuscular", "ANATOMY", 131, 144]]], ["So researchers concluded that alternative delivery systems and adjuvants would be required to enhance and evaluate immune responses following sublingual immunization in humans [23] .", [["sublingual", "ANATOMY", 142, 152], ["sublingual", "IMMATERIAL_ANATOMICAL_ENTITY", 142, 152], ["humans", "ORGANISM", 169, 175], ["humans", "SPECIES", 169, 175], ["humans", "SPECIES", 169, 175], ["alternative delivery systems", "TREATMENT", 30, 58], ["adjuvants", "TREATMENT", 63, 72], ["sublingual immunization", "TREATMENT", 142, 165]]], ["It is an attractive option for vaccine delivery because it is efficient, accessible, and relatively clean.Oral VaccinesBMelt in mouth strips^is an another innovation in vaccine delivery.", [["Oral", "ANATOMY", 106, 110], ["mouth", "ANATOMY", 128, 133], ["VaccinesBMelt", "CHEMICAL", 111, 124], ["vaccine delivery", "TREATMENT", 31, 47], ["Oral VaccinesBMelt in mouth strips", "TREATMENT", 106, 140], ["an another innovation in vaccine delivery", "TREATMENT", 144, 185], ["clean", "OBSERVATION", 100, 105], ["mouth", "ANATOMY", 128, 133]]], ["Researchers at McMaster University are inspired from the chemistry of a consumer product: breath-freshening strips that melt on tongue [24] .", [["tongue", "ANATOMY", 128, 134], ["tongue", "ORGANISM_SUBDIVISION", 128, 134], ["breath-freshening strips", "TREATMENT", 90, 114], ["tongue", "ANATOMY", 128, 134]]], ["Pullulan, a polysaccharide derived from a common fungus is the key ingredient of these strips.", [["Pullulan", "CHEMICAL", 0, 8], ["Pullulan", "SIMPLE_CHEMICAL", 0, 8], ["Pullulan", "TREATMENT", 0, 8], ["a polysaccharide", "PROBLEM", 10, 26], ["a common fungus", "PROBLEM", 40, 55], ["these strips", "TREATMENT", 81, 93]]], ["It normally rests in a solid state but dissolves easily in water.", [["water", "SIMPLE_CHEMICAL", 59, 64]]], ["By casting enzymes and other substrates within this material; they can be preserved in a form that will remain inert until it interacts with water.", [["enzymes", "PROTEIN", 11, 18], ["casting enzymes", "TEST", 3, 18]]], ["Undergraduate biomedical engineering students at John Hopkins University have developed such strips laced with vaccine against rotavirus [25] .Nasal and Aerosol VaccinesWe respire every moment and with every breath we are exposed to several viral and bacterial pathogens that transmit through air-borne particles.", [["Nasal", "ANATOMY", 143, 148], ["rotavirus", "ORGANISM", 127, 136], ["Nasal", "MULTI-TISSUE_STRUCTURE", 143, 148], ["such strips", "TREATMENT", 88, 99], ["vaccine", "TREATMENT", 111, 118], ["rotavirus", "PROBLEM", 127, 136], ["Nasal and Aerosol VaccinesWe respire", "TREATMENT", 143, 179], ["several viral and bacterial pathogens", "PROBLEM", 233, 270]]], ["The large surface area of respiratory system can provide adequate interaction between the immune system and the antigen.", [["surface area", "ANATOMY", 10, 22], ["respiratory system", "ANATOMY", 26, 44], ["immune system", "ANATOMY", 90, 103], ["large", "OBSERVATION_MODIFIER", 4, 9], ["surface", "OBSERVATION_MODIFIER", 10, 17], ["respiratory system", "ANATOMY", 26, 44]]], ["The nasal mucosa and lungs can be considered as an important route for vaccination.", [["nasal mucosa", "ANATOMY", 4, 16], ["lungs", "ANATOMY", 21, 26], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 4, 16], ["lungs", "ORGAN", 21, 26], ["vaccination", "TREATMENT", 71, 82], ["nasal mucosa", "ANATOMY", 4, 16], ["lungs", "ANATOMY", 21, 26]]], ["In addition, the extensive vascularization and thin epithelium in the alveolar lung tissue [26] facilitates efficient systemic delivery of antigens, thereby ensuring both local and systemic antibodies.", [["thin epithelium", "ANATOMY", 47, 62], ["alveolar lung tissue", "ANATOMY", 70, 90], ["thin epithelium", "TISSUE", 47, 62], ["alveolar lung tissue", "TISSUE", 70, 90], ["antigens", "PROTEIN", 139, 147], ["systemic antibodies", "PROTEIN", 181, 200], ["the extensive vascularization", "PROBLEM", 13, 42], ["thin epithelium in the alveolar lung tissue", "PROBLEM", 47, 90], ["efficient systemic delivery of antigens", "TREATMENT", 108, 147], ["extensive", "OBSERVATION_MODIFIER", 17, 26], ["vascularization", "OBSERVATION", 27, 42], ["thin", "OBSERVATION_MODIFIER", 47, 51], ["epithelium", "OBSERVATION_MODIFIER", 52, 62], ["alveolar", "ANATOMY_MODIFIER", 70, 78], ["lung", "ANATOMY", 79, 83], ["tissue", "ANATOMY_MODIFIER", 84, 90], ["systemic", "OBSERVATION_MODIFIER", 118, 126], ["systemic antibodies", "OBSERVATION", 181, 200]]], ["The delivery of vaccines via these routes is recently emerging as an attractive alternative to injection.", [["The delivery of vaccines", "TREATMENT", 0, 24]]], ["It is more potent and a practical way of inducing effective immunity against infectious diseases.", [["infectious diseases", "DISEASE", 77, 96], ["infectious diseases", "PROBLEM", 77, 96], ["more potent", "OBSERVATION_MODIFIER", 6, 17]]], ["It elicits rapid immune response, both locally and systemically.", [["rapid", "OBSERVATION_MODIFIER", 11, 16], ["immune response", "OBSERVATION", 17, 32]]], ["It is gaining advances in the future for being a self-administrative and non-invasive technique, thus causing little discomfort to the patients.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["non-invasive technique", "TREATMENT", 73, 95], ["little discomfort", "PROBLEM", 110, 127]]], ["Another advantage is that both liquid and dry powder formulations can be given, thus saving the cost spend in transportation via cold chain.Nasal and Aerosol VaccinesThe various devices available for nasal route of vaccination are single dose nasal spray, bi-dose nasal spray, multi-dose pump with tip-seal technology (prevents contamination of bottle content), unit-dose nasal powder delivery system, bidose nasal powder delivery system [27] and jet nebulizers.Nasal and Aerosol VaccinesThe live, attenuated influenza vaccine (called LAIV) may be given to healthy, non-pregnant people (2 to 49 y of age) as a nasal spray.", [["Nasal", "ANATOMY", 140, 145], ["nasal", "ANATOMY", 200, 205], ["nasal", "ANATOMY", 243, 248], ["nasal", "ANATOMY", 264, 269], ["nasal", "ANATOMY", 372, 377], ["nasal", "ANATOMY", 409, 414], ["Nasal", "ANATOMY", 462, 467], ["nasal", "ANATOMY", 610, 615], ["influenza", "DISEASE", 509, 518], ["LAIV", "CHEMICAL", 535, 539], ["Nasal", "ORGAN", 140, 145], ["Nasal", "ORGAN", 462, 467], ["people", "ORGANISM", 579, 585], ["nasal", "ORGANISM_SUBDIVISION", 610, 615], ["people", "SPECIES", 579, 585], ["both liquid and dry powder formulations", "TREATMENT", 26, 65], ["Nasal and Aerosol Vaccines", "TREATMENT", 140, 166], ["The various devices", "TREATMENT", 166, 185], ["nasal route of vaccination", "TREATMENT", 200, 226], ["single dose nasal spray", "TREATMENT", 231, 254], ["bi-dose nasal spray", "TREATMENT", 256, 275], ["multi-dose pump", "TREATMENT", 277, 292], ["tip-seal technology", "TREATMENT", 298, 317], ["contamination of bottle content", "TREATMENT", 328, 359], ["unit-dose nasal powder delivery system", "TREATMENT", 362, 400], ["bidose nasal powder delivery system", "TREATMENT", 402, 437], ["jet nebulizers", "TREATMENT", 447, 461], ["Nasal and Aerosol Vaccines", "TREATMENT", 462, 488], ["attenuated influenza vaccine", "TREATMENT", 498, 526], ["a nasal spray", "TREATMENT", 608, 621], ["Aerosol Vaccines", "OBSERVATION", 150, 166], ["Aerosol Vaccines", "OBSERVATION", 472, 488]]], ["It is made from attenuated flu virus so it does not cause flu [28] .", [["flu virus", "ORGANISM", 27, 36], ["flu virus", "SPECIES", 27, 36], ["attenuated flu virus", "PROBLEM", 16, 36], ["flu", "PROBLEM", 58, 61]]], ["There are many flu viruses, and they keep on changing every year.", [["many flu viruses", "PROBLEM", 10, 26], ["many", "OBSERVATION_MODIFIER", 10, 14], ["flu viruses", "OBSERVATION", 15, 26]]], ["Initially it was believed to provide some protection even when the vaccine does not match the current season virus.", [["the vaccine", "TREATMENT", 63, 74]]], ["However, recently, CDC's Advisory Committee on Immunization Practices (ACIP) declared that it should not be used during the 2016-2017 flu season as studies conducted showed just 3% protective benefit [4] .Nasal and Aerosol VaccinesNeedle-free nasal immunization with recombinant HBsAg using nanoemulsions (NEs) has also proved to be a safe and effective hepatitis B vaccine, and has provided an alternative booster administration for the parenteral hepatitis B vaccines [29] .", [["Nasal", "ANATOMY", 205, 210], ["nasal", "ANATOMY", 243, 248], ["HBsAg", "CHEMICAL", 279, 284], ["nanoemulsions", "CHEMICAL", 291, 304], ["NEs", "CHEMICAL", 306, 309], ["hepatitis B", "DISEASE", 354, 365], ["hepatitis B", "DISEASE", 449, 460], ["Nasal", "ORGAN", 205, 210], ["HBsAg", "ORGANISM", 279, 284], ["nanoemulsions", "SIMPLE_CHEMICAL", 291, 304], ["NEs", "SIMPLE_CHEMICAL", 306, 309], ["hepatitis B", "ORGANISM", 354, 365], ["recombinant HBsAg", "PROTEIN", 267, 284], ["hepatitis B", "SPECIES", 354, 365], ["Immunization Practices", "TREATMENT", 47, 69], ["Nasal and Aerosol VaccinesNeedle", "TREATMENT", 205, 237], ["free nasal immunization", "TREATMENT", 238, 261], ["hepatitis B vaccine", "TREATMENT", 354, 373], ["an alternative booster administration", "TREATMENT", 392, 429], ["the parenteral hepatitis B vaccines", "TREATMENT", 434, 469]]], ["NEs (< 400 nm) are emulsions formulated with surfactants, distilled water, refined soybean oil and ethanol as a solvent.", [["oil", "ANATOMY", 91, 94], ["ethanol", "CHEMICAL", 99, 106], ["ethanol", "CHEMICAL", 99, 106], ["NEs", "SIMPLE_CHEMICAL", 0, 3], ["ethanol", "SIMPLE_CHEMICAL", 99, 106], ["soybean", "SPECIES", 83, 90], ["soybean", "SPECIES", 83, 90], ["surfactants", "TREATMENT", 45, 56], ["soybean oil", "TREATMENT", 83, 94], ["a solvent", "TREATMENT", 110, 119]]], ["Initially they were used as broad-spectrum antimicrobial agents.", [["broad-spectrum antimicrobial agents", "TREATMENT", 28, 63]]], ["NEs proved effective as mucosal adjuvants for whole influenza virus, vaccinia viruses, recombinant anthrax protective antigen and HIV gp120 [29] .Nasal and Aerosol VaccinesSuzuki et al. have developed an efficient nasal vaccine delivery system against pneumococcal infection.", [["mucosal", "ANATOMY", 24, 31], ["nasal", "ANATOMY", 214, 219], ["NEs", "CHEMICAL", 0, 3], ["influenza virus", "DISEASE", 52, 67], ["pneumococcal infection", "DISEASE", 252, 274], ["NEs", "SIMPLE_CHEMICAL", 0, 3], ["mucosal", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 31], ["whole influenza virus", "ORGANISM", 46, 67], ["vaccinia viruses", "ORGANISM", 69, 85], ["anthrax protective antigen", "GENE_OR_GENE_PRODUCT", 99, 125], ["HIV gp120", "ORGANISM", 130, 139], ["Nasal", "MULTI-TISSUE_STRUCTURE", 146, 151], ["nasal", "ORGANISM_SUBDIVISION", 214, 219], ["pneumococcal", "ORGANISM", 252, 264], ["recombinant anthrax protective antigen", "PROTEIN", 87, 125], ["HIV gp120", "PROTEIN", 130, 139], ["whole influenza virus", "SPECIES", 46, 67], ["HIV", "SPECIES", 130, 133], ["whole influenza virus", "SPECIES", 46, 67], ["vaccinia viruses", "SPECIES", 69, 85], ["HIV", "SPECIES", 130, 133], ["pneumococcal", "SPECIES", 252, 264], ["mucosal adjuvants", "TREATMENT", 24, 41], ["whole influenza virus", "PROBLEM", 46, 67], ["vaccinia viruses", "TREATMENT", 69, 85], ["recombinant anthrax protective antigen", "TREATMENT", 87, 125], ["HIV gp120", "TEST", 130, 139], ["Nasal and Aerosol VaccinesSuzuki et al", "TREATMENT", 146, 184], ["an efficient nasal vaccine delivery system", "TREATMENT", 201, 243], ["pneumococcal infection", "PROBLEM", 252, 274], ["efficient", "OBSERVATION_MODIFIER", 204, 213], ["nasal", "ANATOMY", 214, 219], ["pneumococcal", "OBSERVATION_MODIFIER", 252, 264], ["infection", "OBSERVATION", 265, 274]]], ["They fused C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE) with pneumococcal surface protein A (PspA).", [["C-CPE", "CHEMICAL", 71, 76], ["C-", "CHEMICAL", 11, 13], ["Clostridium perfringens enterotoxin", "GENE_OR_GENE_PRODUCT", 34, 69], ["C-CPE", "SIMPLE_CHEMICAL", 71, 76], ["pneumococcal surface protein A", "GENE_OR_GENE_PRODUCT", 83, 113], ["PspA", "GENE_OR_GENE_PRODUCT", 115, 119], ["C-terminal fragment", "PROTEIN", 11, 30], ["Clostridium perfringens enterotoxin", "PROTEIN", 34, 69], ["C", "PROTEIN", 71, 72], ["pneumococcal surface protein A", "PROTEIN", 83, 113], ["PspA", "PROTEIN", 115, 119], ["Clostridium perfringens enterotoxin", "SPECIES", 34, 69], ["Clostridium perfringens", "SPECIES", 34, 57], ["pneumococcal", "SPECIES", 83, 95], ["Clostridium perfringens enterotoxin", "PROBLEM", 34, 69], ["pneumococcal surface protein A (PspA)", "TREATMENT", 83, 120], ["terminal", "OBSERVATION_MODIFIER", 13, 21], ["fragment", "OBSERVATION_MODIFIER", 22, 30], ["Clostridium perfringens", "OBSERVATION_MODIFIER", 34, 57]]], ["Nasal immunization with PspA-C-CPE induces PspA-specific IgG in the serum and bronchoalveolar lavage fluid (BALF) as well as IgA in the nasal wash and BALF, which proved sufficient to protect against pneumococcal infection [30] .Nasal and Aerosol VaccinesNantachit et al., delivered dengue immunogen (domain III of dengue serotype-3 E protein -EDIII-D3) loaded into trimethyl chitosan nanoparticles (EDIII-D3 TMC NPs) intranasally.", [["Nasal", "ANATOMY", 0, 5], ["serum", "ANATOMY", 68, 73], ["bronchoalveolar lavage fluid", "ANATOMY", 78, 106], ["BALF", "ANATOMY", 108, 112], ["nasal", "ANATOMY", 136, 141], ["BALF", "ANATOMY", 151, 155], ["Nasal", "ANATOMY", 229, 234], ["PspA-C-", "CHEMICAL", 24, 31], ["pneumococcal infection", "DISEASE", 200, 222], ["dengue", "DISEASE", 283, 289], ["trimethyl chitosan", "CHEMICAL", 366, 384], ["EDIII-D3 TMC NPs", "CHEMICAL", 400, 416], ["trimethyl", "CHEMICAL", 366, 375], ["Nasal", "ORGAN", 0, 5], ["PspA-C-", "SIMPLE_CHEMICAL", 24, 31], ["PspA-", "GENE_OR_GENE_PRODUCT", 43, 48], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 78, 106], ["BALF", "ORGANISM_SUBSTANCE", 108, 112], ["IgA", "GENE_OR_GENE_PRODUCT", 125, 128], ["BALF", "ORGANISM_SUBSTANCE", 151, 155], ["Nasal", "ORGAN", 229, 234], ["EDIII-D3", "SIMPLE_CHEMICAL", 344, 352], ["trimethyl chitosan nanoparticles", "SIMPLE_CHEMICAL", 366, 398], ["EDIII-D3 TMC NPs", "SIMPLE_CHEMICAL", 400, 416], ["PspA-specific IgG", "PROTEIN", 43, 60], ["IgA", "PROTEIN", 125, 128], ["domain III of dengue serotype-3 E protein", "PROTEIN", 301, 342], ["EDIII", "PROTEIN", 344, 349], ["dengue serotype", "SPECIES", 315, 330], ["pneumococcal", "SPECIES", 200, 212], ["dengue", "SPECIES", 283, 289], ["Nasal immunization", "TREATMENT", 0, 18], ["PspA-C-CPE", "PROBLEM", 24, 34], ["PspA-specific IgG", "TEST", 43, 60], ["the serum", "TEST", 64, 73], ["bronchoalveolar lavage fluid (BALF)", "TEST", 78, 113], ["IgA", "TEST", 125, 128], ["the nasal wash", "TREATMENT", 132, 146], ["BALF", "PROBLEM", 151, 155], ["pneumococcal infection", "PROBLEM", 200, 222], ["Nasal and Aerosol Vaccines", "TREATMENT", 229, 255], ["dengue immunogen", "TREATMENT", 283, 299], ["dengue serotype", "TEST", 315, 330], ["EDIII-D3)", "TREATMENT", 344, 353], ["trimethyl chitosan nanoparticles", "TREATMENT", 366, 398], ["EDIII-D3 TMC NPs", "TREATMENT", 400, 416], ["bronchoalveolar lavage", "OBSERVATION", 78, 100], ["nasal", "ANATOMY", 136, 141], ["BALF", "ANATOMY", 151, 155]]], ["This stimulated a strong local innate antiviral response which helped in systemic adaptive immunity [31] .Nasal and Aerosol VaccinesStudies have also been conducted for Ebola virus, which was recently a dreadful outbreak in western Africa.", [["Nasal", "ANATOMY", 106, 111], ["Ebola virus", "DISEASE", 169, 180], ["Nasal", "MULTI-TISSUE_STRUCTURE", 106, 111], ["Ebola virus", "ORGANISM", 169, 180], ["Ebola virus", "SPECIES", 169, 180], ["Ebola virus", "SPECIES", 169, 180], ["Nasal and Aerosol VaccinesStudies", "TREATMENT", 106, 139], ["Ebola virus", "PROBLEM", 169, 180]]], ["Researchers at The University of Texas at Austin have developed nasal vaccine which provided long-term protection for non-human primates against the deadly Ebola virus.", [["nasal", "ANATOMY", 64, 69], ["Ebola virus", "DISEASE", 156, 167], ["Austin", "ORGANISM", 42, 48], ["non-human", "ORGANISM", 118, 127], ["primates", "ORGANISM", 128, 136], ["Ebola virus", "ORGANISM", 156, 167], ["Ebola virus", "SPECIES", 156, 167], ["Ebola virus", "SPECIES", 156, 167], ["nasal vaccine", "TREATMENT", 64, 77], ["long-term protection", "TREATMENT", 93, 113], ["non-human primates", "TREATMENT", 118, 136], ["the deadly Ebola virus", "PROBLEM", 145, 167], ["nasal", "ANATOMY", 64, 69]]], ["Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting [32] .Nasal and Aerosol VaccinesAerosol vaccine delivery involves creating small particles, usually generated by a nebulizer, that reach the lungs [12] .", [["Nasal", "ANATOMY", 161, 166], ["lungs", "ANATOMY", 296, 301], ["Ebola", "DISEASE", 133, 138], ["Ebola", "ORGANISM", 133, 138], ["Nasal", "MULTI-TISSUE_STRUCTURE", 161, 166], ["lungs", "ORGAN", 296, 301], ["a small pre-clinical study", "TEST", 13, 39], ["a non-injectable vaccine platform", "TREATMENT", 95, 128], ["Ebola", "PROBLEM", 133, 138], ["Nasal and Aerosol Vaccines", "TREATMENT", 161, 187], ["Aerosol vaccine delivery", "TREATMENT", 187, 211], ["a nebulizer", "TREATMENT", 268, 279], ["small particles", "OBSERVATION", 230, 245], ["lungs", "ANATOMY", 296, 301]]], ["Two types of pulmonary delivery devices are available and useful for vaccination: Dry Powder Inhalers (DPI) and jet nebulizers.", [["pulmonary", "ANATOMY", 13, 22], ["DPI", "CHEMICAL", 103, 106], ["pulmonary", "ORGAN", 13, 22], ["pulmonary delivery devices", "TREATMENT", 13, 39], ["vaccination", "TREATMENT", 69, 80], ["Dry Powder Inhalers (DPI)", "TREATMENT", 82, 107], ["jet nebulizers", "TREATMENT", 112, 126], ["pulmonary", "ANATOMY", 13, 22]]], ["Pulmonary vaccine formulations for Hepatitis B virus [33] , Measles [34] , Tuberculosis [35] and Yersinia pestis are in preclinical research phase.", [["Pulmonary", "ANATOMY", 0, 9], ["Hepatitis B", "DISEASE", 35, 46], ["Tuberculosis", "DISEASE", 75, 87], ["Yersinia pestis", "DISEASE", 97, 112], ["Pulmonary", "ORGAN", 0, 9], ["Hepatitis B virus", "ORGANISM", 35, 52], ["Measles", "ORGANISM", 60, 67], ["Yersinia pestis", "ORGANISM", 97, 112], ["Hepatitis B virus", "SPECIES", 35, 52], ["Yersinia pestis", "SPECIES", 97, 112], ["Hepatitis B virus", "SPECIES", 35, 52], ["Yersinia pestis", "SPECIES", 97, 112], ["Pulmonary vaccine formulations", "TREATMENT", 0, 30], ["Hepatitis B virus", "PROBLEM", 35, 52], ["Measles", "PROBLEM", 60, 67], ["Tuberculosis", "PROBLEM", 75, 87], ["Yersinia pestis", "PROBLEM", 97, 112]]], ["Measles vaccine, MMR (Measles, Mumps, Rubella) vaccine, BCG vaccine, Influenza, Streptococcus pneumoniae and Human Papilloma virus [36] are in clinical research phase.", [["Measles, Mumps, Rubella) vaccine", "DISEASE", 22, 54], ["Influenza", "DISEASE", 69, 78], ["Streptococcus pneumoniae", "DISEASE", 80, 104], ["Rubella", "ORGANISM", 38, 45], ["Streptococcus pneumoniae", "ORGANISM", 80, 104], ["Human Papilloma virus", "ORGANISM", 109, 130], ["Influenza", "SPECIES", 69, 78], ["Streptococcus pneumoniae", "SPECIES", 80, 104], ["Human Papilloma virus", "SPECIES", 109, 130], ["Streptococcus pneumoniae", "SPECIES", 80, 104], ["Human Papilloma virus", "SPECIES", 109, 130], ["Measles vaccine", "TREATMENT", 0, 15], ["MMR", "PROBLEM", 17, 20], ["Mumps", "TREATMENT", 31, 36], ["Rubella) vaccine", "TREATMENT", 38, 54], ["BCG vaccine", "TREATMENT", 56, 67], ["Influenza", "PROBLEM", 69, 78], ["Streptococcus pneumoniae", "PROBLEM", 80, 104], ["Human Papilloma virus", "PROBLEM", 109, 130]]], ["Clinical trials in Mexico and South Africa have demonstrated significantly higher rate of measles seroconversion following measles vaccination and combined rubella and measles vaccination in children after aerosol delivery than after subcutaneous delivery [37, 38] .", [["subcutaneous", "ANATOMY", 234, 246], ["rubella", "DISEASE", 156, 163], ["measles", "DISEASE", 168, 175], ["children", "ORGANISM", 191, 199], ["children", "SPECIES", 191, 199], ["rubella", "SPECIES", 156, 163], ["measles seroconversion", "TREATMENT", 90, 112], ["measles vaccination", "TREATMENT", 123, 142], ["combined rubella", "PROBLEM", 147, 163], ["measles vaccination", "TREATMENT", 168, 187], ["aerosol delivery", "TREATMENT", 206, 222], ["subcutaneous delivery", "TREATMENT", 234, 255]]], ["Animal experiments have also demonstrated efficacy of Mycoplasma hyopneumoniae aerosol vaccine [39] .", [["Mycoplasma hyopneumoniae", "ORGANISM", 54, 78], ["Mycoplasma hyopneumoniae", "SPECIES", 54, 78], ["Mycoplasma hyopneumoniae", "SPECIES", 54, 78], ["Mycoplasma hyopneumoniae aerosol vaccine", "TREATMENT", 54, 94]]], ["Most of the successful clinical trials have been done using jet nebulizers but the need for a pressurized (clean) air system and stability concerns of aqueous vaccine formulations limits their applicability in mass vaccination programs.", [["jet nebulizers", "TREATMENT", 60, 74], ["a pressurized (clean) air system", "TREATMENT", 92, 124], ["aqueous vaccine formulations", "TREATMENT", 151, 179], ["mass vaccination programs", "TREATMENT", 210, 235]]], ["As production of powder formulations for pulmonary administration is a onestep process, it reduces the risks of contaminations and batchto-batch differences, as well as production costs.", [["pulmonary", "ANATOMY", 41, 50], ["pulmonary", "ORGAN", 41, 50], ["powder formulations", "TREATMENT", 17, 36], ["pulmonary administration", "TREATMENT", 41, 65], ["a onestep process", "TREATMENT", 69, 86], ["contaminations", "PROBLEM", 112, 126], ["pulmonary", "ANATOMY", 41, 50]]], ["Thus, a simple, cheap, compact, disposable, and effective DPI is the most optimal device for pulmonary vaccination for target population.Transdermal RouteSkin has an outermost layer called the stratum corneum, below which lies the viable epidermis that comprises 2% of Langerhans cells.", [["pulmonary", "ANATOMY", 93, 102], ["outermost layer", "ANATOMY", 166, 181], ["stratum corneum", "ANATOMY", 193, 208], ["epidermis", "ANATOMY", 238, 247], ["Langerhans cells", "ANATOMY", 269, 285], ["DPI", "CHEMICAL", 58, 61], ["RouteSkin", "CHEMICAL", 149, 158], ["DPI", "SIMPLE_CHEMICAL", 58, 61], ["pulmonary", "ORGAN", 93, 102], ["outermost layer", "TISSUE", 166, 181], ["stratum corneum", "TISSUE", 193, 208], ["epidermis", "TISSUE", 238, 247], ["Langerhans cells", "CELL", 269, 285], ["Langerhans cells", "CELL_TYPE", 269, 285], ["effective DPI", "TREATMENT", 48, 61], ["pulmonary vaccination", "TREATMENT", 93, 114], ["target population", "PROBLEM", 119, 136], ["Transdermal RouteSkin", "TREATMENT", 137, 158], ["Langerhans cells", "PROBLEM", 269, 285], ["pulmonary", "ANATOMY", 93, 102], ["outermost", "OBSERVATION_MODIFIER", 166, 175], ["layer", "OBSERVATION_MODIFIER", 176, 181], ["stratum corneum", "ANATOMY", 193, 208], ["viable", "OBSERVATION_MODIFIER", 231, 237], ["epidermis", "ANATOMY", 238, 247], ["Langerhans cells", "OBSERVATION", 269, 285]]], ["These are extremely effective antigenpresenting cells, and generate an immune response.", [["antigenpresenting cells", "ANATOMY", 30, 53], ["antigenpresenting cells", "CELL", 30, 53], ["antigenpresenting cells", "CELL_TYPE", 30, 53], ["extremely effective antigenpresenting cells", "PROBLEM", 10, 53], ["extremely", "OBSERVATION_MODIFIER", 10, 19], ["effective", "OBSERVATION", 20, 29], ["immune response", "OBSERVATION", 71, 86]]], ["Vaccination in this cutaneous environment rich in specialized antigen-presenting cells using microneedles and nanopatches has practical and immunological advantages over conventional needle delivery.Transdermal RouteMicroneedles are micro structured projections which range from solid to hollow.", [["cells", "ANATOMY", 81, 86], ["cells", "CELL", 81, 86], ["specialized antigen-presenting cells", "CELL_TYPE", 50, 86], ["Vaccination", "TREATMENT", 0, 11], ["microneedles", "TREATMENT", 93, 105], ["nanopatches", "TREATMENT", 110, 121], ["immunological advantages", "TREATMENT", 140, 164], ["conventional needle delivery", "TREATMENT", 170, 198], ["Transdermal RouteMicroneedles", "TREATMENT", 199, 228], ["cutaneous", "ANATOMY", 20, 29]]], ["There are (i) solid microneedles for skin pretreatment to increase skin permeability, (ii) microneedles coated with drug that dissolves off in the skin, (iii) polymer microneedles that encapsulate drug and fully dissolve in the skin and (iv) hollow microneedles for drug infusion into the skin [40] .", [["skin", "ANATOMY", 37, 41], ["skin", "ANATOMY", 67, 71], ["skin", "ANATOMY", 147, 151], ["skin", "ANATOMY", 228, 232], ["skin", "ANATOMY", 289, 293], ["skin", "ORGAN", 37, 41], ["skin", "ORGAN", 67, 71], ["skin", "ORGAN", 147, 151], ["skin", "ORGAN", 228, 232], ["skin", "ORGAN", 289, 293], ["(i) solid microneedles", "TREATMENT", 10, 32], ["skin pretreatment", "TREATMENT", 37, 54], ["skin permeability, (ii) microneedles coated", "TREATMENT", 67, 110], ["drug", "TREATMENT", 116, 120], ["the skin, (iii) polymer microneedles", "TREATMENT", 143, 179], ["drug", "TREATMENT", 197, 201], ["the skin and (iv) hollow microneedles", "TREATMENT", 224, 261], ["drug infusion", "TREATMENT", 266, 279], ["skin", "ANATOMY", 37, 41], ["skin", "ANATOMY", 67, 71], ["permeability", "OBSERVATION", 72, 84], ["skin", "ANATOMY", 147, 151], ["skin", "ANATOMY", 228, 232], ["skin", "ANATOMY", 289, 293]]], ["Volunteers of clinical studies reported no pain and minimal sensation of these microneedle arrays, likely due to not enough length of these microneedles to stimulate nerves present in the deeper tissues [41] .Transdermal RouteMicroneedles have been employed successfully to vaccinate with diphtheria toxoid adjuvanted with cholera toxin and to increase delivery of a DNA vaccine against hepatitis B, recombinant anthrax vaccine, and live-attenuated Japanese encephalitis vaccine in animal models as well as rabies vaccine in human subjects [40] .", [["nerves", "ANATOMY", 166, 172], ["tissues", "ANATOMY", 195, 202], ["pain", "DISEASE", 43, 47], ["RouteMicroneedles", "CHEMICAL", 221, 238], ["diphtheria toxoid", "CHEMICAL", 289, 306], ["cholera toxin", "CHEMICAL", 323, 336], ["hepatitis B", "DISEASE", 387, 398], ["Japanese encephalitis", "DISEASE", 449, 470], ["nerves", "MULTI-TISSUE_STRUCTURE", 166, 172], ["tissues", "TISSUE", 195, 202], ["RouteMicroneedles", "SIMPLE_CHEMICAL", 221, 238], ["diphtheria toxoid", "ORGANISM", 289, 306], ["cholera toxin", "SIMPLE_CHEMICAL", 323, 336], ["DNA", "CELLULAR_COMPONENT", 367, 370], ["hepatitis B", "ORGANISM", 387, 398], ["recombinant anthrax", "ORGANISM", 400, 419], ["rabies", "ORGANISM", 507, 513], ["human", "ORGANISM", 525, 530], ["diphtheria toxoid", "SPECIES", 289, 306], ["human", "SPECIES", 525, 530], ["hepatitis B", "SPECIES", 387, 398], ["rabies", "SPECIES", 507, 513], ["human", "SPECIES", 525, 530], ["clinical studies", "TEST", 14, 30], ["pain", "PROBLEM", 43, 47], ["these microneedle arrays", "TREATMENT", 73, 97], ["these microneedles", "TREATMENT", 134, 152], ["Transdermal RouteMicroneedles", "TREATMENT", 209, 238], ["diphtheria toxoid adjuvanted", "TREATMENT", 289, 317], ["cholera toxin", "TREATMENT", 323, 336], ["a DNA vaccine", "TREATMENT", 365, 378], ["hepatitis B", "TREATMENT", 387, 398], ["recombinant anthrax vaccine", "TREATMENT", 400, 427], ["live-attenuated Japanese encephalitis vaccine", "TREATMENT", 433, 478], ["rabies vaccine", "TREATMENT", 507, 521], ["nerves", "ANATOMY", 166, 172], ["deeper tissues", "ANATOMY", 188, 202]]], ["Influenza vaccination with coated microneedles has shown complete protection against lethal viral infection after vaccination using H1N1 and H3N2 seasonal strains in mice [40] .", [["Influenza", "DISEASE", 0, 9], ["viral infection", "DISEASE", 92, 107], ["H3N2", "ORGANISM", 141, 145], ["mice", "ORGANISM", 166, 170], ["H3N2", "SPECIES", 141, 145], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 166, 170], ["Influenza vaccination", "TREATMENT", 0, 21], ["coated microneedles", "TREATMENT", 27, 46], ["lethal viral infection", "PROBLEM", 85, 107], ["vaccination", "TREATMENT", 114, 125], ["H1N1", "PROBLEM", 132, 136], ["H3N2 seasonal strains", "TREATMENT", 141, 162]]], ["Substantially improved immunity resulted following administration of Bacillus Calmette-Gu\u00e9rin (BCG) vaccine in guinea pigs using similar coatedmicroneedle devices [40] .", [["Bacillus Calmette-Gu\u00e9rin", "CHEMICAL", 69, 93], ["BCG", "CHEMICAL", 95, 98], ["Bacillus Calmette-Gu\u00e9rin", "ORGANISM", 69, 93], ["BCG", "ORGANISM", 95, 98], ["guinea pigs", "ORGANISM", 111, 122], ["guinea pigs", "SPECIES", 111, 122], ["Bacillus Calmette-Gu\u00e9rin", "SPECIES", 69, 93], ["guinea pigs", "SPECIES", 111, 122], ["Bacillus Calmette", "TREATMENT", 69, 86], ["Gu\u00e9rin (BCG) vaccine", "TREATMENT", 87, 107], ["similar coatedmicroneedle devices", "TREATMENT", 129, 162]]], ["The World Health officials are aiming to eliminate measles and such a microneedle patch can be the game changer [12] .", [["measles", "DISEASE", 51, 58], ["a microneedle patch", "TREATMENT", 68, 87]]], ["Study by Levin et al. and Behrens et al. confirmed the immunogenicity and safety of intradermal delivery of virosomal influenza vaccine and vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhea respectively in humans [42, 43] .Transdermal RouteThe 'Nanopatch' (NP) comprises arrays of densely packed projections with a defined geometry and distribution designed to physically target vaccines directly to thousands of epidermal and dermal antigen presenting cells [44] .", [["epidermal", "ANATOMY", 451, 460], ["dermal antigen presenting cells", "ANATOMY", 465, 496], ["diarrhea", "DISEASE", 219, 227], ["intradermal", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 95], ["virosomal influenza", "ORGANISM", 108, 127], ["Escherichia coli", "ORGANISM", 182, 198], ["travellers", "ORGANISM", 207, 217], ["humans", "ORGANISM", 244, 250], ["epidermal", "CELL", 451, 460], ["dermal antigen presenting cells", "CELL", 465, 496], ["epidermal and dermal antigen presenting cells", "CELL_TYPE", 451, 496], ["Escherichia coli", "SPECIES", 182, 198], ["humans", "SPECIES", 244, 250], ["Escherichia coli", "SPECIES", 182, 198], ["humans", "SPECIES", 244, 250], ["intradermal delivery", "TREATMENT", 84, 104], ["virosomal influenza vaccine", "TREATMENT", 108, 135], ["vaccine", "TREATMENT", 140, 147], ["labile toxin", "PROBLEM", 164, 176], ["Escherichia coli", "PROBLEM", 182, 198], ["travellers' diarrhea", "PROBLEM", 207, 227], ["Transdermal RouteThe 'Nanopatch' (NP) comprises arrays of densely packed projections", "TREATMENT", 261, 345], ["physically target vaccines", "TREATMENT", 399, 425], ["epidermal", "ANATOMY", 451, 460]]], ["These miniaturized arrays are smaller than standard needles used for vaccination and are also much smaller than current microneedle arrays.", [["These miniaturized arrays", "TREATMENT", 0, 25], ["standard needles", "TREATMENT", 43, 59], ["vaccination", "TREATMENT", 69, 80], ["current microneedle arrays", "TREATMENT", 112, 138], ["smaller", "OBSERVATION_MODIFIER", 30, 37], ["smaller", "OBSERVATION_MODIFIER", 99, 106]]], ["The NP immunization has been seen to be efficient using commercial available influenza vaccine antigen [45] , inactivated whole chikungunya virus vaccine and DNAdelivered attenuated West Nile virus vaccine [44] .OthersAnother mode of vaccine delivery known for more than 50 y is via jet injectors.", [["chikungunya virus", "DISEASE", 128, 145], ["whole", "ORGANISM", 122, 127], ["chikungunya virus", "ORGANISM", 128, 145], ["West Nile virus", "ORGANISM", 182, 197], ["chikungunya virus vaccine", "SPECIES", 128, 153], ["Nile virus vaccine", "SPECIES", 187, 205], ["chikungunya virus", "SPECIES", 128, 145], ["West Nile virus", "SPECIES", 182, 197], ["The NP immunization", "TREATMENT", 0, 19], ["commercial available influenza vaccine antigen", "TREATMENT", 56, 102], ["inactivated whole chikungunya virus vaccine", "TREATMENT", 110, 153], ["DNAdelivered attenuated West Nile virus vaccine", "TREATMENT", 158, 205], ["vaccine delivery", "TREATMENT", 234, 250]]], ["Jet injectors are needle-free devices that deliver a prescribed drug, vaccine, or compound intradermally, subcutaneously, or intramuscularly via high pressure produced by either a carbon-dioxide-filled or nitrogen-filled cartridge or a spring [12] .", [["intradermally", "ANATOMY", 91, 104], ["subcutaneously", "ANATOMY", 106, 120], ["intramuscularly", "ANATOMY", 125, 140], ["carbon-dioxide", "CHEMICAL", 180, 194], ["carbon-dioxide", "CHEMICAL", 180, 194], ["nitrogen", "CHEMICAL", 205, 213], ["carbon-dioxide", "SIMPLE_CHEMICAL", 180, 194], ["Jet injectors", "TREATMENT", 0, 13], ["needle-free devices", "TREATMENT", 18, 37], ["a prescribed drug, vaccine", "TREATMENT", 51, 77], ["a carbon-dioxide", "TREATMENT", 178, 194], ["nitrogen-filled cartridge", "TREATMENT", 205, 230], ["free devices", "OBSERVATION", 25, 37]]], ["Antigens delivered by jet injectors are dispersed more widely in the tissue because of high pressure of the fluid stream allowing for a larger contact volume between the vaccine antigen and immune cells.", [["tissue", "ANATOMY", 69, 75], ["fluid stream", "ANATOMY", 108, 120], ["immune cells", "ANATOMY", 190, 202], ["tissue", "TISSUE", 69, 75], ["immune cells", "CELL", 190, 202], ["immune cells", "CELL_TYPE", 190, 202], ["jet injectors", "TREATMENT", 22, 35], ["high pressure of the fluid stream", "PROBLEM", 87, 120], ["a larger contact volume", "PROBLEM", 134, 157], ["the vaccine antigen", "TREATMENT", 166, 185], ["high pressure", "OBSERVATION", 87, 100], ["fluid stream", "OBSERVATION", 108, 120], ["larger", "OBSERVATION_MODIFIER", 136, 142], ["contact volume", "OBSERVATION", 143, 157], ["immune cells", "OBSERVATION", 190, 202]]], ["Several studies have shown that it elicits higher antibody titers and seroconversion rates than traditional needle and syringe [12] .", [["Several studies", "TEST", 0, 15], ["higher antibody titers", "PROBLEM", 43, 65], ["seroconversion rates than traditional needle and syringe", "TREATMENT", 70, 126]]], ["Earlier, multiuse-nozzle jet injectors were used that delivered vaccine through the same fluid stream and nozzle to multiple patients.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["multiuse-nozzle jet injectors", "TREATMENT", 9, 38], ["the same fluid stream", "TREATMENT", 80, 101], ["nozzle", "TREATMENT", 106, 112]]], ["It was commonly used for vaccinating military personnel, and for other mass immunization campaigns.", [["other mass immunization campaigns", "TREATMENT", 65, 98]]], ["However, when the year 1985 witnessed an outbreak of hepatitis B infection due to contamination of the jet injector by body fluids, health authorities, including the Department of Defense and the World Health Organization, discontinued the use of multiuse-nozzle jet injectors.", [["body", "ANATOMY", 119, 123], ["hepatitis B infection", "DISEASE", 53, 74], ["hepatitis B", "ORGANISM", 53, 64], ["body", "ORGANISM_SUBDIVISION", 119, 123], ["hepatitis B", "SPECIES", 53, 64], ["hepatitis B infection", "PROBLEM", 53, 74], ["the jet injector", "TREATMENT", 99, 115], ["multiuse-nozzle jet injectors", "TREATMENT", 247, 276], ["hepatitis", "OBSERVATION", 53, 62], ["infection", "OBSERVATION", 65, 74]]], ["Now-a-days disposable-cartridge jet injectors, where fluid stream is delivered within a disposable vaccine cartridge and nozzle, with a new cartridge and nozzle for each patient and no splash back of blood are under development.", [["blood", "ANATOMY", 200, 205], ["patient", "ORGANISM", 170, 177], ["blood", "ORGANISM_SUBSTANCE", 200, 205], ["patient", "SPECIES", 170, 177], ["disposable-cartridge jet injectors", "TREATMENT", 11, 45], ["fluid stream", "PROBLEM", 53, 65], ["a disposable vaccine cartridge", "TREATMENT", 86, 116], ["nozzle", "TREATMENT", 121, 127], ["a new cartridge and nozzle", "TREATMENT", 134, 160], ["splash back of blood", "PROBLEM", 185, 205], ["fluid stream", "OBSERVATION", 53, 65]]], ["Biovalve's Mini-Ject, Bioject and Powderject are few developing technologies for vaccination.", [["Biovalve", "TEST", 0, 8], ["vaccination", "TREATMENT", 81, 92]]], ["Trials are underway to deliver Inactivated polio vaccine, Measles-Mumps-Rubella vaccine, Yellow fever vaccine, DTP-Hib-hep B vaccine, BCG vaccine and rabies vaccine by jet injection technology [12] .OthersOn August 15, 2014, the U.S. Food and Drug Administration (FDA) approved use of one jet injector device (the PharmaJetStratis) for delivery of one particular flu vaccine in individuals 18 through 64 y of age [46] .", [["Measles-Mumps-Rubella", "DISEASE", 58, 79], ["Yellow fever", "DISEASE", 89, 101], ["DTP-Hib-hep B", "CHEMICAL", 111, 124], ["Measles-Mumps-Rubella", "ORGANISM", 58, 79], ["Yellow fever", "ORGANISM", 89, 101], ["hep B", "ORGANISM", 119, 124], ["rabies", "ORGANISM", 150, 156], ["Yellow fever vaccine", "SPECIES", 89, 109], ["rabies", "SPECIES", 150, 156], ["Inactivated polio vaccine", "TREATMENT", 31, 56], ["Measles", "TREATMENT", 58, 65], ["Mumps", "PROBLEM", 66, 71], ["Rubella vaccine", "TREATMENT", 72, 87], ["Yellow fever vaccine", "TREATMENT", 89, 109], ["DTP", "TREATMENT", 111, 114], ["Hib", "TREATMENT", 115, 118], ["hep B vaccine", "TREATMENT", 119, 132], ["BCG vaccine", "TREATMENT", 134, 145], ["rabies vaccine", "TREATMENT", 150, 164], ["Drug Administration", "TREATMENT", 243, 262], ["one jet injector device", "TREATMENT", 285, 308], ["the PharmaJetStratis)", "TREATMENT", 310, 331], ["delivery", "TREATMENT", 336, 344], ["one particular flu vaccine", "TREATMENT", 348, 374]]], ["However postvaccination, patients have reported tenderness, swelling, pain, redness, itching and bruising at the site of vaccination.OthersEpidermal powder immunization (EPI) is similar to liquid jet injection, but here dried-powder particles of vaccine, rather than liquid, are injected into the skin at supersonic speed.", [["Epidermal powder", "ANATOMY", 139, 155], ["skin", "ANATOMY", 297, 301], ["tenderness", "DISEASE", 48, 58], ["swelling", "DISEASE", 60, 68], ["pain", "DISEASE", 70, 74], ["redness", "DISEASE", 76, 83], ["itching", "DISEASE", 85, 92], ["bruising", "DISEASE", 97, 105], ["patients", "ORGANISM", 25, 33], ["skin", "ORGAN", 297, 301], ["patients", "SPECIES", 25, 33], ["tenderness", "PROBLEM", 48, 58], ["swelling", "PROBLEM", 60, 68], ["pain", "PROBLEM", 70, 74], ["redness", "PROBLEM", 76, 83], ["itching", "PROBLEM", 85, 92], ["bruising", "PROBLEM", 97, 105], ["vaccination", "TREATMENT", 121, 132], ["Epidermal powder immunization (EPI)", "TREATMENT", 139, 174], ["liquid jet injection", "TREATMENT", 189, 209], ["dried-powder particles of vaccine", "TREATMENT", 220, 253], ["tenderness", "OBSERVATION", 48, 58], ["swelling", "OBSERVATION", 60, 68], ["redness", "OBSERVATION", 76, 83], ["itching", "OBSERVATION", 85, 92], ["bruising", "OBSERVATION", 97, 105], ["skin", "ANATOMY", 297, 301]]], ["Another similar concept is particle-mediated epidermal delivery (PMED) in which DNA vaccine coated on gold microparticles are shot into the skin.", [["epidermal", "ANATOMY", 45, 54], ["skin", "ANATOMY", 140, 144], ["epidermal", "MULTI-TISSUE_STRUCTURE", 45, 54], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["gold microparticles", "SIMPLE_CHEMICAL", 102, 121], ["skin", "ORGAN", 140, 144], ["particle-mediated epidermal delivery (PMED)", "TREATMENT", 27, 70], ["DNA vaccine coated on gold microparticles", "TREATMENT", 80, 121], ["particle", "OBSERVATION_MODIFIER", 27, 35], ["skin", "ANATOMY", 140, 144]]], ["Clinical studies of PMED immunization are promising but immunogenic responses were low compared to conventional vaccination methods [47] .OthersAs a whole, jet injection offers multiple benefits.", [["PMED", "CHEMICAL", 20, 24], ["Clinical studies", "TEST", 0, 16], ["PMED immunization", "TREATMENT", 20, 37], ["immunogenic responses", "PROBLEM", 56, 77], ["a whole, jet injection", "TREATMENT", 147, 169]]], ["They are less painful, thus improve compliance, reduce risks of needlestick injuries and cross-contamination, eliminate the need for Bsharps^disposal, and ensure reliable, reproducible, and accurate delivery of medication with minimal training.ConclusionsThe future of immunization depends on the how successfully we are able develop methods for vaccination that are simpler to administer, do not need cold chain for their maintenance, provide long-lasting immune response with minimal sideeffects and, most importantly in a child-friendly way.", [["injuries", "DISEASE", 76, 84], ["less painful", "PROBLEM", 9, 21], ["needlestick injuries", "PROBLEM", 64, 84], ["cross-contamination", "PROBLEM", 89, 108], ["Bsharps^disposal", "TREATMENT", 133, 149], ["medication", "TREATMENT", 211, 221], ["minimal training", "TREATMENT", 227, 243], ["immunization", "TREATMENT", 269, 281], ["vaccination", "TREATMENT", 346, 357], ["less", "OBSERVATION_MODIFIER", 9, 13], ["painful", "OBSERVATION_MODIFIER", 14, 21]]], ["Needle-free and painless vaccination will ensure improved safety for the vaccinator, vaccinee, and community; improved compliance with immunization schedules; reduced anxiety and pain related to injection; easier and speedier vaccine delivery with reduced cost of production, storage and transportation.", [["anxiety", "DISEASE", 167, 174], ["pain", "DISEASE", 179, 183], ["Needle-free and painless vaccination", "TREATMENT", 0, 36], ["the vaccinator, vaccinee", "TREATMENT", 69, 93], ["immunization schedules", "TREATMENT", 135, 157], ["reduced anxiety", "PROBLEM", 159, 174], ["pain", "PROBLEM", 179, 183], ["injection", "TREATMENT", 195, 204], ["easier and speedier vaccine delivery", "TREATMENT", 206, 242]]], ["This will mean less healthcare training needed to give vaccines, especially in mass vaccinations on national or subnational immunization days (campaigns), natural pandemics, and bioterrorism emergencies.ConclusionsContributions The main manuscript was prepared by NG and it was revised by critical outputs from AA.", [["NG", "CHEMICAL", 264, 266], ["AA", "CHEMICAL", 311, 313], ["healthcare training", "TREATMENT", 20, 39], ["vaccines", "TREATMENT", 55, 63], ["main", "OBSERVATION_MODIFIER", 232, 236]]], ["AA will act as guarantor for the paper.", [["AA", "CHEMICAL", 0, 2]]]], "PMC7150222": [["IntroductionIn dynamic combinatorial chemistry (DCC), molecular building blocks are reversibly formed via covalent or noncovalent bonds.", [["IntroductionIn dynamic combinatorial chemistry (DCC)", "TREATMENT", 0, 52], ["molecular building blocks", "TREATMENT", 54, 79], ["noncovalent bonds", "OBSERVATION", 118, 135]]], ["With only a few building blocks, a relatively large number of reversible products can be generated, forming a dynamic combinatorial library (DCL).", [["few", "OBSERVATION_MODIFIER", 12, 15], ["relatively", "OBSERVATION_MODIFIER", 35, 45], ["large", "OBSERVATION_MODIFIER", 46, 51], ["reversible products", "OBSERVATION", 62, 81]]], ["Given that the reaction between the building blocks is reversible, the members of the DCL continuously exchange to eventually reach a thermodynamic equilibrium.", [["DCL", "GENE_OR_GENE_PRODUCT", 86, 89], ["DCL", "PROTEIN", 86, 89], ["the reaction", "PROBLEM", 11, 23], ["the DCL continuously exchange", "TREATMENT", 82, 111], ["reversible", "OBSERVATION_MODIFIER", 55, 65], ["thermodynamic equilibrium", "OBSERVATION", 134, 159]]], ["When an external stimulus, such as a protein target, is introduced, the dynamic system re-equilibrates upon selection and non-covalent binding of the library members with the strongest affinity for the target.", [["an external stimulus", "TEST", 5, 25], ["a protein target", "TEST", 35, 51], ["external stimulus", "OBSERVATION", 8, 25]]], ["Examples of these intermolecular interactions are van der Waals forces, \u03c0\u2013\u03c0- stacking, cation\u2013\u03c0, dipole\u2013dipole, hydrogen-bonding, and ion\u2013dipole interactions, as well as ion pairing.", [["hydrogen", "CHEMICAL", 112, 120], ["cation\u2013\u03c0", "SIMPLE_CHEMICAL", 87, 95], ["dipole\u2013dipole", "SIMPLE_CHEMICAL", 97, 110], ["ion\u2013dipole", "SIMPLE_CHEMICAL", 134, 144], ["dipole\u2013dipole", "TREATMENT", 97, 110], ["hydrogen-bonding", "TREATMENT", 112, 128]]], ["Ultimately, the best binders of the library are amplified at the expense of library members displaying a lower affinity for the target (Fig. 1).", [["a lower affinity", "PROBLEM", 103, 119]]], ["Identification of the best binders circumvents the need for synthesis, purification, and characterization of every individual library member.", [["synthesis, purification", "TREATMENT", 60, 83]]], ["However, up to date, it remains very difficult to analyze DCLs of large size, preventing DCC from becoming a more widely used tool in drug development.1,2 In this article, analytical methods used in protein-templated DCC will be described.", [["1,2", "CHEMICAL", 151, 154], ["DCC", "GENE_OR_GENE_PRODUCT", 217, 220], ["DCC", "PROTEIN", 217, 220], ["large size", "PROBLEM", 66, 76], ["analytical methods", "TREATMENT", 172, 190], ["protein-templated DCC", "TREATMENT", 199, 220], ["large", "OBSERVATION_MODIFIER", 66, 71], ["size", "OBSERVATION_MODIFIER", 72, 76]]]], "PMC7042184": [["Novel coronavirus infection special intensive care teamWe set up a special emergency multi-disciplinary intensive care team to discuss the problems that we might encounter and countermeasures.", [["coronavirus infection", "DISEASE", 6, 27], ["Novel coronavirus infection", "PROBLEM", 0, 27], ["coronavirus", "OBSERVATION_MODIFIER", 6, 17], ["infection", "OBSERVATION", 18, 27]]], ["Team members include intensive care unit (ICU) physician, infectious disease physician, nurse, respiratory therapist, nosocomial infection control expert, and administrative staff.", [["infectious disease", "DISEASE", 58, 76], ["nosocomial infection", "DISEASE", 118, 138], ["nosocomial infection control", "TREATMENT", 118, 146], ["respiratory", "ANATOMY", 95, 106]]], ["We first evaluated the isolation conditions and the capacity of our department to admit a larger number of patients.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115]]], ["Third, we assigned special work such as patient screening, consultation, and transfer to designated staff to minimize the number of health workers who had contact with patients with nCoV infection.Bed and medical equipment preparationWCH is a teaching hospital with 4300 total beds and 8 ICUs of total 206 ICU beds.", [["nCoV infection", "DISEASE", 182, 196], ["patient", "ORGANISM", 40, 47], ["patients", "ORGANISM", 168, 176], ["patient", "SPECIES", 40, 47], ["patients", "SPECIES", 168, 176], ["patient screening", "TEST", 40, 57], ["nCoV infection", "PROBLEM", 182, 196], ["infection", "OBSERVATION", 187, 196]]], ["Under normal conditions, the ICU bed usage is always above 90%.", [["the ICU bed usage", "TREATMENT", 25, 42], ["normal conditions", "OBSERVATION", 6, 23]]], ["It was not appropriate to treat 2019-nCoV-infected patients in the central area because the large stream of people would have a negative impact on infection control measures to curb the spread of the infection.", [["nCoV-infected", "DISEASE", 37, 50], ["infection", "DISEASE", 147, 156], ["infection", "DISEASE", 200, 209], ["patients", "ORGANISM", 51, 59], ["people", "ORGANISM", 108, 114], ["patients", "SPECIES", 51, 59], ["people", "SPECIES", 108, 114], ["nCoV", "TREATMENT", 37, 41], ["infection control measures", "TREATMENT", 147, 173], ["the infection", "PROBLEM", 196, 209], ["infected", "OBSERVATION", 42, 50], ["central", "ANATOMY_MODIFIER", 67, 74], ["area", "ANATOMY", 75, 79], ["large", "OBSERVATION_MODIFIER", 92, 97], ["stream", "OBSERVATION_MODIFIER", 98, 104], ["infection", "OBSERVATION", 147, 156], ["infection", "OBSERVATION", 200, 209]]], ["The hospital authorities decided to vacate 402 beds belonging to the Center of Infectious Disease and the adjacent Fifth Inpatient Building so that both are separated from the rest of the inpatient buildings in WCH (Supplementary Figure 1).", [["Infectious Disease", "DISEASE", 79, 97], ["Infectious", "OBSERVATION", 79, 89]]], ["Based on the initial data [1, 2] and taking into consideration the surge of critically ill patients, we plan to equip 50 ICU beds initially and adjust on the number of patients, as necessary.", [["critically ill", "DISEASE", 76, 90], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 168, 176]]], ["We made a list of requirements for other special medical equipment, such as ventilators, bronchoscopes, hemodialysis machines, ultrasound machines, standard personal protective equipment (PPE), and sterilizing equipment.", [["special medical equipment", "TREATMENT", 41, 66], ["ventilators", "TREATMENT", 76, 87], ["bronchoscopes", "TREATMENT", 89, 102], ["hemodialysis machines", "TREATMENT", 104, 125], ["ultrasound machines", "TREATMENT", 127, 146], ["standard personal protective equipment (PPE)", "TREATMENT", 148, 192], ["sterilizing equipment", "TREATMENT", 198, 219]]], ["During this epidemic period, a large amount of certified PPE, including medical masks, goggles, face shields, and waterproof isolation gowns, is required.", [["certified PPE", "TREATMENT", 47, 60], ["medical masks", "TREATMENT", 72, 85], ["goggles, face shields", "TREATMENT", 87, 108], ["waterproof isolation gowns", "TREATMENT", 114, 140], ["large", "OBSERVATION_MODIFIER", 31, 36], ["amount", "OBSERVATION_MODIFIER", 37, 43], ["certified PPE", "OBSERVATION", 47, 60]]], ["Manufactures of the items on the requirement list were contracted and we drew up an advertisement to the society calling for donations to ensure sufficient supplies.Education and training of staffIt is very important to make all staff aware of the public health significance of the epidemic, and of potential challenges in achieving disease control.", [["achieving disease control", "TREATMENT", 323, 348]]], ["Strict isolation and protection measures are a top priority.", [["Strict isolation and protection measures", "TREATMENT", 0, 40], ["a top priority", "TREATMENT", 45, 59], ["isolation", "OBSERVATION", 7, 16]]], ["Training content includes hand and respiratory hygiene, use of PPE, safe waste management, environmental cleaning, and sterilization of patient-care equipment [6].", [["hand", "ANATOMY", 26, 30], ["respiratory", "ANATOMY", 35, 46], ["hand", "ORGANISM_SUBDIVISION", 26, 30], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["hand and respiratory hygiene", "TREATMENT", 26, 54], ["PPE", "TREATMENT", 63, 66], ["safe waste management", "TREATMENT", 68, 89], ["environmental cleaning", "TREATMENT", 91, 113], ["respiratory", "ANATOMY", 35, 46]]], ["We educate and train staff by means of presentations, short videos, WeChat, and supervision to ensure that staff are following the correct procedures.Protection of medical staffA special access to patients was set up and a boundary between the ward in which the nCoV patients are being treated and the office and living area of medical staff was established.", [["patients", "ORGANISM", 197, 205], ["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 197, 205], ["patients", "SPECIES", 267, 275]]], ["The aim was to minimize the number of medical staff that have contact with a patient at any time, including during daily care, treatment, and transfer; minimize the use of high transmission-risk procedures such as bronchoscopy, manual ventilation, non-invasive ventilation, and tracheotomy.", [["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["treatment", "TREATMENT", 127, 136], ["high transmission-risk procedures", "TREATMENT", 172, 205], ["bronchoscopy", "TEST", 214, 226], ["manual ventilation", "TREATMENT", 228, 246], ["non-invasive ventilation", "TREATMENT", 248, 272], ["tracheotomy", "TREATMENT", 278, 289], ["tracheotomy", "OBSERVATION", 278, 289]]], ["We use airborne precautions if these operations are necessary.", [["airborne precautions", "TREATMENT", 7, 27], ["these operations", "TREATMENT", 31, 47]]], ["Diagnostic imaging procedures such as X-ray and ultrasound at the bedside are prioritized, restricting computed tomography (CT) scans, because they cannot be performed at the bedside.Early case recognition and classification of disease severityA physiological parameter-based warning score is used to facilitate early recognition of patients with severe infection and admission decisions according to the severity classification.", [["infection", "DISEASE", 354, 363], ["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 333, 341], ["Diagnostic imaging procedures", "TEST", 0, 29], ["X-ray", "TEST", 38, 43], ["ultrasound", "TEST", 48, 58], ["computed tomography (CT) scans", "TEST", 103, 133], ["disease severity", "PROBLEM", 228, 244], ["A physiological parameter", "TEST", 244, 269], ["severe infection", "PROBLEM", 347, 363], ["severe", "OBSERVATION_MODIFIER", 347, 353], ["infection", "OBSERVATION", 354, 363]]], ["The score is a modified version of the National Early Warning Score (NEWS) with age \u2265 65 years added as an independent risk factor based on recent reports [7, 8] (Fig. 1).Early case recognition and classification of disease severityPatients are divided into four risk categories based on the score: low, median, high, and exceptional.", [["Patients", "ORGANISM", 232, 240], ["Patients", "SPECIES", 232, 240], ["disease severity", "PROBLEM", 216, 232], ["the score", "TEST", 288, 297], ["disease", "OBSERVATION", 216, 223]]], ["A specially assigned physician or the special critical care team decides which patients need to be treated in the ICU, taking into consideration the disease severity, opportunity to benefit, and sources of support (Fig. 1).Strict restriction of patient contactAll staff are required to report any history of exposure, respiratory symptoms, and temperature before entering the building in which the nCoV patients are treated.", [["respiratory", "ANATOMY", 318, 329], ["respiratory symptoms", "DISEASE", 318, 338], ["patients", "ORGANISM", 79, 87], ["patient", "ORGANISM", 245, 252], ["patients", "ORGANISM", 403, 411], ["patients", "SPECIES", 79, 87], ["patient", "SPECIES", 245, 252], ["patients", "SPECIES", 403, 411], ["the disease severity", "PROBLEM", 145, 165], ["respiratory symptoms", "PROBLEM", 318, 338], ["respiratory", "ANATOMY", 318, 329]]], ["Everyone must wear masks, isolation suits, and wash hands if need to be in the building.", [["masks", "TREATMENT", 19, 24], ["isolation suits", "TREATMENT", 26, 41]]], ["Family members and non-essential medical staff are strictly forbidden from entering the nCoV ward.ResearchAs nCoV infection is a novel disease, knowledge about it is limited [9, 10], especially regarding the management of critically ill patients.", [["infection", "DISEASE", 114, 123], ["critically ill", "DISEASE", 222, 236], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245], ["nCoV infection", "PROBLEM", 109, 123], ["a novel disease", "PROBLEM", 127, 142], ["infection", "OBSERVATION", 114, 123]]], ["We designed a case report form to collect clinical data, proceed with the ethics committee approval of research protocols, and contact with the laboratory that is qualified to conduct research on highly infectious organisms.ResearchIn conclusion, the 2019-nCoV epidemic is a threat, not only to China, but also to global health.", [["research protocols", "TREATMENT", 103, 121], ["highly infectious organisms", "PROBLEM", 196, 223], ["infectious", "OBSERVATION", 203, 213]]], ["As ICU physicians, our focus is on the management of the most severe patients.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["the management", "TREATMENT", 35, 49]]], ["We are unable to predict how many critically ill patients we will receive but are doing the best that we can to be prepared and to work together to overcome the epidemic.", [["critically ill", "DISEASE", 34, 48], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]]], "0d2fa0a93cb53d3404161450e41703d59d81b063": [["IntroductionAgile and hybrid project environments are increasingly becoming the norm within and even beyond the IT industry, and organizations increasingly start scaling Agile 1 beyond IT project teams [1] .", [["IntroductionAgile", "TREATMENT", 0, 17], ["hybrid project environments", "TREATMENT", 22, 49]]], ["There are numerous methodologies for Agile project management and scaling Agile, which claim to embody the Agile Manifesto's principles and values (e.g., Scrum, SAFe, Disciplined Agile etc.).", [["Agile project management", "TREATMENT", 37, 61]]], ["Studies show that embracing Agile leads to generally satisfied individuals and companies, but there are also a variety of obstacles that teams and organizations may face [2] [3] [4] .IntroductionIn a more general perspective, \"most management practices create their own nemesis\" [5 p.", [["[2] [3] [4]", "SIMPLE_CHEMICAL", 170, 181], ["Studies", "TEST", 0, 7]]], ["491] , and Agile is no exception.", [["no exception", "UNCERTAINTY", 20, 32]]], ["As one role of research is to critique the status quo [6] , we do so in this paper for the Agile context by outlining areas of tension which result in paradoxes that Agile teams and organizations running Agile teams may have to navigate.", [["tension", "PROBLEM", 127, 134], ["tension", "OBSERVATION", 127, 134]]], ["72).IntroductionBy providing this critique, we problematize [8] Agile beyond a functionalist view that is centered on performance or effectiveness.", [["a functionalist view", "TEST", 77, 97]]], ["We see these paradoxes as a starting point for more focused theoretical and empirical investigations how Agile teams and organizations encounter, experience, and cope with these Agile paradoxes.", [["empirical investigations", "TEST", 76, 100]]], ["As one key tenet of Agile organizations is continuous learning and change, such in-depth treatments of Agile paradoxes can therefore also contribute to organizational learning and change efforts in practice.IntroductionOur analysis draws on a critical reading of selected Agile methodologies and techniques, the Agile research literature, as well as a critical assessment of Agile environments that the authors are familiar with (see Sect.", [["Agile paradoxes", "TREATMENT", 103, 118], ["organizational learning", "TREATMENT", 152, 175], ["IntroductionOur analysis", "TEST", 207, 231], ["a critical assessment", "TEST", 350, 371]]], ["Note that while there is a quite comprehensive dataset that informed the authors' other research in Agile organizational contexts, there was no specific data analysis conducted for this paper to inform our initial problematization of Agile paradoxes.", [["specific data analysis", "TEST", 144, 166]]], ["We then start discussing sources for agile paradoxes on the levels of the Agile team as well as on the organizational level for those organizations who scaled Agile beyond individual teams.Empirical BackgroundBoth authors are involved in a large-scale cross-industry and cross-country research program on Agile organizational transformation and have collected extensive data across two phases.", [["agile paradoxes", "PROBLEM", 37, 52], ["Agile organizational transformation", "PROBLEM", 305, 340]]], ["The participants had two essential criteria to fulfill: 1) their organization is undergoing a transformation towards organizational agility, and 2) the participants hold a position with in-depth insights on the overall (agile) organizational system.", [["participants", "SPECIES", 4, 16], ["participants", "SPECIES", 152, 164]]], ["Each interview session lasted 45-75 min and was audio-recorded and transcribed.Empirical BackgroundAll gathered data has been qualitatively analyzed to inform research on the implications of Agile for topics such as portfolio management [10] , enterprise architecture [11] , business/IT alignment [12] , and IT governance (currently under review).", [["portfolio management", "TREATMENT", 216, 236]]], ["Beyond these specific topics, however, the authors also observed more general patterns of a paradoxical nature in the Agile organizational contexts the interview and focus group participants gave insight into, and likewise in the (Scaling) Agile frameworks that the interviewees referred to.", [["participants", "SPECIES", 178, 190]]], ["Due to space restrictions in this short paper, we are only able to outline and problematize each paradox on a rather general level.Empirical Background3 Sources for Agile Paradoxes on the Team LevelBeing Agile Versus Doing AgileThe different aspects of Agile such as values, principles, methodologies, or techniques allow us to distinguish between teams that are 'being Agile' (i.e., embrace Agile principles and values in an Agile mind-set and truly focus on delivering customer value while learning continuously) and 'doing Agile' (i.e. adopt an Agile methodology or a set of Agile techniques and simply follow them).", [["Agile Paradoxes", "PROBLEM", 165, 180], ["Agile techniques", "TREATMENT", 578, 594], ["space restrictions", "OBSERVATION", 7, 25]]], ["Especially in volatile environments or in environments where an Agile methodology or framework forms the cornerstone of the Agile transformation, there may be a permanent paradoxical tension between 'doing Agile' and 'being Agile' for Agile teams.Experience Versus 'Appetite' for Change and FlexibilityAgile environments are built around the assumption that information completeness is never achieved due to ever-changing environments and customer needs.", [["a permanent paradoxical tension", "PROBLEM", 159, 190], ["volatile environments", "OBSERVATION", 14, 35], ["paradoxical tension", "OBSERVATION", 171, 190]]], ["However, a high amount of team members' experience in particular may also be a source for a paradox.", [["high", "OBSERVATION_MODIFIER", 11, 15], ["amount", "OBSERVATION_MODIFIER", 16, 22]]], ["Sometimes, a radical change to the way of working or the deliverable may be what the situation or the market requires, and extant experiences may be source for resistance or inertia regarding those changes.", [["a radical change", "PROBLEM", 11, 27], ["resistance", "PROBLEM", 160, 170], ["inertia regarding those changes", "PROBLEM", 174, 205], ["radical", "OBSERVATION", 13, 20]]], ["The paradox here is therefore that an increase in individual and collective experience may lead to a decreased 'appetite' for future change and therefore to less flexibility for a team.Exploration Versus ExploitationAgile teams are also characterized by a high level of self-organization and decisionmaking autonomy.", [["a decreased 'appetite'", "PROBLEM", 99, 121], ["Exploration", "TEST", 185, 196], ["increase", "OBSERVATION_MODIFIER", 38, 46]]], ["In the former case, a paradox arises out of the tension between the requirements of getting work done and continuously sharpening (and potentially re-learning) one'smetaphorical and literaltools.", [["smetaphorical", "CANCER", 164, 177], ["literaltools", "TREATMENT", 182, 194]]], ["Autonomy over one's artefact in the latter case could lead to a similar paradoxical scenario of the well-researched tension between exploration vs. exploitation [20, 21] .", [["exploration", "TEST", 132, 143]]], ["However, there are two general archetypes how these roles could be set up (or choose by themselves) to fulfill their task: Agile coaches and Scrum Masters could either direct a team's development according to what they perceive as best for the team (to be an 'Agile leader' or even an 'Agile police', so to speak), or could nurture the teams instead (i.e. 'help the people to help themselves') and let any changes to a team's way of working emerge from within the team.", [["people", "ORGANISM", 366, 372], ["people", "SPECIES", 366, 372]]], ["Either way, Scrum masters and Agile coaches could even oppose or counteract good Agile practicesperhaps just subconsciouslyin order to continuously create their own work in order to be kept employed or contracted and make themselves seemingly indispensable.", [["Agile coaches", "TREATMENT", 30, 43]]], ["The underlying paradox here is the one of balancing team autonomy with external directions with respect to changes to the team's way of working.Starting/Realizing the Agile (Self-)transformation: 'Big Bang' Versus EmergenceWhen aiming to introduce Agile on a larger scale, organizations have to choose an approach that lies somewhere between an initial 'big bang' top-down transformation towards Agile or an incremental, iterative, and emergent approach where different parts of the organizations can choose whether and how they adopt Agile [23, 24] .", [["a larger scale", "TREATMENT", 257, 271], ["an approach", "TREATMENT", 302, 313], ["emergent approach", "TREATMENT", 436, 453], ["paradox", "OBSERVATION", 15, 22]]], ["For instance, in one situation a common way of working across several Agile teams or units may be more effective to successfully transform (parts of) the organization, whereas in another situation selftaught bottom-up experimentation with Agile techniques and tools may be the more effective approachparticularly when considering how to set the stage for 'being Agile' in a longer-term and sustained perspective.", [["Agile techniques", "TREATMENT", 239, 255]]], ["As Agile implies a high degree of team autonomy instead of having top-down pre-planned decisions, a 'big bang Agile introduction' is therefore paradoxical in itself.", [["a 'big bang Agile introduction", "TREATMENT", 98, 128], ["high degree", "OBSERVATION_MODIFIER", 19, 30], ["paradoxical", "OBSERVATION", 143, 154]]], ["The danger of mixed messages during an Agile transformation lies in a regression to a directive (i.e. non-autonomous) way of working and organizational culture, and also would constrain the Agile units' autonomy to selftransform in the future.", [["an Agile transformation", "PROBLEM", 36, 59], ["organizational culture", "TEST", 137, 159], ["the Agile units' autonomy", "TREATMENT", 186, 211]]], ["Simultaneously, unfettered team autonomy right from the start could lead to the danger of an aimless or quickly stalling transformation process.Directing Teams Versus Team AutonomyThe tension between directing and simultaneously sustaining autonomous Agile teams may not only occur during the initial Agile transformation but may stay with organizations throughout their entire Agile journey.", [["an aimless", "PROBLEM", 90, 100], ["quickly stalling transformation process", "PROBLEM", 104, 143], ["right", "ANATOMY_MODIFIER", 41, 46], ["stalling transformation", "OBSERVATION", 112, 135], ["tension", "OBSERVATION", 184, 191], ["autonomous Agile", "OBSERVATION", 240, 256]]], ["The nature of the resulting paradox, however, shifts to issues related to focus, resources, effectiveness, and efficiency.", [["paradox", "OBSERVATION", 28, 35]]], ["While each team may know their product's customers best, an organization's top management may wish to change or retire some products.", [["an organization's top management", "TREATMENT", 57, 89]]], ["In this situation, the tension arises whether a team should be in charge of a changed purpose or even its own dissolution, or whether an organization wants to override its teams' autonomy in these cases.", [["tension", "OBSERVATION", 23, 30]]], ["All these aspects are manifestations of a systemic contradiction of having autonomous teams within a coherent business organization.", [["systemic", "OBSERVATION_MODIFIER", 42, 50]]], ["In a nutshell, any decision above the team level may ultimately undermine the teams' perceived autonomy.Team Identity and Purpose Versus the Need for Radical Business ChangeWhen an Agile team in a Scaled Agile environment is made responsible for (a) particular product(s)/service(s)/area(s), it achieves its sustained focus through this purpose.", [["Radical Business", "TREATMENT", 150, 166]]], ["However, being responsible for a specific product or service for quite a long period may lead to a 'blindness' and attachment of teams to their built artefact.", [["blindness", "DISEASE", 100, 109], ["a 'blindness'", "PROBLEM", 97, 110]]], ["Consequently, a team may add unnecessary bells and whistles to 'their' artefact to justify the product's as well as the team's continued existence and resourcing in comparison to other teams.", [["unnecessary bells", "TREATMENT", 29, 46]]], ["A team may also become protective of 'their' product or service (area) instead of recognizing the need for a radical change or its retirement, in order to fulfill and surpass changed customer needs and support the organization in thriving in the changing business environment.", [["a radical change", "TREATMENT", 107, 123]]], ["A team's purpose may therefore become a selfreferential part of its identity so that strong repressions of or reactions against a radical change to the purpose occur, with the unanticipated consequence of limiting the effective team agility to self-transform when necessary.", [["reactions", "PROBLEM", 110, 119], ["a radical change", "PROBLEM", 128, 144]]], ["The paradox here therefore is that the same mechanisms that keep an Agile team together and effective may also hinder its ability to detect the best time and ways to re-invent themselves for their best possible contribution to organizational value.Discussion, Conclusion, OutlookIn this paper, we identified and briefly discussed several potential paradoxes in Agile contexts.", [["organizational value", "TEST", 227, 247]]], ["In fact, to harness the true potential of Agile transformations organizations may need to become adept at continuously confronting these paradoxes and utilizing their forces in a constructive and not a destructive way for their ongoing selftransformation.", [["Agile transformations organizations", "PROBLEM", 42, 77], ["their ongoing selftransformation", "PROBLEM", 222, 254], ["Agile transformations", "OBSERVATION", 42, 63]]], ["Some of the underlying tensionssuch as the exploration vs. exploitation oneare already well known in the literature [20, 29] .", [["the underlying tensionssuch", "PROBLEM", 8, 35], ["the exploration", "TEST", 39, 54]]], ["Otherssuch as the tensions around Agile team autonomymay be specific for Agile environments and transformations.", [["Agile environments", "PROBLEM", 73, 91]]], ["We therefore encourage empirical validation and extension of our findings, as the paradoxes in this paper are limited by being based on general insights from IT organizational roles within two countries.", [["empirical validation", "TEST", 23, 43]]], ["Thus, we also advocate for analyzing tensions perceived by the business side in order to capture a truly comprehensive perspective on the paradoxes.", [["analyzing tensions", "TREATMENT", 27, 45]]]], "PMC3532833": [["Study Population and Procedures ::: MATERIALS AND METHODSForty-nine healthy subjects were enrolled in 2 age groups (18\u201332 years and \u226560 years) between March and October 2010.", [["subjects", "ORGANISM", 76, 84]]], ["Subjects with a history of previous laboratory-documented infection or vaccination with A(H1N1)pdm09, vaccination with A/New Jersey/76, egg allergy, immunosuppression, or active neoplastic disease were excluded.", [["egg", "ANATOMY", 136, 139], ["neoplastic", "ANATOMY", 178, 188], ["infection", "DISEASE", 58, 67], ["egg allergy", "DISEASE", 136, 147], ["neoplastic disease", "DISEASE", 178, 196], ["Subjects", "ORGANISM", 0, 8], ["A(H1N1)pdm09", "ORGANISM", 88, 100], ["egg", "ORGANISM", 136, 139], ["neoplastic disease", "CANCER", 178, 196], ["previous laboratory-documented infection", "PROBLEM", 27, 67], ["pdm09", "PROBLEM", 95, 100], ["egg allergy", "PROBLEM", 136, 147], ["immunosuppression", "TREATMENT", 149, 166], ["active neoplastic disease", "PROBLEM", 171, 196], ["infection", "OBSERVATION", 58, 67], ["active", "OBSERVATION_MODIFIER", 171, 177], ["neoplastic disease", "OBSERVATION", 178, 196]]], ["Younger subjects were excluded if they had a baseline A/California/07/09 hemagglutinin inhibition (HAI) titer of >10, but this was not an exclusion criterion for older adults because of greater levels of expected preexisting immunity.", [["hemagglutinin", "GENE_OR_GENE_PRODUCT", 73, 86], ["hemagglutinin inhibition", "TREATMENT", 73, 97]]], ["Blood was obtained before and at days 7, 14, and 28 after administration of inactivated subunit A/California/07/09 monovalent vaccine (Novartis, East Hanover, NJ).", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["California", "ORGANISM", 98, 108], ["Blood", "TEST", 0, 5], ["monovalent vaccine", "TREATMENT", 115, 133]]], ["PBMCs were purified using Accuspin tubes with Histopaque-1077 cell separation media (Sigma-Aldrich, St. Louis, MO) and were frozen at a controlled rate in fetal bovine serum (FBS) containing 10% DMSO.Microneutralization Assay ::: MATERIALS AND METHODSAll sera were tested using the microtiter technique for neutralization of an egg-grown virus derived from the 2009 monovalent live attenuated influenza vaccine (lot 500914P; MedImmune, Gaithersburg, MD).", [["PBMCs", "ANATOMY", 0, 5], ["cell", "ANATOMY", 62, 66], ["fetal bovine serum", "ANATOMY", 155, 173], ["FBS", "ANATOMY", 175, 178], ["sera", "ANATOMY", 255, 259], ["Histopaque-1077", "CHEMICAL", 46, 61], ["DMSO", "CHEMICAL", 195, 199], ["DMSO", "CHEMICAL", 195, 199], ["PBMCs", "CELL", 0, 5], ["Histopaque-1077 cell", "CELL", 46, 66], ["St. Louis", "ORGANISM", 100, 109], ["fetal", "ORGANISM_SUBSTANCE", 155, 160], ["bovine", "ORGANISM", 161, 167], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["FBS", "ORGANISM_SUBSTANCE", 175, 178], ["DMSO", "SIMPLE_CHEMICAL", 195, 199], ["sera", "ORGANISM_SUBSTANCE", 255, 259], ["egg", "ORGANISM", 328, 331], ["PBMCs", "CELL_TYPE", 0, 5], ["bovine", "SPECIES", 161, 167], ["bovine", "SPECIES", 161, 167], ["PBMCs", "TEST", 0, 5], ["Accuspin tubes", "TREATMENT", 26, 40], ["Histopaque", "TREATMENT", 46, 56], ["fetal bovine serum", "TEST", 155, 173], ["Microneutralization Assay", "TEST", 200, 225], ["METHODSAll sera", "TEST", 244, 259], ["the microtiter technique", "TREATMENT", 278, 302], ["neutralization", "TREATMENT", 307, 321], ["an egg", "TEST", 325, 331], ["grown virus", "PROBLEM", 332, 343], ["influenza vaccine", "TREATMENT", 393, 410]]], ["Sera were heat inactivated prior to testing, starting at a 1:10 dilution.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["testing", "TEST", 36, 43]]], ["Viral growth was determined by enzyme-linked immunosorbent assay following fixation with acetone, using NP-specific monoclonal antibodies (WHO reagent kit).", [["acetone", "CHEMICAL", 89, 96], ["acetone", "CHEMICAL", 89, 96], ["acetone", "SIMPLE_CHEMICAL", 89, 96], ["monoclonal antibodies", "PROTEIN", 116, 137], ["Viral growth", "TEST", 0, 12], ["enzyme", "TEST", 31, 37], ["immunosorbent assay", "TEST", 45, 64], ["fixation with acetone", "TREATMENT", 75, 96], ["NP", "TREATMENT", 104, 106]]], ["The antibody titer was defined as the reciprocal of the highest dilution that resulted in 50% inhibition of signal as compared to control wells.", [["The antibody titer", "TEST", 0, 18]]], ["An end point titer was determined on all sera with an initial neutralizing antibody titer of \u22651280.", [["sera", "ANATOMY", 41, 45], ["sera", "ORGANISM_SUBSTANCE", 41, 45], ["an initial neutralizing antibody titer", "TEST", 51, 89]]], ["Sera without detectable neutralization activity were assigned a titer of 5, and values >40 000 were assigned a titer of 40 000 for calculation purposes.HAI Assay ::: MATERIALS AND METHODSHAI testing was performed on all sera in microtiter format, using turkey red blood cells with 4 HA units of egg-grown virus derived from the 2009 monovalent A(H1N1)pdm09 live attenuated influenza vaccine (lot 500914P; MedImmune, Gaithersburg, MD) as antigen.", [["sera", "ANATOMY", 220, 224], ["red blood cells", "ANATOMY", 260, 275], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["sera", "ORGANISM_SUBSTANCE", 220, 224], ["turkey", "ORGANISM", 253, 259], ["red blood cells", "CELL", 260, 275], ["egg", "ORGANISM", 295, 298], ["A(H1N1)pdm09", "ORGANISM", 344, 356], ["turkey red blood cells", "CELL_TYPE", 253, 275], ["turkey", "SPECIES", 253, 259], ["turkey", "SPECIES", 253, 259], ["Sera", "TEST", 0, 4], ["detectable neutralization activity", "PROBLEM", 13, 47], ["a titer", "TEST", 62, 69], ["calculation purposes", "TEST", 131, 151], ["METHODSHAI testing", "TEST", 180, 198], ["all sera", "TEST", 216, 224], ["red blood cells", "TEST", 260, 275], ["4 HA units of egg", "TREATMENT", 281, 298], ["grown virus", "PROBLEM", 299, 310], ["influenza vaccine", "TREATMENT", 373, 390]]], ["Sera were treated with receptor-destroying enzyme (Denka Seiken, Tokyo, Japan) and heat inactivated prior to testing, starting at a 1:10 dilution.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["receptor-destroying enzyme", "TREATMENT", 23, 49], ["testing", "TEST", 109, 116]]], ["The antibody titer was defined as the reciprocal of the highest dilution that resulted in inhibition of hemagglutination.Quantification of CD4+ T-Cell Responses ::: MATERIALS AND METHODSCryopreserved PBMCs were thawed and then rested overnight at 37\u00b0C and 5% CO2 in Roswell Park Memorial Institute 1640 medium containing 10% FBS and gentamicin (Life Technologies, Carlsbad, CA), with a typical yield of >85% viable cells after thawing.", [["CD4+ T-Cell", "ANATOMY", 139, 150], ["PBMCs", "ANATOMY", 200, 205], ["FBS", "ANATOMY", 325, 328], ["cells", "ANATOMY", 415, 420], ["CO2", "CHEMICAL", 259, 262], ["FBS", "CHEMICAL", 325, 328], ["gentamicin", "CHEMICAL", 333, 343], ["CO2", "CHEMICAL", 259, 262], ["gentamicin", "CHEMICAL", 333, 343], ["CD4", "GENE_OR_GENE_PRODUCT", 139, 142], ["PBMCs", "CELL", 200, 205], ["CO2", "SIMPLE_CHEMICAL", 259, 262], ["FBS", "ORGANISM_SUBSTANCE", 325, 328], ["gentamicin", "SIMPLE_CHEMICAL", 333, 343], ["cells", "CELL", 415, 420], ["CD4", "PROTEIN", 139, 142], ["PBMCs", "CELL_TYPE", 200, 205], ["The antibody titer", "TEST", 0, 18], ["hemagglutination", "PROBLEM", 104, 120], ["CD4", "TEST", 139, 142], ["10% FBS", "TREATMENT", 321, 328], ["gentamicin", "TREATMENT", 333, 343], ["hemagglutination", "OBSERVATION", 104, 120], ["CD4", "OBSERVATION", 139, 142], ["T-Cell", "OBSERVATION", 144, 150]]], ["After rest, PBMCs were depleted of CD8+ and CD56+ cells, using MACS positive selection with LD separation columns as per manufacturer's instructions (Miltenyi Biotec, Auburn, CA).", [["PBMCs", "ANATOMY", 12, 17], ["CD8+ and CD56+ cells", "ANATOMY", 35, 55], ["PBMCs", "CELL", 12, 17], ["CD8", "GENE_OR_GENE_PRODUCT", 35, 38], ["CD56", "GENE_OR_GENE_PRODUCT", 44, 48], ["PBMCs", "CELL_TYPE", 12, 17], ["CD8", "PROTEIN", 35, 38], ["CD56", "PROTEIN", 44, 48], ["Miltenyi Biotec", "PROTEIN", 150, 165], ["PBMCs", "TEST", 12, 17], ["CD8", "TEST", 35, 38], ["CD56+ cells", "PROBLEM", 44, 55], ["LD separation columns", "TREATMENT", 92, 113], ["Miltenyi Biotec", "TREATMENT", 150, 165]]], ["ELISPOT assays were performed as previously described [10], with 400 000 or 200 000 CD8- and CD56-depleted PBMCs cocultured with either peptide pool or tetanus toxoid (Calbiochem, Billerica, MA).", [["PBMCs", "ANATOMY", 107, 112], ["CD8", "GENE_OR_GENE_PRODUCT", 84, 87], ["CD56", "GENE_OR_GENE_PRODUCT", 93, 97], ["PBMCs", "CELL", 107, 112], ["CD8", "PROTEIN", 84, 87], ["CD56", "PROTEIN", 93, 97], ["PBMCs", "CELL_TYPE", 107, 112], ["ELISPOT assays", "TEST", 0, 14], ["CD8", "TEST", 84, 87], ["CD56", "TEST", 93, 97], ["PBMCs cocultured", "TREATMENT", 107, 123], ["tetanus toxoid", "TREATMENT", 152, 166]]], ["Plates were analyzed using an Immunospot reader series 2A with Immunospot software, version 3.2 (Cellular Technology, Shaker Heights, OH).", [["an Immunospot", "TEST", 27, 40], ["Immunospot software", "TEST", 63, 82], ["version", "TEST", 84, 91]]], ["Results were normalized to peptide-specific spots per 106 cells after averaging values for duplicate wells and subtracting background.Synthetic Peptides ::: MATERIALS AND METHODSPeptides unique to A/California/07/09 were synthesized in our facility by using an Apex 396 system (AAPPTec, Louisville, KY) as described previously [30].", [["cells", "ANATOMY", 58, 63], ["cells", "CELL", 58, 63], ["106 cells", "CELL_LINE", 54, 63], ["A/California/07/09", "SPECIES", 197, 215], ["peptide", "TEST", 27, 34], ["averaging values", "TEST", 70, 86], ["duplicate wells", "TEST", 91, 106]]], ["Other peptide sets were obtained through the National Institutes of Health Biodefense and Emerging Infections Research Resources Repository (Bethesda, MD) and included the A/California/04/09 HA peptides (NR-15433), the A/New York/384/2005(H3N2) HA (NR-2603) and neuraminidase (NA; NR-2608) peptides, and the A/New York/348/2003(H1N1) NP (NR-2611) and M1 (NR-2613) peptides.Peptide Pools ::: MATERIALS AND METHODSA/California/07/09 HA and NA peptides containing <6 contiguous conserved amino acids as compared to recently circulating A(H1N1) strains were pooled into a HA/NA \u201cunique\u201d pool (38 peptides; Supplementary Table 1).", [["Infections", "DISEASE", 99, 109], ["NR-15433", "CHEMICAL", 204, 212], ["NR-2603", "CHEMICAL", 249, 256], ["NA", "CHEMICAL", 277, 279], ["amino acids", "CHEMICAL", 485, 496], ["amino acids", "CHEMICAL", 485, 496], ["New York/384/2005(H3N2) HA", "ORGANISM", 221, 247], ["NR-2603", "CELL", 249, 256], ["New York/348/2003(H1N1) NP", "ORGANISM", 310, 336], ["NR-2611", "CANCER", 338, 345], ["07/09 HA", "ORGANISM", 425, 433], ["amino acids", "AMINO_ACID", 485, 496], ["A(H1N1) strains", "ORGANISM", 533, 548], ["A/California/04/09", "SPECIES", 172, 190], ["A/New York/384/2005(H3N2)", "SPECIES", 219, 244], ["A/New York/348/2003(H1N1) NP (NR-2611", "SPECIES", 308, 345], ["Other peptide sets", "TEST", 0, 18], ["HA", "TEST", 245, 247], ["neuraminidase", "TEST", 262, 275], ["NA", "TEST", 277, 279], ["HA and NA peptides", "TREATMENT", 431, 449], ["amino acids", "TEST", 485, 496], ["recently circulating A(H1N1) strains", "PROBLEM", 512, 548], ["a HA/NA", "TEST", 566, 573]]], ["A \u201cHA-conserved\u201d pool containing \u22641 divergent amino acid as compared to recently circulating A(H1N1) strains was also used (35 peptides; Supplementary Table 2).", [["amino acid", "CHEMICAL", 46, 56], ["amino acid", "CHEMICAL", 46, 56], ["amino acid", "AMINO_ACID", 46, 56], ["A(H1N1) strains", "ORGANISM", 93, 108], ["A \u201cHA", "PROBLEM", 0, 5], ["\u22641 divergent amino acid", "TREATMENT", 33, 56], ["recently circulating A(H1N1) strains", "PROBLEM", 72, 108]]], ["Because the A(H1N1)pdm09 vaccine was on an A/Puerto Rico/8/34 backbone that was largely conserved as compared to A/New York/348/2003, all NP and M1 peptides were combined into a \u201cNP/M1-conserved\u201d pool (123 peptides).", [["A(H1N1)pdm09", "ORGANISM", 12, 24], ["A/New York/348/2003", "SPECIES", 113, 132], ["all NP and M1 peptides", "TREATMENT", 134, 156], ["a \u201cNP/M1", "TREATMENT", 176, 184], ["M1", "ANATOMY", 182, 184]]], ["As a control, divergent influenza A virus subtype H3N2 (A[H3N2]) peptides with <6 contiguous conserved amino acids as compared to A/California/07/09 (132 peptides) were pooled.", [["H3N2", "DISEASE", 50, 54], ["amino acids", "CHEMICAL", 103, 114], ["amino acids", "CHEMICAL", 103, 114], ["influenza A virus subtype H3N2", "ORGANISM", 24, 54], ["A[H3N2]", "ORGANISM", 56, 63], ["amino acids", "AMINO_ACID", 103, 114], ["influenza A virus subtype H3N2", "SPECIES", 24, 54], ["influenza A virus", "SPECIES", 24, 41], ["A/California/07/09", "SPECIES", 130, 148], ["divergent influenza A virus subtype H3N2", "PROBLEM", 14, 54], ["A[H3N2]) peptides", "TREATMENT", 56, 73], ["amino acids", "TEST", 103, 114]]], ["The \u201ctotal\u201d influenza-specific response was calculated as the sum of the HA/NA unique, HA-conserved, and NP/M1-specific CD4+ T-cell responses.Statistical Analysis ::: MATERIALS AND METHODST-cell responses against A(H1N1)pdm09 vaccine were compared between prevaccination and postvaccination time points, using the Wilcoxon signed rank test.", [["CD4+ T-cell", "ANATOMY", 120, 131], ["METHODST-cell", "ANATOMY", 181, 194], ["M1", "CELL", 108, 110], ["CD4", "GENE_OR_GENE_PRODUCT", 120, 123], ["METHODST-cell", "CELL", 181, 194], ["A(H1N1)pdm09", "ORGANISM", 213, 225], ["CD4", "PROTEIN", 120, 123], ["the HA/NA unique", "PROBLEM", 69, 85], ["HA", "PROBLEM", 87, 89], ["NP", "TEST", 105, 107], ["A(H1N1)pdm09 vaccine", "TREATMENT", 213, 233], ["the Wilcoxon signed rank test", "TEST", 310, 339]]], ["The Mann\u2013Whitney U test was used to compare unpaired groups.", [["The Mann\u2013Whitney U test", "TEST", 0, 23]]], ["Correlations between groups were examined using Spearman rank correlation.", [["Spearman rank correlation", "TEST", 48, 73]]], ["To further investigate whether CD4+ T-cell help was specificity dependent, 2 regression models were used to examine the joint effects of the NP/M1- and HA-conserved pools on the microneutralization titer; details of this analysis are in the Supplementary Materials.", [["CD4+", "ANATOMY", 31, 35], ["T-cell", "ANATOMY", 36, 42], ["CD4", "GENE_OR_GENE_PRODUCT", 31, 34], ["T-cell", "CELL", 36, 42], ["CD4", "PROTEIN", 31, 34], ["M1", "PROTEIN", 144, 146], ["CD4", "TEST", 31, 34], ["the NP/M1", "TEST", 137, 146], ["HA", "PROBLEM", 152, 154], ["the microneutralization titer", "TEST", 174, 203], ["this analysis", "TEST", 216, 229], ["joint", "ANATOMY", 120, 125], ["M1", "ANATOMY", 144, 146]]], ["Statistical analyses were performed using SAS, version 9.2, or GraphPad Prism 5.", [["Statistical analyses", "TEST", 0, 20], ["SAS", "TEST", 42, 45], ["version", "TEST", 47, 54]]], ["All P values < .05 were considered statistically significant.Ethics Statement ::: MATERIALS AND METHODSThe University of Rochester Research Subjects Review Board approved this study protocol, and human experimentation guidelines of the US Department of Health and Human Services and the University of Rochester were followed.", [["human", "ORGANISM", 196, 201], ["Human", "ORGANISM", 264, 269], ["human", "SPECIES", 196, 201], ["Human", "SPECIES", 264, 269], ["human", "SPECIES", 196, 201], ["All P values", "TEST", 0, 12], ["this study protocol", "TREATMENT", 171, 190]]], ["Study procedures were in accordance with the ethical standards of the Declaration of Helsinki.", [["Study procedures", "TEST", 0, 16]]], ["All subjects provided written informed consent prior to study participation.Study Subjects ::: RESULTSForty-nine healthy adults received the inactivated A/California/07/09 monovalent vaccine between March and October 2010.", [["adults", "ORGANISM", 121, 127], ["monovalent vaccine", "TREATMENT", 172, 190]]], ["Younger subjects were excluded if they had a prevaccination HAI titer of >10.", [["subjects", "ORGANISM", 8, 16], ["a prevaccination HAI titer", "TEST", 43, 69]]], ["Twelve older subjects had a baseline HAI titer of >10; 9 older subjects had a baseline HAI titer of \u226540.Humoral Immune Responses ::: RESULTSHAI and microneutralization titers were determined at all visits.", [["subjects", "ORGANISM", 63, 71], ["a baseline HAI titer", "PROBLEM", 26, 46], ["microneutralization titers", "TEST", 148, 174]]], ["Good correlation was seen between the maximum antibody titer as determined by HAI and microneutralization assay (Figure 1; r = 0.91, P < .0001).", [["the maximum antibody titer", "TEST", 34, 60], ["microneutralization assay", "TEST", 86, 111], ["Figure", "TEST", 113, 119]]], ["However, as neutralizing antibodies were fully titrated only with the microneutralization assay, these data are reported here.", [["neutralizing antibodies", "PROTEIN", 12, 35], ["neutralizing antibodies", "TEST", 12, 35], ["the microneutralization assay", "TEST", 66, 95], ["these data", "TEST", 97, 107]]], ["The maximum microneutralization titer ranged between <10 and >40 000, with a geometric mean of 482.", [["The maximum microneutralization titer", "TEST", 0, 37], ["a geometric mean", "TEST", 75, 91], ["maximum", "OBSERVATION_MODIFIER", 4, 11]]], ["Seroresponse (defined as a \u22654-fold increase in microneutralization titer) occurred in 41 subjects (84%).", [["a \u22654-fold increase", "PROBLEM", 25, 43], ["microneutralization titer", "TEST", 47, 72], ["increase", "OBSERVATION_MODIFIER", 35, 43]]]], "faeb9fe9e13d4bb64069905a64c28e2e36adf6a9": [["The 39-terminal domain of the most conserved ORF1b in three of the four families of the order Nidovirales (except for the family Arteriviridae) encodes a (putative) 29-O-methyltransferase (29-O-MTase), known as non structural protein (nsp) 16 in the family Coronaviridae and implicated in methylation of the 59 cap structure of nidoviral mRNAs.", [["ORF1b", "GENE_OR_GENE_PRODUCT", 45, 50], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 94, 105], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 129, 142], ["29-O-MTase", "GENE_OR_GENE_PRODUCT", 189, 199], ["non structural protein (nsp) 16", "GENE_OR_GENE_PRODUCT", 211, 242], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 257, 270], ["39-terminal domain", "PROTEIN", 4, 22], ["ORF1b", "PROTEIN", 45, 50], ["Arteriviridae", "PROTEIN", 129, 142], ["(putative) 29-O-methyltransferase", "PROTEIN", 154, 187], ["29-O-MTase", "PROTEIN", 189, 199], ["structural protein (nsp) 16", "PROTEIN", 215, 242], ["Coronaviridae", "PROTEIN", 257, 270], ["59 cap structure", "RNA", 308, 324], ["nidoviral mRNAs", "RNA", 328, 343], ["methyltransferase", "TREATMENT", 170, 187], ["the family Coronaviridae", "TREATMENT", 246, 270], ["nidoviral mRNAs", "PROBLEM", 328, 343], ["nidoviral mRNAs", "OBSERVATION", 328, 343]]], ["As with coronavirus transcripts, arterivirus mRNAs are assumed to possess a 59 cap although no candidate MTases have been identified thus far.", [["coronavirus", "ORGANISM", 8, 19], ["arterivirus", "GENE_OR_GENE_PRODUCT", 33, 44], ["coronavirus transcripts", "RNA", 8, 31], ["arterivirus mRNAs", "RNA", 33, 50], ["MTases", "PROTEIN", 105, 111], ["coronavirus transcripts", "TREATMENT", 8, 31], ["arterivirus mRNAs", "TREATMENT", 33, 50], ["MTases", "PROBLEM", 105, 111]]], ["To address this knowledge gap, we analysed the uncharacterized nsp12 of arteriviruses, which occupies the ORF1b position equivalent to that of the nidovirus 29-O-MTase (coronavirus nsp16).", [["nsp12", "GENE_OR_GENE_PRODUCT", 63, 68], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 72, 85], ["ORF1b", "GENE_OR_GENE_PRODUCT", 106, 111], ["O-MTase", "GENE_OR_GENE_PRODUCT", 160, 167], ["coronavirus nsp16", "ORGANISM", 169, 186], ["nsp12", "PROTEIN", 63, 68], ["arteriviruses", "PROTEIN", 72, 85], ["ORF1b position", "DNA", 106, 120], ["nidovirus 29-O-MTase", "PROTEIN", 147, 167], ["coronavirus nsp16", "PROTEIN", 169, 186], ["the nidovirus", "TEST", 143, 156]]], ["In our in-depth bioinformatics analysis of nsp12, the protein was confirmed to be family specific whilst having diverged much further than other nidovirus ORF1b-encoded proteins, including those of the family Coronaviridae.", [["nsp12", "GENE_OR_GENE_PRODUCT", 43, 48], ["ORF1b", "GENE_OR_GENE_PRODUCT", 155, 160], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 209, 222], ["nsp12", "PROTEIN", 43, 48], ["nidovirus ORF1b-encoded proteins", "PROTEIN", 145, 177], ["Coronaviridae", "PROTEIN", 209, 222], ["the protein", "TEST", 50, 61], ["the family Coronaviridae", "TREATMENT", 198, 222]]], ["Only one invariant and several partially conserved, predominantly aromatic residues were identified in nsp12, which may adopt a structure with alternating a-helices and b-strands, an organization also found in known MTases.", [["nsp12", "GENE_OR_GENE_PRODUCT", 103, 108], ["a-helices", "GENE_OR_GENE_PRODUCT", 155, 164], ["nsp12", "PROTEIN", 103, 108], ["a-helices", "PROTEIN", 155, 164], ["b-strands", "PROTEIN", 169, 178], ["MTases", "PROTEIN", 216, 222], ["predominantly aromatic residues", "PROBLEM", 52, 83], ["alternating a-helices and b-strands", "PROBLEM", 143, 178], ["invariant", "OBSERVATION_MODIFIER", 9, 18], ["predominantly", "OBSERVATION_MODIFIER", 52, 65], ["aromatic residues", "OBSERVATION", 66, 83]]], ["However, no statistically significant similarity was found between nsp12 and the twofold larger coronavirus nsp16, nor could we detect MTase activity in biochemical assays using recombinant equine arteritis virus (EAV) nsp12.", [["equine arteritis", "DISEASE", 190, 206], ["nsp12", "GENE_OR_GENE_PRODUCT", 67, 72], ["coronavirus", "ORGANISM", 96, 107], ["nsp16", "GENE_OR_GENE_PRODUCT", 108, 113], ["MTase", "GENE_OR_GENE_PRODUCT", 135, 140], ["recombinant equine arteritis virus", "ORGANISM", 178, 212], ["EAV", "ORGANISM", 214, 217], ["nsp12", "GENE_OR_GENE_PRODUCT", 219, 224], ["nsp12", "PROTEIN", 67, 72], ["coronavirus nsp16", "PROTEIN", 96, 113], ["MTase", "PROTEIN", 135, 140], ["equine arteritis virus", "SPECIES", 190, 212], ["equine arteritis virus", "SPECIES", 190, 212], ["EAV", "SPECIES", 214, 217], ["the twofold larger coronavirus nsp16", "PROBLEM", 77, 113], ["MTase activity", "PROBLEM", 135, 149], ["biochemical assays", "TEST", 153, 171], ["recombinant equine arteritis virus", "TREATMENT", 178, 212], ["no", "UNCERTAINTY", 9, 11], ["larger", "OBSERVATION_MODIFIER", 89, 95], ["coronavirus", "OBSERVATION", 96, 107]]], ["Our further analysis established that this subunit is essential for replication of this prototypic arterivirus.", [["arterivirus", "CANCER", 99, 110], ["Our further analysis", "TEST", 0, 20], ["this prototypic arterivirus", "TREATMENT", 83, 110]]], ["Using reverse genetics, we assessed the impact of 25 substitutions at 14 positions, yielding virus phenotypes ranging from WT-like to non-viable.", [["yielding virus phenotypes", "PROBLEM", 84, 109], ["WT", "TEST", 123, 125]]], ["Notably, replacement of the invariant phenylalanine 109 with tyrosine was lethal.", [["phenylalanine 109", "CHEMICAL", 38, 55], ["tyrosine", "CHEMICAL", 61, 69], ["phenylalanine", "CHEMICAL", 38, 51], ["tyrosine", "CHEMICAL", 61, 69], ["phenylalanine 109", "AMINO_ACID", 38, 55], ["tyrosine", "AMINO_ACID", 61, 69], ["replacement", "TREATMENT", 9, 20], ["the invariant phenylalanine", "TREATMENT", 24, 51], ["tyrosine", "TREATMENT", 61, 69], ["replacement", "OBSERVATION", 9, 20]]], ["We concluded that nsp12 plays an essential role during EAV replication, possibly by acting as a co-factor for another enzyme.INTRODUCTIONMembers of the family Arteriviridae are positive-stranded RNA viruses with genome sizes ranging from 13 to 16 kb.", [["nsp12", "CHEMICAL", 18, 23], ["nsp12", "GENE_OR_GENE_PRODUCT", 18, 23], ["EAV", "ORGANISM", 55, 58], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 159, 172], ["nsp12", "PROTEIN", 18, 23], ["EAV", "SPECIES", 55, 58], ["EAV replication", "TREATMENT", 55, 70], ["another enzyme.", "TEST", 110, 125], ["the family Arteriviridae", "TEST", 148, 172], ["stranded RNA viruses", "PROBLEM", 186, 206], ["genome sizes", "TEST", 212, 224], ["stranded RNA viruses", "OBSERVATION", 186, 206], ["sizes", "OBSERVATION_MODIFIER", 219, 224]]], ["The family currently comprises a single genus (Arterivirus) that includes four species: Equine arteritis virus (EAV), Simian hemorrhagic fever virus (SHFV), Lactate dehydrogenase-elevating virus (LDV) and Porcine reproductive and respiratory syndrome virus (PRRSV) (Faaberg et al., 2012; Snijder et al., 2013) .", [["Equine arteritis", "DISEASE", 88, 104], ["Simian hemorrhagic fever", "DISEASE", 118, 142], ["Lactate", "CHEMICAL", 157, 164], ["Porcine reproductive and respiratory syndrome", "DISEASE", 205, 250], ["Lactate", "CHEMICAL", 157, 164], ["Arterivirus", "CANCER", 47, 58], ["Equine arteritis virus", "ORGANISM", 88, 110], ["EAV", "ORGANISM", 112, 115], ["Simian hemorrhagic fever virus", "ORGANISM", 118, 148], ["SHFV", "ORGANISM", 150, 154], ["Lactate dehydrogenase-elevating virus", "ORGANISM", 157, 194], ["LDV", "ORGANISM", 196, 199], ["Porcine reproductive and respiratory syndrome virus", "ORGANISM", 205, 256], ["PRRSV", "ORGANISM", 258, 263], ["Lactate dehydrogenase", "PROTEIN", 157, 178], ["Equine arteritis virus", "SPECIES", 88, 110], ["Simian hemorrhagic fever virus", "SPECIES", 118, 148], ["Porcine", "SPECIES", 205, 212], ["syndrome virus", "SPECIES", 242, 256], ["PRRSV", "SPECIES", 258, 263], ["Equine arteritis virus", "SPECIES", 88, 110], ["EAV", "SPECIES", 112, 115], ["Simian hemorrhagic fever virus", "SPECIES", 118, 148], ["SHFV", "SPECIES", 150, 154], ["LDV", "SPECIES", 196, 199], ["Porcine reproductive and respiratory syndrome virus", "SPECIES", 205, 256], ["PRRSV", "SPECIES", 258, 263], ["a single genus (Arterivirus)", "PROBLEM", 31, 59], ["Equine arteritis virus", "PROBLEM", 88, 110], ["Simian hemorrhagic fever virus (SHFV)", "PROBLEM", 118, 155], ["Lactate dehydrogenase", "TEST", 157, 178], ["elevating virus (LDV)", "PROBLEM", 179, 200], ["Porcine reproductive and respiratory syndrome virus", "PROBLEM", 205, 256], ["Equine arteritis", "OBSERVATION", 88, 104], ["hemorrhagic", "OBSERVATION_MODIFIER", 125, 136], ["respiratory syndrome", "OBSERVATION", 230, 250]]], ["Amongst those, the latter is the economically most relevant species causing annual losses to the American swine industry alone of *$800 million (Sang et al., 2014) .", [["swine", "SPECIES", 106, 111]]], ["Additionally, several recently identified arteriviruses remain to be formally classified, but are likely to prototype multiple novel species or even higher-order taxa (Bailey et al., 2014; Dunowska et al., 2012; Lauck et al., 2011 Lauck et al., , 2013 .", [["arteriviruses", "CANCER", 42, 55], ["prototype multiple novel species", "PROBLEM", 108, 140]]], ["Arterivirus genomes are polycistronic and contain 10-15 (known) ORFs.", [["Arterivirus genomes", "DNA", 0, 19], ["10-15 (known) ORFs", "DNA", 50, 68], ["Arterivirus genomes", "PROBLEM", 0, 19]]], ["The 59-proximal ORFs 1a and 1b are expressed as polyproteins (pps) 1a and 1ab that are autoproteolytically processed into the non structural proteins (nsps) required for genome replication and transcription ( Fig. 1) (Molenkamp et al., 2000) .INTRODUCTIONThe remaining ORFs mostly encode structural proteins that are expressed from a set of subgenomic mRNAs (Pasternak et al., 2006) .", [["1a", "GENE_OR_GENE_PRODUCT", 21, 23], ["1b", "GENE_OR_GENE_PRODUCT", 28, 30], ["pps) 1", "GENE_OR_GENE_PRODUCT", 62, 68], ["nsps", "GENE_OR_GENE_PRODUCT", 151, 155], ["genome", "CELLULAR_COMPONENT", 170, 176], ["59-proximal ORFs 1a and 1b", "DNA", 4, 30], ["polyproteins (pps) 1a and 1ab", "DNA", 48, 77], ["structural proteins", "PROTEIN", 130, 149], ["nsps", "PROTEIN", 151, 155], ["ORFs", "DNA", 269, 273], ["subgenomic mRNAs", "RNA", 341, 357], ["genome replication", "TREATMENT", 170, 188], ["The remaining ORFs", "PROBLEM", 255, 273], ["encode structural proteins", "PROBLEM", 281, 307], ["structural proteins", "OBSERVATION", 288, 307], ["subgenomic mRNAs", "OBSERVATION", 341, 357]]], ["Based on overall similarities in terms of genome expression and organization, as well as synteny and homology of key replicase domains, the family Arteriviridae was united in the order Nidovirales with the families Mesoniviridae, Roniviridae and Coronaviridae, the latter including two distantly related subfamilies, Coronavirinae and Torovirinae (de Groot et al., 2012a, b) .", [["Arteriviridae", "GENE_OR_GENE_PRODUCT", 147, 160], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 185, 196], ["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 215, 228], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 230, 241], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 246, 259], ["replicase domains", "PROTEIN", 117, 134], ["Nidovirales", "TREATMENT", 185, 196], ["the families Mesoniviridae", "TREATMENT", 202, 228], ["Roniviridae", "TREATMENT", 230, 241], ["Coronaviridae", "TREATMENT", 246, 259], ["Torovirinae", "TREATMENT", 335, 346], ["genome expression", "OBSERVATION", 42, 59]]], ["In the nidovirus tree, the arteriviruses form a basal lineage next to the one that combines the three other families, which have substantially larger genomes (Nga et al., 2011) .INTRODUCTIONORF1b is the most conserved part of the nidovirus genome and all ORF1b-encoded proteins characterized thus far are enzymes conserved in two or more nidovirus families.", [["basal lineage", "ANATOMY", 48, 61], ["nidovirus tree", "MULTI-TISSUE_STRUCTURE", 7, 21], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 27, 40], ["nidovirus", "GENE_OR_GENE_PRODUCT", 230, 239], ["ORF1b", "GENE_OR_GENE_PRODUCT", 255, 260], ["INTRODUCTIONORF1b", "PROTEIN", 178, 195], ["nidovirus genome", "DNA", 230, 246], ["ORF1b", "DNA", 255, 260], ["the nidovirus genome", "TREATMENT", 226, 246], ["enzymes", "TEST", 305, 312], ["basal", "ANATOMY_MODIFIER", 48, 53], ["lineage", "OBSERVATION", 54, 61], ["larger", "OBSERVATION_MODIFIER", 143, 149]]], ["The RNA-dependent RNA polymerase and a zinc-binding domain (ZBD) fused with a superfamily 1 helicase (HEL1) are conserved in all nidoviruses.", [["zinc", "CHEMICAL", 39, 43], ["zinc", "CHEMICAL", 39, 43], ["HEL1", "GENE_OR_GENE_PRODUCT", 102, 106], ["nidoviruses", "CANCER", 129, 140], ["RNA-dependent RNA polymerase", "PROTEIN", 4, 32], ["zinc-binding domain", "PROTEIN", 39, 58], ["ZBD", "PROTEIN", 60, 63], ["superfamily 1 helicase", "PROTEIN", 78, 100], ["HEL1", "PROTEIN", 102, 106], ["The RNA", "TEST", 0, 7], ["dependent RNA polymerase", "PROBLEM", 8, 32], ["a zinc-binding domain (ZBD)", "TREATMENT", 37, 64], ["a superfamily 1 helicase", "TREATMENT", 76, 100], ["dependent", "OBSERVATION_MODIFIER", 8, 17], ["RNA polymerase", "OBSERVATION", 18, 32]]], ["In contrast, six other domains are lineage specific.", [["lineage", "OBSERVATION", 35, 42]]], ["Four of these are conserved in two or three nidovirus families only: exoribonuclease (ExoN), N7-methyltransferase (N7-MTase), nidovirus uridylate-specific endoribonuclease (NendoU) and 29-Omethyltransferase (29-O-MTase).", [["exoribonuclease", "GENE_OR_GENE_PRODUCT", 69, 84], ["ExoN", "GENE_OR_GENE_PRODUCT", 86, 90], ["N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 93, 113], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 115, 123], ["nidovirus uridylate-specific endoribonuclease", "GENE_OR_GENE_PRODUCT", 126, 171], ["NendoU", "GENE_OR_GENE_PRODUCT", 173, 179], ["29-Omethyltransferase", "GENE_OR_GENE_PRODUCT", 185, 206], ["29-O-MTase", "GENE_OR_GENE_PRODUCT", 208, 218], ["nidovirus families", "PROTEIN", 44, 62], ["exoribonuclease", "PROTEIN", 69, 84], ["ExoN", "PROTEIN", 86, 90], ["N7-methyltransferase", "PROTEIN", 93, 113], ["N7", "PROTEIN", 115, 117], ["MTase", "PROTEIN", 118, 123], ["nidovirus uridylate-specific endoribonuclease", "PROTEIN", 126, 171], ["NendoU", "PROTEIN", 173, 179], ["29", "PROTEIN", 185, 187], ["Omethyltransferase", "PROTEIN", 188, 206], ["29-O-MTase", "PROTEIN", 208, 218], ["exoribonuclease (ExoN)", "TREATMENT", 69, 91], ["N7-methyltransferase (N7-MTase)", "TREATMENT", 93, 124], ["nidovirus uridylate", "TREATMENT", 126, 145]]], ["Two other domains are as yet uncharacterized and unique to either roniviruses [ronivirus-specific domain (RsD)] or arteriviruses [arterivirus-specific domain (AsD)].", [["roniviruses", "GENE_OR_GENE_PRODUCT", 66, 77], ["ronivirus-specific domain (RsD)", "GENE_OR_GENE_PRODUCT", 79, 110], ["arterivirus-specific domain (AsD)", "GENE_OR_GENE_PRODUCT", 130, 163], ["roniviruses", "PROTEIN", 66, 77], ["ronivirus-specific domain", "PROTEIN", 79, 104], ["RsD", "PROTEIN", 106, 109], ["arteriviruses", "PROTEIN", 115, 128], ["arterivirus-specific domain", "PROTEIN", 130, 157], ["AsD", "PROTEIN", 159, 162], ["roniviruses", "TEST", 66, 77], ["ronivirus", "TEST", 79, 88], ["arteriviruses", "PROBLEM", 115, 128], ["arterivirus", "TEST", 130, 141]]], ["As five of the six lineagespecific domains occupy a unique position in the genome, the pattern of their conservation could be explained by loss or acquisition of a single domain during nidovirus evolution (Nga et al., 2011) .", [["lineagespecific domains", "DNA", 19, 42], ["a single domain during nidovirus evolution", "PROBLEM", 162, 204], ["unique", "OBSERVATION_MODIFIER", 52, 58], ["position", "OBSERVATION_MODIFIER", 59, 67], ["genome", "OBSERVATION", 75, 81], ["could be explained", "UNCERTAINTY", 117, 135], ["loss", "OBSERVATION", 139, 143]]], ["The exception is AsD, which resides in the most C-terminal subunit of the arterivirus ORF1b polyprotein (nsp12), the position occupied by the 29-O-MTase protein in all other nidoviruses (nsp16 in coronaviruses; Fig. 1 ).", [["C", "CHEMICAL", 48, 49], ["AsD", "GENE_OR_GENE_PRODUCT", 17, 20], ["ORF1b", "GENE_OR_GENE_PRODUCT", 86, 91], ["nsp12", "GENE_OR_GENE_PRODUCT", 105, 110], ["nidoviruses", "GENE_OR_GENE_PRODUCT", 174, 185], ["nsp16", "GENE_OR_GENE_PRODUCT", 187, 192], ["AsD", "PROTEIN", 17, 20], ["C-terminal subunit", "PROTEIN", 48, 66], ["arterivirus ORF1b polyprotein", "PROTEIN", 74, 103], ["nsp12", "PROTEIN", 105, 110], ["29-O-MTase protein", "PROTEIN", 142, 160], ["nidoviruses", "PROTEIN", 174, 185], ["nsp16", "PROTEIN", 187, 192], ["AsD", "PROBLEM", 17, 20], ["MTase protein", "TEST", 147, 160], ["AsD", "OBSERVATION", 17, 20], ["terminal", "ANATOMY_MODIFIER", 50, 58], ["subunit", "ANATOMY_MODIFIER", 59, 66]]], ["If these positionally equivalent proteins are unrelated, as reported 14 years ago based on the analysis of only a few genome sequences and prior to the identification of the 29-O-MTase (Gorbalenya, 2001) , their emergence would require the consideration of complex evolutionary hypotheses.", [["positionally equivalent proteins", "PROTEIN", 9, 41], ["genome sequences", "DNA", 118, 134], ["MTase", "PROTEIN", 179, 184], ["the analysis", "TEST", 91, 103], ["positionally", "OBSERVATION_MODIFIER", 9, 21], ["equivalent", "OBSERVATION_MODIFIER", 22, 32]]], ["Thus, the relation of AsD with the 29-O-MTase and other proteins must be re-evaluated whilst taking advantage 1 0 1 11 2 6-8 nsp Fig. 1 .", [["AsD", "GENE_OR_GENE_PRODUCT", 22, 25], ["AsD", "PROTEIN", 22, 25], ["29-O-MTase", "PROTEIN", 35, 45], ["AsD", "TEST", 22, 25]]], ["Organization of key replicase domains encoded by nidovirus ORFs 1a and 1b.", [["nidovirus ORFs 1a", "GENE_OR_GENE_PRODUCT", 49, 66], ["1b", "GENE_OR_GENE_PRODUCT", 71, 73], ["replicase domains", "PROTEIN", 20, 37], ["nidovirus ORFs 1a and 1b", "DNA", 49, 73]]], ["Proteolytic cleavage products described in the text for the coronaviruses and arteriviruses are indicated.", [["coronaviruses", "ORGANISM", 60, 73], ["arteriviruses", "CANCER", 78, 91], ["Proteolytic cleavage products", "PROTEIN", 0, 29], ["Proteolytic cleavage products", "TREATMENT", 0, 29], ["the coronaviruses and arteriviruses", "PROBLEM", 56, 91]]], ["Domains (putatively) involved in capping (HEL, NMT, OMT and AsD) are depicted in bright colours.", [["NMT", "GENE_OR_GENE_PRODUCT", 47, 50], ["AsD", "GENE_OR_GENE_PRODUCT", 60, 63], ["HEL", "PROTEIN", 42, 45], ["NMT", "PROTEIN", 47, 50], ["OMT", "PROTEIN", 52, 55], ["AsD", "PROTEIN", 60, 63], ["capping (HEL", "TREATMENT", 33, 45], ["bright colours", "OBSERVATION", 81, 95]]], ["TM, transmembrane domain; 3CL pro , 3C-like protease; black dot and RFS, ribosomal frameshift site; RdRp, RNA-dependent RNA polymerase; HEL, ZBD, helicase core (HEL1) and variable additional domains; ExoN, exoribonuclease; NMT, N7-MTase; NendoU, endoribonuclease; OMT, 29-O-MTase; RsD, ronivirus-specific domain; AsD, arterivirus-specific domain (nsp12).", [["3CL pro , 3C-like protease", "GENE_OR_GENE_PRODUCT", 26, 52], ["ribosomal", "CELLULAR_COMPONENT", 73, 82], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 106, 134], ["HEL", "GENE_OR_GENE_PRODUCT", 136, 139], ["ZBD", "GENE_OR_GENE_PRODUCT", 141, 144], ["HEL1", "GENE_OR_GENE_PRODUCT", 161, 165], ["ExoN", "GENE_OR_GENE_PRODUCT", 200, 204], ["exoribonuclease", "GENE_OR_GENE_PRODUCT", 206, 221], ["NMT", "GENE_OR_GENE_PRODUCT", 223, 226], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 228, 236], ["NendoU", "GENE_OR_GENE_PRODUCT", 238, 244], ["29-O-MTase", "GENE_OR_GENE_PRODUCT", 269, 279], ["RsD", "GENE_OR_GENE_PRODUCT", 281, 284], ["AsD", "GENE_OR_GENE_PRODUCT", 313, 316], ["arterivirus-specific domain", "GENE_OR_GENE_PRODUCT", 318, 345], ["nsp12", "GENE_OR_GENE_PRODUCT", 347, 352], ["TM", "PROTEIN", 0, 2], ["transmembrane domain", "PROTEIN", 4, 24], ["3CL pro , 3C-like protease", "PROTEIN", 26, 52], ["black dot and RFS, ribosomal frameshift site", "DNA", 54, 98], ["RdRp, RNA-dependent RNA polymerase", "PROTEIN", 100, 134], ["HEL", "PROTEIN", 136, 139], ["ZBD", "PROTEIN", 141, 144], ["helicase core", "PROTEIN", 146, 159], ["HEL1", "PROTEIN", 161, 165], ["variable additional domains", "PROTEIN", 171, 198], ["ExoN", "PROTEIN", 200, 204], ["exoribonuclease", "PROTEIN", 206, 221], ["NMT", "PROTEIN", 223, 226], ["N7", "PROTEIN", 228, 230], ["MTase", "PROTEIN", 231, 236], ["NendoU", "PROTEIN", 238, 244], ["endoribonuclease", "PROTEIN", 246, 262], ["OMT", "PROTEIN", 264, 267], ["29", "PROTEIN", 269, 271], ["O", "PROTEIN", 272, 273], ["MTase", "PROTEIN", 274, 279], ["RsD", "PROTEIN", 281, 284], ["ronivirus", "PROTEIN", 286, 295], ["specific domain", "PROTEIN", 296, 311], ["AsD", "PROTEIN", 313, 316], ["arterivirus", "PROTEIN", 318, 329], ["specific domain", "PROTEIN", 330, 345], ["nsp12", "PROTEIN", 347, 352], ["3C-like protease", "TREATMENT", 36, 52], ["black dot", "PROBLEM", 54, 63], ["RFS", "TEST", 68, 71], ["ribosomal frameshift site", "PROBLEM", 73, 98], ["RdRp", "TEST", 100, 104], ["dependent RNA polymerase", "PROBLEM", 110, 134], ["variable additional domains", "PROBLEM", 171, 198], ["NendoU", "TEST", 238, 244], ["endoribonuclease", "TEST", 246, 262], ["OMT", "TEST", 264, 267], ["RsD", "TEST", 281, 284], ["ronivirus", "TEST", 286, 295], ["AsD", "PROBLEM", 313, 316], ["arterivirus", "TEST", 318, 329], ["ribosomal frameshift", "OBSERVATION", 73, 93]]], ["Genomic organizations are shown for Beluga whale coronavirus SW1 (family Coronaviridae), Gill-associated virus (family Roniviridae), Nam Dinh virus (family Mesoniviridae) and PRRSV, North American genotype (family Arteriviridae).", [["Beluga whale coronavirus SW1", "ORGANISM", 36, 64], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 73, 86], ["Gill-associated virus", "ORGANISM", 89, 110], ["family Roniviridae", "ORGANISM", 112, 130], ["Nam Dinh virus", "ORGANISM", 133, 147], ["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 156, 169], ["PRRSV", "ORGANISM", 175, 180], ["whale coronavirus", "SPECIES", 43, 60], ["Dinh virus", "SPECIES", 137, 147], ["PRRSV", "SPECIES", 175, 180], ["Beluga whale coronavirus", "SPECIES", 36, 60], ["Nam Dinh virus", "SPECIES", 133, 147], ["PRRSV", "SPECIES", 175, 180], ["Nam Dinh virus (family Mesoniviridae)", "TREATMENT", 133, 170], ["Gill", "ANATOMY", 89, 93]]], ["Depicted is a simplified domain organization as most enzymes are multidomain proteins.", [["multidomain proteins", "PROTEIN", 65, 85], ["a simplified domain organization", "PROBLEM", 12, 44], ["most enzymes", "TEST", 48, 60], ["multidomain proteins", "PROBLEM", 65, 85]]], ["Note that viruses of the family Coronaviridae that do not belong to the subfamily Coronavirinae encode a truncated version of NMT.", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 32, 45], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 82, 95], ["NMT", "GENE_OR_GENE_PRODUCT", 126, 129], ["Coronavirinae", "PROTEIN", 82, 95], ["NMT", "PROTEIN", 126, 129], ["viruses", "OBSERVATION", 10, 17]]], ["Adapted from Lauber et al. (2013) .INTRODUCTIONof the increased availability of sequences and improved techniques.INTRODUCTIONUnlike AsD, the coronavirus 29-O-MTase has been characterized experimentally (Bouvet et al., 2010; Chen et al., 2011; Decroly et al., 2008 Decroly et al., , 2011 and was found to provide one of the four activities required for the formation of a socalled type I cap (cap-1) (mGpppNm) structure at the 59 end of coronaviral mRNAs (Lai & Stohlman, 1981; van Vliet et al., 2002) .", [["AsD", "GENE_OR_GENE_PRODUCT", 133, 136], ["O-MTase", "GENE_OR_GENE_PRODUCT", 157, 164], ["cap-1", "GENE_OR_GENE_PRODUCT", 393, 398], ["AsD", "PROTEIN", 133, 136], ["coronavirus 29-O-MTase", "PROTEIN", 142, 164], ["coronaviral mRNAs", "RNA", 437, 454], ["AsD", "PROBLEM", 133, 136], ["the coronavirus", "TEST", 138, 153]]], ["Two other coronavirus enzymes, HEL1 (nsp13) (Ivanov et al., 2004; Ivanov & Ziebuhr, 2004) and the N7-MTase (nsp14) (Bouvet et al., 2010; Chen et al., 2009) , are also suspected or known to be involved in capping, whereas the fourth enzyme required (guanylyltransferase) remains to be identified.", [["HEL1", "GENE_OR_GENE_PRODUCT", 31, 35], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 98, 106], ["nsp14", "GENE_OR_GENE_PRODUCT", 108, 113], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 249, 268], ["coronavirus enzymes", "PROTEIN", 10, 29], ["HEL1", "PROTEIN", 31, 35], ["nsp13", "PROTEIN", 37, 42], ["MTase", "PROTEIN", 101, 106], ["nsp14", "PROTEIN", 108, 113], ["fourth enzyme", "PROTEIN", 225, 238], ["guanylyltransferase", "PROTEIN", 249, 268], ["Two other coronavirus enzymes", "TEST", 0, 29], ["HEL1", "TEST", 31, 35], ["the fourth enzyme", "TEST", 221, 238]]], ["In vitro, the coronavirus N7-MTase and 29-O-MTase were found to cooperate during cap formation.", [["cap", "ANATOMY", 81, 84], ["coronavirus", "ORGANISM", 14, 25], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 26, 34], ["29-O-MTase", "GENE_OR_GENE_PRODUCT", 39, 49], ["cap", "TISSUE", 81, 84], ["coronavirus N7-MTase", "PROTEIN", 14, 34], ["MTase", "PROTEIN", 44, 49], ["the coronavirus N7-MTase", "TREATMENT", 10, 34]]], ["The latter enzyme also requires the ORF1a-encoded nsp10 as a co-factor (Bouvet et al., 2010) .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 36, 41], ["nsp10", "GENE_OR_GENE_PRODUCT", 50, 55], ["ORF1a", "PROTEIN", 36, 41], ["nsp10", "PROTEIN", 50, 55], ["The latter enzyme", "TEST", 0, 17]]], ["Although arteriviruses were not characterized in detail, the SHFV genome was reported to be capped (Sagripanti et al., 1986) and they do encode a HEL1 (Seybert et al., 2000) , which could contribute to capping.", [["arteriviruses", "CANCER", 9, 22], ["SHFV", "GENE_OR_GENE_PRODUCT", 61, 65], ["HEL1", "GENE_OR_GENE_PRODUCT", 146, 150], ["SHFV genome", "DNA", 61, 72], ["SHFV", "SPECIES", 61, 65]]], ["Thus, the discovery of arteriviral N7-MTase and/or 29-O-MTase activities could be readily accommodated in a functionally sensible manner.INTRODUCTIONBased on the above evolutionary and functional considerations, we sought to characterize nsp12 of arteriviruses by testing the hypothesis that it may be an MTase.", [["N7-MTase", "GENE_OR_GENE_PRODUCT", 35, 43], ["29-O-MTase", "SIMPLE_CHEMICAL", 51, 61], ["nsp12", "GENE_OR_GENE_PRODUCT", 238, 243], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 247, 260], ["MTase", "PROTEIN", 38, 43], ["MTase", "PROTEIN", 56, 61], ["nsp12", "PROTEIN", 238, 243], ["MTase", "PROTEIN", 305, 310], ["arteriviral N7-MTase", "TREATMENT", 23, 43]]], ["We show that, unlike the coronavirus 29-O-MTase, nsp12 is poorly conserved amongst known arteriviruses compared with the proteins carrying the endoribonuclease (nsp11) and helicase (nsp10) activities, and that it contains only one evolutionary invariant residue.", [["O-MTase", "GENE_OR_GENE_PRODUCT", 40, 47], ["nsp12", "GENE_OR_GENE_PRODUCT", 49, 54], ["arteriviruses", "CANCER", 89, 102], ["endoribonuclease", "GENE_OR_GENE_PRODUCT", 143, 159], ["nsp11", "GENE_OR_GENE_PRODUCT", 161, 166], ["nsp10", "GENE_OR_GENE_PRODUCT", 182, 187], ["coronavirus 29-O-MTase", "PROTEIN", 25, 47], ["nsp12", "PROTEIN", 49, 54], ["endoribonuclease", "PROTEIN", 143, 159], ["nsp11", "PROTEIN", 161, 166], ["helicase", "PROTEIN", 172, 180], ["nsp10", "PROTEIN", 182, 187], ["the coronavirus", "TEST", 21, 36], ["invariant residue", "OBSERVATION", 244, 261]]], ["No statistically significant similarity was found between arterivirus nsp12 and coronavirus nsp16 or other proteins although the two nidovirus proteins may belong to the same a/b-fold class.", [["arterivirus nsp12", "GENE_OR_GENE_PRODUCT", 58, 75], ["coronavirus", "ORGANISM", 80, 91], ["nsp16", "GENE_OR_GENE_PRODUCT", 92, 97], ["nidovirus", "GENE_OR_GENE_PRODUCT", 133, 142], ["arterivirus nsp12", "PROTEIN", 58, 75], ["coronavirus nsp16", "PROTEIN", 80, 97], ["nidovirus proteins", "PROTEIN", 133, 151], ["coronavirus", "SPECIES", 80, 91], ["arterivirus nsp12", "PROBLEM", 58, 75], ["coronavirus nsp16", "PROBLEM", 80, 97], ["other proteins", "PROBLEM", 101, 115], ["the two nidovirus proteins", "TEST", 125, 151], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["similarity", "OBSERVATION", 29, 39]]], ["Likewise, no MTase activity was detected in carefully controlled assays using recombinant EAV nsp12 in the absence or presence of several other nsps that were included as potential co-factors.", [["MTase", "GENE_OR_GENE_PRODUCT", 13, 18], ["EAV", "ORGANISM", 90, 93], ["nsp12", "GENE_OR_GENE_PRODUCT", 94, 99], ["nsps", "GENE_OR_GENE_PRODUCT", 144, 148], ["MTase", "PROTEIN", 13, 18], ["recombinant EAV nsp12", "PROTEIN", 78, 99], ["EAV", "SPECIES", 90, 93], ["MTase activity", "PROBLEM", 13, 27], ["recombinant EAV nsp12", "TREATMENT", 78, 99], ["no", "UNCERTAINTY", 10, 12], ["MTase activity", "OBSERVATION", 13, 27]]], ["Using reverse genetics, a large set of EAV nsp12 mutants was generated and tested for replication, revealing phenotypes ranging from WT-like to replication-deficient, which broadly correlated with the natural variation of the probed residues.", [["EAV", "ORGANISM", 39, 42], ["nsp12", "GENE_OR_GENE_PRODUCT", 43, 48], ["EAV nsp12 mutants", "PROTEIN", 39, 56], ["EAV", "SPECIES", 39, 42], ["replication", "TEST", 86, 97], ["phenotypes", "PROBLEM", 109, 119], ["WT", "TEST", 133, 135]]], ["We conclude that nsp12 plays an essential role in EAV replication and discuss possible directions to elucidate its enigmatic function.Sequence similarities and dissimilarities between arterivirus nsp12 and (putative) MTases of the Coronaviridae familyWe first analysed the conservation of nsp12 in comparison with that of other proteins deriving from the C-terminal portion of pp1ab of arteriviruses, coronaviruses and toroviruses.", [["nsp12", "CHEMICAL", 17, 22], ["C", "CHEMICAL", 355, 356], ["nsp12", "GENE_OR_GENE_PRODUCT", 17, 22], ["EAV", "ORGANISM", 50, 53], ["arterivirus nsp12", "GENE_OR_GENE_PRODUCT", 184, 201], ["(putative) MTases", "GENE_OR_GENE_PRODUCT", 206, 223], ["nsp12", "GENE_OR_GENE_PRODUCT", 289, 294], ["pp1ab", "GENE_OR_GENE_PRODUCT", 377, 382], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 386, 399], ["coronaviruses", "ORGANISM", 401, 414], ["toroviruses", "CANCER", 419, 430], ["nsp12", "PROTEIN", 17, 22], ["arterivirus nsp12 and (putative) MTases", "PROTEIN", 184, 223], ["Coronaviridae family", "PROTEIN", 231, 251], ["nsp12", "PROTEIN", 289, 294], ["C-terminal portion", "PROTEIN", 355, 373], ["pp1ab", "PROTEIN", 377, 382], ["arteriviruses", "PROTEIN", 386, 399], ["EAV", "SPECIES", 50, 53], ["EAV replication", "TREATMENT", 50, 65], ["Sequence similarities", "TEST", 134, 155], ["arterivirus", "TEST", 184, 195], ["nsp12", "TREATMENT", 289, 294], ["arteriviruses", "TREATMENT", 386, 399], ["coronaviruses", "PROBLEM", 401, 414], ["toroviruses", "TREATMENT", 419, 430]]], ["Starting at the ZBD, the region analysed included the three proteins implicated in 59 cap formation in coronaviruses.", [["cap", "ANATOMY", 86, 89], ["coronaviruses", "ORGANISM", 103, 116], ["ZBD", "DNA", 16, 19], ["coronaviruses", "PROBLEM", 103, 116], ["59 cap", "OBSERVATION_MODIFIER", 83, 89]]], ["We found that nsp12 was conserved in all established and provisional arterivirus species, including the most distantly related wobbly possum disease virus (WPDV).", [["nsp12", "GENE_OR_GENE_PRODUCT", 14, 19], ["wobbly possum disease virus", "ORGANISM", 127, 154], ["nsp12", "PROTEIN", 14, 19], ["wobbly possum disease virus", "SPECIES", 127, 154], ["WPDV", "SPECIES", 156, 160], ["nsp12", "PROBLEM", 14, 19], ["provisional arterivirus species", "PROBLEM", 57, 88], ["possum disease virus", "PROBLEM", 134, 154], ["arterivirus species", "OBSERVATION", 69, 88], ["possum disease", "OBSERVATION", 134, 148]]], ["Inspection of the arterivirus conservation profile showed that the entire nsp12 sequence exhibits similarity values that are below average for this pp1ab region (0.320 on a scale from 20.1 to 1.0; Fig. 2a ).", [["arterivirus", "CANCER", 18, 29], ["nsp12", "GENE_OR_GENE_PRODUCT", 74, 79], ["nsp12 sequence", "DNA", 74, 88], ["pp1ab region", "DNA", 148, 160], ["the arterivirus conservation profile", "TEST", 14, 50], ["the entire nsp12 sequence", "TEST", 63, 88], ["this pp1ab region", "PROBLEM", 143, 160]]], ["Only the C-terminal For the sake of simplicity, we have applied the nsp nomenclature of the subfamily Coronavirinae also to the orthologous torovirus domains for which the processing of pp1a/pp1ab is yet to be fully described.Sequence similarities and dissimilarities between arterivirus nsp12 and (putative) MTases of the Coronaviridae familydomain of nsp10 and to some extent the ZBD were similarly divergent, whilst the similarity of the nsp10 helicase core and particularly nsp11 were above average.", [["Coronavirinae", "GENE_OR_GENE_PRODUCT", 102, 115], ["torovirus", "GENE_OR_GENE_PRODUCT", 140, 149], ["pp1a", "GENE_OR_GENE_PRODUCT", 186, 190], ["pp1ab", "GENE_OR_GENE_PRODUCT", 191, 196], ["arterivirus nsp12", "GENE_OR_GENE_PRODUCT", 276, 293], ["(putative) MTases", "GENE_OR_GENE_PRODUCT", 298, 315], ["nsp10", "GENE_OR_GENE_PRODUCT", 353, 358], ["ZBD", "GENE_OR_GENE_PRODUCT", 382, 385], ["nsp10", "GENE_OR_GENE_PRODUCT", 441, 446], ["nsp11", "GENE_OR_GENE_PRODUCT", 478, 483], ["Coronavirinae", "PROTEIN", 102, 115], ["orthologous torovirus domains", "DNA", 128, 157], ["pp1a", "PROTEIN", 186, 190], ["pp1ab", "PROTEIN", 191, 196], ["arterivirus nsp12 and (putative) MTases", "PROTEIN", 276, 315], ["Coronaviridae familydomain", "PROTEIN", 323, 349], ["nsp10", "PROTEIN", 353, 358], ["ZBD", "DNA", 382, 385], ["nsp10 helicase core", "DNA", 441, 460], ["nsp11", "DNA", 478, 483], ["pp1a/pp1ab", "TREATMENT", 186, 196], ["Sequence similarities", "TEST", 226, 247], ["arterivirus", "TEST", 276, 287], ["the Coronaviridae familydomain of nsp10", "TREATMENT", 319, 358], ["the nsp10 helicase core", "TREATMENT", 437, 460]]], ["This remarkably low conservation distinguishes arterivirus nsp12 also from all proteins in this region of the coronaviruses (average conservation 0.491) and toroviruses (0.270), including nsp16 (Fig. 2b, c) .", [["nsp12", "GENE_OR_GENE_PRODUCT", 59, 64], ["coronaviruses", "ORGANISM", 110, 123], ["arterivirus nsp12", "PROTEIN", 47, 64], ["nsp16", "PROTEIN", 188, 193], ["Fig. 2b, c)", "PROTEIN", 195, 206], ["the coronaviruses", "PROBLEM", 106, 123], ["toroviruses", "TEST", 157, 168], ["nsp16", "TEST", 188, 193], ["low conservation", "OBSERVATION", 16, 32], ["coronaviruses", "OBSERVATION", 110, 123]]], ["Accordingly, arterivirus nsp12 contains the smallest number of conserved residues amongst the analysed proteins, with only a single phenylalanine (F109 in EAV) being evolutionarily invariant (Fig. 3 ).", [["phenylalanine", "CHEMICAL", 132, 145], ["phenylalanine", "CHEMICAL", 132, 145], ["arterivirus nsp12", "GENE_OR_GENE_PRODUCT", 13, 30], ["phenylalanine", "SIMPLE_CHEMICAL", 132, 145], ["arterivirus nsp12", "PROTEIN", 13, 30], ["arterivirus nsp12", "TREATMENT", 13, 30], ["conserved residues", "PROBLEM", 63, 81], ["a single phenylalanine (F109 in EAV", "TREATMENT", 123, 158], ["smallest", "OBSERVATION_MODIFIER", 44, 52], ["number", "OBSERVATION_MODIFIER", 53, 59], ["conserved residues", "OBSERVATION", 63, 81], ["invariant", "OBSERVATION_MODIFIER", 181, 190]]], ["Other notable conserved nsp12 residues (out of 18 in total) were an asparagine, a serine/threonine andZinc fingerpEAV030 six aromatic residues.", [["asparagine", "CHEMICAL", 68, 78], ["threonine", "CHEMICAL", 89, 98], ["Zinc", "CHEMICAL", 102, 106], ["asparagine", "CHEMICAL", 68, 78], ["serine", "CHEMICAL", 82, 88], ["threonine", "CHEMICAL", 89, 98], ["Zinc", "CHEMICAL", 102, 106], ["nsp12", "GENE_OR_GENE_PRODUCT", 24, 29], ["asparagine", "AMINO_ACID", 68, 78], ["serine", "AMINO_ACID", 82, 88], ["threonine", "AMINO_ACID", 89, 98], ["Zinc fingerpEAV030", "SIMPLE_CHEMICAL", 102, 120], ["nsp12 residues", "PROTEIN", 24, 38], ["an asparagine", "TREATMENT", 65, 78], ["a serine/threonine", "TREATMENT", 80, 98], ["Zinc", "TREATMENT", 102, 106], ["nsp12 residues", "OBSERVATION", 24, 38], ["aromatic residues", "OBSERVATION", 125, 142]]], ["We also noted the presence of four conserved cysteines in a pattern typical for zinc fingers in the C-terminal part of nsp12 in the five simian arteriviruses, which constitute a phylogenetically compact cluster.", [["zinc", "CHEMICAL", 80, 84], ["simian arteriviruses", "DISEASE", 137, 157], ["cysteines", "CHEMICAL", 45, 54], ["zinc", "CHEMICAL", 80, 84], ["C", "CHEMICAL", 100, 101], ["nsp12", "GENE_OR_GENE_PRODUCT", 119, 124], ["simian", "ORGANISM", 137, 143], ["arteriviruses", "CANCER", 144, 157], ["zinc fingers", "PROTEIN", 80, 92], ["C-terminal part", "PROTEIN", 100, 115], ["nsp12", "PROTEIN", 119, 124], ["simian arteriviruses", "SPECIES", 137, 157], ["zinc fingers", "PROBLEM", 80, 92], ["cysteines", "OBSERVATION", 45, 54], ["zinc fingers", "OBSERVATION", 80, 92], ["terminal part", "ANATOMY_MODIFIER", 102, 115], ["five simian arteriviruses", "ANATOMY", 132, 157]]], ["Patristic pair-wise distances (PPDs) of nsp12 compared with those of ZBD, HEL1 and NendoU were consistently larger, whilst PPDs of (putative) 29-O-MTases were comparable on average with those of five other domains in the coronaviruses and toroviruses (Fig. S1 , available in the online Supplementary Material).", [["nsp12", "GENE_OR_GENE_PRODUCT", 40, 45], ["ZBD", "GENE_OR_GENE_PRODUCT", 69, 72], ["HEL1", "GENE_OR_GENE_PRODUCT", 74, 78], ["NendoU", "GENE_OR_GENE_PRODUCT", 83, 89], ["29-O-MTases", "GENE_OR_GENE_PRODUCT", 142, 153], ["coronaviruses", "ORGANISM", 221, 234], ["toroviruses", "GENE_OR_GENE_PRODUCT", 239, 250], ["nsp12", "DNA", 40, 45], ["ZBD", "DNA", 69, 72], ["HEL1", "DNA", 74, 78], ["NendoU", "DNA", 83, 89], ["S1", "PROTEIN", 257, 259], ["nsp12", "PROBLEM", 40, 45], ["MTases", "PROBLEM", 147, 153], ["larger", "OBSERVATION_MODIFIER", 108, 114], ["coronaviruses", "OBSERVATION", 221, 234]]], ["These results showed that, in comparison with the coronavirus 29-O-MTase, nsp12 must have evolved under unusually relaxed constraints or in a changing molecular environment.", [["O-MTase", "GENE_OR_GENE_PRODUCT", 65, 72], ["nsp12", "GENE_OR_GENE_PRODUCT", 74, 79], ["coronavirus 29-O-MTase", "PROTEIN", 50, 72], ["nsp12", "PROTEIN", 74, 79], ["the coronavirus", "TEST", 46, 61], ["unusually", "OBSERVATION_MODIFIER", 104, 113], ["relaxed constraints", "OBSERVATION", 114, 133]]], ["Secondary structure predictions using JPred and PSIPRED consistently indicated the alternation of ahelices and b-strands in arterivirus nsp12 (Fig. 3) .", [["ahelices", "GENE_OR_GENE_PRODUCT", 98, 106], ["JPred", "PROTEIN", 38, 43], ["PSIPRED", "DNA", 48, 55], ["ahelices", "PROTEIN", 98, 106], ["arterivirus nsp12", "PROTEIN", 124, 141], ["Secondary structure predictions", "PROBLEM", 0, 31], ["JPred", "TREATMENT", 38, 43], ["PSIPRED", "TREATMENT", 48, 55], ["the alternation of ahelices", "PROBLEM", 79, 106]]], ["Interestingly, the coronavirus MTases also belong to the a/b structural class and contain conserved aromatic residues (Chen et al., 2011; Decroly et al., 2011) .", [["coronavirus MTases", "ORGANISM", 19, 37], ["coronavirus MTases", "PROTEIN", 19, 37], ["the coronavirus MTases", "PROBLEM", 15, 37], ["conserved aromatic residues", "PROBLEM", 90, 117], ["coronavirus MTases", "OBSERVATION", 19, 37], ["aromatic residues", "OBSERVATION", 100, 117]]], ["Nevertheless, HH-suite profile-profile comparison did not reveal sequence similarity above the background between nsp12 and the 29-O-MTase of coronaviruses or toroviruses, E 5 0.41 and 0.53, respectively (Fig. S2 ).", [["nsp12", "GENE_OR_GENE_PRODUCT", 114, 119], ["coronaviruses", "ORGANISM", 142, 155], ["nsp12", "DNA", 114, 119], ["MTase", "PROTEIN", 133, 138], ["nsp12", "TEST", 114, 119], ["coronaviruses", "PROBLEM", 142, 155], ["toroviruses", "TEST", 159, 170]]], ["Furthermore, these proteins are also of different sizes: 119-178 (arterivirus nsp12) versus 263-312 aa (coronavirus nsp16), with the arterivirus proteins being also smaller than MTases of other origins.", [["nsp12", "GENE_OR_GENE_PRODUCT", 78, 83], ["nsp16", "GENE_OR_GENE_PRODUCT", 116, 121], ["coronavirus nsp16", "PROTEIN", 104, 121], ["arterivirus proteins", "PROTEIN", 133, 153], ["MTases", "PROTEIN", 178, 184], ["these proteins", "TEST", 13, 27], ["arterivirus nsp12", "TEST", 66, 83], ["aa (coronavirus nsp16", "TEST", 100, 121], ["the arterivirus proteins", "TEST", 129, 153], ["sizes", "OBSERVATION_MODIFIER", 50, 55], ["smaller", "OBSERVATION_MODIFIER", 165, 172], ["origins", "ANATOMY_MODIFIER", 194, 201]]], ["The above HHbased negative result contrasted with the strong similarity signal observed in (control) comparisons between arteriviruses and coronaviruses or toroviruses for HEL1 and NendoU (Ej3.5|10 -17 ) or in the control comparison between coronavirus and torovirus nsp16, E 5 2.3|10 -32 (Fig. S2 ).", [["arteriviruses", "CANCER", 121, 134], ["coronaviruses", "ORGANISM", 139, 152], ["toroviruses", "GENE_OR_GENE_PRODUCT", 156, 167], ["HEL1", "GENE_OR_GENE_PRODUCT", 172, 176], ["coronavirus", "ORGANISM", 241, 252], ["torovirus nsp16", "ORGANISM", 257, 272], ["HEL1", "PROTEIN", 172, 176], ["NendoU", "PROTEIN", 181, 187], ["arteriviruses", "TEST", 121, 134], ["coronaviruses", "PROBLEM", 139, 152], ["toroviruses", "TEST", 156, 167], ["HEL1", "TEST", 172, 176], ["NendoU", "TEST", 181, 187], ["coronavirus", "TEST", 241, 252]]], ["No statistically significant similarity was observed between nsp12 and other proteins in a hidden Markov model (HMM)-based scan of the Pfam-A database (top hit: PF12581, E 5 1.0).", [["nsp12", "GENE_OR_GENE_PRODUCT", 61, 66], ["nsp12", "PROTEIN", 61, 66], ["Pfam", "PROTEIN", 135, 139], ["the Pfam", "TEST", 131, 139], ["A database", "TEST", 140, 150], ["PF12581", "TEST", 161, 168], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["similarity", "OBSERVATION", 29, 39]]], ["We thus concluded that nsp12 has diverged beyond recognition from its homologues and differs considerably from the 29-O-MTase of large nidoviruses.", [["nsp12", "CHEMICAL", 23, 28], ["nsp12", "GENE_OR_GENE_PRODUCT", 23, 28], ["nidoviruses", "GENE_OR_GENE_PRODUCT", 135, 146], ["nsp12", "PROTEIN", 23, 28], ["29-O-MTase", "PROTEIN", 115, 125], ["large nidoviruses", "PROBLEM", 129, 146], ["large", "OBSERVATION_MODIFIER", 129, 134], ["nidoviruses", "OBSERVATION", 135, 146]]], ["Nevertheless, the results obtained did not rule out the possibility that it could be a deviant MTase, and we therefore set out to test this hypothesis experimentally by biochemical and molecular virological methods.Zinc fingerPurification of recombinant EAV nsp12 and several ORF1a-encoded proteinsZinc fingerWe engineered vectors encoding recombinant EAV nsp12 derivatives carrying either an N-terminal or a C-terminal His6-tag and expressed them in Escherichia coli.", [["Zinc", "CHEMICAL", 215, 219], ["Zinc", "CHEMICAL", 215, 219], ["Zinc", "CHEMICAL", 298, 302], ["N", "CHEMICAL", 393, 394], ["C", "CHEMICAL", 409, 410], ["MTase", "GENE_OR_GENE_PRODUCT", 95, 100], ["Zinc", "SIMPLE_CHEMICAL", 215, 219], ["EAV", "ORGANISM", 254, 257], ["nsp12", "GENE_OR_GENE_PRODUCT", 258, 263], ["ORF1a", "GENE_OR_GENE_PRODUCT", 276, 281], ["Zinc", "GENE_OR_GENE_PRODUCT", 298, 302], ["EAV", "ORGANISM", 352, 355], ["nsp12", "GENE_OR_GENE_PRODUCT", 356, 361], ["Escherichia coli", "ORGANISM", 451, 467], ["MTase", "PROTEIN", 95, 100], ["recombinant EAV nsp12", "PROTEIN", 242, 263], ["ORF1a", "PROTEIN", 276, 281], ["Zinc fingerWe engineered vectors", "DNA", 298, 330], ["recombinant EAV nsp12 derivatives", "PROTEIN", 340, 373], ["N-terminal", "PROTEIN", 393, 403], ["C-terminal His6-tag", "PROTEIN", 409, 428], ["Escherichia coli", "SPECIES", 451, 467], ["EAV", "SPECIES", 254, 257], ["EAV", "SPECIES", 352, 355], ["Escherichia coli", "SPECIES", 451, 467], ["a deviant MTase", "PROBLEM", 85, 100], ["Zinc fingerPurification", "TEST", 215, 238], ["recombinant EAV nsp12", "TREATMENT", 242, 263], ["several ORF1a", "TREATMENT", 268, 281], ["encoded proteinsZinc fingerWe engineered vectors", "TREATMENT", 282, 330], ["recombinant EAV nsp12 derivatives", "TREATMENT", 340, 373], ["Escherichia coli", "PROBLEM", 451, 467], ["recombinant EAV", "OBSERVATION", 242, 257], ["Escherichia coli", "OBSERVATION", 451, 467]]], ["Only the N-terminally tagged protein was successfully expressed and purified by metal affinity chromatography using Co 2+ (Talon) beads (Fig. 4a) .", [["Co 2", "CHEMICAL", 116, 120], ["N", "CHEMICAL", 9, 10], ["Co 2+", "CHEMICAL", 116, 121], ["Co 2+", "SIMPLE_CHEMICAL", 116, 121], ["N-terminally tagged protein", "PROTEIN", 9, 36], ["metal affinity chromatography", "TEST", 80, 109], ["Co 2+ (Talon) beads", "TREATMENT", 116, 135]]], ["The protein appeared to be reasonably stable under all conditions tested, including a pH range from 6.0 to 7.5 and protein concentrations of up to 500 mM.", [["The protein", "TEST", 0, 11], ["a pH range", "TEST", 84, 94], ["protein concentrations", "TEST", 115, 137], ["stable", "OBSERVATION", 38, 44]]], ["Yet upon storage the protein increasingly formed dimers and higher-order multimers, even in the presence of 1 mM DTT.", [["DTT", "CHEMICAL", 113, 116], ["DTT", "SIMPLE_CHEMICAL", 113, 116], ["1 mM DTT", "TREATMENT", 108, 116], ["formed dimers", "OBSERVATION", 42, 55]]], ["In gel filtration experiments with fresh protein these oligomers were not evident.", [["gel filtration experiments", "TREATMENT", 3, 29], ["fresh protein these oligomers", "PROBLEM", 35, 64], ["not evident", "UNCERTAINTY", 70, 81]]], ["Instead, a single peak was observed (not shown) that corresponded well to the expected size of an nsp12 monomer (calculated weight 13 kDa versus predicted weight based on Stokes radius 16 kDa).Zinc fingerIn addition to nsp12, we also expressed five small mature proteins and cleavage intermediates from the nsp7 region of pp1a [nsp6-7, nsp6-7-8, nsp7a, nsp7b and nsp7 (i.e. nsp7a-7b)] (van Aken et al., 2006; Wassenaar et al., 1997) (Fig. 4b) .", [["Zinc", "CHEMICAL", 193, 197], ["Zinc", "CHEMICAL", 193, 197], ["nsp12", "GENE_OR_GENE_PRODUCT", 98, 103], ["Zinc fingerIn", "GENE_OR_GENE_PRODUCT", 193, 206], ["nsp12", "GENE_OR_GENE_PRODUCT", 219, 224], ["nsp7", "GENE_OR_GENE_PRODUCT", 307, 311], ["pp1a", "GENE_OR_GENE_PRODUCT", 322, 326], ["nsp6-7", "GENE_OR_GENE_PRODUCT", 328, 334], ["nsp6-7-8", "GENE_OR_GENE_PRODUCT", 336, 344], ["nsp7a", "GENE_OR_GENE_PRODUCT", 346, 351], ["nsp7b", "GENE_OR_GENE_PRODUCT", 353, 358], ["nsp7", "GENE_OR_GENE_PRODUCT", 363, 367], ["nsp12 monomer", "PROTEIN", 98, 111], ["nsp12", "PROTEIN", 219, 224], ["small mature proteins", "PROTEIN", 249, 270], ["nsp7 region", "PROTEIN", 307, 318], ["pp1a", "PROTEIN", 322, 326], ["nsp6", "PROTEIN", 328, 332], ["nsp6", "PROTEIN", 336, 340], ["nsp7a", "PROTEIN", 346, 351], ["nsp7b", "DNA", 353, 358], ["nsp7", "DNA", 363, 367], ["nsp7a", "PROTEIN", 374, 379], ["a single peak", "TEST", 9, 22], ["an nsp12 monomer", "TREATMENT", 95, 111], ["weight", "TEST", 124, 130], ["weight", "TEST", 155, 161], ["nsp12", "TREATMENT", 219, 224], ["small mature proteins", "PROBLEM", 249, 270], ["pp1a", "TEST", 322, 326], ["nsp6", "TEST", 328, 332], ["nsp6", "TEST", 336, 340], ["nsp7a", "TEST", 346, 351], ["nsp7b", "TEST", 353, 358], ["nsp7", "TEST", 363, 367], ["nsp7a", "TEST", 374, 379], ["Wassenaar et al.", "TEST", 409, 425], ["Fig.", "TEST", 434, 438], ["size", "OBSERVATION_MODIFIER", 87, 91]]], ["In coronaviruses, the corresponding part of ORF1a encodes nsp10, an essential co-factor for the 29-O-MTase (Bouvet et al., 2010) .", [["coronaviruses", "ORGANISM", 3, 16], ["ORF1a", "GENE_OR_GENE_PRODUCT", 44, 49], ["nsp10", "GENE_OR_GENE_PRODUCT", 58, 63], ["ORF1a", "PROTEIN", 44, 49], ["nsp10", "PROTEIN", 58, 63], ["MTase", "PROTEIN", 101, 106], ["coronaviruses", "OBSERVATION", 3, 16]]], ["Consequently, we added these purified recombinant proteins to nsp12 in MTase activity assays (see below).Recombinant nsp12 does not display in vitroMTase activity using a variety of substrates Using purified arterivirus proteins, we proceeded to test for MTase activity in the presence of different methyl acceptors by employing an in vitro assay similar to that previously established for severe acute respiratory syndrome coronavirus (SARS-CoV) nsp14 and nsp16 (Bouvet et al., 2010) .", [["methyl", "CHEMICAL", 299, 305], ["acute respiratory syndrome coronavirus", "DISEASE", 397, 435], ["methyl", "CHEMICAL", 299, 305], ["nsp12", "GENE_OR_GENE_PRODUCT", 62, 67], ["MTase", "GENE_OR_GENE_PRODUCT", 71, 76], ["nsp12", "GENE_OR_GENE_PRODUCT", 117, 122], ["vitroMTase", "GENE_OR_GENE_PRODUCT", 143, 153], ["MTase", "GENE_OR_GENE_PRODUCT", 255, 260], ["methyl acceptors", "SIMPLE_CHEMICAL", 299, 315], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 390, 435], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 437, 445], ["nsp14", "GENE_OR_GENE_PRODUCT", 447, 452], ["nsp16", "GENE_OR_GENE_PRODUCT", 457, 462], ["purified recombinant proteins", "PROTEIN", 29, 58], ["nsp12", "PROTEIN", 62, 67], ["MTase", "PROTEIN", 71, 76], ["nsp12", "PROTEIN", 117, 122], ["vitroMTase", "PROTEIN", 143, 153], ["purified arterivirus proteins", "PROTEIN", 199, 228], ["MTase", "PROTEIN", 255, 260], ["severe acute respiratory syndrome coronavirus", "SPECIES", 390, 435], ["SARS-CoV", "SPECIES", 437, 445], ["these purified recombinant proteins", "TREATMENT", 23, 58], ["nsp12", "TREATMENT", 62, 67], ["MTase activity assays", "TEST", 71, 92], ["a variety of substrates", "TREATMENT", 169, 192], ["MTase activity", "PROBLEM", 255, 269], ["different methyl acceptors", "TREATMENT", 289, 315], ["an in vitro assay", "TEST", 329, 346], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 390, 435], ["nsp14", "TREATMENT", 447, 452], ["severe", "OBSERVATION_MODIFIER", 390, 396], ["acute", "OBSERVATION_MODIFIER", 397, 402], ["respiratory syndrome", "OBSERVATION", 403, 423]]], ["In agreement with the published results (Bouvet et al., 2010; Chen et al., 2009; Jin et al., 2013) , both SARS-CoV MTases (kindly provided by Dr Etienne Decroly, AFMB, Marseille, France), which were used as positive controls, transferred the radioactive methyl group from the universal methyl donor S-adenosylmethionine to non-methylated or N7-methylated cap analogues (Fig. 5) .", [["methyl", "CHEMICAL", 254, 260], ["methyl", "CHEMICAL", 286, 292], ["S-adenosylmethionine", "CHEMICAL", 299, 319], ["methyl", "CHEMICAL", 254, 260], ["methyl", "CHEMICAL", 286, 292], ["S-adenosylmethionine", "CHEMICAL", 299, 319], ["N7", "CHEMICAL", 341, 343], ["SARS-CoV MTases", "GENE_OR_GENE_PRODUCT", 106, 121], ["methyl", "SIMPLE_CHEMICAL", 254, 260], ["methyl donor S-adenosylmethionine", "SIMPLE_CHEMICAL", 286, 319], ["N7-methylated cap analogues", "SIMPLE_CHEMICAL", 341, 368], ["SARS-CoV", "SPECIES", 106, 114], ["the radioactive methyl group", "TREATMENT", 238, 266], ["the universal methyl donor S-adenosylmethionine", "TREATMENT", 272, 319], ["N7-methylated cap analogues", "TREATMENT", 341, 368]]], ["Likewise, vaccinia virus capping enzyme, obtained from a commercial source and known to harbour N7-MTase activity, also demonstrated the expected activity.", [["vaccinia virus", "ORGANISM", 10, 24], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 96, 104], ["vaccinia virus capping enzyme", "PROTEIN", 10, 39], ["MTase", "PROTEIN", 99, 104], ["vaccinia virus", "SPECIES", 10, 24], ["vaccinia virus capping enzyme", "TEST", 10, 39], ["vaccinia virus", "OBSERVATION", 10, 24], ["activity", "OBSERVATION_MODIFIER", 146, 154]]], ["Based on these activities and the results of two negative control reactions (assays using BSA and no acceptor), we defined an incorporation threshold of 1000 c.p.m. to distinguish the enzyme activity in this assay.", [["BSA", "SIMPLE_CHEMICAL", 90, 93], ["enzyme", "PROTEIN", 184, 190], ["BSA", "TEST", 90, 93], ["an incorporation threshold", "TEST", 123, 149], ["the enzyme activity in this assay", "PROBLEM", 180, 213]]], ["According to this definition, EAV nsp12 did not display activity with any of the methyl acceptors in the absence or presence of any of the potential ORF1aencoded co-factors described above (nsp6-7, nsp6-7-8, nsp7a, nsp7b and nsp7).", [["methyl", "CHEMICAL", 81, 87], ["methyl", "CHEMICAL", 81, 87], ["EAV", "ORGANISM", 30, 33], ["nsp12", "GENE_OR_GENE_PRODUCT", 34, 39], ["methyl acceptors", "SIMPLE_CHEMICAL", 81, 97], ["ORF1aencoded", "GENE_OR_GENE_PRODUCT", 149, 161], ["nsp6-7", "GENE_OR_GENE_PRODUCT", 190, 196], ["nsp6-7-8", "GENE_OR_GENE_PRODUCT", 198, 206], ["nsp7a", "GENE_OR_GENE_PRODUCT", 208, 213], ["nsp7b", "GENE_OR_GENE_PRODUCT", 215, 220], ["nsp7", "GENE_OR_GENE_PRODUCT", 225, 229], ["EAV nsp12", "DNA", 30, 39], ["ORF1aencoded co-factors", "PROTEIN", 149, 172], ["nsp6", "PROTEIN", 190, 194], ["nsp6", "PROTEIN", 198, 202], ["nsp7a", "PROTEIN", 208, 213], ["nsp7b", "PROTEIN", 215, 220], ["nsp7", "PROTEIN", 225, 229], ["EAV", "SPECIES", 30, 33], ["EAV nsp12", "TEST", 30, 39], ["the methyl acceptors", "TREATMENT", 77, 97], ["the potential ORF1aencoded co-factors", "PROBLEM", 135, 172], ["nsp6", "TEST", 190, 194], ["nsp6", "TEST", 198, 202], ["nsp7a", "TEST", 208, 213]]], ["However, we can not exclude the possibility that the relatively high background may have obscured any low-level activity, if present.Recombinant nsp12 does not display in vitroTolerance of EAV replication to nsp12 mutagenesis correlates with the natural variation of probed residuesRecombinant nsp12 does not display in vitroTo establish the general importance of nsp12 for EAV replication, we used reverse genetics to assess whether EAV tolerated replacements at conserved positions, including the single absolutely (F109) and 10 partially (F26, N35, S45, Y49, S56, Y64, Y70, F82, C84 and F107) conserved residues (Fig. 3) .", [["F26, N35, S45, Y49, S56, Y64, Y70, F82, C84 and F107", "CHEMICAL", 542, 594], ["nsp12", "GENE_OR_GENE_PRODUCT", 145, 150], ["EAV", "ORGANISM", 189, 192], ["nsp12", "GENE_OR_GENE_PRODUCT", 208, 213], ["nsp12", "GENE_OR_GENE_PRODUCT", 294, 299], ["nsp12", "GENE_OR_GENE_PRODUCT", 364, 369], ["EAV", "ORGANISM", 374, 377], ["nsp12", "PROTEIN", 145, 150], ["nsp12", "DNA", 208, 213], ["nsp12", "PROTEIN", 294, 299], ["nsp12", "PROTEIN", 364, 369], ["EAV", "SPECIES", 189, 192], ["EAV", "SPECIES", 374, 377], ["EAV", "SPECIES", 434, 437], ["any low-level activity", "PROBLEM", 98, 120], ["EAV replication", "TREATMENT", 189, 204], ["nsp12", "TREATMENT", 364, 369], ["EAV replication", "TREATMENT", 374, 389], ["EAV tolerated replacements", "TREATMENT", 434, 460], ["can not exclude the possibility", "UNCERTAINTY", 12, 43], ["low-level activity", "OBSERVATION_MODIFIER", 102, 120]]], ["We also tested replacements of three poorly conserved residues (S25, S30 and Y32) that served as controls.", [["replacements", "TREATMENT", 15, 27], ["S25, S30 and Y32)", "TREATMENT", 64, 81]]], ["Furthermore, we also abolished nsp12 expression by replacing its codons 6-8 with three consecutive translation termination codons (STOP mutant).", [["nsp12", "GENE_OR_GENE_PRODUCT", 31, 36], ["nsp12", "PROTEIN", 31, 36], ["codons 6-8", "DNA", 65, 75], ["translation termination codons", "DNA", 99, 129], ["STOP mutant", "DNA", 131, 142], ["its codons", "TREATMENT", 61, 71], ["three consecutive translation termination codons", "TREATMENT", 81, 129]]], ["The engineered cDNA clones were used for in vitro transcription, yielding full-length RNA that was subsequently electroporated into BHK-21 cells.", [["BHK-21 cells", "ANATOMY", 132, 144], ["cDNA clones", "CELL", 15, 26], ["BHK-21 cells", "CELL", 132, 144], ["cDNA clones", "DNA", 15, 26], ["BHK-21 cells", "CELL_LINE", 132, 144], ["The engineered cDNA clones", "TREATMENT", 0, 26], ["full-length RNA", "TREATMENT", 74, 89], ["cDNA clones", "OBSERVATION", 15, 26]]], ["The effects of the replacements were first assessed on the level of viral protein expression by immunofluorescence microscopy utilizing antibodies against nsp3 and the structural nucleocapsid (N) protein.", [["nsp3", "GENE_OR_GENE_PRODUCT", 155, 159], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 179, 195], ["viral protein", "PROTEIN", 68, 81], ["antibodies", "PROTEIN", 136, 146], ["nsp3", "PROTEIN", 155, 159], ["structural nucleocapsid (N) protein", "PROTEIN", 168, 203], ["the replacements", "TREATMENT", 15, 31], ["viral protein expression", "TREATMENT", 68, 92], ["immunofluorescence microscopy", "TEST", 96, 125], ["antibodies", "TEST", 136, 146], ["nsp3", "PROBLEM", 155, 159], ["viral protein", "OBSERVATION", 68, 81]]], ["Furthermore, we monitored the production of virus progeny by harvesting transfected cell culture supernatants and performing plaque assays (Table 1) .Recombinant nsp12 does not display in vitroNeither protein expression nor progeny production was observed for the STOP mutant, indicating that nsp12 performed an indispensable function during virus replication.", [["cell", "ANATOMY", 84, 88], ["supernatants", "ANATOMY", 97, 109], ["plaque", "ANATOMY", 125, 131], ["cell", "CELL", 84, 88], ["nsp12", "GENE_OR_GENE_PRODUCT", 162, 167], ["vitroNeither", "GENE_OR_GENE_PRODUCT", 188, 200], ["STOP", "GENE_OR_GENE_PRODUCT", 264, 268], ["nsp12", "GENE_OR_GENE_PRODUCT", 293, 298], ["nsp12", "PROTEIN", 162, 167], ["STOP mutant", "PROTEIN", 264, 275], ["nsp12", "PROTEIN", 293, 298], ["virus progeny", "TREATMENT", 44, 57], ["plaque assays", "TEST", 125, 138], ["virus replication", "TREATMENT", 342, 359]]], ["Alternatively, the truncation of nps12 may have affected virus viability indirectly, e.g. by impairing proteolytic cleavage of the nsp11/nsp12 junction, which might be detrimental to the activity of the nsp11 endoribonuclease.", [["nps12", "CHEMICAL", 33, 38], ["nps12", "GENE_OR_GENE_PRODUCT", 33, 38], ["nsp11", "GENE_OR_GENE_PRODUCT", 131, 136], ["nsp12", "GENE_OR_GENE_PRODUCT", 137, 142], ["nsp11", "GENE_OR_GENE_PRODUCT", 203, 208], ["nps12", "PROTEIN", 33, 38], ["nsp11", "PROTEIN", 131, 136], ["nsp12", "PROTEIN", 137, 142], ["nsp11 endoribonuclease", "PROTEIN", 203, 225], ["the truncation of nps12", "PROBLEM", 15, 38], ["affected virus viability", "PROBLEM", 48, 72], ["impairing proteolytic cleavage", "PROBLEM", 93, 123], ["virus viability", "OBSERVATION", 57, 72], ["impairing", "OBSERVATION_MODIFIER", 93, 102], ["proteolytic cleavage", "OBSERVATION", 103, 123], ["nsp12 junction", "ANATOMY", 137, 151]]], ["This concern was addressed by replacing individual nsp12 residues.Recombinant nsp12 does not display in vitroThe 14 residues probed by making 25 mutants could be classified into four groups based on the impact of their replacement.", [["nsp12", "GENE_OR_GENE_PRODUCT", 51, 56], ["nsp12", "GENE_OR_GENE_PRODUCT", 78, 83], ["nsp12 residues", "PROTEIN", 51, 65], ["nsp12", "PROTEIN", 78, 83], ["individual nsp12 residues", "TREATMENT", 40, 65], ["The 14 residues", "TREATMENT", 109, 124], ["their replacement", "TREATMENT", 213, 230], ["replacement", "OBSERVATION", 219, 230]]], ["The first group included residues F107 and F109, with the four mutants carrying alanine or (more conservative) tyrosine substitutions at these positions not producing any virus progeny.", [["alanine", "CHEMICAL", 80, 87], ["tyrosine", "CHEMICAL", 111, 119], ["alanine", "CHEMICAL", 80, 87], ["tyrosine", "CHEMICAL", 111, 119], ["alanine", "AMINO_ACID", 80, 87], ["tyrosine", "AMINO_ACID", 111, 119], ["F109", "TREATMENT", 43, 47], ["conservative) tyrosine substitutions", "TREATMENT", 97, 133]]], ["Interestingly, in contrast to both alanine mutants and F109Y, which also did not produce viral proteins, immunofluorescence signal for nsp3 and N protein was detected for F107Y at 24 and 48 h posttransfection (p.t.), with a stronger signal being observed at the earlier time point.", [["alanine", "CHEMICAL", 35, 42], ["alanine", "CHEMICAL", 35, 42], ["alanine", "AMINO_ACID", 35, 42], ["F109Y", "AMINO_ACID", 55, 60], ["nsp3", "GENE_OR_GENE_PRODUCT", 135, 139], ["alanine mutants", "PROTEIN", 35, 50], ["F109Y", "PROTEIN", 55, 60], ["viral proteins", "PROTEIN", 89, 103], ["nsp3", "PROTEIN", 135, 139], ["N protein", "PROTEIN", 144, 153], ["F107Y", "PROTEIN", 171, 176], ["viral proteins", "PROBLEM", 89, 103], ["immunofluorescence signal", "TEST", 105, 130], ["nsp3 and N protein", "TEST", 135, 153], ["a stronger signal", "PROBLEM", 222, 239]]], ["Collectively, these results showed that F107 or F109 were most strongly constrained in EAV and indicated a vital role of these residues in virus viability.Recombinant nsp12 does not display in vitroThe second group comprised residues F26, N35 and C84, which appeared to be only slightly less important than the aforementioned F107 and F109, based on the phenotype of five mutants.", [["F107", "GENE_OR_GENE_PRODUCT", 40, 44], ["F109", "GENE_OR_GENE_PRODUCT", 48, 52], ["EAV", "ORGANISM", 87, 90], ["nsp12", "GENE_OR_GENE_PRODUCT", 167, 172], ["nsp12", "PROTEIN", 167, 172], ["F107", "PROTEIN", 326, 330], ["F109", "PROTEIN", 335, 339], ["EAV", "SPECIES", 87, 90], ["these residues in virus viability", "PROBLEM", 121, 154], ["virus viability", "OBSERVATION", 139, 154], ["slightly", "OBSERVATION_MODIFIER", 278, 286], ["less", "OBSERVATION_MODIFIER", 287, 291]]], ["Alanine substitutions at position F26 and N35 were either lethal (F26A) or severely detrimental (N35A), whereas tyrosine or aspartate substitutions of these residues (F26Y and N35D) were compatible with at least some residual replication, which allowed early reversion of these mutants.", [["Alanine", "CHEMICAL", 0, 7], ["tyrosine", "CHEMICAL", 112, 120], ["aspartate", "CHEMICAL", 124, 133], ["Alanine", "CHEMICAL", 0, 7], ["tyrosine", "CHEMICAL", 112, 120], ["aspartate", "CHEMICAL", 124, 133], ["Alanine", "AMINO_ACID", 0, 7], ["N35", "AMINO_ACID", 42, 45], ["tyrosine", "AMINO_ACID", 112, 120], ["aspartate", "AMINO_ACID", 124, 133], ["Alanine substitutions at position F26", "TREATMENT", 0, 37], ["N35", "TREATMENT", 42, 45], ["severely detrimental (N35A)", "PROBLEM", 75, 102], ["aspartate substitutions of these residues", "PROBLEM", 124, 165], ["some residual replication", "PROBLEM", 212, 237], ["these mutants", "PROBLEM", 272, 285], ["residual replication", "OBSERVATION", 217, 237]]], ["Similarly, the C84Y mutant also reverted, which was notable given the presence of a tyrosine at this position in most other arteriviruses.Recombinant nsp12 does not display in vitro(75 nM, N 7 -MTase); SARS nsp10/nsp16 (2 mM complex, 29-O-MTase); SARS, SARS coronavirus; BSA served as negative control.", [["arteriviruses", "ANATOMY", 124, 137], ["tyrosine", "CHEMICAL", 84, 92], ["SARS", "DISEASE", 247, 251], ["SARS coronavirus", "DISEASE", 253, 269], ["tyrosine", "CHEMICAL", 84, 92], ["C84Y", "GENE_OR_GENE_PRODUCT", 15, 19], ["tyrosine", "AMINO_ACID", 84, 92], ["arteriviruses", "CANCER", 124, 137], ["nsp12", "GENE_OR_GENE_PRODUCT", 150, 155], ["p16", "GENE_OR_GENE_PRODUCT", 215, 218], ["29-O-MTase", "SIMPLE_CHEMICAL", 234, 244], ["SARS coronavirus", "ORGANISM", 253, 269], ["BSA", "SIMPLE_CHEMICAL", 271, 274], ["C84Y mutant", "PROTEIN", 15, 26], ["nsp12", "PROTEIN", 150, 155], ["MTase", "PROTEIN", 194, 199], ["SARS nsp10", "PROTEIN", 202, 212], ["p16", "PROTEIN", 215, 218], ["MTase", "PROTEIN", 239, 244], ["SARS coronavirus", "SPECIES", 253, 269], ["a tyrosine", "TREATMENT", 82, 92], ["vitro", "TEST", 176, 181], ["N", "TEST", 189, 190], ["SARS nsp10", "TEST", 202, 212], ["SARS", "PROBLEM", 247, 251], ["SARS coronavirus", "PROBLEM", 253, 269], ["BSA", "TEST", 271, 274]]], ["Reslults are presented as mean\u00a1SD of two independent experiments.", [["two", "OBSERVATION_MODIFIER", 37, 40], ["independent", "OBSERVATION_MODIFIER", 41, 52], ["experiments", "OBSERVATION", 53, 64]]], ["The background variation evident for several of the protein combinations using GTP, GpppG, GpppAC 4 or mGpppA most likely represents an artefact originating from a position effect, which was observed repeatedly in the employed 96-well format.Recombinant nsp12 does not display in vitroIn contrast to the above results, EAV tolerated replacements by another aromatic residue at four other partially conserved aromatic residues, Y49, Y64, Y70 and F82, which form group 3.", [["GTP", "CHEMICAL", 79, 82], ["GTP", "CHEMICAL", 79, 82], ["Y49, Y64, Y70 and F82", "CHEMICAL", 427, 448], ["GTP", "SIMPLE_CHEMICAL", 79, 82], ["GpppG", "GENE_OR_GENE_PRODUCT", 84, 89], ["GpppAC 4", "GENE_OR_GENE_PRODUCT", 91, 99], ["mGpppA", "GENE_OR_GENE_PRODUCT", 103, 109], ["nsp12", "GENE_OR_GENE_PRODUCT", 254, 259], ["GpppG", "PROTEIN", 84, 89], ["GpppAC 4", "PROTEIN", 91, 99], ["mGpppA", "PROTEIN", 103, 109], ["nsp12", "PROTEIN", 254, 259], ["EAV", "SPECIES", 319, 322], ["GTP", "TEST", 79, 82], ["GpppG", "TREATMENT", 84, 89], ["GpppAC", "TEST", 91, 97], ["mGpppA", "TREATMENT", 103, 109], ["an artefact", "PROBLEM", 133, 144], ["EAV tolerated replacements", "TREATMENT", 319, 345], ["another aromatic residue", "PROBLEM", 349, 373], ["most likely represents", "UNCERTAINTY", 110, 132], ["artefact", "OBSERVATION", 136, 144], ["position effect", "OBSERVATION", 164, 179], ["aromatic residue", "OBSERVATION", 357, 373], ["aromatic residues", "OBSERVATION", 408, 425]]], ["These virus mutants were stable and yielded progeny titres up to 1 log below that of the WT control.", [["These virus mutants", "PROBLEM", 0, 19], ["progeny titres", "PROBLEM", 44, 58], ["the WT control", "TREATMENT", 85, 99], ["stable", "OBSERVATION_MODIFIER", 25, 31]]], ["Interestingly, although the titre of Y49F was not very different from that of the parental virus, this mutant exhibited a small-plaque phenotype (Fig. 6) .", [["plaque", "ANATOMY", 128, 134], ["Y49F", "GENE_OR_GENE_PRODUCT", 37, 41], ["Y49F", "PROTEIN", 37, 41], ["the parental virus", "PROBLEM", 78, 96], ["a small-plaque phenotype", "PROBLEM", 120, 144], ["small", "OBSERVATION_MODIFIER", 122, 127], ["plaque", "OBSERVATION", 128, 134]]], ["In contrast, alanine substitutions at these positions were again lethal.Recombinant nsp12 does not display in vitroThe replacement -more or less conservative -of all residues mentioned thus far had a moderate to severe impact on virus replication.", [["alanine", "CHEMICAL", 13, 20], ["alanine", "CHEMICAL", 13, 20], ["alanine", "AMINO_ACID", 13, 20], ["nsp12", "GENE_OR_GENE_PRODUCT", 84, 89], ["nsp12", "PROTEIN", 84, 89], ["alanine substitutions", "TREATMENT", 13, 34], ["The replacement", "TREATMENT", 115, 130], ["all residues", "PROBLEM", 162, 174], ["a moderate to severe impact on virus replication", "PROBLEM", 198, 246], ["alanine substitutions", "OBSERVATION", 13, 34], ["replacement", "OBSERVATION", 119, 130], ["moderate", "OBSERVATION_MODIFIER", 200, 208], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["virus replication", "OBSERVATION", 229, 246]]], ["In contrast, the fourth group included five residues whose replacement neither affected viral protein production nor progeny titres.", [["viral protein", "PROTEIN", 88, 101], ["five residues whose replacement", "TREATMENT", 39, 70], ["affected viral protein production", "PROBLEM", 79, 112], ["viral protein", "OBSERVATION", 88, 101]]], ["Nevertheless, S30A exhibited a small-plaque phenotype (Fig. 6) .", [["plaque", "ANATOMY", 37, 43], ["S30A", "GENE_OR_GENE_PRODUCT", 14, 18], ["S30A", "PROTEIN", 14, 18], ["a small-plaque phenotype", "PROBLEM", 29, 53], ["small", "OBSERVATION_MODIFIER", 31, 36], ["plaque", "OBSERVATION", 37, 43]]], ["Unexpectedly, we also repeatedly observed the pseudo-reversion of Y32A to Y32V, which required only a single nucleotide change.", [["nucleotide", "CHEMICAL", 109, 119], ["nucleotide", "CHEMICAL", 109, 119], ["Y32A", "GENE_OR_GENE_PRODUCT", 66, 70], ["Y32A", "PROTEIN", 66, 70], ["Y32V", "DNA", 74, 78], ["a single nucleotide change", "TREATMENT", 100, 126]]], ["Although valine is not amongst the naturally occurring amino acid residues at this position (Fig. 3) , a hydrophobic residue is observed in several arteriviruses other than EAV.", [["valine", "CHEMICAL", 9, 15], ["amino acid", "CHEMICAL", 55, 65], ["valine", "CHEMICAL", 9, 15], ["amino acid", "CHEMICAL", 55, 65], ["valine", "AMINO_ACID", 9, 15], ["amino acid", "AMINO_ACID", 55, 65], ["arteriviruses", "CANCER", 148, 161], ["EAV", "SPECIES", 173, 176], ["valine", "TREATMENT", 9, 15], ["amino acid residues", "TREATMENT", 55, 74], ["a hydrophobic residue", "PROBLEM", 103, 124], ["EAV", "PROBLEM", 173, 176], ["hydrophobic residue", "OBSERVATION", 105, 124]]], ["In addition to substitutions of these control residues, EAV also tolerated the substitution of S56 with alanine or threonine.", [["S56", "CHEMICAL", 95, 98], ["alanine", "CHEMICAL", 104, 111], ["threonine", "CHEMICAL", 115, 124], ["alanine", "CHEMICAL", 104, 111], ["threonine", "CHEMICAL", 115, 124], ["S56", "SIMPLE_CHEMICAL", 95, 98], ["alanine", "AMINO_ACID", 104, 111], ["threonine", "AMINO_ACID", 115, 124], ["these control residues", "TREATMENT", 32, 54], ["EAV", "TREATMENT", 56, 59], ["the substitution of S56", "TREATMENT", 75, 98], ["alanine", "TREATMENT", 104, 111], ["threonine", "TREATMENT", 115, 124]]], ["Given the strict conservation of serine and threonine, this lack of impact was the expected outcome for S56T, but was rather surprising for S56A.", [["threonine", "CHEMICAL", 44, 53], ["serine", "CHEMICAL", 33, 39], ["threonine", "CHEMICAL", 44, 53], ["serine", "AMINO_ACID", 33, 39], ["threonine", "AMINO_ACID", 44, 53], ["S56T", "GENE_OR_GENE_PRODUCT", 104, 108], ["S56A", "GENE_OR_GENE_PRODUCT", 140, 144], ["S56T", "PROTEIN", 104, 108], ["S56A", "PROTEIN", 140, 144], ["serine and threonine", "TREATMENT", 33, 53], ["S56T", "TREATMENT", 104, 108]]], ["Finally, S45A was stable and indistinguishable from the parental virus, whilst S45T reverted.", [["S45A", "GENE_OR_GENE_PRODUCT", 9, 13], ["S45T", "GENE_OR_GENE_PRODUCT", 79, 83], ["S45A", "PROTEIN", 9, 13], ["S45T", "PROTEIN", 79, 83], ["the parental virus", "PROBLEM", 52, 70], ["stable", "OBSERVATION_MODIFIER", 18, 24]]], ["Together with the sequence variation at this position, which is limited to the small amino acids glycine, alanine and serine, this probably indicates a certain degree of steric hindrance by any residue larger than serine.", [["amino acids", "CHEMICAL", 85, 96], ["glycine", "CHEMICAL", 97, 104], ["alanine", "CHEMICAL", 106, 113], ["amino acids", "CHEMICAL", 85, 96], ["glycine", "CHEMICAL", 97, 104], ["alanine", "CHEMICAL", 106, 113], ["serine", "CHEMICAL", 118, 124], ["serine", "CHEMICAL", 214, 220], ["amino acids", "AMINO_ACID", 85, 96], ["glycine", "AMINO_ACID", 97, 104], ["alanine", "AMINO_ACID", 106, 113], ["serine", "AMINO_ACID", 118, 124], ["serine", "AMINO_ACID", 214, 220], ["the sequence variation", "TEST", 14, 36], ["the small amino acids glycine", "TREATMENT", 75, 104], ["steric hindrance", "PROBLEM", 170, 186], ["any residue", "PROBLEM", 190, 201], ["small", "OBSERVATION_MODIFIER", 79, 84], ["steric hindrance", "OBSERVATION", 170, 186], ["larger", "OBSERVATION_MODIFIER", 202, 208]]], ["Overall, the observed mutant phenotypes were compatible with the natural variation observed at the respective positions, with the possible exception of the C84Y mutant.", [["C84Y", "GENE_OR_GENE_PRODUCT", 156, 160], ["C84Y mutant", "PROTEIN", 156, 167], ["the observed mutant phenotypes", "PROBLEM", 9, 39], ["mutant phenotypes", "OBSERVATION", 22, 39], ["natural variation", "OBSERVATION", 65, 82]]], ["These correlations supported the multiple sequence alignment (MSA) of the highly variable nsp12 and suggested that EAV replication in BHK-21 is a faithful model system for probing nsp12 function by mutagenesis.Recombinant nsp12 does not display in vitroBoth mutants displaying a small-plaque phenotype (S30A and Y49F), as well as the unexpected Y32V pseudorevertant, were further investigated in terms of growth kinetics and accumulation of intracellular viral RNA (not shown).", [["BHK-21", "ANATOMY", 134, 140], ["plaque", "ANATOMY", 285, 291], ["intracellular", "ANATOMY", 441, 454], ["nsp12", "GENE_OR_GENE_PRODUCT", 90, 95], ["EAV", "ORGANISM", 115, 118], ["BHK-21", "CELL", 134, 140], ["nsp12", "GENE_OR_GENE_PRODUCT", 180, 185], ["nsp12", "GENE_OR_GENE_PRODUCT", 222, 227], ["vitroBoth", "GENE_OR_GENE_PRODUCT", 248, 257], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 441, 454], ["nsp12", "DNA", 90, 95], ["BHK-21", "CELL_LINE", 134, 140], ["nsp12", "PROTEIN", 180, 185], ["nsp12", "PROTEIN", 222, 227], ["vitroBoth mutants", "PROTEIN", 248, 265], ["Y32V pseudorevertant", "PROTEIN", 345, 365], ["intracellular viral RNA", "RNA", 441, 464], ["EAV", "SPECIES", 115, 118], ["BHK-21", "SPECIES", 134, 140], ["the multiple sequence alignment", "TEST", 29, 60], ["EAV replication", "TREATMENT", 115, 130], ["BHK", "TEST", 134, 137], ["a small-plaque phenotype", "PROBLEM", 277, 301], ["growth kinetics", "PROBLEM", 405, 420], ["intracellular viral RNA", "PROBLEM", 441, 464], ["small", "OBSERVATION_MODIFIER", 279, 284], ["plaque", "OBSERVATION", 285, 291], ["growth kinetics", "OBSERVATION", 405, 420], ["intracellular viral RNA", "OBSERVATION", 441, 464]]], ["Compared with the WT control, S30A and Y49F demonstrated a slight delay in replication early during infection [8 h post-infection (p.i.)], but eventually reached comparable titres by 24 h p.i.", [["infection", "DISEASE", 100, 109], ["S30A", "GENE_OR_GENE_PRODUCT", 30, 34], ["Y49F", "GENE_OR_GENE_PRODUCT", 39, 43], ["S30A", "PROTEIN", 30, 34], ["the WT control", "TEST", 14, 28], ["a slight delay", "PROBLEM", 57, 71], ["infection", "PROBLEM", 100, 109], ["infection", "PROBLEM", 120, 129], ["slight", "OBSERVATION_MODIFIER", 59, 65], ["delay", "OBSERVATION_MODIFIER", 66, 71], ["replication", "OBSERVATION_MODIFIER", 75, 86], ["early", "OBSERVATION_MODIFIER", 87, 92]]], ["In line with this finding, the amounts of genomic and subgenomic mRNA at 8 h p.i. were reduced for both mutants.", [["subgenomic mRNA", "RNA", 54, 69], ["genomic and subgenomic mRNA", "PROBLEM", 42, 69], ["amounts", "OBSERVATION_MODIFIER", 31, 38], ["subgenomic mRNA", "OBSERVATION", 54, 69]]], ["Whether this was due to a decreased synthesis or lower stability of their RNAs remains to be investigated.", [["RNAs", "RNA", 74, 78], ["a decreased synthesis", "PROBLEM", 24, 45], ["lower stability of their RNAs", "PROBLEM", 49, 78], ["decreased", "OBSERVATION", 26, 35], ["lower", "OBSERVATION_MODIFIER", 49, 54], ["stability", "OBSERVATION_MODIFIER", 55, 64]]], ["In contrast, the stable Y32V mutant was essentially indistinguishable from the WT control both in terms of growth kinetics and amounts of RNA produced.DISCUSSIONThe most conserved ORF1b of nidoviruses encodes only two proteins that have not been studied before in any virus.", [["Y32V", "GENE_OR_GENE_PRODUCT", 24, 28], ["ORF1b", "GENE_OR_GENE_PRODUCT", 180, 185], ["nidoviruses", "GENE_OR_GENE_PRODUCT", 189, 200], ["Y32V mutant", "PROTEIN", 24, 35], ["ORF1b", "DNA", 180, 185], ["nidoviruses", "DNA", 189, 200], ["the WT control", "TREATMENT", 75, 89], ["amounts of RNA", "PROBLEM", 127, 141], ["any virus", "PROBLEM", 264, 273], ["stable", "OBSERVATION_MODIFIER", 17, 23], ["growth kinetics", "OBSERVATION", 107, 122]]], ["Our study aimed to address this knowledge gap for one of these proteins, arterivirus nsp12.", [["arterivirus nsp12", "PROTEIN", 73, 90], ["Our study", "TEST", 0, 9], ["these proteins", "TEST", 57, 71]]], ["It established (i) the exceptional divergence of nsp12, (ii) the lack of strong bioinformatics and biochemical support for nsp12 being an MTase, and (iii) the fact that nsp12 is essential for arterivirus replication.DISCUSSIONSo far, none of the four enzymic activities required for conventional cap-1 synthesis, or any of the known alternative capping strategies, has been uncovered for arteriviruses, although arteriviral mRNAs are presumed to be capped.", [["arterivirus", "ANATOMY", 192, 203], ["nsp12", "GENE_OR_GENE_PRODUCT", 49, 54], ["nsp12", "GENE_OR_GENE_PRODUCT", 123, 128], ["nsp12", "GENE_OR_GENE_PRODUCT", 169, 174], ["arterivirus", "GENE_OR_GENE_PRODUCT", 192, 203], ["cap-1", "GENE_OR_GENE_PRODUCT", 296, 301], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 388, 401], ["nsp12", "PROTEIN", 49, 54], ["nsp12", "PROTEIN", 123, 128], ["MTase", "PROTEIN", 138, 143], ["nsp12", "PROTEIN", 169, 174], ["arteriviral mRNAs", "RNA", 412, 429], ["biochemical support", "TREATMENT", 99, 118], ["nsp12", "TREATMENT", 123, 128], ["arterivirus replication", "TREATMENT", 192, 215], ["the four enzymic activities", "TEST", 242, 269], ["conventional cap", "TEST", 283, 299], ["alternative capping strategies", "TREATMENT", 333, 363], ["arteriviruses", "PROBLEM", 388, 401], ["arteriviral mRNAs", "TREATMENT", 412, 429], ["presumed to be", "UNCERTAINTY", 434, 448]]], ["In the conserved relative arrangement of replicative enzymes within nidovirus pp1a and pp1ab, the unique arterivirus nsp12 is encoded in a genome position equivalent to that of the coronavirus 29-O-MTase, which is also conserved in invertebrate nidoviruses (Fig. 1) .", [["nidovirus pp1a", "GENE_OR_GENE_PRODUCT", 68, 82], ["pp1ab", "GENE_OR_GENE_PRODUCT", 87, 92], ["nsp12", "GENE_OR_GENE_PRODUCT", 117, 122], ["O-MTase", "GENE_OR_GENE_PRODUCT", 196, 203], ["invertebrate nidoviruses", "ORGANISM", 232, 256], ["replicative enzymes", "PROTEIN", 41, 60], ["nidovirus pp1a", "PROTEIN", 68, 82], ["pp1ab", "PROTEIN", 87, 92], ["arterivirus nsp12", "DNA", 105, 122], ["coronavirus 29-O-MTase", "DNA", 181, 203], ["coronavirus", "SPECIES", 181, 192], ["replicative enzymes", "TEST", 41, 60], ["the coronavirus", "TEST", 177, 192], ["genome position", "OBSERVATION", 139, 154], ["invertebrate nidoviruses", "OBSERVATION", 232, 256]]], ["We thus asked whether this so far uncharacterized subunit may represent an MTase, potentially able to perform both methylation reactions as, for example, the flavivirus NS5 MTase domain is (Zhou et al., 2007) .", [["MTase", "PROTEIN", 75, 80], ["flavivirus NS5 MTase domain", "PROTEIN", 158, 185], ["both methylation reactions", "PROBLEM", 110, 136], ["the flavivirus NS5 MTase domain", "PROBLEM", 154, 185]]], ["Upon our bioinformatics analysis of nsp12 sequences, we found that this subunit, similar to the N7-MTase residing in coronavirus nsp14, is enriched with (partially) conserved aromatic amino acids and is predicted to fold in alternating a-helices and b-strands (Fig. 3) .", [["amino acids", "CHEMICAL", 184, 195], ["amino acids", "CHEMICAL", 184, 195], ["nsp12", "GENE_OR_GENE_PRODUCT", 36, 41], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 96, 104], ["coronavirus", "ORGANISM", 117, 128], ["nsp14", "GENE_OR_GENE_PRODUCT", 129, 134], ["amino acids", "AMINO_ACID", 184, 195], ["nsp12 sequences", "DNA", 36, 51], ["N7-MTase", "PROTEIN", 96, 104], ["coronavirus nsp14", "PROTEIN", 117, 134], ["our bioinformatics analysis", "TEST", 5, 32], ["nsp12 sequences", "TEST", 36, 51], ["the N7-MTase", "TREATMENT", 92, 104], ["aromatic amino acids", "TREATMENT", 175, 195], ["coronavirus nsp14", "OBSERVATION", 117, 134], ["aromatic", "OBSERVATION", 175, 183], ["amino acids", "OBSERVATION", 184, 195]]], ["Nevertheless, no statistically significant similarity was found between nsp12 and other MTases of viral or cellular origin.DISCUSSIONWhen we subsequently sought to verify our hypothesis using an in vitro MTase assay, we could not detect activity above background for recombinant EAV nsp12, whereas our positive controls confirmed the functionality of the assay.DISCUSSIONTo explain this lack of activity, we argued that, as for coronavirus nsp16, a second EAV protein may be required to form a functional MTase complex.", [["cellular", "ANATOMY", 107, 115], ["nsp12", "GENE_OR_GENE_PRODUCT", 72, 77], ["cellular", "CELL", 107, 115], ["EAV", "ORGANISM", 279, 282], ["nsp12", "GENE_OR_GENE_PRODUCT", 283, 288], ["coronavirus", "ORGANISM", 428, 439], ["nsp16", "GENE_OR_GENE_PRODUCT", 440, 445], ["EAV", "ORGANISM", 456, 459], ["MTase", "GENE_OR_GENE_PRODUCT", 505, 510], ["nsp12", "PROTEIN", 72, 77], ["MTases", "PROTEIN", 88, 94], ["recombinant EAV nsp12", "PROTEIN", 267, 288], ["coronavirus nsp16", "PROTEIN", 428, 445], ["EAV protein", "PROTEIN", 456, 467], ["MTase complex", "PROTEIN", 505, 518], ["EAV", "SPECIES", 279, 282], ["EAV", "SPECIES", 456, 459], ["an in vitro MTase assay", "TEST", 192, 215], ["coronavirus nsp16", "PROBLEM", 428, 445], ["a second EAV protein", "TREATMENT", 447, 467], ["viral", "OBSERVATION", 98, 103], ["cellular origin", "OBSERVATION", 107, 122]]], ["By analogy with the coronavirus nsp10 co-factor, we tested the possibility that this second protein might be encoded just upstream of the ORF1a/1b ribosomal frameshift site.", [["coronavirus", "ORGANISM", 20, 31], ["nsp10", "GENE_OR_GENE_PRODUCT", 32, 37], ["ORF1a/1b", "GENE_OR_GENE_PRODUCT", 138, 146], ["coronavirus nsp10 co-factor", "PROTEIN", 20, 47], ["ORF1a/1b ribosomal frameshift site", "DNA", 138, 172], ["coronavirus", "SPECIES", 20, 31], ["this second protein", "PROBLEM", 80, 99], ["1b", "OBSERVATION", 144, 146], ["ribosomal frameshift", "OBSERVATION", 147, 167]]], ["Plaque phenotypes of viable EAV nsp12 mutants.", [["Plaque", "ANATOMY", 0, 6], ["EAV", "ORGANISM", 28, 31], ["nsp12", "GENE_OR_GENE_PRODUCT", 32, 37], ["EAV nsp12 mutants", "PROTEIN", 28, 45], ["EAV", "SPECIES", 28, 31], ["Plaque phenotypes", "PROBLEM", 0, 17], ["viable EAV", "OBSERVATION", 21, 31], ["nsp12 mutants", "OBSERVATION", 32, 45]]], ["Virus-containing supernatants obtained 48 h p.t. were serially diluted and used to infect BHK-21 cells.", [["supernatants", "ANATOMY", 17, 29], ["BHK-21 cells", "ANATOMY", 90, 102], ["Virus", "ORGANISM", 0, 5], ["BHK-21 cells", "CELL", 90, 102], ["BHK-21 cells", "CELL_LINE", 90, 102], ["BHK-21", "SPECIES", 90, 96], ["Virus", "PROBLEM", 0, 5], ["BHK", "TEST", 90, 93]]], ["After 72 h the cells were fixed with 4 % formaldehyde and stained with crystal violet.DISCUSSIONnsp7a and nsp7b, as well as three polyprotein cleavage intermediates containing these two proteins, and included them in our assays (Fig. 5) .", [["cells", "ANATOMY", 15, 20], ["formaldehyde", "CHEMICAL", 41, 53], ["formaldehyde", "CHEMICAL", 41, 53], ["cells", "CELL", 15, 20], ["formaldehyde", "SIMPLE_CHEMICAL", 41, 53], ["DISCUSSIONnsp7a", "GENE_OR_GENE_PRODUCT", 86, 101], ["nsp7b", "GENE_OR_GENE_PRODUCT", 106, 111], ["DISCUSSIONnsp7a", "PROTEIN", 86, 101], ["nsp7b", "PROTEIN", 106, 111], ["crystal violet", "TREATMENT", 71, 85], ["three polyprotein cleavage intermediates", "TREATMENT", 124, 164], ["crystal violet", "OBSERVATION", 71, 85]]], ["However, in these extended assays we also could not detect any MTase activity.", [["MTase", "GENE_OR_GENE_PRODUCT", 63, 68], ["MTase", "PROTEIN", 63, 68], ["these extended assays", "TEST", 12, 33], ["MTase activity", "OBSERVATION", 63, 77]]], ["This could be for multiple reasons. (i) The proteins tested here may not be the correct co-factors or may be unable to properly associate with nsp12 under the conditions employed. (ii) More than one co-factor may be needed to spur nsp12's MTase activity or different RNA substrates containing specific sequences may be required. (iii) It may be that nsp12, which is smaller than other viral MTases, does not possess MTase activity, in which case other hypotheses about its function should be considered (see below).DISCUSSIONTo explore nsp12's relevance for arterivirus replication, we engineered one truncation and 25 point mutations of EAV nsp12, and launched the corresponding mutant genomes in BHK-21 cells.", [["arterivirus", "ANATOMY", 558, 569], ["BHK-21 cells", "ANATOMY", 698, 710], ["(iii)", "CHEMICAL", 329, 334], ["nsp12", "GENE_OR_GENE_PRODUCT", 143, 148], ["nsp12's MTase", "GENE_OR_GENE_PRODUCT", 231, 244], ["nsp12", "GENE_OR_GENE_PRODUCT", 350, 355], ["MTase", "GENE_OR_GENE_PRODUCT", 416, 421], ["nsp12", "GENE_OR_GENE_PRODUCT", 536, 541], ["arterivirus", "CANCER", 558, 569], ["EAV", "ORGANISM", 638, 641], ["nsp12", "GENE_OR_GENE_PRODUCT", 642, 647], ["BHK-21 cells", "CELL", 698, 710], ["nsp12", "PROTEIN", 143, 148], ["nsp", "PROTEIN", 231, 234], ["MTase", "PROTEIN", 239, 244], ["nsp12", "PROTEIN", 350, 355], ["viral MTases", "PROTEIN", 385, 397], ["MTase", "PROTEIN", 416, 421], ["nsp12", "PROTEIN", 536, 541], ["EAV nsp12", "DNA", 638, 647], ["mutant genomes", "DNA", 680, 694], ["BHK-21 cells", "CELL_LINE", 698, 710], ["EAV", "SPECIES", 638, 641], ["BHK-21", "SPECIES", 698, 704], ["The proteins", "TEST", 40, 52], ["different RNA substrates containing specific sequences", "PROBLEM", 257, 311], ["nsp12", "PROBLEM", 350, 355], ["other viral MTases", "PROBLEM", 379, 397], ["arterivirus replication", "TREATMENT", 558, 581], ["EAV nsp12", "TEST", 638, 647], ["may be", "UNCERTAINTY", 338, 344], ["smaller", "OBSERVATION_MODIFIER", 366, 373], ["viral MTases", "OBSERVATION", 385, 397], ["MTase activity", "OBSERVATION", 416, 430]]], ["Reflecting the conservation of several aromatic residues in arteriviruses, substitution with alanine was not tolerated in any of the cases, whereas more conservative substitutions maintaining the residue's aromatic nature were tolerated in most of the partially conserved positions (Table 1 ).", [["alanine", "CHEMICAL", 93, 100], ["alanine", "CHEMICAL", 93, 100], ["arteriviruses", "SIMPLE_CHEMICAL", 60, 73], ["alanine", "AMINO_ACID", 93, 100], ["several aromatic residues in arteriviruses", "PROBLEM", 31, 73], ["substitution with alanine", "TREATMENT", 75, 100], ["conservative substitutions", "TREATMENT", 153, 179], ["several", "OBSERVATION_MODIFIER", 31, 38], ["aromatic residues", "OBSERVATION", 39, 56]]], ["The only exception was F107Y, which interestingly showed a certain level of protein expression, but did not produce infectious progeny.", [["protein expression", "PROBLEM", 76, 94], ["protein expression", "OBSERVATION", 76, 94], ["infectious", "OBSERVATION", 116, 126]]], ["As two arteriviruses distantly related to EAV, LDV and PRRSV genotype 1, naturally encode a tyrosine at this position (Fig. 3) , this result suggests an epistatic interaction between residue 107 and other unknown residue(s).", [["tyrosine", "CHEMICAL", 92, 100], ["tyrosine", "CHEMICAL", 92, 100], ["EAV", "ORGANISM", 42, 45], ["LDV", "GENE_OR_GENE_PRODUCT", 47, 50], ["PRRSV genotype 1", "ORGANISM", 55, 71], ["tyrosine", "AMINO_ACID", 92, 100], ["PRRSV", "SPECIES", 55, 60], ["EAV", "SPECIES", 42, 45], ["LDV", "SPECIES", 47, 50], ["PRRSV genotype 1", "SPECIES", 55, 71], ["EAV", "PROBLEM", 42, 45], ["LDV", "PROBLEM", 47, 50], ["PRRSV genotype 1", "PROBLEM", 55, 71], ["a tyrosine", "TREATMENT", 90, 100], ["an epistatic interaction between residue", "PROBLEM", 150, 190], ["EAV", "OBSERVATION", 42, 45], ["epistatic", "OBSERVATION", 153, 162]]], ["EAV also did not tolerate a block of nsp12 expression (STOP mutant) or the replacement of its single absolutely conserved nsp12 residue, F109, with alanine or tyrosine.", [["alanine", "CHEMICAL", 148, 155], ["tyrosine", "CHEMICAL", 159, 167], ["alanine", "CHEMICAL", 148, 155], ["tyrosine", "CHEMICAL", 159, 167], ["EAV", "ORGANISM", 0, 3], ["nsp12", "GENE_OR_GENE_PRODUCT", 37, 42], ["STOP mutant)", "GENE_OR_GENE_PRODUCT", 55, 67], ["nsp12", "GENE_OR_GENE_PRODUCT", 122, 127], ["F109", "SIMPLE_CHEMICAL", 137, 141], ["alanine", "AMINO_ACID", 148, 155], ["tyrosine", "AMINO_ACID", 159, 167], ["nsp12", "PROTEIN", 37, 42], ["STOP mutant", "PROTEIN", 55, 66], ["nsp12 residue", "PROTEIN", 122, 135], ["EAV", "SPECIES", 0, 3], ["nsp12 expression", "TREATMENT", 37, 53], ["the replacement", "TREATMENT", 71, 86], ["alanine or tyrosine", "TREATMENT", 148, 167]]], ["This phenotype could be explained by a trans-dominant negative effect of these mutations on an interaction partner of nsp12, if this partner is essential for EAV replication.", [["nsp12", "GENE_OR_GENE_PRODUCT", 118, 123], ["EAV", "ORGANISM", 158, 161], ["nsp12", "PROTEIN", 118, 123], ["EAV", "SPECIES", 158, 161], ["these mutations", "PROBLEM", 73, 88], ["EAV replication", "TREATMENT", 158, 173], ["could be explained", "UNCERTAINTY", 15, 33], ["dominant", "OBSERVATION_MODIFIER", 45, 53], ["negative", "OBSERVATION", 54, 62]]], ["This explanation is also compatible with the non-viable phenotype of several other mutants and suggests a particularly important role of the most constrained and proximal F107 and F109 in such a putative interaction.DISCUSSIONThe fact that EAV does not tolerate substitution of its single invariant nsp12 residue stands in remarkable contrast to phenotypes described for mutants of the invariant residues of the NendoU or 29-O-MTase of nidoviruses (Kang et al., 2007; Menachery et al., 2014; Posthuma et al., 2006; Z\u00fcst et al., 2011) , which are both more strongly conserved than nsp12.", [["F107", "GENE_OR_GENE_PRODUCT", 171, 175], ["F109", "GENE_OR_GENE_PRODUCT", 180, 184], ["EAV", "ORGANISM", 240, 243], ["NendoU", "GENE_OR_GENE_PRODUCT", 412, 418], ["nsp12", "GENE_OR_GENE_PRODUCT", 580, 585], ["F107", "PROTEIN", 171, 175], ["F109", "PROTEIN", 180, 184], ["nsp12 residue", "PROTEIN", 299, 312], ["NendoU or 29-O-MTase", "PROTEIN", 412, 432], ["nsp12", "PROTEIN", 580, 585], ["EAV", "SPECIES", 240, 243], ["substitution", "TREATMENT", 262, 274], ["its single invariant nsp12 residue", "TREATMENT", 278, 312]]], ["In these studies, alanine substitutions of absolutely conserved putative active-site residues resulted in lower virus progeny titres and in part in smallplaque phenotypes in cell culture, but did not entirely abolish virus replication.DISCUSSIONIn conclusion, our combined results may be most compatible with the notion that nsp12 is not an MTase and possibly not even an enzyme, but rather a co-factor of an essential component of the arterivirus replicase.", [["smallplaque", "ANATOMY", 148, 159], ["cell culture", "ANATOMY", 174, 186], ["alanine", "CHEMICAL", 18, 25], ["alanine", "CHEMICAL", 18, 25], ["alanine", "AMINO_ACID", 18, 25], ["cell culture", "CELL", 174, 186], ["nsp12", "GENE_OR_GENE_PRODUCT", 325, 330], ["MTase", "GENE_OR_GENE_PRODUCT", 341, 346], ["arterivirus", "GENE_OR_GENE_PRODUCT", 436, 447], ["nsp12", "PROTEIN", 325, 330], ["MTase", "PROTEIN", 341, 346], ["arterivirus replicase", "PROTEIN", 436, 457], ["these studies", "TEST", 3, 16], ["alanine substitutions", "TREATMENT", 18, 39], ["site residues", "PROBLEM", 80, 93], ["lower virus progeny titres", "PROBLEM", 106, 132], ["smallplaque phenotypes", "PROBLEM", 148, 170], ["cell culture", "TEST", 174, 186], ["an enzyme", "TEST", 369, 378], ["the arterivirus replicase", "PROBLEM", 432, 457], ["active", "OBSERVATION_MODIFIER", 73, 79], ["lower virus progeny titres", "OBSERVATION", 106, 132], ["cell culture", "OBSERVATION", 174, 186], ["arterivirus replicase", "OBSERVATION", 436, 457]]], ["In this context, a future in-depth analysis of the nsp12 interaction network could be most informative.", [["nsp12", "GENE_OR_GENE_PRODUCT", 51, 56], ["nsp12", "PROTEIN", 51, 56]]], ["If nsp12 is not an MTase, this activity must be provided by another protein, but it is unlikely to be one of the three other ORF1b proteins, which are known to possess non-MTase enzymatic activities.", [["nsp12", "GENE_OR_GENE_PRODUCT", 3, 8], ["MTase", "GENE_OR_GENE_PRODUCT", 19, 24], ["ORF1b", "GENE_OR_GENE_PRODUCT", 125, 130], ["nsp12", "PROTEIN", 3, 8], ["MTase", "PROTEIN", 19, 24], ["ORF1b proteins", "PROTEIN", 125, 139], ["MTase", "PROTEIN", 172, 177]]], ["This implies that arteriviruses may be (very) different from other nidoviruses with respect to either the nature of the 59 end of their mRNAs and/or the mechanism generating it.", [["arteriviruses", "GENE_OR_GENE_PRODUCT", 18, 31], ["59 end", "RNA", 120, 126], ["mRNAs", "RNA", 136, 141]]], ["We note that the presence of a 59-terminal cap-1 structure was reported for the SHFV genome (Sagripanti et al., 1986) , but that monophosphates were claimed to present at the 59 end of LDV mRNAs (Chen et al., 1994) , calling for additional studies to resolve the apparent conflict.", [["monophosphates", "CHEMICAL", 129, 143], ["monophosphates", "CHEMICAL", 129, 143], ["monophosphates", "SIMPLE_CHEMICAL", 129, 143], ["LDV", "ORGANISM", 185, 188], ["59-terminal cap-1 structure", "DNA", 31, 58], ["SHFV genome", "DNA", 80, 91], ["LDV mRNAs", "RNA", 185, 194], ["a 59-terminal cap-1 structure", "PROBLEM", 29, 58], ["monophosphates", "TREATMENT", 129, 143], ["additional studies", "TEST", 229, 247]]], ["Finally, the possibility of cap-snatching, the strategy employed by some families of negative-stranded RNA viruses (Fujimura & Esteban, 2011; Mir et al., 2008; Reich et al., 2014) , may be explored for arteriviruses.", [["cap", "PROBLEM", 28, 31], ["arteriviruses", "PROBLEM", 202, 215]]], ["This mechanism might accommodate the nsp11 NendoU as endoribonuclease and nsp12 as a cap-binding protein, which would connect coronavirus nsp16 and arterivirus nsp12 to a common target in an unorthodox way.METHODSBioinformatics.", [["nsp11", "GENE_OR_GENE_PRODUCT", 37, 42], ["nsp12", "GENE_OR_GENE_PRODUCT", 74, 79], ["coronavirus", "ORGANISM", 126, 137], ["nsp16", "GENE_OR_GENE_PRODUCT", 138, 143], ["arterivirus nsp12", "GENE_OR_GENE_PRODUCT", 148, 165], ["nsp11", "PROTEIN", 37, 42], ["NendoU", "PROTEIN", 43, 49], ["endoribonuclease", "PROTEIN", 53, 69], ["nsp12", "PROTEIN", 74, 79], ["cap-binding protein", "PROTEIN", 85, 104], ["coronavirus nsp16", "PROTEIN", 126, 143], ["arterivirus nsp12", "PROTEIN", 148, 165], ["nsp12", "TREATMENT", 74, 79], ["a cap-binding protein", "TEST", 83, 104], ["arterivirus", "TREATMENT", 148, 159]]], ["Genomes of members of the families Arteriviridae and Coronaviridae were retrieved from GenBank (Benson et al., 2013) and RefSeq (Pruitt et al., 2014) using the HAYGENS (homologyannotation hybrid retrieval of genetic sequences) tool (http://veb. lumc.nl/HAYGENS).", [["Arteriviridae", "GENE_OR_GENE_PRODUCT", 35, 48], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 53, 66], ["HAYGENS", "DNA", 160, 167], ["HAYGENS", "PROTEIN", 253, 260], ["Coronaviridae", "TREATMENT", 53, 66], ["the HAYGENS (homologyannotation hybrid retrieval", "TREATMENT", 156, 204]]], ["Codon-based MSAs of virus genomes were produced using the Viralis platform , and assisted by HMMER 3.1 (Finn et al., 2011) , MUSCLE 3.8.31 (Edgar, 2004) and CLUSTAL W 2.012 (Larkin et al., 2007) .", [["Codon-based MSAs", "DNA", 0, 16], ["virus genomes", "DNA", 20, 33], ["Codon-based MSAs of virus genomes", "PROBLEM", 0, 33], ["MUSCLE", "TEST", 125, 131], ["virus genomes", "OBSERVATION", 20, 33], ["MUSCLE", "ANATOMY", 125, 131]]], ["Only one virus per established or tentative species, which were defined with the help of DEmARC1.3 (Lauber & Gorbalenya, 2012) , was retained for bioinformatics analyses.", [["one virus", "PROBLEM", 5, 14], ["bioinformatics analyses", "TEST", 146, 169], ["virus", "OBSERVATION", 9, 14], ["species", "OBSERVATION_MODIFIER", 44, 51]]], ["To reveal the full extent of similarity between pairs of alignments, they were converted into HMM profiles, which were compared and visualized in a dot-plot fashion using a routine in HH-suite 2.0.15 (Remmert et al., 2012; S\u00f6ding, 2005) .", [["full extent", "OBSERVATION_MODIFIER", 14, 25]]], ["Distribution of similarity density in alignments was plotted using R package Bio3D (Grant et al., 2006) under the conservation assessment method SIMILARITY, substitution matrix Blosum62 (Henikoff & Henikoff, 1992 ) and a sliding window of 11 alignment columns.", [["similarity density in alignments", "PROBLEM", 16, 48], ["the conservation assessment", "TEST", 110, 137], ["a sliding window of 11 alignment columns", "TREATMENT", 219, 259], ["similarity", "OBSERVATION_MODIFIER", 16, 26], ["density", "OBSERVATION", 27, 34]]], ["HHsuite 2.0.15 (Remmert et al., 2012; S\u00f6ding, 2005) was used to search for homologues amongst profiles in the Pfam-A database (Finn et al., 2014) ; the secondary structure of proteins was predicted by applying JPred 3 (Cole et al., 2008) and PSIPRED (Buchan et al., 2013) to MSAs.", [["Pfam", "PROTEIN", 110, 114]]], ["Reconstruction of phylogenetic trees was performed using PhyML 3.0, with the WAG amino acid substitution matrix (Whelan & Goldman, 2001) , allowing substitution rate heterogeneity amongst sites (four categories) and 1000 iterations of non-parametric bootstrapping (Guindon et al., 2010) .", [["amino acid", "CHEMICAL", 81, 91], ["amino acid", "CHEMICAL", 81, 91], ["amino acid", "AMINO_ACID", 81, 91], ["PhyML", "TEST", 57, 62], ["the WAG amino acid substitution matrix", "TREATMENT", 73, 111], ["substitution rate heterogeneity", "TREATMENT", 148, 179], ["non-parametric bootstrapping", "TREATMENT", 235, 263], ["phylogenetic trees", "OBSERVATION", 18, 36]]], ["PPDs between viruses were calculated from protein trees using R package APE (Paradis et al., 2004) .", [["PPDs", "GENE_OR_GENE_PRODUCT", 0, 4], ["PPDs between viruses", "PROBLEM", 0, 20], ["R package APE", "TREATMENT", 62, 75], ["viruses", "OBSERVATION", 13, 20]]], ["Linear regression was calculated using R package STATS (R Development Core Team, 2011).METHODSReverse genetics of EAV.", [["EAV", "DISEASE", 114, 117], ["EAV", "ORGANISM", 114, 117], ["EAV", "SPECIES", 114, 117], ["Linear regression", "PROBLEM", 0, 17], ["R package STATS", "TREATMENT", 39, 54], ["regression", "OBSERVATION", 7, 17]]], ["Mutations specifying alanine and conservative replacements of (partially) conserved and control residues in nsp12 were generated using the QuikChange protocol.", [["alanine", "CHEMICAL", 21, 28], ["alanine", "CHEMICAL", 21, 28], ["alanine", "AMINO_ACID", 21, 28], ["nsp12", "GENE_OR_GENE_PRODUCT", 108, 113], ["nsp12", "PROTEIN", 108, 113], ["Mutations specifying alanine", "TREATMENT", 0, 28], ["conservative replacements of (partially)", "TREATMENT", 33, 73], ["control residues in nsp12", "TEST", 88, 113], ["the QuikChange protocol", "TREATMENT", 135, 158]]], ["In all cases translationally silent marker mutations were introduced to allow discrimination between (partial) reversion of mutants after transfection and (possible) contamination with WT virus.", [["WT virus", "ORGANISM", 185, 193], ["silent marker mutations", "PROBLEM", 29, 52], ["mutants after transfection", "PROBLEM", 124, 150], ["WT virus", "PROBLEM", 185, 193]]], ["Mutated gene fragments were introduced into full-length cDNA clone pEAV211 (van den Born et al., 2004), a pEAV030 derivative (van Dinten et al., 1997) , using appropriate shuttle vectors and restriction enzymes.", [["Mutated gene fragments", "DNA", 0, 22], ["shuttle vectors", "DNA", 171, 186], ["restriction enzymes", "PROTEIN", 191, 210], ["Mutated gene fragments", "PROBLEM", 0, 22], ["appropriate shuttle vectors", "TREATMENT", 159, 186], ["restriction enzymes", "TEST", 191, 210], ["gene fragments", "OBSERVATION", 8, 22]]], ["The presence of the mutations was confirmed by sequencing. pEAV211 DNA was in vitro transcribed and RNA was purified by LiCl precipitation.", [["LiCl", "CHEMICAL", 120, 124], ["LiCl", "CHEMICAL", 120, 124], ["pEAV211", "GENE_OR_GENE_PRODUCT", 59, 66], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["LiCl", "SIMPLE_CHEMICAL", 120, 124], ["pEAV211 DNA", "DNA", 59, 70], ["the mutations", "PROBLEM", 16, 29], ["LiCl precipitation", "OBSERVATION", 120, 138]]], ["RNA was transfected into BHK-21 cells as described previously (Nedialkova et al., 2010) .", [["BHK-21 cells", "ANATOMY", 25, 37], ["BHK-21 cells", "CELL", 25, 37], ["RNA", "RNA", 0, 3], ["BHK-21 cells", "CELL_LINE", 25, 37], ["BHK-21", "SPECIES", 25, 31], ["21 cells", "OBSERVATION_MODIFIER", 29, 37]]], ["Transfected cells were monitored by immunofluorescence microscopy until 68 h p.t. using antibodies directed against EAV nsp3 and N protein as described previously (van der Meer et al., 1998) .", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["EAV", "ORGANISM", 116, 119], ["nsp3", "GENE_OR_GENE_PRODUCT", 120, 124], ["N protein", "GENE_OR_GENE_PRODUCT", 129, 138], ["antibodies", "PROTEIN", 88, 98], ["EAV nsp3", "PROTEIN", 116, 124], ["N protein", "PROTEIN", 129, 138], ["EAV", "SPECIES", 116, 119], ["Transfected cells", "PROBLEM", 0, 17], ["immunofluorescence microscopy", "TEST", 36, 65], ["antibodies", "TREATMENT", 88, 98], ["EAV nsp3", "TREATMENT", 116, 124]]], ["To monitor the production of viral progeny, plaque assays were performed with supernatants collected at 14 and 48 h p.t. or during the first 24 h p.i. to determine growth kinetics, as described previously (Nedialkova et al., 2010) .", [["plaque", "ANATOMY", 44, 50], ["supernatants", "ANATOMY", 78, 90], ["plaque assays", "TEST", 44, 57], ["supernatants", "TREATMENT", 78, 90]]], ["To verify the presence of the introduced mutations or reversions in viable mutants, fresh BHK-21 cells were infected with supernatants harvested at time points at which transfected cells were positive in immunofluorescence microscopy.", [["BHK-21 cells", "ANATOMY", 90, 102], ["supernatants", "ANATOMY", 122, 134], ["cells", "ANATOMY", 181, 186], ["BHK-21 cells", "CELL", 90, 102], ["cells", "CELL", 181, 186], ["BHK-21 cells", "CELL_LINE", 90, 102], ["transfected cells", "CELL_LINE", 169, 186], ["BHK-21", "SPECIES", 90, 96], ["the introduced mutations", "PROBLEM", 26, 50], ["reversions in viable mutants", "PROBLEM", 54, 82], ["fresh BHK", "TEST", 84, 93], ["supernatants", "TREATMENT", 122, 134], ["immunofluorescence microscopy", "TEST", 204, 233]]], ["RNA was isolated after 18 h or when a cytopathic effect was detected.", [["RNA", "RNA", 0, 3], ["a cytopathic effect", "PROBLEM", 36, 55]]], ["Finally, the nsp12-coding region was amplified by reverse transcription (RT)-PCR using random hexameric primers in the RT step and EAV-specific primers for the PCR.", [["nsp12", "GENE_OR_GENE_PRODUCT", 13, 18], ["nsp12-coding region", "DNA", 13, 32], ["reverse transcription (RT)-PCR", "DNA", 50, 80], ["EAV-specific primers", "DNA", 131, 151], ["EAV", "SPECIES", 131, 134], ["the nsp12-coding region", "TREATMENT", 9, 32], ["PCR", "TEST", 77, 80], ["random hexameric primers", "TREATMENT", 87, 111], ["the RT step", "TEST", 115, 126], ["EAV", "TEST", 131, 134], ["the PCR", "TEST", 156, 163]]], ["PCR fragments were purified and sequenced.METHODSProtein expression and purification.", [["PCR fragments", "DNA", 0, 13], ["PCR fragments", "TEST", 0, 13], ["METHODSProtein expression", "TREATMENT", 42, 67]]], ["N-and C-terminal His-tag fusion proteins of WT nsp12 were expressed from a pDEST vector.", [["His", "CHEMICAL", 17, 20], ["nsp12", "GENE_OR_GENE_PRODUCT", 47, 52], ["pDEST", "GENE_OR_GENE_PRODUCT", 75, 80], ["N-and C-terminal His-tag fusion proteins", "PROTEIN", 0, 40], ["WT nsp12", "PROTEIN", 44, 52], ["pDEST vector", "DNA", 75, 87], ["N", "TEST", 0, 1], ["C-terminal His-tag fusion proteins", "TREATMENT", 6, 40], ["WT nsp12", "PROBLEM", 44, 52]]], ["Plasmids were transformed into E. coli BL21(DE3) and cells were grown in Luria Broth (LB) with 100 mg ampicillin ml 21 at 37 uC until OD600 0.7.", [["cells", "ANATOMY", 53, 58], ["ampicillin", "CHEMICAL", 102, 112], ["ampicillin", "CHEMICAL", 102, 112], ["E. coli", "ORGANISM", 31, 38], ["BL21", "ORGANISM", 39, 43], ["DE3", "CELL", 44, 47], ["cells", "CELL", 53, 58], ["E. coli BL21", "SPECIES", 31, 43], ["E. coli BL21", "SPECIES", 31, 43], ["DE3", "SPECIES", 44, 47], ["Plasmids", "TREATMENT", 0, 8], ["E. coli BL21", "TEST", 31, 43], ["cells", "TEST", 53, 58], ["100 mg ampicillin ml", "TREATMENT", 95, 115], ["coli BL21", "OBSERVATION", 34, 43]]], ["Expression was induced after addition of 0.5 mM IPTG and cells were grown for further 4 h at 37 uC.METHODSEAV ORF1a-encoded proteins were expressed with N-terminal ubiquitin and C-terminal His-tags from pASK vectors (Gohara et al., 1999) .", [["cells", "ANATOMY", 57, 62], ["IPTG", "CHEMICAL", 48, 52], ["IPTG", "CHEMICAL", 48, 52], ["N", "CHEMICAL", 153, 154], ["His", "CHEMICAL", 189, 192], ["IPTG", "SIMPLE_CHEMICAL", 48, 52], ["cells", "CELL", 57, 62], ["ORF1a", "GENE_OR_GENE_PRODUCT", 110, 115], ["pASK", "GENE_OR_GENE_PRODUCT", 203, 207], ["ORF1a", "PROTEIN", 110, 115], ["N-terminal ubiquitin", "PROTEIN", 153, 173], ["C-terminal His-tags", "PROTEIN", 178, 197], ["pASK vectors", "DNA", 203, 215], ["0.5 mM IPTG", "TREATMENT", 41, 52], ["cells", "TREATMENT", 57, 62]]], ["Plasmids were transformed into E. coli C2523 containing the pCG1 plasmid, which leads to constitutive expression of the ubiquitin-specific protease UBP1.", [["plasmid", "ANATOMY", 65, 72], ["E. coli C2523", "ORGANISM", 31, 44], ["pCG1", "GENE_OR_GENE_PRODUCT", 60, 64], ["ubiquitin-specific protease UBP1", "GENE_OR_GENE_PRODUCT", 120, 152], ["pCG1 plasmid", "DNA", 60, 72], ["ubiquitin-specific protease", "PROTEIN", 120, 147], ["UBP1", "PROTEIN", 148, 152], ["E. coli", "SPECIES", 31, 38], ["E. coli", "SPECIES", 31, 38], ["Plasmids", "TREATMENT", 0, 8], ["E. coli", "PROBLEM", 31, 38], ["the pCG1 plasmid", "TREATMENT", 56, 72], ["the ubiquitin", "TREATMENT", 116, 129], ["specific protease UBP1", "TREATMENT", 130, 152], ["E. coli", "OBSERVATION_MODIFIER", 31, 38], ["constitutive expression", "OBSERVATION", 89, 112]]], ["Cells were grown in LB with 100 mg ampicillin ml 21 and 34 mg chloramphenicol ml 21 at 37 uC until OD600 0.7.", [["Cells", "ANATOMY", 0, 5], ["ampicillin", "CHEMICAL", 35, 45], ["chloramphenicol", "CHEMICAL", 62, 77], ["ampicillin", "CHEMICAL", 35, 45], ["chloramphenicol", "CHEMICAL", 62, 77], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["100 mg ampicillin ml", "TREATMENT", 28, 48], ["chloramphenicol ml", "TREATMENT", 62, 80]]], ["Expression was induced after addition of 200 ng anhydrotetracycline ml 21 and cells were grown for another 18 h at 20 uC.", [["cells", "ANATOMY", 78, 83], ["anhydrotetracycline", "CHEMICAL", 48, 67], ["anhydrotetracycline", "CHEMICAL", 48, 67], ["cells", "CELL", 78, 83], ["200 ng anhydrotetracycline ml", "TREATMENT", 41, 70]]], ["All pellets were harvested by centrifugation and stored at 220 uC until further use.METHODSProteins were batch purified by metal affinity chromatography using Co 2+ (Talon beads).", [["Co 2", "CHEMICAL", 159, 163], ["Co 2+", "CHEMICAL", 159, 164], ["Co 2+", "SIMPLE_CHEMICAL", 159, 164], ["Talon beads", "SIMPLE_CHEMICAL", 166, 177], ["All pellets", "TREATMENT", 0, 11], ["METHODSProteins", "TREATMENT", 84, 99], ["metal affinity chromatography", "TEST", 123, 152], ["Co 2+ (Talon beads", "TREATMENT", 159, 177], ["pellets", "OBSERVATION", 4, 11]]], ["Cells were resuspended in nsp12 resuspension buffer (20 mM HEPES, pH 7.5, 5 mM b-mercaptoethanol) or co-factor resuspension buffer [20 mM HEPES, pH 7.5, 10 % glycerol (v/v), 5 mM b-mercaptoethanol] containing 500 mM NaCl and Roche complete EDTA-free protease inhibitor cocktail.", [["Cells", "ANATOMY", 0, 5], ["b-mercaptoethanol", "CHEMICAL", 79, 96], ["glycerol", "CHEMICAL", 158, 166], ["b-mercaptoethanol", "CHEMICAL", 179, 196], ["NaCl", "CHEMICAL", 216, 220], ["HEPES", "CHEMICAL", 59, 64], ["b-mercaptoethanol", "CHEMICAL", 79, 96], ["HEPES", "CHEMICAL", 138, 143], ["glycerol", "CHEMICAL", 158, 166], ["b-mercaptoethanol", "CHEMICAL", 179, 196], ["NaCl", "CHEMICAL", 216, 220], ["EDTA", "CHEMICAL", 240, 244], ["Cells", "CELL", 0, 5], ["nsp12", "SIMPLE_CHEMICAL", 26, 31], ["b-mercaptoethanol", "SIMPLE_CHEMICAL", 79, 96], ["glycerol", "SIMPLE_CHEMICAL", 158, 166], ["b-mercaptoethanol", "SIMPLE_CHEMICAL", 179, 196], ["EDTA", "SIMPLE_CHEMICAL", 240, 244], ["Cells", "TEST", 0, 5], ["HEPES", "TEST", 59, 64], ["pH", "TEST", 66, 68], ["b-mercaptoethanol)", "TREATMENT", 79, 97], ["co-factor resuspension buffer", "TREATMENT", 101, 130], ["HEPES", "TEST", 138, 143], ["pH", "TEST", 145, 147], ["glycerol (v/v)", "TREATMENT", 158, 172], ["5 mM b-mercaptoethanol]", "TREATMENT", 174, 197], ["NaCl", "TREATMENT", 216, 220], ["Roche complete EDTA", "TREATMENT", 225, 244], ["free protease inhibitor cocktail", "TREATMENT", 245, 277]]], ["Lysis was achieved by 30 min incubation with lysozyme (0.1 mg ml 21 ).", [["lysozyme", "GENE_OR_GENE_PRODUCT", 45, 53], ["lysozyme", "PROTEIN", 45, 53], ["Lysis", "TREATMENT", 0, 5], ["lysozyme", "TREATMENT", 45, 53]]], ["Genomic DNA was sheared during four sonication cycles of 10 s with intermittent cooling.", [["DNA", "CELLULAR_COMPONENT", 8, 11], ["Genomic DNA", "PROBLEM", 0, 11], ["four sonication cycles", "TREATMENT", 31, 53], ["intermittent cooling", "TREATMENT", 67, 87], ["DNA", "OBSERVATION", 8, 11]]], ["Cell debris was removed by centrifugation at 20 000 g for 20 min.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell debris", "PROBLEM", 0, 11], ["debris", "OBSERVATION", 5, 11]]], ["Cleared supernatants were incubated with an appropriate amount of Talon beads for 1 h under slow rolling.", [["supernatants", "ANATOMY", 8, 20], ["Talon beads", "TREATMENT", 66, 77]]], ["Beads were collected and washed four times for 15 min with a 20-fold volume of the respective resuspension buffer supplemented with 10 mM imidazole, and first 500 mM, then 250 mM and finally twice 100 mM NaCl.", [["imidazole", "CHEMICAL", 138, 147], ["NaCl", "CHEMICAL", 204, 208], ["imidazole", "CHEMICAL", 138, 147], ["NaCl", "CHEMICAL", 204, 208], ["Beads", "CELL", 0, 5], ["imidazole", "SIMPLE_CHEMICAL", 138, 147], ["a 20-fold volume of the respective resuspension buffer", "TREATMENT", 59, 113], ["10 mM imidazole", "TREATMENT", 132, 147]]], ["Proteins were eluted with the respective resuspension buffer containing 300 mM imidazole and 100 mM NaCl.", [["imidazole", "CHEMICAL", 79, 88], ["NaCl", "CHEMICAL", 100, 104], ["imidazole", "CHEMICAL", 79, 88], ["NaCl", "CHEMICAL", 100, 104], ["imidazole", "SIMPLE_CHEMICAL", 79, 88], ["Proteins", "TEST", 0, 8], ["the respective resuspension buffer", "TREATMENT", 26, 60], ["300 mM imidazole", "TREATMENT", 72, 88], ["100 mM NaCl", "TREATMENT", 93, 104]]], ["Elution fractions were examined by SDS-PAGE, pooled and dialysed against 20 mM HEPES, pH 7.5, 100 mM NaCl, 25 % glycerol, 1 mM DTT.", [["NaCl", "CHEMICAL", 101, 105], ["glycerol", "CHEMICAL", 112, 120], ["HEPES", "CHEMICAL", 79, 84], ["NaCl", "CHEMICAL", 101, 105], ["glycerol", "CHEMICAL", 112, 120], ["DTT", "CHEMICAL", 127, 130], ["glycerol", "SIMPLE_CHEMICAL", 112, 120], ["DTT", "SIMPLE_CHEMICAL", 127, 130], ["Elution fractions", "TEST", 0, 17], ["HEPES", "TEST", 79, 84], ["pH", "TEST", 86, 88], ["NaCl", "TEST", 101, 105], ["25 % glycerol", "TREATMENT", 107, 120]]], ["All proteins were stored at 220 uC.", [["All proteins", "TEST", 0, 12]]], ["Typical yields were 1-2 mg l 21 culture for all proteins.", [["Typical yields", "TEST", 0, 14], ["all proteins", "PROBLEM", 44, 56]]], ["Protein concentrations were calculated based on theoretical extinction coefficients and A 280 .METHODSGel filtration of nsp12 was performed on a Superdex 75 10/300 GL gel filtration column with 10 mM sodium phosphate buffer, pH 6.0, 100 mM NaCl, 1 mM DTT at 4 uC and a flow rate of 0.5 ml min 21 .METHODSMTase assay.", [["sodium phosphate", "CHEMICAL", 200, 216], ["NaCl", "CHEMICAL", 240, 244], ["sodium phosphate", "CHEMICAL", 200, 216], ["NaCl", "CHEMICAL", 240, 244], ["DTT", "CHEMICAL", 251, 254], ["nsp12", "GENE_OR_GENE_PRODUCT", 120, 125], ["sodium phosphate", "SIMPLE_CHEMICAL", 200, 216], ["nsp12", "PROTEIN", 120, 125], ["Protein concentrations", "TEST", 0, 22], ["METHODSGel filtration of nsp12", "TREATMENT", 95, 125], ["a Superdex", "TREATMENT", 143, 153], ["GL gel filtration column", "TREATMENT", 164, 188], ["10 mM sodium phosphate buffer", "TREATMENT", 194, 223], ["pH", "TEST", 225, 227], ["1 mM DTT", "TREATMENT", 246, 254], ["a flow rate", "TEST", 267, 278], ["METHODSMTase assay", "TEST", 297, 315]]], ["MTase assays were performed essentially as described previously (Bouvet et al., 2010) .", [["MTase", "PROTEIN", 0, 5], ["MTase assays", "TEST", 0, 12]]], ["Proteins at the indicated final concentrations were incubated at 30 uC for 30, 60 or 180 min in a buffer containing 20 mM HEPES, pH 7.5, 5 mM DTT, 0.5 mM MgCl 2 , 0.5 mM MnCl 2 , 10 mM S-adenosylmethionine, 2 mM capping substrate and 1|10 3 Bq S-[methyl-3 H]adenosylmethionine ml 21 .", [["MgCl", "CHEMICAL", 154, 158], ["S-adenosylmethionine", "CHEMICAL", 185, 205], ["1|10 3 Bq S-[methyl-3 H]adenosylmethionine", "CHEMICAL", 234, 276], ["HEPES", "CHEMICAL", 122, 127], ["DTT", "CHEMICAL", 142, 145], ["MgCl 2", "CHEMICAL", 154, 160], ["MnCl 2", "CHEMICAL", 170, 176], ["S-adenosylmethionine", "CHEMICAL", 185, 205], ["S-[methyl-3 H]adenosylmethionine", "CHEMICAL", 244, 276], ["DTT", "SIMPLE_CHEMICAL", 142, 145], ["MnCl 2", "SIMPLE_CHEMICAL", 170, 176], ["S-adenosylmethionine", "SIMPLE_CHEMICAL", 185, 205], ["1|10 3 Bq S-[methyl-3 H]adenosylmethionine ml 21", "SIMPLE_CHEMICAL", 234, 282], ["Proteins", "TEST", 0, 8], ["pH", "TEST", 129, 131], ["DTT", "TEST", 142, 145], ["MgCl", "TEST", 154, 158], ["MnCl", "TEST", 170, 174], ["S-adenosylmethionine", "TREATMENT", 185, 205], ["2 mM capping substrate", "TREATMENT", 207, 229], ["methyl-3 H]adenosylmethionine ml", "TREATMENT", 247, 279]]], ["Additionally 7.5 mM NaCl was carried over from the protein storage buffer.", [["NaCl", "CHEMICAL", 20, 24], ["NaCl", "CHEMICAL", 20, 24], ["7.5 mM NaCl", "TREATMENT", 13, 24], ["the protein storage buffer", "TREATMENT", 47, 73], ["7.5 mM", "OBSERVATION_MODIFIER", 13, 19]]], ["Vaccinia virus capping enzyme (New England Biolabs) was incubated in the buffer supplied by the vendor.", [["Vaccinia virus", "ORGANISM", 0, 14], ["Biolabs", "GENE_OR_GENE_PRODUCT", 43, 50], ["Vaccinia virus capping enzyme", "PROTEIN", 0, 29], ["Vaccinia virus", "SPECIES", 0, 14], ["Vaccinia virus", "SPECIES", 0, 14], ["Vaccinia virus capping enzyme", "TREATMENT", 0, 29], ["New England Biolabs", "TEST", 31, 50]]], ["A 10-fold volume of ice-cold S-adenosylhomocysteine (100 mM) was added to stop the reaction.", [["S-adenosylhomocysteine", "CHEMICAL", 29, 51], ["S-adenosylhomocysteine", "CHEMICAL", 29, 51], ["S-adenosylhomocysteine", "SIMPLE_CHEMICAL", 29, 51], ["A 10-fold volume of ice-cold S-adenosylhomocysteine (100 mM)", "TREATMENT", 0, 60], ["the reaction", "PROBLEM", 79, 91], ["10-fold", "OBSERVATION_MODIFIER", 2, 9]]], ["Samples were spotted on DEAE filtermats (Perkin Elmer), which were subsequently washed twice with 10 mM ammonium formate, pH 8.0, then twice with water and finally with ethanol.", [["Samples", "ANATOMY", 0, 7], ["ammonium formate", "CHEMICAL", 104, 120], ["ethanol", "CHEMICAL", 169, 176], ["ammonium formate", "CHEMICAL", 104, 120], ["ethanol", "CHEMICAL", 169, 176], ["ammonium formate", "SIMPLE_CHEMICAL", 104, 120], ["ethanol", "SIMPLE_CHEMICAL", 169, 176], ["Samples", "TEST", 0, 7], ["10 mM ammonium formate", "TREATMENT", 98, 120], ["pH", "TEST", 122, 124], ["ethanol", "TREATMENT", 169, 176]]], ["Filtermats were cut and radioactivity was measured by scintillation counting.", [["scintillation counting", "TEST", 54, 76], ["radioactivity", "OBSERVATION_MODIFIER", 24, 37]]]], "PMC6093206": [["IntroductionMedia information about health risks depicts both long-standing threats (e.g., the risk of contracting the flu in winter) as well as emerging risks (e.g., the risk of the Zika virus in 2016) (for a discussion of emerging risks, see Kousky et al., 2010).", [["flu", "DISEASE", 119, 122], ["Zika virus", "ORGANISM", 183, 193], ["the Zika virus", "PROBLEM", 179, 193]]], ["Recipients of information about emerging threats have limited, or no knowledge of the threat (e.g., the disease) and thus may benefit from receiving health information, particularly when the information travels quickly, and the format is brief and accessible (Shearer and Gottfried, 2017).", [["the disease)", "PROBLEM", 100, 112]]], ["Do these associations vary across subpopulations with higher (vs. lower) risk of Zika infection?", [["Zika infection", "DISEASE", 81, 95], ["Zika infection", "PROBLEM", 81, 95], ["subpopulations", "OBSERVATION_MODIFIER", 34, 48], ["higher", "OBSERVATION_MODIFIER", 54, 60], ["Zika infection", "OBSERVATION", 81, 95]]], ["Understanding the influences of social and legacy media coverage of a novel health risk is important for health prevention and control as well as an optimal communication policy (Srinivasan, 2010).IntroductionOn November 6, 2015, the World Health Organization (WHO)'s Weekly Epidemiological Record pointed out that \u201crecent outbreaks of Zika infection in different regions of the world underscore the potential for the virus to spread further in the Americas and beyond, wherever the vector is present.\u201d", [["Zika infection", "DISEASE", 336, 350], ["social and legacy media coverage", "TREATMENT", 32, 64], ["Zika infection", "PROBLEM", 336, 350], ["the virus", "PROBLEM", 414, 423], ["Zika infection", "OBSERVATION", 336, 350], ["virus", "OBSERVATION", 418, 423]]], ["The Zika virus can be transmitted to people primarily through the bite of an infected mosquito of the Aedes genus, possibly through sexual transmission, and from a pregnant woman to her fetus.", [["fetus", "ANATOMY", 186, 191], ["Zika virus", "ORGANISM", 4, 14], ["people", "ORGANISM", 37, 43], ["Aedes genus", "ORGANISM", 102, 113], ["woman", "ORGANISM", 173, 178], ["fetus", "ORGANISM_SUBDIVISION", 186, 191], ["people", "SPECIES", 37, 43], ["woman", "SPECIES", 173, 178], ["Zika virus", "SPECIES", 4, 14], ["The Zika virus", "PROBLEM", 0, 14], ["Zika virus", "OBSERVATION", 4, 14], ["infected", "OBSERVATION", 77, 85]]], ["Other less confirmed modes of transmission are blood transfusions and exposure to infected patients in healthcare settings (CDC, 2017a; WHO, 2017).", [["blood", "ANATOMY", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["blood transfusions", "TREATMENT", 47, 65], ["infected", "OBSERVATION_MODIFIER", 82, 90]]], ["The first sexual transmission of the Zika virus in the United States was reported on February 2, 2016 (CDC, 2017a; WHO, 2017); by mid-to-late summer of that year, local cases were identified in Florida (CDC, 2017b).", [["Zika virus", "ORGANISM", 37, 47], ["Zika virus", "SPECIES", 37, 47]]], ["These patterns suggest the potential for rapid growth in areas where the Ae. aegypti and Ae. albopictus mosquitos live, and a high volume of inhabitants who travel to and from Zika-affected regions.", [["Ae. aegypti", "ORGANISM", 73, 84], ["Ae. albopictus", "ORGANISM", 89, 103], ["mosquitos", "ORGANISM", 104, 113], ["Ae. aegypti", "SPECIES", 73, 84], ["Ae. albopictus", "SPECIES", 89, 103], ["Ae. aegypti", "SPECIES", 73, 84], ["Ae. albopictus", "SPECIES", 89, 103], ["rapid growth in areas", "PROBLEM", 41, 62], ["suggest the potential for", "UNCERTAINTY", 15, 40], ["rapid", "OBSERVATION_MODIFIER", 41, 46], ["growth", "OBSERVATION_MODIFIER", 47, 53]]], ["Despite recordings of Zika infections as early as 1952, only recently was the Zika virus conclusively linked to Guillain-Barr\u00e9 Syndrome (PAHO/WHO, 2016), a rare neurological disorder in which the immune system attacks the peripheral nerves (Oduyebo et al., 2016), and to microcephaly, a rare condition in which the virus attacks the nervous system of fetuses and children (Mlakar et al., 2016; WHO, 2016).IntroductionUnderstanding risk perceptions of a public health crisis and the protective behaviors are critical for disease prevention and control: Outbreaks of Zika virus cases in the year 2016 represented an ideal opportunity to observe population levels of risk perceptions and behaviors and the extent to which social and legacy media coverage influence these levels.", [["neurological", "ANATOMY", 161, 173], ["immune system", "ANATOMY", 196, 209], ["peripheral nerves", "ANATOMY", 222, 239], ["nervous system", "ANATOMY", 333, 347], ["fetuses", "ANATOMY", 351, 358], ["Zika infections", "DISEASE", 22, 37], ["Guillain-Barr\u00e9 Syndrome", "DISEASE", 112, 135], ["neurological disorder", "DISEASE", 161, 182], ["microcephaly", "DISEASE", 271, 283], ["Zika virus", "DISEASE", 565, 575], ["Zika virus", "ORGANISM", 78, 88], ["Guillain-Barr\u00e9", "ORGANISM", 112, 126], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 222, 239], ["nervous system", "ANATOMICAL_SYSTEM", 333, 347], ["fetuses", "ORGANISM", 351, 358], ["children", "ORGANISM", 363, 371], ["Zika virus", "ORGANISM", 565, 575], ["children", "SPECIES", 363, 371], ["Zika virus", "SPECIES", 78, 88], ["Guillain-Barr\u00e9 Syndrome (PAHO/WHO, 2016)", "SPECIES", 112, 152], ["Zika virus", "SPECIES", 565, 575], ["Zika infections", "PROBLEM", 22, 37], ["the Zika virus", "PROBLEM", 74, 88], ["Barr\u00e9 Syndrome", "PROBLEM", 121, 135], ["a rare neurological disorder", "PROBLEM", 154, 182], ["microcephaly", "PROBLEM", 271, 283], ["a rare condition", "PROBLEM", 285, 301], ["a public health crisis", "PROBLEM", 451, 473], ["disease prevention", "TREATMENT", 520, 538], ["social and legacy media coverage", "TREATMENT", 719, 751], ["Zika infections", "OBSERVATION", 22, 37], ["rare", "OBSERVATION_MODIFIER", 156, 160], ["neurological disorder", "OBSERVATION", 161, 182], ["peripheral", "ANATOMY_MODIFIER", 222, 232], ["nerves", "ANATOMY", 233, 239], ["microcephaly", "OBSERVATION", 271, 283]]], ["The present study of the 2016 media messages concerning Zika considered the view that emerging risk perceptions and protective behaviors in a population are best instilled by quickly updated information in social media.", [["The present study", "TEST", 0, 17]]], ["In contrast, when protective behaviors cannot fully reduce the risk of infection, such as when an infection (e.g., Zika) is asymptomatic and reducing contact is difficult, protective behaviors and perceived risk may remain functionally independent (Rogers, 1983).", [["infection", "DISEASE", 71, 80], ["infection", "DISEASE", 98, 107], ["infection", "PROBLEM", 71, 80], ["an infection", "PROBLEM", 95, 107], ["Zika", "PROBLEM", 115, 119], ["asymptomatic", "PROBLEM", 124, 136], ["infection", "OBSERVATION", 71, 80], ["infection", "OBSERVATION", 98, 107]]], ["All in all, however, the presence of a large volume of social and legacy media messages about the Zika virus may both increase risk perceptions and protective behaviors.", [["Zika virus", "ORGANISM", 98, 108], ["Zika virus", "SPECIES", 98, 108], ["the Zika virus", "PROBLEM", 94, 108], ["large", "OBSERVATION_MODIFIER", 39, 44], ["volume", "OBSERVATION_MODIFIER", 45, 51]]], ["Furthermore, perceived risk should depend on the level of actual vulnerability to infection (CDC, 2017b; McCarthy, 2016; PAHO/WHO, 2016), which, in the case of Zika virus, should be higher in households with current and/or intended pregnancy and in geographic areas of high activity of the Aedes mosquito.IntroductionPrior research has demonstrated that legacy media, such as television broadcasts and newspapers, shape perceptions of public health issues (Dudo et al., 2007).", [["infection", "DISEASE", 82, 91], ["Zika virus", "ORGANISM", 160, 170], ["Aedes mosquito", "ORGANISM", 290, 304], ["Zika virus", "SPECIES", 160, 170], ["Aedes mosquito", "SPECIES", 290, 304], ["Zika virus", "PROBLEM", 160, 170], ["intended pregnancy", "PROBLEM", 223, 241], ["infection", "OBSERVATION", 82, 91], ["high activity", "OBSERVATION", 269, 282]]], ["For example, exposure to H1N1 flu news on television has been linked to the heightened perceived risk of the pandemic disease in Taiwan (Chang, 2012).", [["flu", "DISEASE", 30, 33], ["pandemic", "DISEASE", 109, 117], ["H1N1", "PROBLEM", 25, 29], ["the pandemic disease", "PROBLEM", 105, 125], ["H1N1", "OBSERVATION", 25, 29], ["pandemic", "OBSERVATION_MODIFIER", 109, 117], ["disease", "OBSERVATION", 118, 125]]], ["When the first few Zika infections were confirmed, fast-paced social media, rather than legacy media, may have provided a more adequate channel to disseminate information than the more formal, slower legacy media channels.IntroductionSomewhat surprisingly, however, no studies to date have directly examined the differential impact of social and legacy media on perceptions of the risk for infectious diseases (i.e., whether these media are differentially associated with risk perceptions when a health risk emerges) (Choi et al., 2017; Song et al., 2017).", [["infections", "DISEASE", 24, 34], ["infectious diseases", "DISEASE", 390, 409], ["Zika infections", "PROBLEM", 19, 34], ["fast-paced social media", "TREATMENT", 51, 74], ["infectious diseases", "PROBLEM", 390, 409]]], ["Choi et al. (2017) asked participants to report social media exposure and found a positive relation between exposure and risk perceptions of Middle East Respiratory Syndrome (MERS).", [["Middle East Respiratory Syndrome", "DISEASE", 141, 173], ["MERS", "DISEASE", 175, 179], ["participants", "SPECIES", 25, 37], ["Middle East Respiratory Syndrome", "PROBLEM", 141, 173], ["Middle", "ANATOMY_MODIFIER", 141, 147], ["Respiratory Syndrome", "OBSERVATION", 153, 173]]], ["These studies neither addressed the connections between media coverage and community risk perceptions and behaviors nor provided answers to the question of differential effects of social and legacy media.", [["These studies", "TEST", 0, 13], ["media coverage", "TREATMENT", 56, 70]]], ["This gap in knowledge is worth filling, because while the media are ideally positioned to influence risk perceptions and subsequent behavioral responses, legacy and social media may play different roles in alerting the public.IntroductionTo determine whether the volume of legacy and social media coverage week by week corresponds to the levels of risk perceptions and protected behaviors, we conducted a survey of the U.S. population over a period of 25 weeks and recorded references to the Zika virus in legacy media (i.e., radio, television, newspapers) and on Twitter.", [["Zika virus", "SPECIES", 492, 502], ["social media", "TREATMENT", 165, 177], ["social media coverage", "TREATMENT", 284, 305]]], ["These data allowed us to gauge the relations between the volume of media coverage, risk perceptions, and protective behaviors.", [["the volume of media coverage", "TREATMENT", 53, 81]]], ["The present study used econometric analyses to observe the associations of legacy and social media coverage with risk perceptions and behaviors in the U.S. population.", [["The present study", "TEST", 0, 17], ["econometric analyses", "TEST", 23, 43], ["legacy and social media coverage", "TREATMENT", 75, 107]]], ["Subgroup analyses were performed on survey responses of priority populations, including respondents in households with a member who is pregnant or intending to become pregnant and different demographic groups.Social and legacy media data ::: MethodWe measured the total legacy media coverage of Zika during April\u2013October 2016 by conducting searches of the term \u201cZika\u201d on news websites and legacy media databases, including Factiva, Newsbank, and Internet Archive.", [["Subgroup analyses", "TEST", 0, 17], ["MethodWe", "TREATMENT", 242, 250], ["the total legacy media coverage", "TREATMENT", 260, 291]]], ["We limited the records to the following legacy media sources located in the United States (i.e., The Wall Street Journal, The New York Times, USA Today, The Washington Post, The Miami Herald, The Orlando Sentinel, The Sun Sentinel, The Tampa Bay Times, ABC, CBS, NBC, CNN, Fox News, and MSNBC).", [["ABC", "TEST", 253, 256], ["CBS", "TEST", 258, 261]]], ["We also included local broadcasts created by these legacy media sources in the search results.Social and legacy media data ::: MethodThe Twitter data were collected with software developed by Crimson Hexagon.", [["local broadcasts", "TREATMENT", 17, 33]]], ["(The English keywords included: \u201cZika\u201d or \u201cdengue\u201d or \u201cyellow fever\u201d or \u201cZika fever\u201d or \u201cZika virus\u201d or \u201cflaviviridae\u201d or \u201cbrains shrink\u201d or \u201cfetal brain disruption sequence\u201d or \u201cmosquitoes\u201d or \u201cbirth defects\u201d or \u201cinsect bites\u201d or \u201cmosquito bites\u201d or \u201cinsect-borne virus\u201d or \u201cmosquito-borne flavivirus\u201d or \u201cmicrocephaly\u201d or \u201cGuillain-Barr\u00e9 Syndrome.\u201d", [["brains", "ANATOMY", 123, 129], ["fetal brain", "ANATOMY", 142, 153], ["dengue", "DISEASE", 43, 49], ["fever", "DISEASE", 62, 67], ["Zika fever", "DISEASE", 73, 83], ["birth defects", "DISEASE", 195, 208], ["insect bites", "DISEASE", 214, 226], ["mosquito bites", "DISEASE", 232, 246], ["flavivirus\u201d", "DISEASE", 291, 302], ["microcephaly", "DISEASE", 307, 319], ["Guillain-Barr\u00e9 Syndrome", "DISEASE", 325, 348], ["brain", "ORGAN", 148, 153], ["yellow fever", "PROBLEM", 55, 67], ["Zika fever", "PROBLEM", 73, 83], ["Zika virus", "PROBLEM", 89, 99], ["fetal brain disruption sequence", "PROBLEM", 142, 173], ["birth defects", "PROBLEM", 195, 208], ["\u201cinsect", "PROBLEM", 251, 258], ["borne virus\u201d", "PROBLEM", 259, 271], ["microcephaly", "PROBLEM", 307, 319], ["Barr\u00e9 Syndrome", "PROBLEM", 334, 348], ["Barr\u00e9 Syndrome", "OBSERVATION", 334, 348]]], ["The Spanish keywords included: \u201cfiebre amarilla\u201d or \u201cFiebre Zika\u201d or \u201cVirus Zika\u201d or \u201cFlaviviridae\u201d or \u201cLos cerebros se encogen\u201d or \u201cSecuencia de interrupci\u00f3n del cerebro fetal\u201d or \u201cMosquitos\u201d or \u201cdefectos de nacimiento\u201d or \u201cpicaduras de insectos\u201d or \u201cpicadura de mosquito\u201d or \u201cVirus transmitidos por insectos\u201d or \u201cFlavivirus transmitido por mosquitos\u201d or \u201cMicrocefalia\u201d or \u201cS\u00edndorme de Guillain-Barr\u00e9\u201d.)Survey data ::: MethodA US-wide survey about the Zika virus was conducted weekly over a period of 25 weeks, between April 11 and October 2, 2016.", [["Virus Zika\u201d or \u201cFlaviviridae\u201d", "DISEASE", 70, 99], ["Zika virus", "ORGANISM", 453, 463], ["Virus transmitidos", "SPECIES", 278, 296], ["Zika virus", "SPECIES", 453, 463], ["MethodA US", "TEST", 420, 430], ["the Zika virus", "PROBLEM", 449, 463]]], ["On each week, the survey involved a dual-frame sample (i.e., a fully-replicated, single-stage, random-digit-dialing sample of landline telephone households, along with randomly-generated cell phone numbers) designed to represent the adult U.S. population, including Hawaii and Alaska.", [["cell", "ANATOMY", 187, 191], ["cell", "CELL", 187, 191]]], ["About 1000 interviews were conducted each week, of which at least 600 were obtained from cell phone respondents.", [["cell", "ANATOMY", 89, 93], ["cell", "CELL", 89, 93]]], ["Cell phone respondents were considered separately from landlines as the interview could take place outside the respondent's home.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4]]], ["The weighting process considered the disproportionate probabilities of household and respondent selection due to the number of separate telephone landlines and cell phones answered by respondents and their households, as well as the probability associated with the random selection of an individual household member.", [["cell", "ANATOMY", 160, 164], ["cell", "CELL", 160, 164]]], ["Following application of the weights, the sample was appropriately post-stratified and balanced by the key demographics of age, ethnicity, sex, region, and education.", [["the weights", "TREATMENT", 25, 36]]], ["The sample was also weighted to reflect the distribution of phone usage in the general population, indicating the proportion of respondents who use a cell phone only, use a landline only, or a mix of both.", [["cell", "ANATOMY", 150, 154], ["cell", "CELL", 150, 154], ["The sample", "TEST", 0, 10]]], ["There was no monetary remuneration for participation.Survey data ::: MethodThe survey included dichotomous responses and polychotomous scales.", [["dichotomous responses", "TEST", 95, 116], ["no", "UNCERTAINTY", 10, 12], ["monetary remuneration", "OBSERVATION", 13, 34]]], ["Among these measures were items assessing risk perceptions on a 5-point scale (1 = extremely high risk to 5 = no risk, i.e., What is the risk that you will be infected with Zika in the next 6 months?), and protective behaviors on a dichotomous-choice format (1 = yes and 2 = no, i.e., In the past three months, have you done anything to protect yourself from getting Zika?, In the past three months, have you discussed Zika virus with a medical doctor or other healthcare professionals, or not?) as well as on the scale (1 = once, 2 = two times, 3 = three times, 4 = four times, 5 = five or more times, i.e., In the past three months, how many times have you discussed Zika virus with a medical doctor or other healthcare professional?).", [["Zika", "DISEASE", 367, 371], ["Zika virus", "ORGANISM", 669, 679], ["a 5-point scale", "TREATMENT", 62, 77]]], ["The item measuring risk perceptions was reverse-coded so that a higher risk perception received a higher score, while the dichotomous items measuring protective behaviors were dummy-coded to represent the presence of a protective behavior (a score of 1) versus the absence of a behavior (a score of 0).Survey data ::: MethodAdditionally, respondents were asked questions about the pregnancy status of their household, i.e., As far as you know, is anyone in your household currently pregnant? and As far as you know, is anyone in your household considering getting pregnant within the next 12 months?", [["a higher risk perception", "PROBLEM", 62, 86], ["a higher score", "PROBLEM", 96, 110]]], ["The raw number of records was calculated for each of the 25 waves based on their publication date, Mdn = 93, M = 106.40, SD = 54.53, and then standardized with a mean of zero.", [["Mdn", "TEST", 99, 102], ["SD", "TEST", 121, 123]]], ["The search on Crimson Hexagon located over 1.6 million tweets during the study period.", [["the study", "TEST", 69, 78]]], ["The average number of tweets was also calculated for each of the 25 waves, Mdn = 8424, M = 9211.28, SD = 3938.31, and these values were standardized as well.Survey data ::: Statistical procedures and analyses ::: MethodA total of 29062 adults (51% women, Mage = 54, SDage = 20.52) responded to the survey.", [["adults", "ORGANISM", 236, 242], ["women", "ORGANISM", 248, 253], ["women", "SPECIES", 248, 253], ["Mdn", "TEST", 75, 78], ["SD", "TEST", 100, 102], ["these values", "TEST", 118, 130], ["Mage", "TEST", 255, 259], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["The average response rate over the data collection period was 7.5%, which is typical of this kind of study (Keeter et al., 2006; Kohut et al., 2012).", [["average", "OBSERVATION_MODIFIER", 4, 11], ["response", "OBSERVATION_MODIFIER", 12, 20], ["rate", "OBSERVATION_MODIFIER", 21, 25]]], ["The measures of risk perceptions and protective behaviors were calculated for each of the 25 weeks.", [["protective behaviors", "PROBLEM", 37, 57]]], ["The standardized values of the variables of interest were calculated for the overall sample as well as for segments of interest based on pregnancy status (i.e., households with vs. without current and/or intended pregnancy), geographic regions (i.e., respondents residing in a high- vs. low-risk region of Zika infections), income (i.e., high vs. low household median income), education level (i.e., more vs. less education), age (i.e., young adult vs. adult vs. senior), and ethnicity (i.e., White vs. Black vs. Hispanic vs. \u2018other\u2019).Correlation and Granger causality analyses ::: Statistical procedures and analyses ::: MethodWe first correlated risk perception and protective behavior over the 25 weeks of the study to see if the variables were associated or occurred in parallel.", [["Zika infections", "DISEASE", 306, 321], ["pregnancy status", "PROBLEM", 137, 153], ["vs", "TEST", 177, 179], ["intended pregnancy", "PROBLEM", 204, 222], ["Zika infections", "PROBLEM", 306, 321], ["Granger causality analyses", "TEST", 551, 577], ["the study", "TEST", 709, 718], ["risk region", "OBSERVATION_MODIFIER", 291, 302], ["Zika infections", "OBSERVATION", 306, 321]]], ["We tested for lags of one week, two weeks, and three weeks to determine if the volume of media coverage was associated with levels of risk perceptions or behaviors a week, two weeks, or three weeks following particularized media coverage.", [["the volume of media coverage", "TREATMENT", 75, 103], ["particularized media coverage", "TREATMENT", 208, 237]]], ["In addition to establishing significance, the multiple linear regression models of the Granger causality tests assessed the strength of the associations.Social and legacy media associations with risk perceptions and protective behaviors ::: ResultsThe Granger causality tests in Table 2show that social and legacy media were associated with risk perceptions, F (1, 13) = 33.38, p < .001, and protective behaviors a week later, F (2, 18) = 4.00, p = .037.", [["the Granger causality tests", "TEST", 83, 110], ["The Granger causality tests", "TEST", 248, 275], ["multiple", "OBSERVATION_MODIFIER", 46, 54], ["linear", "OBSERVATION_MODIFIER", 55, 61], ["regression", "OBSERVATION_MODIFIER", 62, 72]]], ["The multiple linear regression model showed a strong association between social media and risk perceptions after 1 week, blag1 = 0.59, SElag1 = 0.11, 95% CIlag1 = 0.34 to 0.85, which accounted for 82% variance in risk perceptions in total, p < .001.", [["blag1", "TEST", 121, 126], ["SElag1", "TEST", 135, 141], ["CIlag1", "TEST", 154, 160], ["multiple", "OBSERVATION_MODIFIER", 4, 12], ["linear", "OBSERVATION_MODIFIER", 13, 19], ["strong", "OBSERVATION_MODIFIER", 46, 52]]], ["Furthermore, the association between legacy media and protective behaviors a week later was of moderate strength, blag1 = 0.30, SElag1 = 0.14, 95%, CIlag1 = 0.01 to 0.58, blag2 = 0.16, SElag2 = 0.15, 95%, CIlag2 = \u22120.15 to 0.47.", [["blag1", "TEST", 114, 119], ["SElag1", "TEST", 128, 134], ["CIlag1", "TEST", 148, 154], ["blag2", "TEST", 171, 176], ["SElag2", "TEST", 185, 191], ["CIlag2", "TEST", 205, 211], ["moderate", "OBSERVATION_MODIFIER", 95, 103]]], ["This model accounted for 28% variance in protective behaviors, p = .040.Social and legacy media associations with risk perceptions and protective behaviors ::: Results", [["28% variance in protective behaviors", "PROBLEM", 25, 61]]]], "PMC7123492": [["Intrathoracic and Intra-abdominal InjuriesA soccer player sustains trauma to his abdomen in a collision with an opponent.", [["abdomen", "ANATOMY", 81, 88], ["trauma", "DISEASE", 67, 73], ["abdomen", "ORGAN", 81, 88], ["Intrathoracic and Intra-abdominal InjuriesA", "PROBLEM", 0, 43], ["trauma to his abdomen", "PROBLEM", 67, 88], ["Intra-abdominal", "ANATOMY", 18, 33], ["abdomen", "ANATOMY", 81, 88]]], ["He is noted to be coughing but is able to continue.", [["coughing", "DISEASE", 18, 26], ["coughing", "PROBLEM", 18, 26], ["coughing", "OBSERVATION", 18, 26]]], ["After the game, he is complaining of left upper quadrant abdominal pain.", [["left upper quadrant abdominal", "ANATOMY", 37, 66], ["abdominal pain", "DISEASE", 57, 71], ["upper quadrant", "ORGANISM_SUBDIVISION", 42, 56], ["abdominal", "ORGANISM_SUBDIVISION", 57, 66], ["left upper quadrant abdominal pain", "PROBLEM", 37, 71], ["left", "ANATOMY_MODIFIER", 37, 41], ["upper", "ANATOMY_MODIFIER", 42, 47], ["quadrant", "ANATOMY_MODIFIER", 48, 56], ["abdominal", "ANATOMY", 57, 66], ["pain", "OBSERVATION", 67, 71]]], ["The athletic trainer relates that the player has had a recent upper respiratory tract infection.Intrathoracic and Intra-abdominal InjuriesDid the player sustain a splenic rupture because of underlying splenomegaly, caused by infectious mononucleosis, or is this an abdominal wall hematoma or muscle strain?", [["upper respiratory tract", "ANATOMY", 62, 85], ["Intra-abdominal", "ANATOMY", 114, 129], ["splenic", "ANATOMY", 163, 170], ["splenomegaly", "ANATOMY", 201, 213], ["abdominal wall hematoma", "ANATOMY", 265, 288], ["muscle", "ANATOMY", 292, 298], ["respiratory tract infection", "DISEASE", 68, 95], ["splenic rupture", "DISEASE", 163, 178], ["splenomegaly", "DISEASE", 201, 213], ["infectious mononucleosis", "DISEASE", 225, 249], ["hematoma", "DISEASE", 280, 288], ["upper respiratory", "ORGANISM_SUBDIVISION", 62, 79], ["tract", "ORGANISM_SUBDIVISION", 80, 85], ["splenic", "ORGAN", 163, 170], ["splenomegaly", "PATHOLOGICAL_FORMATION", 201, 213], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 265, 279], ["muscle", "ORGAN", 292, 298], ["a recent upper respiratory tract infection", "PROBLEM", 53, 95], ["Intrathoracic and Intra-abdominal Injuries", "PROBLEM", 96, 138], ["a splenic rupture", "PROBLEM", 161, 178], ["underlying splenomegaly", "PROBLEM", 190, 213], ["infectious mononucleosis", "PROBLEM", 225, 249], ["this an abdominal wall hematoma", "PROBLEM", 257, 288], ["muscle strain", "PROBLEM", 292, 305], ["upper", "ANATOMY_MODIFIER", 62, 67], ["respiratory tract", "ANATOMY", 68, 85], ["infection", "OBSERVATION", 86, 95], ["Intra-abdominal", "ANATOMY", 114, 129], ["Injuries", "OBSERVATION", 130, 138], ["splenic", "ANATOMY", 163, 170], ["rupture", "OBSERVATION", 171, 178], ["splenomegaly", "OBSERVATION", 201, 213], ["infectious", "OBSERVATION_MODIFIER", 225, 235], ["mononucleosis", "OBSERVATION", 236, 249], ["abdominal", "ANATOMY", 265, 274], ["wall", "ANATOMY_MODIFIER", 275, 279], ["hematoma", "OBSERVATION", 280, 288], ["muscle", "ANATOMY", 292, 298], ["strain", "OBSERVATION", 299, 305]]], ["Alternatively, could the coughing be indicative of an intrathoracic injury, such as a pneumothorax?Intrathoracic and Intra-abdominal InjuriesThis scene illustrates the difficulties involved in diagnosing injuries to the chest and abdomen.", [["intrathoracic", "ANATOMY", 54, 67], ["Intra-abdominal", "ANATOMY", 117, 132], ["chest", "ANATOMY", 220, 225], ["abdomen", "ANATOMY", 230, 237], ["intrathoracic injury", "DISEASE", 54, 74], ["pneumothorax", "DISEASE", 86, 98], ["Intrathoracic and Intra-abdominal Injuries", "DISEASE", 99, 141], ["injuries to the chest and abdomen", "DISEASE", 204, 237], ["intrathoracic", "ORGAN", 54, 67], ["chest", "ORGANISM_SUBDIVISION", 220, 225], ["abdomen", "ORGAN", 230, 237], ["the coughing", "PROBLEM", 21, 33], ["an intrathoracic injury", "PROBLEM", 51, 74], ["a pneumothorax", "PROBLEM", 84, 98], ["Intrathoracic and Intra-abdominal Injuries", "PROBLEM", 99, 141], ["diagnosing injuries to the chest and abdomen", "PROBLEM", 193, 237], ["intrathoracic", "ANATOMY", 54, 67], ["injury", "OBSERVATION", 68, 74], ["pneumothorax", "OBSERVATION", 86, 98], ["Intra-abdominal", "ANATOMY", 117, 132], ["Injuries", "OBSERVATION", 133, 141], ["chest", "ANATOMY", 220, 225], ["abdomen", "ANATOMY", 230, 237]]], ["Unless there is a low threshold to pursue investigation, athletes may suffer serious consequences.", [["a low threshold", "PROBLEM", 16, 31], ["serious consequences", "PROBLEM", 77, 97]]], ["Injuries to the chest and abdomen are often more subtle in presentation than other injuries, such as an acute ligament rupture.", [["chest", "ANATOMY", 16, 21], ["abdomen", "ANATOMY", 26, 33], ["ligament", "ANATOMY", 110, 118], ["Injuries to the chest and abdomen", "DISEASE", 0, 33], ["injuries", "DISEASE", 83, 91], ["acute ligament rupture", "DISEASE", 104, 126], ["chest", "ORGAN", 16, 21], ["abdomen", "ORGAN", 26, 33], ["ligament", "TISSUE", 110, 118], ["Injuries to the chest and abdomen", "PROBLEM", 0, 33], ["other injuries", "PROBLEM", 77, 91], ["an acute ligament rupture", "PROBLEM", 101, 126], ["chest", "ANATOMY", 16, 21], ["abdomen", "ANATOMY", 26, 33], ["more subtle", "OBSERVATION_MODIFIER", 44, 55], ["injuries", "OBSERVATION", 83, 91], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["ligament", "ANATOMY", 110, 118], ["rupture", "OBSERVATION", 119, 126]]], ["Thoracoabdominal injuries are uncommon, and catastrophic events can occur if an intra-abdominal or intrathoracic injury is unrecognized.", [["Thoracoabdominal", "ANATOMY", 0, 16], ["intra-abdominal", "ANATOMY", 80, 95], ["intrathoracic", "ANATOMY", 99, 112], ["Thoracoabdominal injuries", "DISEASE", 0, 25], ["intrathoracic", "ORGAN", 99, 112], ["Thoracoabdominal injuries", "PROBLEM", 0, 25], ["catastrophic events", "PROBLEM", 44, 63], ["an intra-abdominal or intrathoracic injury", "PROBLEM", 77, 119], ["injuries", "OBSERVATION", 17, 25], ["catastrophic", "OBSERVATION_MODIFIER", 44, 56], ["intra-abdominal", "ANATOMY", 80, 95], ["intrathoracic", "ANATOMY", 99, 112], ["injury", "OBSERVATION", 113, 119]]], ["Awareness of the organs that can be injured, and how such injuries may present, is the best defense against missing potentially life-threatening thoracic and abdominal trauma [1].AnatomyThe thorax contains the heart, the great vessels, and the lungs.", [["organs", "ANATOMY", 17, 23], ["thoracic", "ANATOMY", 145, 153], ["abdominal", "ANATOMY", 158, 167], ["thorax", "ANATOMY", 190, 196], ["heart", "ANATOMY", 210, 215], ["great vessels", "ANATOMY", 221, 234], ["lungs", "ANATOMY", 244, 249], ["injuries", "DISEASE", 58, 66], ["thoracic and abdominal trauma", "DISEASE", 145, 174], ["organs", "ORGAN", 17, 23], ["thoracic", "ORGANISM_SUBDIVISION", 145, 153], ["abdominal", "ORGANISM_SUBDIVISION", 158, 167], ["thorax", "ORGAN", 190, 196], ["heart", "ORGAN", 210, 215], ["great vessels", "MULTI-TISSUE_STRUCTURE", 221, 234], ["lungs", "ORGAN", 244, 249], ["abdominal trauma", "PROBLEM", 158, 174], ["organs", "ANATOMY", 17, 23], ["thoracic", "ANATOMY", 145, 153], ["abdominal", "ANATOMY", 158, 167], ["trauma", "OBSERVATION", 168, 174], ["thorax", "ANATOMY", 190, 196], ["heart", "ANATOMY", 210, 215], ["great vessels", "ANATOMY", 221, 234], ["lungs", "ANATOMY", 244, 249]]], ["The lungs are surrounded by two layers of pleurae protected by the ribs and the thoracic musculature.", [["lungs", "ANATOMY", 4, 9], ["pleurae", "ANATOMY", 42, 49], ["ribs", "ANATOMY", 67, 71], ["thoracic musculature", "ANATOMY", 80, 100], ["lungs", "ORGAN", 4, 9], ["pleurae", "CANCER", 42, 49], ["ribs", "ORGAN", 67, 71], ["thoracic musculature", "MULTI-TISSUE_STRUCTURE", 80, 100], ["lungs", "ANATOMY", 4, 9], ["two", "OBSERVATION_MODIFIER", 28, 31], ["layers", "OBSERVATION_MODIFIER", 32, 38], ["pleurae", "OBSERVATION", 42, 49], ["ribs", "ANATOMY", 67, 71], ["thoracic musculature", "ANATOMY", 80, 100]]], ["The diaphragm divides the thoracic and peritoneal cavities with a variable position throughout respiration [2].", [["diaphragm", "ANATOMY", 4, 13], ["thoracic", "ANATOMY", 26, 34], ["peritoneal cavities", "ANATOMY", 39, 58], ["diaphragm", "ORGAN", 4, 13], ["thoracic", "MULTI-TISSUE_STRUCTURE", 26, 34], ["peritoneal cavities", "MULTI-TISSUE_STRUCTURE", 39, 58], ["diaphragm", "ANATOMY", 4, 13], ["thoracic", "ANATOMY", 26, 34], ["peritoneal", "ANATOMY", 39, 49], ["cavities", "ANATOMY_MODIFIER", 50, 58], ["variable", "OBSERVATION_MODIFIER", 66, 74], ["position", "OBSERVATION_MODIFIER", 75, 83]]], ["The expulsive motion of the diaphragm can raise the right crus to the level of the fourth anterior costal cartilage.", [["diaphragm", "ANATOMY", 28, 37], ["right crus", "ANATOMY", 52, 62], ["anterior costal cartilage", "ANATOMY", 90, 115], ["diaphragm", "ORGAN", 28, 37], ["crus", "ORGAN", 58, 62], ["anterior costal cartilage", "TISSUE", 90, 115], ["expulsive motion", "OBSERVATION", 4, 20], ["diaphragm", "ANATOMY", 28, 37], ["right", "ANATOMY_MODIFIER", 52, 57], ["crus", "ANATOMY_MODIFIER", 58, 62], ["fourth", "ANATOMY_MODIFIER", 83, 89], ["anterior", "ANATOMY_MODIFIER", 90, 98], ["costal", "ANATOMY_MODIFIER", 99, 105], ["cartilage", "ANATOMY", 106, 115]]], ["Importantly, the abdominal contents may be raised well into the chest and exposed to chest wall trauma.AnatomyThe peritoneal cavity contains solid organs, such as the liver, spleen, and pancreas, plus hollow viscous organs, including the stomach and the small and large intestines.", [["abdominal", "ANATOMY", 17, 26], ["chest", "ANATOMY", 64, 69], ["chest wall", "ANATOMY", 85, 95], ["peritoneal cavity", "ANATOMY", 114, 131], ["solid organs", "ANATOMY", 141, 153], ["liver", "ANATOMY", 167, 172], ["spleen", "ANATOMY", 174, 180], ["pancreas", "ANATOMY", 186, 194], ["organs", "ANATOMY", 216, 222], ["stomach", "ANATOMY", 238, 245], ["small", "ANATOMY", 254, 259], ["intestines", "ANATOMY", 270, 280], ["chest wall trauma", "DISEASE", 85, 102], ["abdominal", "ORGAN", 17, 26], ["chest", "ORGANISM_SUBDIVISION", 64, 69], ["chest wall", "MULTI-TISSUE_STRUCTURE", 85, 95], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 114, 131], ["solid organs", "MULTI-TISSUE_STRUCTURE", 141, 153], ["liver", "ORGAN", 167, 172], ["spleen", "ORGAN", 174, 180], ["pancreas", "ORGAN", 186, 194], ["organs", "ORGAN", 216, 222], ["stomach", "ORGAN", 238, 245], ["intestines", "ORGAN", 270, 280], ["chest wall trauma", "PROBLEM", 85, 102], ["hollow viscous organs, including the stomach and the small and large intestines", "PROBLEM", 201, 280], ["abdominal", "ANATOMY", 17, 26], ["chest", "ANATOMY", 64, 69], ["chest", "ANATOMY", 85, 90], ["wall", "ANATOMY_MODIFIER", 91, 95], ["trauma", "OBSERVATION", 96, 102], ["peritoneal", "ANATOMY", 114, 124], ["cavity", "OBSERVATION", 125, 131], ["solid organs", "OBSERVATION", 141, 153], ["liver", "ANATOMY", 167, 172], ["spleen", "ANATOMY", 174, 180], ["pancreas", "ANATOMY", 186, 194], ["hollow", "ANATOMY_MODIFIER", 201, 207], ["viscous organs", "OBSERVATION", 208, 222], ["stomach", "ANATOMY", 238, 245], ["small", "ANATOMY_MODIFIER", 254, 259], ["large", "ANATOMY_MODIFIER", 264, 269], ["intestines", "ANATOMY", 270, 280]]], ["Also in this area are the lower ribs, the abdominal wall musculature, vascular structures, the bladder, and retroperitoneal organs and spaces.Thoracic Injury ::: Clinical EvaluationAthletes with a thoracic injury may present with chest wall pain and, often, shortness of breath.", [["area", "ANATOMY", 13, 17], ["lower ribs", "ANATOMY", 26, 36], ["abdominal wall musculature", "ANATOMY", 42, 68], ["vascular structures", "ANATOMY", 70, 89], ["bladder", "ANATOMY", 95, 102], ["retroperitoneal organs", "ANATOMY", 108, 130], ["thoracic", "ANATOMY", 197, 205], ["chest wall", "ANATOMY", 230, 240], ["thoracic injury", "DISEASE", 197, 212], ["chest wall pain", "DISEASE", 230, 245], ["shortness of breath", "DISEASE", 258, 277], ["ribs", "ORGANISM_SUBDIVISION", 32, 36], ["abdominal wall musculature", "TISSUE", 42, 68], ["vascular structures", "MULTI-TISSUE_STRUCTURE", 70, 89], ["bladder", "ORGAN", 95, 102], ["retroperitoneal organs", "MULTI-TISSUE_STRUCTURE", 108, 130], ["thoracic", "ORGAN", 197, 205], ["chest wall", "MULTI-TISSUE_STRUCTURE", 230, 240], ["Thoracic Injury", "PROBLEM", 142, 157], ["Clinical Evaluation", "TEST", 162, 181], ["a thoracic injury", "PROBLEM", 195, 212], ["chest wall pain", "PROBLEM", 230, 245], ["shortness of breath", "PROBLEM", 258, 277], ["area", "ANATOMY_MODIFIER", 13, 17], ["lower", "ANATOMY_MODIFIER", 26, 31], ["ribs", "ANATOMY", 32, 36], ["abdominal", "ANATOMY_MODIFIER", 42, 51], ["wall", "ANATOMY_MODIFIER", 52, 56], ["musculature", "ANATOMY", 57, 68], ["vascular structures", "ANATOMY", 70, 89], ["bladder", "ANATOMY", 95, 102], ["retroperitoneal", "ANATOMY_MODIFIER", 108, 123], ["organs", "ANATOMY", 124, 130], ["Injury", "OBSERVATION", 151, 157], ["thoracic", "ANATOMY", 197, 205], ["injury", "OBSERVATION", 206, 212], ["chest", "ANATOMY", 230, 235], ["wall", "ANATOMY_MODIFIER", 236, 240], ["pain", "OBSERVATION", 241, 245]]], ["Inspection for ecchymosis can also be helpful with intrathoracic injuries incurred in sport.", [["intrathoracic", "ANATOMY", 51, 64], ["ecchymosis", "DISEASE", 15, 25], ["intrathoracic injuries", "DISEASE", 51, 73], ["Inspection", "TEST", 0, 10], ["ecchymosis", "PROBLEM", 15, 25], ["intrathoracic injuries", "PROBLEM", 51, 73], ["ecchymosis", "OBSERVATION", 15, 25], ["intrathoracic", "ANATOMY", 51, 64], ["injuries", "OBSERVATION", 65, 73]]], ["Pulmonary auscultation is essential for assessment for lung pathology.", [["Pulmonary", "ANATOMY", 0, 9], ["lung", "ANATOMY", 55, 59], ["Pulmonary", "ORGAN", 0, 9], ["lung", "ORGAN", 55, 59], ["Pulmonary auscultation", "TEST", 0, 22], ["assessment", "TEST", 40, 50], ["lung pathology", "PROBLEM", 55, 69], ["auscultation", "OBSERVATION", 10, 22], ["lung", "ANATOMY", 55, 59], ["pathology", "OBSERVATION", 60, 69]]], ["Cardiac auscultation may be indicated for myocardial contusion or arrythmias.", [["Cardiac", "ANATOMY", 0, 7], ["myocardial", "ANATOMY", 42, 52], ["myocardial contusion", "DISEASE", 42, 62], ["arrythmias", "DISEASE", 66, 76], ["Cardiac", "ORGAN", 0, 7], ["myocardial", "MULTI-TISSUE_STRUCTURE", 42, 52], ["Cardiac auscultation", "TEST", 0, 20], ["myocardial contusion", "PROBLEM", 42, 62], ["arrythmias", "PROBLEM", 66, 76], ["auscultation", "OBSERVATION", 8, 20], ["may be indicated for", "UNCERTAINTY", 21, 41], ["contusion", "OBSERVATION", 53, 62], ["arrythmias", "OBSERVATION", 66, 76]]], ["Further examination may include palpation for tenderness over a suspected rib fracture.Abdominal Injury ::: Clinical EvaluationAthletes can present with an immediate onset of pain or a more insidious onset [1].", [["rib", "ANATOMY", 74, 77], ["Abdominal", "ANATOMY", 87, 96], ["tenderness", "DISEASE", 46, 56], ["rib fracture", "DISEASE", 74, 86], ["pain", "DISEASE", 175, 179], ["rib", "ORGAN", 74, 77], ["Further examination", "TEST", 0, 19], ["palpation", "TEST", 32, 41], ["tenderness", "PROBLEM", 46, 56], ["a suspected rib fracture", "PROBLEM", 62, 86], ["Abdominal Injury", "PROBLEM", 87, 103], ["pain", "PROBLEM", 175, 179], ["rib", "ANATOMY", 74, 77], ["fracture", "OBSERVATION", 78, 86], ["Injury", "OBSERVATION", 97, 103]]], ["Athletes who have a history of a high-risk mechanism, such as a rapid deceleration or high-energy impact, or who have continuous, persisting abdominal pain should be examined.Abdominal Injury ::: Clinical EvaluationPhysical exam should begin with the measurement of vital signs, which may be normal or reflect a state of shock.", [["abdominal", "ANATOMY", 141, 150], ["Abdominal", "ANATOMY", 175, 184], ["abdominal pain", "DISEASE", 141, 155], ["shock", "DISEASE", 321, 326], ["abdominal", "ORGANISM_SUBDIVISION", 141, 150], ["a high-risk mechanism", "PROBLEM", 31, 52], ["a rapid deceleration", "PROBLEM", 62, 82], ["persisting abdominal pain", "PROBLEM", 130, 155], ["Abdominal Injury", "PROBLEM", 175, 191], ["Clinical EvaluationPhysical exam", "TEST", 196, 228], ["vital signs", "TEST", 266, 277], ["shock", "PROBLEM", 321, 326], ["abdominal", "ANATOMY", 141, 150], ["pain", "OBSERVATION", 151, 155], ["Injury", "OBSERVATION", 185, 191], ["shock", "OBSERVATION", 321, 326]]], ["Inspection for ecchymosis and tenderness on abdominal palpation helps detect the potentially affected organ.", [["abdominal", "ANATOMY", 44, 53], ["organ", "ANATOMY", 102, 107], ["ecchymosis", "DISEASE", 15, 25], ["tenderness", "DISEASE", 30, 40], ["ecchymosis", "PATHOLOGICAL_FORMATION", 15, 25], ["abdominal", "ORGANISM_SUBDIVISION", 44, 53], ["organ", "ORGAN", 102, 107], ["Inspection", "TEST", 0, 10], ["ecchymosis", "PROBLEM", 15, 25], ["tenderness", "PROBLEM", 30, 40], ["abdominal palpation", "TEST", 44, 63], ["the potentially affected organ", "PROBLEM", 77, 107], ["ecchymosis", "OBSERVATION", 15, 25], ["tenderness", "OBSERVATION", 30, 40], ["abdominal", "ANATOMY", 44, 53]]], ["Abdominal wall muscular contusion can be difficult to distinguish from intra-abdominal injury.", [["Abdominal wall muscular", "ANATOMY", 0, 23], ["intra-abdominal", "ANATOMY", 71, 86], ["muscular contusion", "DISEASE", 15, 33], ["intra-abdominal injury", "DISEASE", 71, 93], ["Abdominal wall muscular", "TISSUE", 0, 23], ["intra-abdominal", "ORGANISM_SUBDIVISION", 71, 86], ["Abdominal wall muscular contusion", "PROBLEM", 0, 33], ["intra-abdominal injury", "PROBLEM", 71, 93], ["wall", "ANATOMY_MODIFIER", 10, 14], ["muscular", "ANATOMY", 15, 23], ["contusion", "OBSERVATION", 24, 33], ["intra-abdominal", "ANATOMY", 71, 86], ["injury", "OBSERVATION", 87, 93]]], ["Contusions are usually only tender over the area of sustained injury, and pain may be evident with contraction of the underlying muscle.", [["muscle", "ANATOMY", 129, 135], ["pain", "DISEASE", 74, 78], ["muscle", "ORGAN", 129, 135], ["Contusions", "PROBLEM", 0, 10], ["tender", "PROBLEM", 28, 34], ["sustained injury", "PROBLEM", 52, 68], ["pain", "PROBLEM", 74, 78], ["tender", "OBSERVATION_MODIFIER", 28, 34], ["sustained", "OBSERVATION_MODIFIER", 52, 61], ["injury", "OBSERVATION", 62, 68], ["pain", "OBSERVATION", 74, 78], ["contraction", "OBSERVATION", 99, 110], ["underlying muscle", "ANATOMY", 118, 135]]], ["Conversely, intra-abdominal injuries may elicit tenderness from various angles of palpation.Abdominal Injury ::: Clinical EvaluationAmong athletes with significant abdominal trauma, 50% will have a negative initial exam, so reexamination can be crucial.", [["intra-abdominal", "ANATOMY", 12, 27], ["Abdominal", "ANATOMY", 92, 101], ["abdominal", "ANATOMY", 164, 173], ["intra-abdominal injuries", "DISEASE", 12, 36], ["tenderness", "DISEASE", 48, 58], ["abdominal trauma", "DISEASE", 164, 180], ["abdominal", "ORGANISM_SUBDIVISION", 164, 173], ["intra-abdominal injuries", "PROBLEM", 12, 36], ["tenderness", "PROBLEM", 48, 58], ["palpation", "TEST", 82, 91], ["Abdominal Injury", "PROBLEM", 92, 108], ["Clinical EvaluationAmong athletes", "TEST", 113, 146], ["significant abdominal trauma", "PROBLEM", 152, 180], ["a negative initial exam", "TEST", 196, 219], ["reexamination", "TEST", 224, 237], ["intra-abdominal", "ANATOMY", 12, 27], ["injuries", "OBSERVATION", 28, 36], ["tenderness", "OBSERVATION", 48, 58], ["palpation", "OBSERVATION", 82, 91], ["Injury", "OBSERVATION", 102, 108], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["abdominal", "ANATOMY", 164, 173], ["trauma", "OBSERVATION", 174, 180]]], ["One estimate is that 20% of patients with an acute hemoperitoneum have an initial benign abdominal exam [3].Abdominal Injury ::: Clinical EvaluationLiver or spleen injuries can bleed, causing intra-abdominal irritation and pain.", [["abdominal", "ANATOMY", 89, 98], ["Abdominal", "ANATOMY", 108, 117], ["spleen", "ANATOMY", 157, 163], ["intra-abdominal", "ANATOMY", 192, 207], ["hemoperitoneum", "DISEASE", 51, 65], ["spleen injuries", "DISEASE", 157, 172], ["intra-abdominal irritation", "DISEASE", 192, 218], ["pain", "DISEASE", 223, 227], ["patients", "ORGANISM", 28, 36], ["spleen", "ORGAN", 157, 163], ["intra-abdominal", "ORGANISM_SUBDIVISION", 192, 207], ["patients", "SPECIES", 28, 36], ["an acute hemoperitoneum", "PROBLEM", 42, 65], ["an initial benign abdominal exam", "TEST", 71, 103], ["Abdominal Injury", "PROBLEM", 108, 124], ["Clinical EvaluationLiver", "TEST", 129, 153], ["spleen injuries", "PROBLEM", 157, 172], ["bleed", "PROBLEM", 177, 182], ["intra-abdominal irritation", "PROBLEM", 192, 218], ["pain", "PROBLEM", 223, 227], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["hemoperitoneum", "OBSERVATION", 51, 65], ["benign", "OBSERVATION_MODIFIER", 82, 88], ["abdominal", "ANATOMY", 89, 98], ["Injury", "OBSERVATION", 118, 124], ["spleen", "ANATOMY", 157, 163], ["injuries", "OBSERVATION", 164, 172], ["intra-abdominal", "ANATOMY", 192, 207], ["irritation", "OBSERVATION", 208, 218], ["pain", "OBSERVATION", 223, 227]]], ["Pain is often mild, without palpable tenderness.", [["Pain", "DISEASE", 0, 4], ["tenderness", "DISEASE", 37, 47], ["Pain", "PROBLEM", 0, 4], ["palpable tenderness", "PROBLEM", 28, 47], ["mild", "OBSERVATION_MODIFIER", 14, 18], ["without", "UNCERTAINTY", 20, 27], ["palpable", "OBSERVATION_MODIFIER", 28, 36], ["tenderness", "OBSERVATION", 37, 47]]], ["Injuries to hollow viscera and the pancreas cause peritonitis, often resulting in severe pain.", [["hollow viscera", "ANATOMY", 12, 26], ["pancreas", "ANATOMY", 35, 43], ["Injuries", "DISEASE", 0, 8], ["peritonitis", "DISEASE", 50, 61], ["pain", "DISEASE", 89, 93], ["viscera", "ORGAN", 19, 26], ["pancreas", "ORGAN", 35, 43], ["Injuries to hollow viscera", "PROBLEM", 0, 26], ["peritonitis", "PROBLEM", 50, 61], ["severe pain", "PROBLEM", 82, 93], ["hollow", "ANATOMY_MODIFIER", 12, 18], ["viscera", "ANATOMY", 19, 26], ["pancreas", "ANATOMY", 35, 43], ["peritonitis", "OBSERVATION", 50, 61], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["pain", "OBSERVATION", 89, 93]]], ["Initially, this is localized to the site of injury.", [["site", "ANATOMY", 36, 40], ["injury", "PROBLEM", 44, 50], ["injury", "OBSERVATION", 44, 50]]], ["Peritoneal signs, such as referred tenderness and loss of bowel sounds, are found with progression of intra-abdominal injury.", [["Peritoneal", "ANATOMY", 0, 10], ["bowel", "ANATOMY", 58, 63], ["intra-abdominal", "ANATOMY", 102, 117], ["tenderness", "DISEASE", 35, 45], ["loss of bowel sounds", "DISEASE", 50, 70], ["intra-abdominal injury", "DISEASE", 102, 124], ["Peritoneal", "MULTI-TISSUE_STRUCTURE", 0, 10], ["bowel", "ORGAN", 58, 63], ["intra-abdominal", "ORGANISM_SUBDIVISION", 102, 117], ["Peritoneal signs", "TEST", 0, 16], ["referred tenderness", "PROBLEM", 26, 45], ["loss of bowel sounds", "PROBLEM", 50, 70], ["intra-abdominal injury", "PROBLEM", 102, 124], ["signs", "OBSERVATION", 11, 16], ["tenderness", "OBSERVATION", 35, 45], ["loss", "OBSERVATION_MODIFIER", 50, 54], ["bowel", "ANATOMY", 58, 63], ["sounds", "OBSERVATION", 64, 70], ["progression", "OBSERVATION_MODIFIER", 87, 98], ["intra-abdominal", "ANATOMY", 102, 117], ["injury", "OBSERVATION", 118, 124]]], ["Auscultation for bowel sounds can be misleading, as the presence of bowel sounds does not exclude injury.", [["bowel", "ANATOMY", 17, 22], ["bowel", "ANATOMY", 68, 73], ["bowel", "ORGAN", 17, 22], ["bowel", "ORGAN", 68, 73], ["Auscultation", "TEST", 0, 12], ["bowel sounds", "TEST", 17, 29], ["bowel sounds", "TEST", 68, 80], ["injury", "PROBLEM", 98, 104], ["bowel", "ANATOMY", 17, 22], ["sounds", "OBSERVATION", 23, 29], ["bowel", "ANATOMY", 68, 73], ["sounds", "OBSERVATION", 74, 80]]], ["Walking or coughing can also precipitate pain.", [["coughing", "DISEASE", 11, 19], ["pain", "DISEASE", 41, 45], ["coughing", "PROBLEM", 11, 19], ["pain", "PROBLEM", 41, 45]]], ["Retroperitoneal injuries may occur without peritoneal signs when there is minor trauma.", [["Retroperitoneal", "ANATOMY", 0, 15], ["peritoneal", "ANATOMY", 43, 53], ["Retroperitoneal injuries", "DISEASE", 0, 24], ["trauma", "DISEASE", 80, 86], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 43, 53], ["Retroperitoneal injuries", "PROBLEM", 0, 24], ["peritoneal signs", "PROBLEM", 43, 59], ["minor trauma", "PROBLEM", 74, 86], ["injuries", "OBSERVATION", 16, 24], ["without", "UNCERTAINTY", 35, 42], ["peritoneal", "ANATOMY", 43, 53], ["minor", "OBSERVATION_MODIFIER", 74, 79], ["trauma", "OBSERVATION", 80, 86]]], ["Hematuria is often the only clinical manifestation of renal trauma.Coexisting Injuries ::: Clinical EvaluationIt has been well recognized that lower chest wall trauma places the upper abdominal organs at risk for injury.", [["renal", "ANATOMY", 54, 59], ["chest wall", "ANATOMY", 149, 159], ["abdominal organs", "ANATOMY", 184, 200], ["Hematuria", "DISEASE", 0, 9], ["renal trauma", "DISEASE", 54, 66], ["Injuries", "DISEASE", 78, 86], ["chest wall trauma", "DISEASE", 149, 166], ["renal", "ORGAN", 54, 59], ["chest wall", "MULTI-TISSUE_STRUCTURE", 149, 159], ["upper abdominal", "ORGANISM_SUBDIVISION", 178, 193], ["organs", "ORGAN", 194, 200], ["Hematuria", "PROBLEM", 0, 9], ["renal trauma", "PROBLEM", 54, 66], ["Clinical Evaluation", "TEST", 91, 110], ["lower chest wall trauma", "PROBLEM", 143, 166], ["injury", "PROBLEM", 213, 219], ["renal", "ANATOMY", 54, 59], ["trauma", "OBSERVATION", 60, 66], ["Injuries", "OBSERVATION", 78, 86], ["lower", "ANATOMY_MODIFIER", 143, 148], ["chest", "ANATOMY", 149, 154], ["wall", "ANATOMY_MODIFIER", 155, 159], ["trauma", "OBSERVATION", 160, 166], ["upper", "ANATOMY_MODIFIER", 178, 183], ["abdominal organs", "ANATOMY", 184, 200], ["risk for", "UNCERTAINTY", 204, 212], ["injury", "OBSERVATION", 213, 219]]], ["Most commonly, a blow to the lower left chest wall can result in an injury to the spleen [1].", [["lower left chest wall", "ANATOMY", 29, 50], ["spleen", "ANATOMY", 82, 88], ["injury to the spleen", "DISEASE", 68, 88], ["chest wall", "MULTI-TISSUE_STRUCTURE", 40, 50], ["spleen", "ORGAN", 82, 88], ["an injury to the spleen", "PROBLEM", 65, 88], ["lower", "ANATOMY_MODIFIER", 29, 34], ["left", "ANATOMY_MODIFIER", 35, 39], ["chest", "ANATOMY", 40, 45], ["wall", "ANATOMY_MODIFIER", 46, 50], ["injury", "OBSERVATION", 68, 74], ["spleen", "ANATOMY", 82, 88]]], ["Conversely, several case reports exist in the literature of abdominal impact resulting in an intrathoracic injury, such as a pneumothorax.", [["abdominal", "ANATOMY", 60, 69], ["intrathoracic", "ANATOMY", 93, 106], ["intrathoracic injury", "DISEASE", 93, 113], ["pneumothorax", "DISEASE", 125, 137], ["abdominal", "ORGANISM_SUBDIVISION", 60, 69], ["abdominal impact", "PROBLEM", 60, 76], ["an intrathoracic injury", "PROBLEM", 90, 113], ["a pneumothorax", "PROBLEM", 123, 137], ["abdominal", "ANATOMY", 60, 69], ["intrathoracic", "ANATOMY", 93, 106], ["injury", "OBSERVATION", 107, 113], ["pneumothorax", "OBSERVATION", 125, 137]]], ["One such report by Roberts [4] described an ice hockey player who was checked into the boards and sustained an impact over his left lower ribs.", [["left lower ribs", "ANATOMY", 127, 142], ["lower ribs", "ORGANISM_SUBDIVISION", 132, 142], ["impact", "OBSERVATION", 111, 117], ["left", "ANATOMY_MODIFIER", 127, 131], ["lower", "ANATOMY_MODIFIER", 132, 137], ["ribs", "ANATOMY", 138, 142]]], ["Initial concern for a splenic injury proved unfounded, and he was allowed to return to the game.", [["splenic", "ANATOMY", 22, 29], ["splenic injury", "DISEASE", 22, 36], ["splenic", "ORGAN", 22, 29], ["a splenic injury", "PROBLEM", 20, 36], ["concern for", "UNCERTAINTY", 8, 19], ["splenic", "ANATOMY", 22, 29], ["injury", "OBSERVATION", 30, 36]]], ["However, he was too uncomfortable to continue, and assessment afterward revealed a 15% pneumothorax on chest x-ray.", [["pneumothorax", "DISEASE", 87, 99], ["chest", "ORGAN", 103, 108], ["too uncomfortable", "PROBLEM", 16, 33], ["assessment", "TEST", 51, 61], ["a 15% pneumothorax", "PROBLEM", 81, 99], ["chest x-ray", "TEST", 103, 114], ["pneumothorax", "OBSERVATION", 87, 99], ["chest", "ANATOMY", 103, 108]]], ["Hence, pulmonary injury from abdominal trauma can occur without disruption of the diaphragm.", [["pulmonary", "ANATOMY", 7, 16], ["abdominal", "ANATOMY", 29, 38], ["diaphragm", "ANATOMY", 82, 91], ["pulmonary injury", "DISEASE", 7, 23], ["abdominal trauma", "DISEASE", 29, 45], ["pulmonary", "ORGAN", 7, 16], ["abdominal", "ORGANISM_SUBDIVISION", 29, 38], ["diaphragm", "ORGAN", 82, 91], ["pulmonary injury", "PROBLEM", 7, 23], ["abdominal trauma", "PROBLEM", 29, 45], ["disruption of the diaphragm", "PROBLEM", 64, 91], ["pulmonary", "ANATOMY", 7, 16], ["injury", "OBSERVATION", 17, 23], ["abdominal", "ANATOMY", 29, 38], ["trauma", "OBSERVATION", 39, 45], ["diaphragm", "ANATOMY", 82, 91]]], ["Diaphragm rupture is uncommon but is usually left sided (70\u201390%), as the liver appears to protect the right side.Diagnostic Assessment ::: Clinical EvaluationLaboratory investigations , including serial determination of hematocrit, diagnostic imaging, and diagnostic peritoneal lavage (DPL), can be performed in a hospital setting.", [["Diaphragm", "ANATOMY", 0, 9], ["liver", "ANATOMY", 73, 78], ["peritoneal lavage", "ANATOMY", 267, 284], ["Diaphragm rupture", "DISEASE", 0, 17], ["liver", "ORGAN", 73, 78], ["peritoneal lavage", "MULTI-TISSUE_STRUCTURE", 267, 284], ["Diaphragm rupture", "PROBLEM", 0, 17], ["Diagnostic Assessment", "TEST", 113, 134], ["Clinical EvaluationLaboratory investigations", "TEST", 139, 183], ["hematocrit", "TEST", 220, 230], ["diagnostic imaging", "TEST", 232, 250], ["diagnostic peritoneal lavage", "TEST", 256, 284], ["rupture", "OBSERVATION", 10, 17], ["left", "ANATOMY_MODIFIER", 45, 49], ["liver", "ANATOMY", 73, 78], ["right", "ANATOMY_MODIFIER", 102, 107], ["peritoneal", "ANATOMY", 267, 277], ["lavage", "OBSERVATION", 278, 284]]], ["DPL has become less commonly performed with the increased availability of diagnostic ultrasound and computed tomography (CT).", [["DPL", "TEST", 0, 3], ["diagnostic ultrasound", "TEST", 74, 95], ["computed tomography", "TEST", 100, 119], ["CT", "TEST", 121, 123], ["less", "OBSERVATION_MODIFIER", 15, 19]]], ["A chest x-ray is usually indicated.", [["chest", "ANATOMY", 2, 7], ["chest", "ORGAN", 2, 7], ["A chest x-ray", "TEST", 0, 13], ["chest", "ANATOMY", 2, 7]]], ["An erect view is helpful to exclude air under the diaphragm, suggesting bowel perforation.Diagnostic Assessment ::: Clinical EvaluationAn emerging imaging modality for chest and abdominal trauma is diagnostic ultrasound, which has useful applications in the evaluation of thoracic trauma and may be a better diagnostic tool than supine x-ray for pneumothoraces and lung contusions [5\u20137].Diagnostic Assessment ::: Clinical EvaluationAbdominal CT scan after blunt trauma has 67% sensitivity in its ability to predict the need for surgery in a pediatric population [8].", [["diaphragm", "ANATOMY", 50, 59], ["bowel", "ANATOMY", 72, 77], ["chest", "ANATOMY", 168, 173], ["abdominal", "ANATOMY", 178, 187], ["thoracic", "ANATOMY", 272, 280], ["lung", "ANATOMY", 365, 369], ["bowel perforation", "DISEASE", 72, 89], ["chest and abdominal trauma", "DISEASE", 168, 194], ["thoracic trauma", "DISEASE", 272, 287], ["pneumothoraces", "DISEASE", 346, 360], ["lung contusions", "DISEASE", 365, 380], ["blunt trauma", "DISEASE", 456, 468], ["diaphragm", "ORGAN", 50, 59], ["bowel", "ORGAN", 72, 77], ["chest", "ORGANISM_SUBDIVISION", 168, 173], ["abdominal", "ORGANISM_SUBDIVISION", 178, 187], ["thoracic", "ORGAN", 272, 280], ["lung", "ORGAN", 365, 369], ["An erect view", "TEST", 0, 13], ["air under the diaphragm", "PROBLEM", 36, 59], ["bowel perforation", "PROBLEM", 72, 89], ["Diagnostic Assessment", "TEST", 90, 111], ["Clinical Evaluation", "TEST", 116, 135], ["An emerging imaging modality", "TEST", 135, 163], ["chest and abdominal trauma", "TEST", 168, 194], ["diagnostic ultrasound", "TEST", 198, 219], ["the evaluation", "TEST", 254, 268], ["thoracic trauma", "PROBLEM", 272, 287], ["supine x-ray", "TEST", 329, 341], ["pneumothoraces", "PROBLEM", 346, 360], ["lung contusions", "PROBLEM", 365, 380], ["Diagnostic Assessment", "TEST", 387, 408], ["Clinical EvaluationAbdominal CT scan", "TEST", 413, 449], ["blunt trauma", "PROBLEM", 456, 468], ["surgery", "TREATMENT", 528, 535], ["air", "OBSERVATION", 36, 39], ["diaphragm", "ANATOMY", 50, 59], ["suggesting", "UNCERTAINTY", 61, 71], ["bowel", "ANATOMY", 72, 77], ["perforation", "OBSERVATION", 78, 89], ["chest", "ANATOMY", 168, 173], ["abdominal", "ANATOMY", 178, 187], ["thoracic", "ANATOMY", 272, 280], ["trauma", "OBSERVATION", 281, 287], ["pneumothoraces", "OBSERVATION", 346, 360], ["lung", "ANATOMY", 365, 369], ["contusions", "OBSERVATION", 370, 380]]], ["The negative predictive value was 98.7% in the same study.", [["the same study", "TEST", 43, 57]]], ["A combination of clinical exam and CT scan did not miss any significant injuries.", [["clinical exam", "TEST", 17, 30], ["CT scan", "TEST", 35, 42], ["any significant injuries", "PROBLEM", 56, 80], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["injuries", "OBSERVATION", 72, 80]]], ["Serial examination may be performed in a hospital setting.", [["Serial examination", "TEST", 0, 18]]], ["CT scan alone may miss clinically significant injuries.Diagnostic Assessment ::: Clinical EvaluationCT is the best choice for imaging solid organs such as the liver and spleen [9] and remains the gold standard in evaluating blunt abdominal trauma in hemodynamically stable patients [10\u201313] though diagnostic ultrasound has advantages.", [["solid organs", "ANATOMY", 134, 146], ["liver", "ANATOMY", 159, 164], ["spleen", "ANATOMY", 169, 175], ["abdominal", "ANATOMY", 230, 239], ["abdominal trauma", "DISEASE", 230, 246], ["organs", "ORGAN", 140, 146], ["liver", "ORGAN", 159, 164], ["spleen", "ORGAN", 169, 175], ["abdominal", "ORGANISM_SUBDIVISION", 230, 239], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 273, 281], ["CT scan", "TEST", 0, 7], ["significant injuries", "PROBLEM", 34, 54], ["Diagnostic Assessment", "TEST", 55, 76], ["imaging solid organs", "TEST", 126, 146], ["blunt abdominal trauma", "PROBLEM", 224, 246], ["diagnostic ultrasound", "TEST", 297, 318], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["injuries", "OBSERVATION", 46, 54], ["liver", "ANATOMY", 159, 164], ["spleen", "ANATOMY", 169, 175], ["abdominal", "ANATOMY", 230, 239], ["trauma", "OBSERVATION", 240, 246], ["stable", "OBSERVATION_MODIFIER", 266, 272]]], ["While ultrasonography is not as sensitive for intra-abdominal trauma, does not provide as much anatomic detail, does not allow for injury grading [14], and remains operator dependent, it does have a role, for instance, in the hemodynamically unstable patient [15, 16].", [["intra-abdominal", "ANATOMY", 46, 61], ["intra-abdominal trauma", "DISEASE", 46, 68], ["intra-abdominal", "ORGANISM_SUBDIVISION", 46, 61], ["patient", "ORGANISM", 251, 258], ["patient", "SPECIES", 251, 258], ["ultrasonography", "TEST", 6, 21], ["intra-abdominal trauma", "PROBLEM", 46, 68], ["injury grading", "TEST", 131, 145], ["intra-abdominal", "ANATOMY", 46, 61], ["trauma", "OBSERVATION", 62, 68]]], ["Hoffman et al. described a sensitivity of 85% and a specificity of 99% in detecting intra-abdominal injuries [16], while Berkoff suggests sensitivity of 60% (95% CI 49\u201370) [17].", [["intra-abdominal", "ANATOMY", 84, 99], ["intra-abdominal injuries", "DISEASE", 84, 108], ["a sensitivity", "TEST", 25, 38], ["a specificity", "TEST", 50, 63], ["intra-abdominal injuries", "PROBLEM", 84, 108], ["sensitivity", "TEST", 138, 149], ["CI", "TEST", 162, 164], ["intra-abdominal", "ANATOMY", 84, 99], ["injuries", "OBSERVATION", 100, 108]]], ["Ultrasound visualizes free intraperitoneal fluid well, though it may not identify the injured organ [18].", [["intraperitoneal fluid", "ANATOMY", 27, 48], ["organ", "ANATOMY", 94, 99], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 42], ["fluid", "ORGANISM_SUBSTANCE", 43, 48], ["organ", "ORGAN", 94, 99], ["Ultrasound", "TEST", 0, 10], ["intraperitoneal", "ANATOMY", 27, 42], ["fluid", "OBSERVATION", 43, 48]]], ["Conditions identified on ultrasound in unstable patients will eventually require CT to identify the injury and to guide management [18].", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["ultrasound", "TEST", 25, 35], ["CT", "TEST", 81, 83], ["the injury", "PROBLEM", 96, 106], ["injury", "OBSERVATION", 100, 106]]], ["The use of abdominal ultrasound for evaluation of unstable patients has been described by the term \u201cfocused assessment with sonography for trauma\u201d (FAST) [19].", [["abdominal", "ANATOMY", 11, 20], ["trauma", "DISEASE", 139, 145], ["abdominal", "ORGANISM_SUBDIVISION", 11, 20], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["abdominal ultrasound", "TEST", 11, 31], ["evaluation", "TEST", 36, 46], ["focused assessment", "TEST", 100, 118], ["sonography", "TEST", 124, 134], ["trauma", "PROBLEM", 139, 145], ["abdominal", "ANATOMY", 11, 20], ["unstable", "OBSERVATION", 50, 58]]], ["The FAST examination aims to recognize peritoneal fluid/blood, which typically arises from a solid organ injury.", [["peritoneal fluid", "ANATOMY", 39, 55], ["blood", "ANATOMY", 56, 61], ["solid organ", "ANATOMY", 93, 104], ["organ injury", "DISEASE", 99, 111], ["peritoneal fluid", "ORGANISM_SUBSTANCE", 39, 55], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["organ", "ORGAN", 99, 104], ["The FAST examination", "TEST", 0, 20], ["peritoneal fluid/blood", "PROBLEM", 39, 61], ["a solid organ injury", "PROBLEM", 91, 111], ["peritoneal", "ANATOMY", 39, 49], ["fluid", "OBSERVATION", 50, 55], ["blood", "ANATOMY", 56, 61], ["solid", "ANATOMY_MODIFIER", 93, 98], ["organ", "ANATOMY", 99, 104], ["injury", "OBSERVATION", 105, 111]]], ["A hypotensive athlete who has suffered abdominal trauma with a positive finding on a FAST examination has a higher likelihood of operative management [17, 19\u201326].Treatment ::: Clinical EvaluationField treatment for shock, before and during transfer to a trauma center, is essential when shock is detected.", [["abdominal", "ANATOMY", 39, 48], ["hypotensive", "DISEASE", 2, 13], ["abdominal trauma", "DISEASE", 39, 55], ["shock", "DISEASE", 215, 220], ["trauma", "DISEASE", 254, 260], ["shock", "DISEASE", 287, 292], ["abdominal", "ORGANISM_SUBDIVISION", 39, 48], ["A hypotensive athlete", "PROBLEM", 0, 21], ["abdominal trauma", "PROBLEM", 39, 55], ["a FAST examination", "TEST", 83, 101], ["operative management", "TREATMENT", 129, 149], ["Clinical Evaluation", "TEST", 176, 195], ["shock", "PROBLEM", 215, 220], ["shock", "PROBLEM", 287, 292], ["hypotensive", "OBSERVATION_MODIFIER", 2, 13], ["abdominal", "ANATOMY", 39, 48], ["trauma", "OBSERVATION", 49, 55], ["shock", "OBSERVATION", 215, 220]]], ["Intravenous access with a large-bore cannula should be established at two sites with rapid infusion of 0.9% saline, rather than dextrose-containing fluids.Treatment ::: Clinical EvaluationCurrent surgical goals are for organ salvage and repair, rather than removal of injured intra-abdominal organs.", [["organ", "ANATOMY", 219, 224], ["intra-abdominal organs", "ANATOMY", 276, 298], ["dextrose", "CHEMICAL", 128, 136], ["dextrose", "CHEMICAL", 128, 136], ["saline", "SIMPLE_CHEMICAL", 108, 114], ["dextrose", "SIMPLE_CHEMICAL", 128, 136], ["organ", "ORGAN", 219, 224], ["intra-abdominal organs", "ORGAN", 276, 298], ["Intravenous access", "TREATMENT", 0, 18], ["a large-bore cannula", "TREATMENT", 24, 44], ["rapid infusion", "TREATMENT", 85, 99], ["0.9% saline", "TREATMENT", 103, 114], ["dextrose", "TREATMENT", 128, 136], ["fluids", "TREATMENT", 148, 154], ["organ salvage", "TREATMENT", 219, 232], ["repair", "TREATMENT", 237, 243], ["removal", "TREATMENT", 257, 264], ["injured intra-abdominal organs", "PROBLEM", 268, 298], ["large", "OBSERVATION_MODIFIER", 26, 31], ["repair", "OBSERVATION", 237, 243], ["injured", "OBSERVATION", 268, 275], ["intra-abdominal", "ANATOMY_MODIFIER", 276, 291], ["organs", "ANATOMY", 292, 298]]], ["Indications for removal revolve around uncontrolled bleeding, particularly when associated with coagulopathy.", [["bleeding", "DISEASE", 52, 60], ["coagulopathy", "DISEASE", 96, 108], ["removal", "TREATMENT", 16, 23], ["uncontrolled bleeding", "PROBLEM", 39, 60], ["coagulopathy", "PROBLEM", 96, 108], ["uncontrolled", "OBSERVATION_MODIFIER", 39, 51], ["bleeding", "OBSERVATION", 52, 60], ["coagulopathy", "OBSERVATION", 96, 108]]], ["In such circumstances, the risks of surgery are outweighed by the benefit of achieving hemostatic control, with a low likelihood of control being achieved any other way.", [["surgery", "TREATMENT", 36, 43], ["hemostatic control", "TREATMENT", 87, 105]]], ["However, caution is required regarding delayed rupture of the spleen at 7\u201310 days.Pneumothorax ::: Lung Injuries ::: Thoracic InjuriesThis is the most common intrathoracic injury after blunt thoracic trauma [30].", [["spleen", "ANATOMY", 62, 68], ["Lung", "ANATOMY", 99, 103], ["Thoracic", "ANATOMY", 117, 125], ["intrathoracic", "ANATOMY", 158, 171], ["thoracic", "ANATOMY", 191, 199], ["rupture of the spleen", "DISEASE", 47, 68], ["Pneumothorax", "DISEASE", 82, 94], ["Lung Injuries", "DISEASE", 99, 112], ["Thoracic Injuries", "DISEASE", 117, 134], ["intrathoracic injury", "DISEASE", 158, 178], ["blunt thoracic trauma", "DISEASE", 185, 206], ["spleen", "ORGAN", 62, 68], ["Lung", "ORGAN", 99, 103], ["intrathoracic", "ORGAN", 158, 171], ["thoracic", "ORGAN", 191, 199], ["delayed rupture of the spleen", "PROBLEM", 39, 68], ["Pneumothorax", "PROBLEM", 82, 94], ["Lung Injuries", "PROBLEM", 99, 112], ["Thoracic Injuries", "PROBLEM", 117, 134], ["the most common intrathoracic injury", "PROBLEM", 142, 178], ["blunt thoracic trauma", "PROBLEM", 185, 206], ["rupture", "OBSERVATION", 47, 54], ["spleen", "ANATOMY", 62, 68], ["Injuries", "OBSERVATION", 104, 112], ["Injuries", "OBSERVATION", 126, 134], ["intrathoracic", "ANATOMY", 158, 171], ["injury", "OBSERVATION", 172, 178], ["blunt", "OBSERVATION_MODIFIER", 185, 190], ["thoracic", "ANATOMY", 191, 199], ["trauma", "OBSERVATION", 200, 206]]], ["Among all children who sustain high-energy thoracic trauma, approximately one quarter to one third will develop a pneumothorax [31, 32].", [["high-energy thoracic trauma", "DISEASE", 31, 58], ["pneumothorax", "DISEASE", 114, 126], ["children", "ORGANISM", 10, 18], ["children", "SPECIES", 10, 18], ["high-energy thoracic trauma", "PROBLEM", 31, 58], ["a pneumothorax", "PROBLEM", 112, 126], ["thoracic", "ANATOMY", 43, 51], ["trauma", "OBSERVATION", 52, 58], ["pneumothorax", "OBSERVATION", 114, 126]]], ["Pneumothorax related to sporting activity or injury is relatively uncommon.", [["Pneumothorax", "DISEASE", 0, 12], ["Pneumothorax", "PROBLEM", 0, 12], ["injury", "PROBLEM", 45, 51], ["sporting activity", "OBSERVATION", 24, 41], ["injury", "OBSERVATION", 45, 51], ["relatively", "OBSERVATION_MODIFIER", 55, 65], ["uncommon", "OBSERVATION_MODIFIER", 66, 74]]], ["Spontaneous occurrences have been reported in a number of sports such as soccer [33] and weight lifting [34].", [["Spontaneous occurrences", "PROBLEM", 0, 23]]], ["Pneumothorax as a result of blunt trauma during sports generally involves deceleration of the athlete\u2019s thorax against a moving or a stationary object, as has been reported in skiing and snowboarding [35], bicycling [36], football, and ice hockey [37].Pneumothorax ::: Lung Injuries ::: Thoracic Injuries", [["thorax", "ANATOMY", 104, 110], ["Lung", "ANATOMY", 269, 273], ["Thoracic", "ANATOMY", 287, 295], ["Pneumothorax", "DISEASE", 0, 12], ["trauma", "DISEASE", 34, 40], ["Pneumothorax", "DISEASE", 252, 264], ["Lung Injuries", "DISEASE", 269, 282], ["Thoracic Injuries", "DISEASE", 287, 304], ["thorax", "ORGAN", 104, 110], ["Lung", "ORGAN", 269, 273], ["Pneumothorax", "PROBLEM", 0, 12], ["blunt trauma", "PROBLEM", 28, 40], ["Pneumothorax", "PROBLEM", 252, 264], ["Lung Injuries", "PROBLEM", 269, 282], ["Thoracic Injuries", "PROBLEM", 287, 304], ["thorax", "ANATOMY", 104, 110], ["Injuries", "OBSERVATION", 274, 282], ["Injuries", "OBSERVATION", 296, 304]]]], "ee0e2700a9fc5124895d30a13abb1777303951a3": [["the index case, and who are susceptible to MS.", [["MS", "DISEASE", 43, 45], ["MS", "PROBLEM", 43, 45]]]], "PMC4821650": [["Human B cell technologies to identify functional Abs against infectious diseasesNearly all licensed vaccines confer protection against infectious diseases by stimulating the production of pathogen-specific Abs by B cells.", [["B cell", "ANATOMY", 6, 12], ["B cells", "ANATOMY", 213, 220], ["infectious diseases", "DISEASE", 61, 80], ["infectious diseases", "DISEASE", 135, 154], ["Human", "ORGANISM", 0, 5], ["B cell", "CELL", 6, 12], ["B cells", "CELL", 213, 220], ["Abs", "PROTEIN", 49, 52], ["Abs", "PROTEIN", 206, 209], ["B cells", "CELL_TYPE", 213, 220], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human B cell technologies", "TREATMENT", 0, 25], ["infectious diseases", "PROBLEM", 61, 80], ["all licensed vaccines", "TREATMENT", 87, 108], ["infectious diseases", "PROBLEM", 135, 154], ["B cells", "OBSERVATION", 213, 220]]], ["Understanding the nature of a successful Ab response is therefore a fundamental step to providing new tools for the design of novel or better vaccines.", [["Ab", "GENE_OR_GENE_PRODUCT", 41, 43], ["better vaccines", "TREATMENT", 135, 150]]], ["The isolation and characterization of the Ab repertoire produced by antigen-specific B cells has acquired a central importance in the last decade to unravel the response to vaccine antigens.Human B cell technologies to identify functional Abs against infectious diseasesDissecting the basic mechanisms that define the dynamics of the Ab responses to vaccination and deepening the knowledge of the correlates of vaccine-induced protection or biological signatures of responsiveness are becoming fundamental in the development of novel vaccines.", [["B cells", "ANATOMY", 85, 92], ["B cell", "ANATOMY", 196, 202], ["infectious diseases", "DISEASE", 251, 270], ["Ab", "GENE_OR_GENE_PRODUCT", 42, 44], ["antigen", "GENE_OR_GENE_PRODUCT", 68, 75], ["B cells", "CELL", 85, 92], ["Human", "ORGANISM", 190, 195], ["B cell", "CELL", 196, 202], ["Ab", "GENE_OR_GENE_PRODUCT", 334, 336], ["Ab repertoire", "PROTEIN", 42, 55], ["antigen-specific B cells", "CELL_TYPE", 68, 92], ["vaccine antigens", "PROTEIN", 173, 189], ["Abs", "PROTEIN", 239, 242], ["Human", "SPECIES", 190, 195], ["Human", "SPECIES", 190, 195], ["The isolation", "TREATMENT", 0, 13], ["the Ab repertoire", "TEST", 38, 55], ["vaccine antigens", "TREATMENT", 173, 189], ["Human B cell technologies", "TREATMENT", 190, 215], ["infectious diseases", "PROBLEM", 251, 270], ["vaccination", "TREATMENT", 350, 361], ["vaccine", "TREATMENT", 411, 418], ["biological signatures of responsiveness", "PROBLEM", 441, 480], ["novel vaccines", "TREATMENT", 528, 542]]], ["Both memory B cells (MBCs) and plasmablasts (peaking at day 8 after vaccination) have been used to generate naturally derived antigen-specific mAbs.", [["memory B cells", "ANATOMY", 5, 19], ["MBCs", "ANATOMY", 21, 25], ["plasmablasts", "ANATOMY", 31, 43], ["memory B cells", "CELL", 5, 19], ["MBCs", "CELL", 21, 25], ["plasmablasts", "CELL", 31, 43], ["antigen", "GENE_OR_GENE_PRODUCT", 126, 133], ["mAbs", "GENE_OR_GENE_PRODUCT", 143, 147], ["memory B cells", "CELL_TYPE", 5, 19], ["MBCs", "CELL_TYPE", 21, 25], ["plasmablasts", "CELL_TYPE", 31, 43], ["mAbs", "PROTEIN", 143, 147], ["plasmablasts", "PROBLEM", 31, 43], ["vaccination", "TREATMENT", 68, 79], ["memory B cells", "OBSERVATION", 5, 19]]], ["MBCs were shown to be more suitable for this kind of application because of their capability to secrete Abs after EBV immortalization and in the presence of a TLR9 ligand and/or allogeneic irradiated mononuclear cells (Traggiai et al., 2004).", [["MBCs", "ANATOMY", 0, 4], ["mononuclear cells", "ANATOMY", 200, 217], ["MBCs", "CHEMICAL", 0, 4], ["MBCs", "CELL", 0, 4], ["Abs", "GENE_OR_GENE_PRODUCT", 104, 107], ["EBV", "ORGANISM", 114, 117], ["TLR9", "GENE_OR_GENE_PRODUCT", 159, 163], ["mononuclear cells", "CELL", 200, 217], ["MBCs", "CELL_TYPE", 0, 4], ["Abs", "PROTEIN", 104, 107], ["TLR9 ligand", "PROTEIN", 159, 170], ["allogeneic irradiated mononuclear cells", "CELL_TYPE", 178, 217], ["EBV", "SPECIES", 114, 117], ["MBCs", "TEST", 0, 4], ["EBV immortalization", "PROBLEM", 114, 133], ["a TLR9 ligand", "TREATMENT", 157, 170], ["allogeneic irradiated mononuclear cells", "TREATMENT", 178, 217], ["mononuclear cells", "OBSERVATION", 200, 217]]], ["Usually, total peripheral blood lymphocytes or sorted IgG+ MBCs are cultured and the released Abs can be screened for antigen specificity and/or functionality.", [["peripheral blood lymphocytes", "ANATOMY", 15, 43], ["IgG+ MBCs", "ANATOMY", 54, 63], ["peripheral blood lymphocytes", "CELL", 15, 43], ["IgG", "GENE_OR_GENE_PRODUCT", 54, 57], ["MBCs", "CELL", 59, 63], ["Abs", "GENE_OR_GENE_PRODUCT", 94, 97], ["total peripheral blood lymphocytes", "CELL_TYPE", 9, 43], ["IgG", "PROTEIN", 54, 57], ["MBCs", "CELL_TYPE", 59, 63], ["Abs", "PROTEIN", 94, 97], ["total peripheral blood lymphocytes", "TEST", 9, 43], ["sorted IgG", "TEST", 47, 57], ["MBCs", "TEST", 59, 63], ["the released Abs", "TEST", 81, 97], ["antigen specificity", "TEST", 118, 137], ["peripheral", "ANATOMY_MODIFIER", 15, 25], ["blood lymphocytes", "ANATOMY", 26, 43]]], ["More recently, it has been discovered that even single plasmablasts can be cultured without immortalization, and they can produce sufficient amounts of Abs to allow screening for Ab specificity and function (Jin et al., 2009; Corti et al., 2011b).", [["plasmablasts", "ANATOMY", 55, 67], ["plasmablasts", "CELL", 55, 67], ["Ab", "GENE_OR_GENE_PRODUCT", 179, 181], ["plasmablasts", "CELL_TYPE", 55, 67], ["Abs", "PROTEIN", 152, 155], ["screening", "TEST", 165, 174], ["Ab specificity", "TEST", 179, 193]]], ["This approach has been particularly successful in isolating NAbs from individuals infected by rapidly evolving viral pathogens, leading to the identification of new target molecules that induce the most potent or broadly neutralizing response without prior knowledge of their nature.", [["NAbs", "PROTEIN", 60, 64], ["isolating NAbs", "PROBLEM", 50, 64], ["rapidly evolving viral pathogens", "PROBLEM", 94, 126], ["new target molecules", "PROBLEM", 161, 181], ["successful", "OBSERVATION_MODIFIER", 36, 46], ["NAbs", "OBSERVATION_MODIFIER", 60, 64], ["rapidly", "OBSERVATION_MODIFIER", 94, 101], ["evolving", "OBSERVATION_MODIFIER", 102, 110], ["viral pathogens", "OBSERVATION", 111, 126], ["new", "OBSERVATION_MODIFIER", 161, 164], ["target molecules", "OBSERVATION", 165, 181], ["most potent", "OBSERVATION_MODIFIER", 198, 209]]], ["The power of the characterization of the Abs produced by human B cells that were generated in vivo in response to specific infections has been proved so far for different viruses, such as influenza, HCMV, dengue, and RSV (Beltramello et al., 2010; Corti et al., 2010, 2013; Macagno et al., 2010; Krause et al., 2011; de Alwis et al., 2012).", [["B cells", "ANATOMY", 63, 70], ["infections", "DISEASE", 123, 133], ["influenza, HCMV, dengue, and RSV", "DISEASE", 188, 220], ["Abs", "GENE_OR_GENE_PRODUCT", 41, 44], ["human", "ORGANISM", 57, 62], ["B cells", "CELL", 63, 70], ["influenza", "ORGANISM", 188, 197], ["HCMV", "ORGANISM", 199, 203], ["RSV", "ORGANISM", 217, 220], ["Abs", "PROTEIN", 41, 44], ["human B cells", "CELL_TYPE", 57, 70], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["HCMV", "SPECIES", 199, 203], ["dengue", "SPECIES", 205, 211], ["RSV", "SPECIES", 217, 220], ["the Abs", "TEST", 37, 44], ["human B cells", "TREATMENT", 57, 70], ["specific infections", "PROBLEM", 114, 133], ["different viruses", "PROBLEM", 161, 178], ["influenza", "PROBLEM", 188, 197], ["HCMV", "PROBLEM", 199, 203], ["power", "OBSERVATION_MODIFIER", 4, 9], ["infections", "OBSERVATION", 123, 133]]], ["Two emblematic examples of how human mAbs can be valuable tools to discover or design new antigens come from HCMV and RSV.", [["human", "ORGANISM", 31, 36], ["mAbs", "GENE_OR_GENE_PRODUCT", 37, 41], ["HCMV", "ORGANISM", 109, 113], ["RSV", "ORGANISM", 118, 121], ["human mAbs", "PROTEIN", 31, 41], ["antigens", "PROTEIN", 90, 98], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["HCMV", "SPECIES", 109, 113], ["RSV", "SPECIES", 118, 121], ["design new antigens", "PROBLEM", 79, 98], ["HCMV", "PROBLEM", 109, 113], ["RSV", "PROBLEM", 118, 121]]], ["Most studies on HCMV have focused on the viral glycoproteins gB or gHgL as targets of NAbs.", [["HCMV", "ORGANISM", 16, 20], ["gB", "GENE_OR_GENE_PRODUCT", 61, 63], ["gHgL", "GENE_OR_GENE_PRODUCT", 67, 71], ["viral glycoproteins", "PROTEIN", 41, 60], ["gB", "PROTEIN", 61, 63], ["gHgL", "PROTEIN", 67, 71], ["NAbs", "PROTEIN", 86, 90], ["HCMV", "SPECIES", 16, 20], ["Most studies", "TEST", 0, 12], ["HCMV", "PROBLEM", 16, 20], ["the viral glycoproteins gB", "TEST", 37, 63], ["NAbs", "OBSERVATION", 86, 90]]], ["By screening mAbs from an immune donor based on their capacity to neutralize infection in vitro, a panel of potent NAbs was identified.", [["infection", "DISEASE", 77, 86], ["mAbs", "GENE_OR_GENE_PRODUCT", 13, 17], ["mAbs", "PROTEIN", 13, 17], ["NAbs", "PROTEIN", 115, 119], ["screening mAbs", "TEST", 3, 17], ["an immune donor", "TREATMENT", 23, 38], ["their capacity", "PROBLEM", 48, 62], ["neutralize infection", "PROBLEM", 66, 86], ["a panel", "TEST", 97, 104], ["potent NAbs", "PROBLEM", 108, 119], ["neutralize", "OBSERVATION_MODIFIER", 66, 76], ["infection", "OBSERVATION", 77, 86], ["potent", "OBSERVATION_MODIFIER", 108, 114], ["NAbs", "OBSERVATION", 115, 119]]], ["These Abs recognize multiple antigenic sites on a pentameric complex of gH/gL/pUL128/pUL130/pUL131A, which was not previously known to be the target of NAbs (Macagno et al., 2010).", [["Abs", "GENE_OR_GENE_PRODUCT", 6, 9], ["gH", "GENE_OR_GENE_PRODUCT", 72, 74], ["UL130", "GENE_OR_GENE_PRODUCT", 86, 91], ["pUL131A", "GENE_OR_GENE_PRODUCT", 92, 99], ["Abs", "PROTEIN", 6, 9], ["pentameric complex", "PROTEIN", 50, 68], ["gH", "PROTEIN", 72, 74], ["gL", "PROTEIN", 75, 77], ["UL128", "PROTEIN", 79, 84], ["UL130", "PROTEIN", 86, 91], ["pUL131A", "PROTEIN", 92, 99], ["NAbs", "PROTEIN", 152, 156], ["multiple antigenic sites", "PROBLEM", 20, 44], ["UL128", "TEST", 79, 84], ["UL130/pUL131A", "TEST", 86, 99], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["antigenic sites", "OBSERVATION", 29, 44], ["gL", "ANATOMY", 75, 77]]], ["In a follow-up study, a pentamer-based vaccine was reported to elicit very high NAb titers in mice (Kabanova et al., 2014), providing evidence of the power of the reverse vaccinology 2.0 approach for the identification and design of improved HCMV vaccine candidates.", [["mice", "ORGANISM", 94, 98], ["HCMV", "ORGANISM", 242, 246], ["NAb", "PROTEIN", 80, 83], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["HCMV", "SPECIES", 242, 246], ["a follow-up study", "TEST", 3, 20], ["a pentamer-based vaccine", "TREATMENT", 22, 46], ["the identification", "TEST", 200, 218], ["improved HCMV vaccine candidates", "TREATMENT", 233, 265]]], ["Furthermore, independent structural and immunological studies have also demonstrated the antigenic potential of the HCMV pentamer in mice (Wen et al., 2014; Ciferri et al., 2015).", [["HCMV", "ORGANISM", 116, 120], ["mice", "ORGANISM", 133, 137], ["HCMV pentamer", "PROTEIN", 116, 129], ["mice", "SPECIES", 133, 137], ["HCMV", "SPECIES", 116, 120], ["mice", "SPECIES", 133, 137], ["immunological studies", "TEST", 40, 61]]], ["A second example comes from the analysis of the NAb response to the F protein of RSV.", [["RSV", "ORGANISM", 81, 84], ["NAb", "PROTEIN", 48, 51], ["F protein", "PROTEIN", 68, 77], ["RSV", "SPECIES", 81, 84], ["the analysis", "TEST", 28, 40], ["RSV", "PROBLEM", 81, 84], ["RSV", "OBSERVATION", 81, 84]]], ["Initially, the postfusion F protein of RSV was chosen as a candidate to develop a vaccine because it is a very stable protein and is recognized by a neutralizing mAb (palivizumab) that is used to prevent RSV infection in newborns (The IMpact-RSV Study Group, 1998).", [["palivizumab", "CHEMICAL", 167, 178], ["RSV infection", "DISEASE", 204, 217], ["postfusion F", "GENE_OR_GENE_PRODUCT", 15, 27], ["RSV", "ORGANISM", 39, 42], ["palivizumab", "SIMPLE_CHEMICAL", 167, 178], ["RSV", "ORGANISM", 204, 207], ["newborns", "ORGANISM", 221, 229], ["postfusion F protein", "PROTEIN", 15, 35], ["neutralizing mAb", "PROTEIN", 149, 165], ["RSV", "SPECIES", 39, 42], ["RSV", "SPECIES", 204, 207], ["RSV", "SPECIES", 242, 245], ["the postfusion F protein", "TEST", 11, 35], ["RSV", "PROBLEM", 39, 42], ["a vaccine", "TREATMENT", 80, 89], ["a neutralizing mAb (palivizumab)", "TREATMENT", 147, 179], ["RSV infection", "PROBLEM", 204, 217], ["RSV", "OBSERVATION", 39, 42], ["RSV", "OBSERVATION_MODIFIER", 204, 207], ["infection", "OBSERVATION", 208, 217]]], ["However, a promising alternative to the postfusion F antigen has also been identified.", [["postfusion F antigen", "GENE_OR_GENE_PRODUCT", 40, 60], ["postfusion F antigen", "PROTEIN", 40, 60], ["the postfusion F antigen", "TEST", 36, 60]]], ["RSV-specific human B cells transduced with Bcl-6 and Bcl-xL were used as a source to identify Abs that effectively neutralized the virus.", [["B cells", "ANATOMY", 19, 26], ["RSV", "ORGANISM", 0, 3], ["human", "ORGANISM", 13, 18], ["B cells", "CELL", 19, 26], ["Bcl-6", "GENE_OR_GENE_PRODUCT", 43, 48], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 53, 59], ["human B cells", "CELL_TYPE", 13, 26], ["Bcl-6", "PROTEIN", 43, 48], ["Bcl-xL", "PROTEIN", 53, 59], ["Abs", "PROTEIN", 94, 97], ["human", "SPECIES", 13, 18], ["RSV", "SPECIES", 0, 3], ["human", "SPECIES", 13, 18], ["RSV", "TEST", 0, 3], ["Bcl", "TEST", 43, 46], ["Bcl-xL", "TEST", 53, 59], ["the virus", "PROBLEM", 127, 136], ["virus", "OBSERVATION", 131, 136]]], ["By screening B cell culture supernatants, a NAb called D25\u2014many times more potent than palivizumab\u2014was isolated and shown to completely prevent viral replication in an in vivo RSV infection model in cotton rats (Kwakkenbos et al., 2010).", [["B cell culture supernatants", "ANATOMY", 13, 40], ["RSV infection", "DISEASE", 176, 189], ["B cell", "CELL", 13, 19], ["D25", "GENE_OR_GENE_PRODUCT", 55, 58], ["RSV", "ORGANISM", 176, 179], ["rats", "ORGANISM", 206, 210], ["NAb", "PROTEIN", 44, 47], ["rats", "SPECIES", 206, 210], ["RSV", "SPECIES", 176, 179], ["cotton", "SPECIES", 199, 205], ["screening B cell culture", "TEST", 3, 27], ["palivizumab\u2014was", "TREATMENT", 87, 102], ["viral replication", "PROBLEM", 144, 161], ["viral replication", "OBSERVATION", 144, 161], ["RSV infection", "OBSERVATION", 176, 189]]], ["In a subsequent study, it was shown that D25 and two additional highly potent RSV-specific NAbs were specific for the prefusion form of RSV F (McLellan et al., 2013b).", [["D25", "SIMPLE_CHEMICAL", 41, 44], ["RSV", "ORGANISM", 78, 81], ["NAbs", "ORGANISM", 91, 95], ["RSV", "ORGANISM", 136, 139], ["NAbs", "PROTEIN", 91, 95], ["RSV", "SPECIES", 78, 81], ["RSV", "SPECIES", 136, 139], ["a subsequent study", "TEST", 3, 21], ["D25", "TREATMENT", 41, 44], ["potent", "OBSERVATION_MODIFIER", 71, 77], ["RSV", "OBSERVATION", 78, 81]]], ["Furthermore, by analyzing many different mAbs isolated from an RSV sero-positive individual, Corti et al. (2013) have also shown that the most potent NAbs recognize the prefusion form of the F antigen, suggesting that the prefusion protein could be considered as the most effective vaccine antigen.", [["mAbs", "GENE_OR_GENE_PRODUCT", 41, 45], ["RSV", "ORGANISM", 63, 66], ["F antigen", "GENE_OR_GENE_PRODUCT", 191, 200], ["mAbs", "PROTEIN", 41, 45], ["NAbs", "PROTEIN", 150, 154], ["F antigen", "PROTEIN", 191, 200], ["prefusion protein", "PROTEIN", 222, 239], ["RSV", "SPECIES", 63, 66], ["an RSV sero-positive individual", "PROBLEM", 60, 91], ["the prefusion protein", "PROBLEM", 218, 239], ["most potent", "OBSERVATION_MODIFIER", 138, 149], ["NAbs", "OBSERVATION", 150, 154]]], ["These examples of isolation and characterization of bNAbs induced by infection have highlighted how understanding the mechanisms leading to the elicitation of a protective response can aid the design of more effective vaccines.", [["infection", "DISEASE", 69, 78], ["bNAbs", "GENE_OR_GENE_PRODUCT", 52, 57], ["bNAbs", "PROTEIN", 52, 57], ["isolation", "TREATMENT", 18, 27], ["bNAbs", "PROBLEM", 52, 57], ["infection", "PROBLEM", 69, 78], ["more effective vaccines", "TREATMENT", 203, 226], ["infection", "OBSERVATION", 69, 78]]], ["However, the identification of mAbs of the desired specificity usually requires the interrogation of thousands of B cells, with labor-intensive culture and screening steps of the B cell culture supernatants that lead to the isolation of a few dozen Abs.", [["B cells", "ANATOMY", 114, 121], ["B cell", "ANATOMY", 179, 185], ["supernatants", "ANATOMY", 194, 206], ["mAbs", "GENE_OR_GENE_PRODUCT", 31, 35], ["B cells", "CELL", 114, 121], ["B cell", "CELL", 179, 185], ["mAbs", "PROTEIN", 31, 35], ["B cells", "CELL_TYPE", 114, 121], ["dozen Abs", "PROTEIN", 243, 252], ["the interrogation", "TEST", 80, 97], ["B cells", "PROBLEM", 114, 121], ["labor", "PROBLEM", 128, 133], ["intensive culture", "TEST", 134, 151], ["screening steps", "TEST", 156, 171], ["the B cell culture supernatants", "TEST", 175, 206], ["mAbs", "OBSERVATION", 31, 35]]], ["Moreover, this approach does not allow the gain of substantial information on the shaping of the Ig gene repertoire induced by the response to a given pathogen or vaccine.Human B cell technologies to identify functional Abs against infectious diseasesA milestone in understanding the nature and generation of successful Ab responses has been the development of Ab repertoire sequencing technologies for the identification and generation of recombinant human mAbs.", [["B cell", "ANATOMY", 177, 183], ["infectious diseases", "DISEASE", 232, 251], ["Ig", "GENE_OR_GENE_PRODUCT", 97, 99], ["Human", "ORGANISM", 171, 176], ["B cell", "CELL", 177, 183], ["Ab", "GENE_OR_GENE_PRODUCT", 320, 322], ["human", "ORGANISM", 452, 457], ["mAbs", "GENE_OR_GENE_PRODUCT", 458, 462], ["Ig gene repertoire", "DNA", 97, 115], ["Abs", "PROTEIN", 220, 223], ["recombinant human mAbs", "PROTEIN", 440, 462], ["Human", "SPECIES", 171, 176], ["human", "SPECIES", 452, 457], ["Human", "SPECIES", 171, 176], ["human", "SPECIES", 452, 457], ["pathogen", "PROBLEM", 151, 159], ["vaccine", "TREATMENT", 163, 170], ["Human B cell technologies", "TREATMENT", 171, 196], ["infectious diseases", "PROBLEM", 232, 251], ["Ab repertoire sequencing technologies", "TREATMENT", 361, 398], ["the identification", "TEST", 403, 421], ["recombinant human mAbs", "TREATMENT", 440, 462]]], ["The first description of the single-cell RT-PCR method showed the possibility of isolating the Ig heavy (VH) and light (VL) variable chain genes from single B cells, followed by the expression of chimeric murine and rabbit mAbs (Babcook et al., 1996).", [["B cells", "ANATOMY", 157, 164], ["Ig heavy (VH) and light (VL) variable chain", "GENE_OR_GENE_PRODUCT", 95, 138], ["single B cells", "CELL", 150, 164], ["murine", "ORGANISM", 205, 211], ["rabbit", "ORGANISM", 216, 222], ["Ig heavy (VH) and light (VL) variable chain genes", "DNA", 95, 144], ["B cells", "CELL_TYPE", 157, 164], ["chimeric murine and rabbit mAbs", "PROTEIN", 196, 227], ["murine", "SPECIES", 205, 211], ["rabbit", "SPECIES", 216, 222], ["rabbit", "SPECIES", 216, 222], ["PCR method", "TEST", 44, 54], ["light (VL) variable chain genes", "PROBLEM", 113, 144], ["single B cells", "PROBLEM", 150, 164]]], ["Another hallmark in the field of human immunology has been the demonstration that cloning and expression of human mAbs could be achieved through the recovery of the Ig sequences from single B cells derived from the bone marrow and blood of healthy donors and by transfection of producer cells with the VH and VL chain genes (Wardemann et al., 2003).", [["B cells", "ANATOMY", 190, 197], ["bone marrow", "ANATOMY", 215, 226], ["blood", "ANATOMY", 231, 236], ["cells", "ANATOMY", 287, 292], ["human", "ORGANISM", 33, 38], ["human", "ORGANISM", 108, 113], ["mAbs", "GENE_OR_GENE_PRODUCT", 114, 118], ["Ig", "GENE_OR_GENE_PRODUCT", 165, 167], ["B cells", "CELL", 190, 197], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 215, 226], ["blood", "ORGANISM_SUBSTANCE", 231, 236], ["donors", "ORGANISM", 248, 254], ["cells", "CELL", 287, 292], ["VH", "GENE_OR_GENE_PRODUCT", 302, 304], ["VL chain", "GENE_OR_GENE_PRODUCT", 309, 317], ["human mAbs", "PROTEIN", 108, 118], ["Ig sequences", "DNA", 165, 177], ["B cells", "CELL_TYPE", 190, 197], ["producer cells", "CELL_TYPE", 278, 292], ["VH and VL chain genes", "DNA", 302, 323], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 108, 113], ["human mAbs", "TREATMENT", 108, 118], ["the Ig sequences", "TEST", 161, 177], ["single B cells", "PROBLEM", 183, 197], ["the bone marrow", "TEST", 211, 226], ["healthy donors", "PROBLEM", 240, 254], ["transfection of producer cells", "TREATMENT", 262, 292], ["hallmark", "OBSERVATION_MODIFIER", 8, 16], ["bone marrow", "ANATOMY", 215, 226]]], ["Furthermore, the possibility of using fluorescently labeled antigens to sort antigen-specific B cells by flow cytometry has facilitated more focused analyses of the Ig gene repertoire usage and of the corresponding Ab binding and/or functional capability toward targeted antigen-specific and often rare B cell subpopulations after vaccination or infection (Tiller et al., 2008; Wrammert et al., 2008; Scheid et al., 2009a).", [["B cells", "ANATOMY", 94, 101], ["B cell", "ANATOMY", 303, 309], ["infection", "DISEASE", 346, 355], ["antigen", "GENE_OR_GENE_PRODUCT", 77, 84], ["B cells", "CELL", 94, 101], ["Ig", "GENE_OR_GENE_PRODUCT", 165, 167], ["Ab", "GENE_OR_GENE_PRODUCT", 215, 217], ["antigen", "GENE_OR_GENE_PRODUCT", 271, 278], ["B cell", "CELL", 303, 309], ["B cells", "CELL_TYPE", 94, 101], ["B cell subpopulations", "CELL_TYPE", 303, 324], ["sort antigen", "TEST", 72, 84], ["flow cytometry", "TEST", 105, 119], ["the corresponding Ab binding", "PROBLEM", 197, 225], ["targeted antigen", "TEST", 262, 278], ["rare B cell subpopulations", "PROBLEM", 298, 324], ["infection", "PROBLEM", 346, 355], ["cell subpopulations", "OBSERVATION", 305, 324]]], ["Although this methodology allows for sequencing and expression of the Abs encoded by a small number of B cells and individuals, it has brought numerous immunological insights to the development of the B cell response to antigens of a different nature.", [["B cells", "ANATOMY", 103, 110], ["B cell", "ANATOMY", 201, 207], ["Abs", "GENE_OR_GENE_PRODUCT", 70, 73], ["B cells", "CELL", 103, 110], ["B cell", "CELL", 201, 207], ["Abs", "PROTEIN", 70, 73], ["B cells", "CELL_TYPE", 103, 110], ["antigens", "PROTEIN", 220, 228], ["the Abs", "PROBLEM", 66, 73], ["small", "OBSERVATION_MODIFIER", 87, 92], ["B cell response", "OBSERVATION", 201, 216]]], ["For example, it has been demonstrated that the B cell responses to polysaccharides, such as Streptococcus pneumoniae polysaccharides, show high clonality with a limited Ig gene usage and can be different in diverse age groups (Kolibab et al., 2005; Smith et al., 2013).", [["B cell", "ANATOMY", 47, 53], ["B cell", "CELL", 47, 53], ["Streptococcus pneumoniae", "ORGANISM", 92, 116], ["Ig", "GENE_OR_GENE_PRODUCT", 169, 171], ["Ig gene", "DNA", 169, 176], ["Streptococcus pneumoniae", "SPECIES", 92, 116], ["Streptococcus pneumoniae", "SPECIES", 92, 116], ["polysaccharides", "TEST", 67, 82], ["Streptococcus pneumoniae polysaccharides", "PROBLEM", 92, 132], ["high clonality", "PROBLEM", 139, 153], ["high clonality", "OBSERVATION", 139, 153]]], ["Instead, greater repertoire diversity has been highlighted between different individuals and even within a single individual at different time points after vaccination with protein antigens, such as influenza hemagglutinin (HA) and tetanus toxoid (TT; Wrammert et al., 2008; Fr\u00f6lich et al., 2010).", [["tetanus toxoid", "DISEASE", 232, 246], ["influenza hemagglutinin", "ORGANISM", 199, 222], ["tetanus toxoid", "ORGANISM", 232, 246], ["protein antigens", "PROTEIN", 173, 189], ["tetanus toxoid", "SPECIES", 232, 246], ["vaccination with protein antigens", "TREATMENT", 156, 189], ["influenza hemagglutinin (HA)", "TREATMENT", 199, 227], ["tetanus toxoid", "TREATMENT", 232, 246], ["greater", "OBSERVATION_MODIFIER", 9, 16]]], ["However, it is mainly the research in the HIV field that has demonstrated how the characterization of bNAbs, isolated from immune donors, and the knowledge of their pathway of generation can provide new insights into how to induce them through new vaccination strategies.", [["bNAbs", "GENE_OR_GENE_PRODUCT", 102, 107], ["immune donors", "CELL", 123, 136], ["bNAbs", "PROTEIN", 102, 107], ["HIV", "SPECIES", 42, 45], ["bNAbs", "PROBLEM", 102, 107], ["immune donors", "TREATMENT", 123, 136], ["new vaccination strategies", "TREATMENT", 244, 270]]], ["Novel recombinant and soluble HIV-1 envelope (Env) proteins have been used as baits to identify and capture Env (gp160)\u2013specific B cells by flow cytometry in selected HIV-infected donors (Scheid et al., 2009b; Wu et al., 2010).", [["B cells", "ANATOMY", 129, 136], ["HIV-infected", "DISEASE", 167, 179], ["HIV-1 envelope", "ORGANISM", 30, 44], ["Env", "ORGANISM", 46, 49], ["HIV", "ORGANISM", 167, 170], ["donors", "ORGANISM", 180, 186], ["recombinant and soluble HIV-1 envelope (Env) proteins", "PROTEIN", 6, 59], ["Env (gp160)\u2013specific B cells", "CELL_LINE", 108, 136], ["HIV-1", "SPECIES", 30, 35], ["HIV-1", "SPECIES", 30, 35], ["HIV", "SPECIES", 167, 170], ["Novel recombinant and soluble HIV-1 envelope (Env) proteins", "TREATMENT", 0, 59], ["\u2013specific B cells", "PROBLEM", 119, 136], ["flow cytometry", "TEST", 140, 154]]], ["Single-cell Ab cloning techniques have successfully generated hundreds of HIV-specific Abs and, among them, dozens of new extremely potent next-generation bNAbs (Doria-Rose and Connors, 2009; Klein et al., 2013; Burton and Mascola, 2015; Haynes, 2015).", [["Single-cell", "ANATOMY", 0, 11], ["cell", "CELL", 7, 11], ["HIV", "ORGANISM", 74, 77], ["bNAbs", "ORGANISM", 155, 160], ["HIV-specific Abs", "PROTEIN", 74, 90], ["HIV", "SPECIES", 74, 77], ["Ab cloning techniques", "TREATMENT", 12, 33], ["cell", "OBSERVATION", 7, 11]]], ["The real challenge now is to take advantage of our understanding of the generation of bNAbs to design new immunogens able to induce the affinity maturation of B cell lineages expressing bNAbs.", [["B cell", "ANATOMY", 159, 165], ["bNAbs", "SIMPLE_CHEMICAL", 86, 91], ["B cell lineages", "CELL", 159, 174], ["bNAbs", "GENE_OR_GENE_PRODUCT", 186, 191], ["bNAbs", "PROTEIN", 86, 91], ["B cell lineages", "CELL_TYPE", 159, 174], ["bNAbs", "PROTEIN", 186, 191], ["the generation of bNAbs", "TREATMENT", 68, 91], ["new immunogens", "TREATMENT", 102, 116]]], ["Essentially, this means being able to orchestrate a fine-tuned interplay between the host immune system and a tailored antigen (or antigens) that should prime the B cell precursors in an effective way (discussed further in the section A vacciny strategy targeting germline Abs).Human B cell technologies to identify functional Abs against infectious diseasesBoth of the aforementioned methods have two limitations for the identification of the best protective Abs: first, the required EBV transformation of B cells can have a bias on the secretion of mAbs; and second, in vitro\u2013expressed synthetic Abs might not always faithfully reflect their natural functional capability.", [["immune system", "ANATOMY", 90, 103], ["B cell", "ANATOMY", 163, 169], ["B cell", "ANATOMY", 284, 290], ["B cells", "ANATOMY", 507, 514], ["infectious diseases", "DISEASE", 339, 358], ["B cell", "CELL", 163, 169], ["germline Abs", "GENE_OR_GENE_PRODUCT", 264, 276], ["Human", "ORGANISM", 278, 283], ["B cell", "CELL", 284, 290], ["EBV", "ORGANISM", 485, 488], ["B cells", "CELL", 507, 514], ["mAbs", "GENE_OR_GENE_PRODUCT", 551, 555], ["antigens", "PROTEIN", 131, 139], ["B cell precursors", "CELL_TYPE", 163, 180], ["germline Abs", "PROTEIN", 264, 276], ["Abs", "PROTEIN", 327, 330], ["protective Abs", "PROTEIN", 449, 463], ["B cells", "CELL_TYPE", 507, 514], ["mAbs", "PROTEIN", 551, 555], ["Abs", "PROTEIN", 598, 601], ["Human", "SPECIES", 278, 283], ["Human", "SPECIES", 278, 283], ["the B cell precursors", "TREATMENT", 159, 180], ["Human B cell technologies", "TREATMENT", 278, 303], ["infectious diseases", "PROBLEM", 339, 358], ["EBV transformation of B cells", "TREATMENT", 485, 514], ["might not always", "UNCERTAINTY", 602, 618], ["natural functional capability", "OBSERVATION", 644, 673]]], ["To overcome these limits, Burtion, Poignard, and co-workers have isolated HIV-specific human mAbs from MBCs expanded in vitro with the addition of feeder cells and conditioned medium generated from mitogen-stimulated human T cells and screened the supernatants for neutralization activity (Walker et al., 2009, 2011).", [["MBCs", "ANATOMY", 103, 107], ["feeder cells", "ANATOMY", 147, 159], ["T cells", "ANATOMY", 223, 230], ["supernatants", "ANATOMY", 248, 260], ["HIV", "ORGANISM", 74, 77], ["human", "ORGANISM", 87, 92], ["mAbs", "CELL", 93, 97], ["MBCs", "CELL", 103, 107], ["feeder cells", "CELL", 147, 159], ["human", "ORGANISM", 217, 222], ["T cells", "CELL", 223, 230], ["human mAbs", "PROTEIN", 87, 97], ["MBCs", "CELL_TYPE", 103, 107], ["feeder cells", "CELL_TYPE", 147, 159], ["mitogen-stimulated human T cells", "CELL_LINE", 198, 230], ["HIV", "SPECIES", 74, 77], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 217, 222], ["HIV", "SPECIES", 74, 77], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 217, 222], ["isolated HIV", "PROBLEM", 65, 77], ["feeder cells", "TREATMENT", 147, 159], ["mitogen-stimulated human T cells", "TREATMENT", 198, 230]]], ["A modified high-throughput approach has also recently been developed based on the isolation of MBCs from PBMCs and expansion in vitro without the need for activated T cell supernatants, allowing secretion of sufficient amounts of Abs in culture to be screened in binding and functional assays (Huang et al., 2013).", [["MBCs", "ANATOMY", 95, 99], ["PBMCs", "ANATOMY", 105, 110], ["T cell supernatants", "ANATOMY", 165, 184], ["MBCs", "CHEMICAL", 95, 99], ["MBCs", "CELL", 95, 99], ["PBMCs", "CELL", 105, 110], ["T cell", "CELL", 165, 171], ["MBCs", "CELL_TYPE", 95, 99], ["PBMCs", "CELL_TYPE", 105, 110], ["Abs", "PROTEIN", 230, 233], ["A modified high-throughput approach", "TREATMENT", 0, 35], ["MBCs", "PROBLEM", 95, 99], ["PBMCs", "PROBLEM", 105, 110], ["expansion in vitro", "TREATMENT", 115, 133], ["activated T cell supernatants", "TREATMENT", 155, 184], ["Abs in culture", "TEST", 230, 244], ["high", "OBSERVATION_MODIFIER", 11, 15], ["expansion", "OBSERVATION_MODIFIER", 115, 124]]], ["The main advantage of this technique is provided by the possibility of isolating and directly characterizing the Abs produced by individually cloned B cells without the need for cloning and expression of all the recombinant mAbs and, more importantly, maintaining the original natural properties of binding and functionality.", [["B cells", "ANATOMY", 149, 156], ["Abs", "GENE_OR_GENE_PRODUCT", 113, 116], ["B cells", "CELL", 149, 156], ["mAbs", "GENE_OR_GENE_PRODUCT", 224, 228], ["Abs", "PROTEIN", 113, 116], ["B cells", "CELL_TYPE", 149, 156], ["recombinant mAbs", "PROTEIN", 212, 228], ["this technique", "TREATMENT", 22, 36], ["cloning", "TREATMENT", 178, 185], ["main", "OBSERVATION_MODIFIER", 4, 8], ["Abs", "OBSERVATION", 113, 116]]], ["After characterization of the binding and/or functional capacities of the Abs, the Ig gene sequences can be recovered.", [["Abs", "GENE_OR_GENE_PRODUCT", 74, 77], ["Ig", "GENE_OR_GENE_PRODUCT", 83, 85], ["Abs", "PROTEIN", 74, 77], ["Ig gene sequences", "DNA", 83, 100], ["the binding", "PROBLEM", 26, 37], ["the Abs", "TEST", 70, 77], ["the Ig gene sequences", "TEST", 79, 100]]], ["In turn, repertoire analyses to understand the origin and evolution of the Abs of interest can be performed, and further cloning and expression steps for deeper structural characterizations can be performed (Fig. 1).", [["Abs", "PROTEIN", 75, 78], ["repertoire analyses", "TEST", 9, 28], ["deeper structural characterizations", "TEST", 154, 189]]], ["Recently, through this new approach, broad and potent HIV NAbs have been discovered in the pool of antigen-specific MBCs, highlighting new vulnerability sites on the HIV Env antigen (Huang et al., 2014).", [["MBCs", "ANATOMY", 116, 120], ["HIV", "ORGANISM", 54, 57], ["antigen", "GENE_OR_GENE_PRODUCT", 99, 106], ["MBCs", "CELL", 116, 120], ["HIV", "ORGANISM", 166, 169], ["Env antigen", "GENE_OR_GENE_PRODUCT", 170, 181], ["HIV NAbs", "PROTEIN", 54, 62], ["HIV Env antigen", "PROTEIN", 166, 181], ["HIV", "SPECIES", 166, 169], ["HIV", "SPECIES", 54, 57], ["HIV", "SPECIES", 166, 169], ["this new approach", "TREATMENT", 18, 35], ["broad and potent HIV NAbs", "PROBLEM", 37, 62], ["new vulnerability sites", "PROBLEM", 135, 158], ["new", "OBSERVATION_MODIFIER", 135, 138], ["vulnerability", "OBSERVATION_MODIFIER", 139, 152]]], ["This efficient new methodology, applicable both to preselected antigen-specific single-sorted MBCs or to B cell subpopulations of unknown specificity, will enable the identification of new target antigens or epitopes involved in a protective Ab response (Fig. 1).Human B cell technologies to identify functional Abs against infectious diseasesOverall, the single B cell cloning approaches used to isolate mAbs have been demonstrated to be extremely powerful for the identification and characterization of key protective antigens but have the drawback of being low-throughput technologies, revealing only a very limited slice of the full Ab repertoire.", [["MBCs", "ANATOMY", 94, 98], ["B cell", "ANATOMY", 105, 111], ["B cell", "ANATOMY", 269, 275], ["B cell", "ANATOMY", 363, 369], ["infectious diseasesOverall", "DISEASE", 324, 350], ["antigen", "GENE_OR_GENE_PRODUCT", 63, 70], ["MBCs", "CELL", 94, 98], ["B cell", "CELL", 105, 111], ["Ab", "GENE_OR_GENE_PRODUCT", 242, 244], ["Human", "ORGANISM", 263, 268], ["B cell", "CELL", 269, 275], ["B cell", "CELL", 363, 369], ["Ab", "GENE_OR_GENE_PRODUCT", 637, 639], ["B cell subpopulations", "CELL_TYPE", 105, 126], ["target antigens", "PROTEIN", 189, 204], ["epitopes", "PROTEIN", 208, 216], ["Abs", "PROTEIN", 312, 315], ["mAbs", "PROTEIN", 405, 409], ["Ab repertoire", "PROTEIN", 637, 650], ["Human", "SPECIES", 263, 268], ["Human", "SPECIES", 263, 268], ["preselected antigen", "TEST", 51, 70], ["B cell subpopulations", "PROBLEM", 105, 126], ["new target antigens", "PROBLEM", 185, 204], ["epitopes", "PROBLEM", 208, 216], ["Human B cell technologies", "TREATMENT", 263, 288], ["infectious diseasesOverall", "PROBLEM", 324, 350], ["the single B cell cloning approaches", "TREATMENT", 352, 388], ["the identification", "TEST", 462, 480], ["cell subpopulations", "OBSERVATION", 107, 126]]], ["Therefore, using these techniques to analyze the impact that a vaccine antigen or a vaccine formulation can have in inducing specific repertoire signatures shared by different individuals may lead to erroneous and misleading conclusions.", [["these techniques", "TREATMENT", 17, 33], ["a vaccine antigen", "TREATMENT", 61, 78], ["a vaccine formulation", "TREATMENT", 82, 103], ["erroneous and misleading conclusions", "PROBLEM", 200, 236]]], ["Recent advances in next-generation sequencing technology have enabled the sequencing of Ig genes from millions of B cells simultaneously, giving a high-resolution characterization of the Ab sequence repertoire (Reddy and Georgiou, 2011).", [["B cells", "ANATOMY", 114, 121], ["Ig", "GENE_OR_GENE_PRODUCT", 88, 90], ["B cells", "CELL", 114, 121], ["Ab", "GENE_OR_GENE_PRODUCT", 187, 189], ["Ig genes", "DNA", 88, 96], ["B cells", "CELL_TYPE", 114, 121], ["next-generation sequencing technology", "TREATMENT", 19, 56], ["Ig genes", "PROBLEM", 88, 96]]], ["Nevertheless, the ability of this approach to recognize the antigen-specific Ab repertoire inside the totality of the individual Ab repertoire and evaluate specific changes induced by a vaccine or pathogen still remains questionable.", [["Ab", "GENE_OR_GENE_PRODUCT", 129, 131], ["Ab repertoire", "PROTEIN", 129, 142], ["this approach", "TREATMENT", 29, 42], ["the antigen", "TEST", 56, 67], ["the individual Ab repertoire", "TEST", 114, 142], ["a vaccine", "TREATMENT", 184, 193], ["pathogen", "PROBLEM", 197, 205]]], ["One approach is to computationally search the total repertoire data for Ab sequences that are shared among individuals that have been exposed to the same antigen through infection or vaccination, identifying a \u201cconvergent repertoire.\u201d", [["infection", "DISEASE", 170, 179], ["Ab", "GENE_OR_GENE_PRODUCT", 72, 74], ["Ab sequences", "DNA", 72, 84], ["Ab sequences", "TEST", 72, 84], ["infection", "PROBLEM", 170, 179], ["infection", "OBSERVATION", 170, 179]]], ["Three recent studies found that conserved CDR3 sequences were produced in patients recovering from acute dengue infection (Parameswaran et al., 2013), or during the immune response to pandemic influenza H1N1 vaccination (Jackson et al., 2014) and Hib-polysaccharide vaccination (Tr\u00fcck et al., 2015).", [["dengue infection", "DISEASE", 105, 121], ["influenza H1N1", "DISEASE", 193, 207], ["Hib-polysaccharide", "CHEMICAL", 247, 265], ["CDR3", "GENE_OR_GENE_PRODUCT", 42, 46], ["patients", "ORGANISM", 74, 82], ["Hib-polysaccharide", "SIMPLE_CHEMICAL", 247, 265], ["CDR3 sequences", "DNA", 42, 56], ["patients", "SPECIES", 74, 82], ["pandemic influenza H1N1", "SPECIES", 184, 207], ["Three recent studies", "TEST", 0, 20], ["CDR3 sequences", "TEST", 42, 56], ["acute dengue infection", "PROBLEM", 99, 121], ["pandemic influenza H1N1 vaccination", "TREATMENT", 184, 219], ["Hib-polysaccharide vaccination", "TREATMENT", 247, 277], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["dengue", "OBSERVATION_MODIFIER", 105, 111], ["infection", "OBSERVATION", 112, 121]]], ["Although the \u201cconvergent repertoire\u201d demonstrates changes in the large-scale structural features of the repertoire, the antigen specificity of the identified Ab sequences always needs experimental confirmation through the expression, purification, and functional testing of recombinant Abs.", [["Ab", "GENE_OR_GENE_PRODUCT", 158, 160], ["Abs", "GENE_OR_GENE_PRODUCT", 286, 289], ["Ab sequences", "DNA", 158, 170], ["recombinant Abs", "PROTEIN", 274, 289], ["Ab sequences", "TEST", 158, 170], ["experimental confirmation", "TEST", 184, 209], ["purification", "TEST", 234, 246], ["large", "OBSERVATION_MODIFIER", 65, 70]]], ["However, only a small subset of Abs are usually expressed and investigated after the exhaustive interrogation of the repertoire, missing the possibility of having a full picture of the properties and functionality of all Abs directed against one specific antigen.", [["Abs", "GENE_OR_GENE_PRODUCT", 32, 35], ["Abs", "PROTEIN", 32, 35], ["Abs", "PROTEIN", 221, 224], ["a small subset of Abs", "PROBLEM", 14, 35], ["all Abs", "TREATMENT", 217, 224], ["small", "OBSERVATION_MODIFIER", 16, 21], ["subset", "OBSERVATION_MODIFIER", 22, 28], ["Abs", "OBSERVATION", 32, 35]]], ["To start from an enriched antigen-specific B cell population, most studies have used PBMCs isolated at day 8 after immunization, when there is the peak of circulating plasmablasts.", [["B cell", "ANATOMY", 43, 49], ["PBMCs", "ANATOMY", 85, 90], ["plasmablasts", "ANATOMY", 167, 179], ["antigen", "GENE_OR_GENE_PRODUCT", 26, 33], ["B cell", "CELL", 43, 49], ["PBMCs", "CELL", 85, 90], ["plasmablasts", "CELL", 167, 179], ["B cell population", "CELL_TYPE", 43, 60], ["PBMCs", "CELL_TYPE", 85, 90], ["circulating plasmablasts", "CELL_TYPE", 155, 179], ["specific B cell population", "TREATMENT", 34, 60], ["PBMCs", "TEST", 85, 90], ["immunization", "TREATMENT", 115, 127], ["circulating plasmablasts", "PROBLEM", 155, 179], ["circulating plasmablasts", "OBSERVATION", 155, 179]]], ["Yet, this approach entails a loss of information on the longitudinal evolution of the B cell memory repertoire and eventually of bNAbs and their maintenance in the long-term memory population.Human B cell technologies to identify functional Abs against infectious diseasesFinally, in recent studies, the sequencing of paired VH/VL Ig gene repertoire by next-generation sequencing technology has been combined with novel proteomic methods mining the antigen-specific Ab repertoire that comprises the human serum polyclonal response (Wine et al., 2015).", [["B cell", "ANATOMY", 86, 92], ["B cell", "ANATOMY", 198, 204], ["serum", "ANATOMY", 505, 510], ["infectious diseases", "DISEASE", 253, 272], ["B cell", "CELL", 86, 92], ["bNAbs", "GENE_OR_GENE_PRODUCT", 129, 134], ["Human", "ORGANISM", 192, 197], ["B cell", "CELL", 198, 204], ["Ig", "GENE_OR_GENE_PRODUCT", 331, 333], ["human", "ORGANISM", 499, 504], ["serum", "ORGANISM_SUBSTANCE", 505, 510], ["bNAbs", "PROTEIN", 129, 134], ["Abs", "PROTEIN", 241, 244], ["paired VH", "DNA", 318, 327], ["Ig gene repertoire", "DNA", 331, 349], ["Ab repertoire", "PROTEIN", 466, 479], ["Human", "SPECIES", 192, 197], ["human", "SPECIES", 499, 504], ["Human", "SPECIES", 192, 197], ["human", "SPECIES", 499, 504], ["bNAbs", "PROBLEM", 129, 134], ["Human B cell technologies", "TREATMENT", 192, 217], ["infectious diseases", "PROBLEM", 253, 272], ["recent studies", "TEST", 284, 298], ["Ig gene repertoire", "TREATMENT", 331, 349], ["the antigen", "TEST", 445, 456], ["cell memory repertoire", "OBSERVATION", 88, 110], ["long-term", "OBSERVATION_MODIFIER", 164, 173], ["VL", "ANATOMY", 328, 330]]], ["The new perspective offered by combining the analysis of the B cell and Ab repertoire induced by TT vaccination has highlighted that the anti-TT serum IgG repertoire is composed of a limited number of Ab clonotypes (80\u2013100), whereas the B cell receptor repertoire diversity in the memory and plasmablast compartments is orders of magnitude greater than that of the serological repertoire (Lavinder et al., 2014).", [["B cell", "ANATOMY", 61, 67], ["serum", "ANATOMY", 145, 150], ["B cell", "ANATOMY", 237, 243], ["plasmablast compartments", "ANATOMY", 292, 316], ["B cell", "CELL", 61, 67], ["Ab", "GENE_OR_GENE_PRODUCT", 72, 74], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["IgG", "GENE_OR_GENE_PRODUCT", 151, 154], ["Ab", "GENE_OR_GENE_PRODUCT", 201, 203], ["B cell receptor", "GENE_OR_GENE_PRODUCT", 237, 252], ["plasmablast compartments", "MULTI-TISSUE_STRUCTURE", 292, 316], ["B cell and Ab repertoire", "PROTEIN", 61, 85], ["anti-TT serum IgG repertoire", "PROTEIN", 137, 165], ["Ab clonotypes", "PROTEIN", 201, 214], ["the analysis", "TEST", 41, 53], ["the B cell", "TREATMENT", 57, 67], ["Ab repertoire", "TREATMENT", 72, 85], ["TT vaccination", "TREATMENT", 97, 111], ["the anti-TT serum IgG repertoire", "TEST", 133, 165], ["Ab clonotypes", "TEST", 201, 214], ["new", "OBSERVATION_MODIFIER", 4, 7], ["diversity", "OBSERVATION_MODIFIER", 264, 273]]], ["This observation suggests that most peripheral B cell\u2013encoded Abs are unlikely to be present in detectable amounts as soluble proteins, leaving unanswered questions regarding the nature and dynamics of the elements regulating the serological memory.", [["Abs", "GENE_OR_GENE_PRODUCT", 62, 65], ["peripheral B cell\u2013encoded Abs", "PROTEIN", 36, 65], ["soluble proteins", "PROTEIN", 118, 134], ["This observation", "TEST", 0, 16], ["most peripheral B cell\u2013encoded Abs", "PROBLEM", 31, 65], ["Abs", "OBSERVATION", 62, 65], ["unlikely to be", "UNCERTAINTY", 70, 84]]], ["Collectively, all of the technologies that allow the dissection of the human Ab response to pathogens are increasing our understanding of how protection is induced and can drive the design of more efficacious antigens for the development of vaccines to prevent current and future pathogenic threats.HIV ::: Use of protective Abs in structure-based antigen designThe incredible antigenic variability of HIV Env initially led to the belief that bNAbs would be nearly impossible to elicit, and that the only way to tackle HIV efficiently would be by generating T cell\u2013mediated immunity.", [["human", "ORGANISM", 71, 76], ["Ab", "GENE_OR_GENE_PRODUCT", 77, 79], ["HIV Env", "ORGANISM", 402, 409], ["bNAbs", "SIMPLE_CHEMICAL", 443, 448], ["HIV", "ORGANISM", 519, 522], ["T cell\u2013mediated", "CELL", 558, 573], ["protective Abs", "PROTEIN", 314, 328], ["HIV Env", "PROTEIN", 402, 409], ["human", "SPECIES", 71, 76], ["HIV", "SPECIES", 299, 302], ["HIV", "SPECIES", 402, 405], ["human", "SPECIES", 71, 76], ["HIV", "SPECIES", 299, 302], ["HIV", "SPECIES", 402, 405], ["HIV", "SPECIES", 519, 522], ["pathogens", "PROBLEM", 92, 101], ["vaccines", "TREATMENT", 241, 249], ["protective Abs in structure", "TREATMENT", 314, 341], ["HIV Env", "PROBLEM", 402, 409], ["bNAbs", "PROBLEM", 443, 448], ["dissection", "OBSERVATION", 53, 63], ["incredible", "OBSERVATION_MODIFIER", 366, 376], ["antigenic variability", "OBSERVATION", 377, 398]]], ["However, this viewpoint was dramatically impacted by landmark discoveries reported in 1994; namely, the generation of two new recombinant mAbs: mAb b12 from a combinatorial Fab phage display library (Burton et al., 1991) and the human mAb 2F5 isolated from an HIV-1\u2013positive volunteer (Conley et al., 1994), both of which were shown to be broadly neutralizing against panels of HIV strains.", [["mAb b12", "GENE_OR_GENE_PRODUCT", 144, 151], ["human", "ORGANISM", 229, 234], ["mAb 2F5", "ORGANISM", 235, 242], ["HIV-1\u2013positive", "ORGANISM", 260, 274], ["HIV", "ORGANISM", 378, 381], ["recombinant mAbs", "PROTEIN", 126, 142], ["mAb b12", "PROTEIN", 144, 151], ["human mAb 2F5", "PROTEIN", 229, 242], ["human", "SPECIES", 229, 234], ["HIV-", "SPECIES", 260, 264], ["HIV", "SPECIES", 378, 381], ["human", "SPECIES", 229, 234], ["HIV-1\u2013positive", "SPECIES", 260, 274], ["HIV", "SPECIES", 378, 381], ["mAb b12", "TREATMENT", 144, 151], ["a combinatorial Fab phage", "TEST", 157, 182], ["the human mAb 2F5", "TEST", 225, 242], ["an HIV", "TEST", 257, 263], ["HIV strains", "PROBLEM", 378, 389]]], ["In particular, mAb b12 binds the conserved CD4 binding site (CD4bs) on the Env gp120 subunit and was shown to neutralize 50\u201375% of primary HIV isolates tested (Burton et al., 1994; Binley et al., 2004).", [["mAb b12", "GENE_OR_GENE_PRODUCT", 15, 22], ["CD4", "GENE_OR_GENE_PRODUCT", 43, 46], ["CD4bs", "GENE_OR_GENE_PRODUCT", 61, 66], ["HIV", "ORGANISM", 139, 142], ["mAb b12", "PROTEIN", 15, 22], ["CD4 binding site", "DNA", 43, 59], ["CD4bs", "DNA", 61, 66], ["Env gp120 subunit", "PROTEIN", 75, 92], ["HIV", "SPECIES", 139, 142], ["HIV", "SPECIES", 139, 142], ["CD4bs", "TEST", 61, 66], ["the Env gp120 subunit", "TREATMENT", 71, 92], ["CD4 binding", "OBSERVATION", 43, 54]]], ["However, a clear limit of b12 was the somewhat low potency of this mAb, which required up to 25 \u00b5g/ml for neutralization of most HIV strains in the United States.", [["mAb", "GENE_OR_GENE_PRODUCT", 67, 70], ["HIV", "ORGANISM", 129, 132], ["b12", "PROTEIN", 26, 29], ["mAb", "PROTEIN", 67, 70], ["HIV", "SPECIES", 129, 132], ["this mAb", "TREATMENT", 62, 70], ["neutralization", "TREATMENT", 106, 120], ["low potency", "OBSERVATION_MODIFIER", 47, 58]]], ["Moreover, mAb b12 showed a very limited effect in controlling viremia in vivo, even when combined with 4E10, a distinct bNAb with similar potency (Poignard et al., 1999; Cardoso et al., 2005); in more recent analyses, b12 neutralized only 30\u201360% of diverse HIV strains (Walker et al., 2011).", [["viremia", "DISEASE", 62, 69], ["mAb b12", "GENE_OR_GENE_PRODUCT", 10, 17], ["bNAb", "CANCER", 120, 124], ["b12", "GENE_OR_GENE_PRODUCT", 218, 221], ["HIV", "ORGANISM", 257, 260], ["mAb b12", "PROTEIN", 10, 17], ["4E10", "PROTEIN", 103, 107], ["b12", "PROTEIN", 218, 221], ["HIV", "SPECIES", 257, 260], ["HIV", "SPECIES", 257, 260], ["mAb b12", "TEST", 10, 17], ["a distinct bNAb", "PROBLEM", 109, 124], ["b12 neutralized", "TREATMENT", 218, 233], ["diverse HIV strains", "PROBLEM", 249, 268], ["viremia", "OBSERVATION", 62, 69]]], ["These findings again led researchers to believe that Ab-based therapies and vaccines would be useless for HIV control, and the development of vaccines based on Env components lost some momentum.HIV ::: Use of protective Abs in structure-based antigen designThe HIV field changed completely around 2009/2010 with the identification of \u201csecond generation\u201d bNAbs.", [["Ab", "GENE_OR_GENE_PRODUCT", 53, 55], ["HIV", "ORGANISM", 106, 109], ["Env", "ORGANISM", 160, 163], ["HIV", "ORGANISM", 194, 197], ["protective Abs", "PROTEIN", 209, 223], ["HIV", "SPECIES", 194, 197], ["HIV", "SPECIES", 106, 109], ["HIV", "SPECIES", 194, 197], ["HIV", "SPECIES", 261, 264], ["Ab-based therapies", "TREATMENT", 53, 71], ["vaccines", "TREATMENT", 76, 84], ["HIV control", "TREATMENT", 106, 117], ["vaccines", "TREATMENT", 142, 150], ["protective Abs", "TREATMENT", 209, 223], ["\u201csecond generation\u201d bNAbs", "TREATMENT", 334, 359]]], ["First, using a neutralization screening of supernatants from thousands of MBCs from an HIV-infected donor, two more potent human mAbs (PG9 and PG16) targeting a broadly neutralizing epitope were described as able to neutralize 70\u201380% of the tested HIV strains with an IC50 <50 \u00b5g/ml and 50\u201360% with an IC50 <1 \u00b5g/ml (Walker et al., 2009).", [["supernatants", "ANATOMY", 43, 55], ["MBCs", "ANATOMY", 74, 78], ["MBCs", "CHEMICAL", 74, 78], ["HIV-infected", "DISEASE", 87, 99], ["MBCs", "CANCER", 74, 78], ["human", "ORGANISM", 123, 128], ["mAbs", "GENE_OR_GENE_PRODUCT", 129, 133], ["PG9", "GENE_OR_GENE_PRODUCT", 135, 138], ["PG16", "GENE_OR_GENE_PRODUCT", 143, 147], ["HIV", "ORGANISM", 248, 251], ["MBCs", "CELL_TYPE", 74, 78], ["human mAbs", "PROTEIN", 123, 133], ["PG9", "PROTEIN", 135, 138], ["PG16", "PROTEIN", 143, 147], ["HIV", "SPECIES", 87, 90], ["human", "SPECIES", 123, 128], ["HIV", "SPECIES", 248, 251], ["HIV", "SPECIES", 87, 90], ["human", "SPECIES", 123, 128], ["HIV", "SPECIES", 248, 251], ["a neutralization screening", "TEST", 13, 39], ["MBCs", "PROBLEM", 74, 78], ["an HIV", "PROBLEM", 84, 90], ["infected donor", "TREATMENT", 91, 105], ["a broadly neutralizing epitope", "TREATMENT", 159, 189], ["an IC50", "TEST", 265, 272], ["an IC50", "TEST", 299, 306], ["infected", "OBSERVATION", 91, 99]]], ["Then, by using antigen-specific human B cell sorting and engineered \u201cprobe\u201d Env antigens that better exposed conserved epitopes, powerful new bNAbs (e.g., mAbs of the group called VRC01) targeting the conserved CD4bs on the Env gp120 subunit were identified, and one of them was found able to neutralize up to 90% of HIV isolates at an IC50 <50 \u00b5g/ml and \u223c70% at an IC50 <1 \u00b5g/ml, with an overall low geometric mean IC50 of 0.3 \u00b5g/ml (Wu et al., 2010).", [["B cell", "ANATOMY", 38, 44], ["antigen", "GENE_OR_GENE_PRODUCT", 15, 22], ["human", "ORGANISM", 32, 37], ["B cell", "CELL", 38, 44], ["bNAbs", "GENE_OR_GENE_PRODUCT", 142, 147], ["VRC01", "GENE_OR_GENE_PRODUCT", 180, 185], ["CD4bs", "GENE_OR_GENE_PRODUCT", 211, 216], ["HIV", "ORGANISM", 317, 320], ["engineered \u201cprobe\u201d Env antigens", "PROTEIN", 57, 88], ["bNAbs", "PROTEIN", 142, 147], ["mAbs", "PROTEIN", 155, 159], ["VRC01", "PROTEIN", 180, 185], ["CD4bs", "PROTEIN", 211, 216], ["Env gp120 subunit", "PROTEIN", 224, 241], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["HIV", "SPECIES", 317, 320], ["engineered \u201cprobe\u201d Env antigens", "TREATMENT", 57, 88], ["powerful new bNAbs", "PROBLEM", 129, 147], ["the Env gp120 subunit", "TREATMENT", 220, 241], ["HIV isolates", "TEST", 317, 329], ["an IC50", "TEST", 333, 340], ["an IC50", "TEST", 363, 370]]], ["Subsequently, the ability to use single-cell technologies allowed for the identification of several hundred anti-HIV human mAbs, some of which were bNAbs with a median IC50 as low as 0.02 \u00b5g/ml, >1,000-fold better than the recombinant b12 Ab isolated in 1994 (Scheid et al., 2011; Walker et al., 2011; Burton and Mascola, 2015).", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44], ["human", "ORGANISM", 117, 122], ["bNAbs", "SIMPLE_CHEMICAL", 148, 153], ["anti-HIV human mAbs", "PROTEIN", 108, 127], ["recombinant b12 Ab", "PROTEIN", 223, 241], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["single-cell technologies", "TREATMENT", 33, 57], ["several hundred anti-HIV human mAbs", "TREATMENT", 92, 127], ["a median IC50", "TREATMENT", 159, 172], ["the recombinant b12 Ab", "TEST", 219, 241]]], ["Epitope mapping studies using the new Abs showed that in addition to the original CD4bs epitope, several other regions of HIV Env were able to induce bNAbs.", [["CD4bs", "GENE_OR_GENE_PRODUCT", 82, 87], ["HIV Env", "ORGANISM", 122, 129], ["bNAbs", "GENE_OR_GENE_PRODUCT", 150, 155], ["Abs", "PROTEIN", 38, 41], ["CD4bs epitope", "PROTEIN", 82, 95], ["HIV Env", "PROTEIN", 122, 129], ["bNAbs", "PROTEIN", 150, 155], ["HIV", "SPECIES", 122, 125], ["HIV", "SPECIES", 122, 125], ["Epitope mapping studies", "TEST", 0, 23], ["the new Abs", "TEST", 30, 41], ["the original CD4bs epitope", "PROBLEM", 69, 95], ["HIV Env", "PROBLEM", 122, 129], ["CD4", "OBSERVATION", 82, 85], ["bs epitope", "OBSERVATION", 85, 95], ["HIV Env", "OBSERVATION", 122, 129]]], ["The new Abs also showed remarkable therapeutic effects in vivo: in rhesus monkeys chronically infected with pathogenic simian\u2013human immunodeficiency virus SHIV-SF162P3, they were able to rapidly reduce plasma viremia to undetectable levels and keep it at bay for months (Barouch et al., 2013).", [["plasma", "ANATOMY", 202, 208], ["simian\u2013human immunodeficiency virus", "DISEASE", 119, 154], ["viremia", "DISEASE", 209, 216], ["rhesus", "ORGANISM", 67, 73], ["monkeys", "ORGANISM", 74, 81], ["simian\u2013human immunodeficiency virus", "ORGANISM", 119, 154], ["SHIV", "ORGANISM", 155, 159], ["-SF162P3", "ORGANISM", 159, 167], ["plasma", "ORGANISM_SUBSTANCE", 202, 208], ["Abs", "PROTEIN", 8, 11], ["rhesus monkeys", "SPECIES", 67, 81], ["simian\u2013human immunodeficiency virus SHIV", "SPECIES", 119, 159], ["rhesus monkeys", "SPECIES", 67, 81], ["simian\u2013human immunodeficiency virus SHIV", "SPECIES", 119, 159], ["The new Abs", "TEST", 0, 11], ["pathogenic simian\u2013human immunodeficiency virus SHIV", "PROBLEM", 108, 159], ["plasma viremia", "PROBLEM", 202, 216], ["remarkable", "OBSERVATION_MODIFIER", 24, 34], ["therapeutic effects", "OBSERVATION", 35, 54]]], ["Similarly, therapeutic benefits were observed by the suppression of viremia in SHIV-infected macaques (Shingai et al., 2013).", [["viremia", "DISEASE", 68, 75], ["SHIV-infected", "DISEASE", 79, 92], ["SHIV", "ORGANISM", 79, 83], ["macaques", "ORGANISM", 93, 101], ["macaques", "SPECIES", 93, 101], ["SHIV", "SPECIES", 79, 83], ["viremia", "PROBLEM", 68, 75], ["viremia", "OBSERVATION", 68, 75], ["infected", "OBSERVATION_MODIFIER", 84, 92]]], ["Excitingly, one such therapeutic bNAb, 3BNC117, which targets the CD4bs epitope on gp120, was tested in phase 1 clinical trials and was recently reported to reduce plasma viremia in chronically infected humans (Caskey et al., 2015).", [["plasma", "ANATOMY", 164, 170], ["3BNC117", "CHEMICAL", 39, 46], ["viremia", "DISEASE", 171, 178], ["chronically infected humans", "DISEASE", 182, 209], ["3BNC117", "CHEMICAL", 39, 46], ["bNAb", "CANCER", 33, 37], ["3BNC117", "SIMPLE_CHEMICAL", 39, 46], ["CD4bs", "GENE_OR_GENE_PRODUCT", 66, 71], ["gp120", "GENE_OR_GENE_PRODUCT", 83, 88], ["plasma", "ORGANISM_SUBSTANCE", 164, 170], ["humans", "ORGANISM", 203, 209], ["CD4bs epitope", "PROTEIN", 66, 79], ["gp120", "PROTEIN", 83, 88], ["humans", "SPECIES", 203, 209], ["humans", "SPECIES", 203, 209], ["the CD4bs epitope", "TEST", 62, 79], ["gp120", "TEST", 83, 88], ["plasma viremia", "PROBLEM", 164, 178], ["viremia", "OBSERVATION", 171, 178], ["chronically", "OBSERVATION_MODIFIER", 182, 193], ["infected", "OBSERVATION", 194, 202]]], ["Likewise, a phase 1 study using infusion of a VRC01 class Ab showed promising results, reducing plasma viremia and suppressing neutralization-sensitive strains in a subset of HIV-1\u2013infected subjects (Lynch et al., 2015).HIV ::: Use of protective Abs in structure-based antigen designThe new findings described in the previous paragraph may completely change the approach to HIV prevention and therapy, and today, Ab-mediated protection is believed to be a promising approach to HIV control.", [["plasma", "ANATOMY", 96, 102], ["viremia", "DISEASE", 103, 110], ["HIV-1\u2013infected", "DISEASE", 175, 189], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["HIV-1\u2013infected", "ORGANISM", 175, 189], ["subjects", "ORGANISM", 190, 198], ["HIV", "ORGANISM", 374, 377], ["Ab", "GENE_OR_GENE_PRODUCT", 413, 415], ["HIV", "ORGANISM", 478, 481], ["VRC01 class Ab", "PROTEIN", 46, 60], ["protective Abs", "PROTEIN", 235, 249], ["HIV-1\u2013infected", "SPECIES", 175, 189], ["HIV", "SPECIES", 220, 223], ["HIV-1\u2013infected", "SPECIES", 175, 189], ["HIV", "SPECIES", 220, 223], ["HIV", "SPECIES", 374, 377], ["HIV", "SPECIES", 478, 481], ["a phase 1 study", "TEST", 10, 25], ["a VRC01 class Ab", "TEST", 44, 60], ["plasma viremia", "PROBLEM", 96, 110], ["suppressing neutralization", "PROBLEM", 115, 141], ["sensitive strains", "PROBLEM", 142, 159], ["protective Abs", "TREATMENT", 235, 249], ["HIV prevention", "TREATMENT", 374, 388], ["therapy", "TREATMENT", 393, 400], ["Ab-mediated protection", "TREATMENT", 413, 435], ["HIV control", "TREATMENT", 478, 489], ["new", "OBSERVATION_MODIFIER", 287, 290]]], ["The immunological and structural information available is being used to design vaccine antigens, notably including the emerging class of recombinant Env SOSIP (soluble gp140 stabilized by disulphide bridges and by an Ile to Pro mutation) immunogens stabilized in native-like conformations and able to induce NAbs against neutralization-resistant (tier 2) HIV in rabbits and, to a lesser extent, macaques (Sanders et al., 2015).", [["disulphide", "CHEMICAL", 188, 198], ["Ile", "CHEMICAL", 217, 220], ["Pro", "CHEMICAL", 224, 227], ["Env SOSIP", "ORGANISM", 149, 158], ["gp140", "GENE_OR_GENE_PRODUCT", 168, 173], ["HIV", "ORGANISM", 355, 358], ["rabbits", "ORGANISM", 362, 369], ["macaques", "ORGANISM", 395, 403], ["vaccine antigens", "PROTEIN", 79, 95], ["recombinant Env SOSIP", "PROTEIN", 137, 158], ["soluble gp140", "PROTEIN", 160, 173], ["disulphide bridges", "PROTEIN", 188, 206], ["NAbs", "PROTEIN", 308, 312], ["HIV", "SPECIES", 355, 358], ["rabbits", "SPECIES", 362, 369], ["HIV", "SPECIES", 355, 358], ["rabbits", "SPECIES", 362, 369], ["recombinant Env SOSIP (soluble gp140", "TREATMENT", 137, 173], ["disulphide bridges", "TREATMENT", 188, 206], ["an Ile to Pro mutation) immunogens", "TREATMENT", 214, 248], ["neutralization", "PROBLEM", 321, 335], ["resistant (tier 2) HIV in rabbits", "PROBLEM", 336, 369], ["lesser extent", "OBSERVATION_MODIFIER", 380, 393]]], ["Alternatively, such information could be used to produce a cocktail of therapeutic Abs to be delivered simultaneously by passive immunization.", [["Abs", "PROTEIN", 83, 86], ["passive immunization", "TREATMENT", 121, 141]]], ["Delivery of bNAb-encoding genes by gene therapy\u2014vectored immunoprophylaxis\u2014has also been shown to be an efficient method to prevent HIV infection in humanized mice, and it will be interesting to see if this strategy can be translated to protect humans against HIV (Balazs et al., 2012, 2014).RSV ::: Use of protective Abs in structure-based antigen designThe quest for an RSV vaccine has met many challenges that have inspired research breakthroughs, illustrating how information from human immunology and structural biology studies can be used in combination to instruct vaccine antigen design.", [["immunoprophylaxis\u2014has", "CHEMICAL", 57, 78], ["HIV infection", "DISEASE", 132, 145], ["bNAb", "GENE_OR_GENE_PRODUCT", 12, 16], ["HIV", "ORGANISM", 132, 135], ["mice", "ORGANISM", 159, 163], ["humans", "ORGANISM", 245, 251], ["HIV", "ORGANISM", 260, 263], ["RSV", "ORGANISM", 292, 295], ["RSV", "ORGANISM", 372, 375], ["human", "ORGANISM", 485, 490], ["bNAb-encoding genes", "DNA", 12, 31], ["protective Abs", "PROTEIN", 307, 321], ["HIV", "SPECIES", 132, 135], ["mice", "SPECIES", 159, 163], ["humans", "SPECIES", 245, 251], ["HIV", "SPECIES", 260, 263], ["human", "SPECIES", 485, 490], ["HIV", "SPECIES", 132, 135], ["mice", "SPECIES", 159, 163], ["humans", "SPECIES", 245, 251], ["HIV", "SPECIES", 260, 263], ["RSV", "SPECIES", 292, 295], ["RSV", "SPECIES", 372, 375], ["human", "SPECIES", 485, 490], ["Delivery of bNAb", "TREATMENT", 0, 16], ["gene therapy\u2014vectored immunoprophylaxis\u2014has", "TREATMENT", 35, 78], ["an efficient method", "TREATMENT", 101, 120], ["HIV infection", "PROBLEM", 132, 145], ["RSV", "PROBLEM", 292, 295], ["protective Abs", "TREATMENT", 307, 321], ["an RSV vaccine", "TREATMENT", 369, 383], ["structural biology studies", "TEST", 506, 532], ["infection", "OBSERVATION", 136, 145]]], ["RSV is the main viral cause of severe respiratory tract disease in children worldwide (Nair et al., 2010) and also afflicts elderly and immunocompromised adults (Falsey et al., 2005).", [["respiratory tract", "ANATOMY", 38, 55], ["RSV", "DISEASE", 0, 3], ["respiratory tract disease", "DISEASE", 38, 63], ["RSV", "ORGANISM", 0, 3], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["children", "ORGANISM", 67, 75], ["children", "SPECIES", 67, 75], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["severe respiratory tract disease", "PROBLEM", 31, 63], ["main", "OBSERVATION_MODIFIER", 11, 15], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["respiratory tract disease", "OBSERVATION", 38, 63]]], ["The membrane-anchored fusion glycoprotein F present on the surface of this virus is the major target of NAbs (Anderson et al., 2010).", [["membrane", "ANATOMY", 4, 12], ["surface", "ANATOMY", 59, 66], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["glycoprotein F", "GENE_OR_GENE_PRODUCT", 29, 43], ["surface", "CELLULAR_COMPONENT", 59, 66], ["membrane-anchored fusion glycoprotein F", "PROTEIN", 4, 43], ["NAbs", "PROTEIN", 104, 108], ["The membrane-anchored fusion glycoprotein F", "TREATMENT", 0, 43], ["this virus", "PROBLEM", 70, 80], ["membrane", "OBSERVATION_MODIFIER", 4, 12], ["fusion", "OBSERVATION", 22, 28]]], ["However, although an approved therapeutic mAb treatment (palivizumab) targeting F has existed for nearly two decades (The IMpact-RSV Study Group, 1998), attempts to develop an RSV vaccine using recombinant F antigen have been hampered by its poor behavior in solution and its tendency to undergo large conformational changes.", [["palivizumab", "CHEMICAL", 57, 68], ["palivizumab", "SIMPLE_CHEMICAL", 57, 68], ["RSV", "ORGANISM", 176, 179], ["recombinant F antigen", "GENE_OR_GENE_PRODUCT", 194, 215], ["recombinant F antigen", "PROTEIN", 194, 215], ["RSV", "SPECIES", 176, 179], ["an approved therapeutic mAb treatment", "TREATMENT", 18, 55], ["palivizumab)", "TREATMENT", 57, 69], ["an RSV vaccine", "TREATMENT", 173, 187], ["recombinant F antigen", "TREATMENT", 194, 215], ["large conformational changes", "PROBLEM", 296, 324], ["large", "OBSERVATION_MODIFIER", 296, 301], ["conformational", "OBSERVATION", 302, 316]]], ["Early epitope-focused rational antigen designs were enabled by the cocrystal structure of the Fab region of an RSV-neutralizing mAb (motavizumab, an affinity-enhanced form of palivizumab) bound to its target F epitope prepared as a synthetic 24-residue peptide that adopted a helix-turn-helix motif in the crystal (McLellan et al., 2010).", [["motavizumab", "CHEMICAL", 133, 144], ["palivizumab", "CHEMICAL", 175, 186], ["palivizumab", "CHEMICAL", 175, 186], ["RSV", "ORGANISM", 111, 114], ["motavizumab", "SIMPLE_CHEMICAL", 133, 144], ["palivizumab", "SIMPLE_CHEMICAL", 175, 186], ["Fab region", "PROTEIN", 94, 104], ["RSV-neutralizing mAb", "PROTEIN", 111, 131], ["motavizumab", "PROTEIN", 133, 144], ["F epitope", "PROTEIN", 208, 217], ["helix-turn-helix motif", "PROTEIN", 276, 298], ["RSV", "SPECIES", 111, 114], ["Early epitope", "PROBLEM", 0, 13], ["an RSV", "TREATMENT", 108, 114], ["neutralizing mAb", "TREATMENT", 115, 131], ["motavizumab", "TREATMENT", 133, 144], ["palivizumab) bound", "PROBLEM", 175, 193], ["a synthetic 24-residue peptide", "TREATMENT", 230, 260], ["RSV", "OBSERVATION", 111, 114], ["neutralizing mAb", "OBSERVATION", 115, 131]]], ["However, initial attempts to design an immunogen comprised of a scaffold protein presenting this F epitope with the observed helix-turn-helix conformation were only partially successful: after immunization, conformation-specific anti-F Abs were elicited but lacked the ability to neutralize RSV (McLellan et al., 2011).", [["RSV", "ORGANISM", 291, 294], ["scaffold protein", "PROTEIN", 64, 80], ["F epitope", "PROTEIN", 97, 106], ["Abs", "PROTEIN", 236, 239], ["RSV", "SPECIES", 291, 294], ["an immunogen", "TREATMENT", 36, 48], ["a scaffold protein", "TREATMENT", 62, 80], ["immunization", "TREATMENT", 193, 205]]], ["Subsequently, Correia et al. (2014) reported a proof-of-principle study, wherein they developed a new structure-based approach for the computational design and optimization of improved biophysically robust scaffold proteins displaying the desired RSV peptide epitope in a conformationally faithful manner that was able to elicit RSV NAbs in nonhuman primates (NHPs).", [["RSV", "ORGANISM", 247, 250], ["RSV", "ORGANISM", 329, 332], ["nonhuman primates", "ORGANISM", 341, 358], ["NHPs", "ORGANISM", 360, 364], ["biophysically robust scaffold proteins", "PROTEIN", 185, 223], ["RSV NAbs", "PROTEIN", 329, 337], ["RSV", "SPECIES", 247, 250], ["RSV", "SPECIES", 329, 332], ["principle study", "TEST", 56, 71], ["improved biophysically robust scaffold proteins", "PROBLEM", 176, 223], ["the desired RSV peptide epitope", "PROBLEM", 235, 266], ["RSV NAbs", "PROBLEM", 329, 337], ["RSV peptide epitope", "OBSERVATION", 247, 266]]], ["Furthermore, when the RSV peptide epitope scaffold antigen was mounted in multicopy ordered arrays on the surface of a virus-like particle by linking to the hepatitis B core antigen, at least half of the NHPs raised RSV-neutralizing activity comparable to that induced by natural human infection.", [["surface", "ANATOMY", 106, 113], ["hepatitis B", "DISEASE", 157, 168], ["human infection", "DISEASE", 280, 295], ["RSV", "ORGANISM", 22, 25], ["surface", "CELLULAR_COMPONENT", 106, 113], ["hepatitis B core antigen", "GENE_OR_GENE_PRODUCT", 157, 181], ["NHPs", "ORGANISM", 204, 208], ["RSV", "ORGANISM", 216, 219], ["human", "ORGANISM", 280, 285], ["RSV peptide epitope scaffold antigen", "PROTEIN", 22, 58], ["hepatitis B core antigen", "PROTEIN", 157, 181], ["human", "SPECIES", 280, 285], ["RSV", "SPECIES", 22, 25], ["hepatitis B", "SPECIES", 157, 168], ["RSV", "SPECIES", 216, 219], ["human", "SPECIES", 280, 285], ["the RSV peptide epitope scaffold antigen", "TREATMENT", 18, 58], ["a virus", "PROBLEM", 117, 124], ["RSV", "PROBLEM", 216, 219], ["natural human infection", "PROBLEM", 272, 295], ["virus", "OBSERVATION", 119, 124], ["hepatitis", "OBSERVATION", 157, 166], ["neutralizing activity", "OBSERVATION", 220, 241], ["natural human infection", "OBSERVATION", 272, 295]]], ["Thus, careful manipulations to properly present a structurally optimized form of a single well-defined protective epitope resulted in the generation of the desired immune response, demonstrating the feasibility of this novel immune-focusing approach.", [["careful manipulations", "TREATMENT", 6, 27], ["a single well-defined protective epitope", "PROBLEM", 81, 121], ["this novel immune-focusing approach", "TREATMENT", 214, 249]]], ["Nevertheless, variability of the immune response in a diverse human population, together with the risk of the emergence of naturally occurring epitope escape mutants, makes a vaccine approach relying on a single protective epitope potentially less robust compared with immunization strategies based on a full-length antigen, such as the entire ectodomain of the RSV F protein, which would potentially offer a broader immune response.RSV ::: Use of protective Abs in structure-based antigen designThe trimeric F protein of RSV undergoes a major conformational change from a relatively compact meta-stable prefusion state to a more elongated highly stable postfusion state (McLellan et al., 2013c).", [["human", "ORGANISM", 62, 67], ["RSV F", "GENE_OR_GENE_PRODUCT", 362, 367], ["RSV", "ORGANISM", 433, 436], ["trimeric F", "GENE_OR_GENE_PRODUCT", 500, 510], ["RSV", "ORGANISM", 522, 525], ["full-length antigen", "PROTEIN", 304, 323], ["ectodomain", "PROTEIN", 344, 354], ["RSV F protein", "PROTEIN", 362, 375], ["protective Abs", "PROTEIN", 448, 462], ["trimeric F protein", "PROTEIN", 500, 518], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["RSV", "SPECIES", 362, 365], ["RSV", "SPECIES", 433, 436], ["RSV", "SPECIES", 522, 525], ["the immune response", "PROBLEM", 29, 48], ["a diverse human population", "PROBLEM", 52, 78], ["epitope escape mutants", "PROBLEM", 143, 165], ["a vaccine approach", "TREATMENT", 173, 191], ["a single protective epitope", "TREATMENT", 203, 230], ["immunization strategies", "TREATMENT", 269, 292], ["RSV", "PROBLEM", 433, 436], ["protective Abs in structure", "TREATMENT", 448, 475], ["RSV", "PROBLEM", 522, 525], ["a major conformational change", "PROBLEM", 536, 565], ["RSV", "OBSERVATION", 522, 525], ["stable", "OBSERVATION_MODIFIER", 597, 603], ["prefusion state", "OBSERVATION", 604, 619], ["elongated", "OBSERVATION_MODIFIER", 630, 639], ["highly", "OBSERVATION_MODIFIER", 640, 646], ["stable", "OBSERVATION_MODIFIER", 647, 653], ["postfusion", "OBSERVATION", 654, 664]]], ["Because of its exposure on the virion surface, the prefusion structure was an obvious candidate vaccine antigen, but the spontaneous conversion of recombinant prefusion F to the post-fusion state discouraged initial efforts in this direction.", [["surface", "ANATOMY", 38, 45], ["virion surface", "CELLULAR_COMPONENT", 31, 45], ["prefusion F", "GENE_OR_GENE_PRODUCT", 159, 170], ["the virion surface", "TREATMENT", 27, 45], ["the prefusion structure", "PROBLEM", 47, 70], ["prefusion structure", "OBSERVATION", 51, 70]]], ["However, although an engineered postfusion F antigen elicited NAbs in animals (Swanson et al., 2011), an alternative study by Magro et al. (2012) using immunized rabbit sera and sero-positive human sera reported that Abs targeting the prefusion F protein accounted for most of the RSV-neutralizing activity.", [["sera", "ANATOMY", 169, 173], ["sera", "ANATOMY", 198, 202], ["postfusion F antigen", "GENE_OR_GENE_PRODUCT", 32, 52], ["rabbit", "ORGANISM", 162, 168], ["sera", "ORGANISM_SUBSTANCE", 169, 173], ["human", "ORGANISM", 192, 197], ["sera", "ORGANISM_SUBSTANCE", 198, 202], ["Abs", "GENE_OR_GENE_PRODUCT", 217, 220], ["prefusion F", "GENE_OR_GENE_PRODUCT", 235, 246], ["RSV", "ORGANISM", 281, 284], ["postfusion F antigen", "PROTEIN", 32, 52], ["NAbs", "PROTEIN", 62, 66], ["Abs", "PROTEIN", 217, 220], ["prefusion F protein", "PROTEIN", 235, 254], ["rabbit", "SPECIES", 162, 168], ["human", "SPECIES", 192, 197], ["rabbit", "SPECIES", 162, 168], ["human", "SPECIES", 192, 197], ["RSV", "SPECIES", 281, 284], ["an alternative study", "TEST", 102, 122], ["immunized rabbit sera", "TREATMENT", 152, 173], ["sero-positive human sera", "TEST", 178, 202], ["Abs", "TEST", 217, 220], ["the prefusion F protein", "TEST", 231, 254], ["RSV", "OBSERVATION", 281, 284], ["neutralizing activity", "OBSERVATION", 285, 306]]], ["The latter highlighted the importance of renewed attempts to make a stable and efficacious prefusion F antigen, which was facilitated by the discovery and structural characterization of new mouse and human RSV-neutralizing mAbs specific for prefusion F. Crucially, a cocrystal structure reported by McLellan et al. (2013b) showed how the potently RSV-neutralizing human Fab D25 binds and traps F in a previously unobserved prefusion conformation.", [["prefusion F antigen", "GENE_OR_GENE_PRODUCT", 91, 110], ["mouse", "ORGANISM", 190, 195], ["human", "ORGANISM", 200, 205], ["RSV", "ORGANISM", 206, 209], ["RSV", "ORGANISM", 347, 350], ["human", "ORGANISM", 364, 369], ["Fab", "GENE_OR_GENE_PRODUCT", 370, 373], ["prefusion F antigen", "PROTEIN", 91, 110], ["mouse and human RSV-neutralizing mAbs", "PROTEIN", 190, 227], ["human Fab D25", "PROTEIN", 364, 377], ["mouse", "SPECIES", 190, 195], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 364, 369], ["mouse", "SPECIES", 190, 195], ["human", "SPECIES", 200, 205], ["RSV", "SPECIES", 206, 209], ["RSV", "SPECIES", 347, 350], ["human", "SPECIES", 364, 369], ["new mouse and human RSV", "TREATMENT", 186, 209], ["neutralizing mAbs", "TREATMENT", 210, 227], ["the potently RSV", "TREATMENT", 334, 350], ["neutralizing human Fab D25 binds", "TREATMENT", 351, 383], ["prefusion conformation", "OBSERVATION", 423, 445]]], ["The structure revealed a large quaternary epitope on the prefusion F trimer apex, defining a major site of vulnerability on a novel antigenic structure.", [["a large quaternary epitope", "PROBLEM", 23, 49], ["large", "OBSERVATION_MODIFIER", 25, 30], ["quaternary", "OBSERVATION_MODIFIER", 31, 41], ["epitope", "OBSERVATION", 42, 49], ["prefusion F trimer", "OBSERVATION_MODIFIER", 57, 75], ["apex", "ANATOMY_MODIFIER", 76, 80], ["major", "OBSERVATION_MODIFIER", 93, 98], ["vulnerability", "OBSERVATION", 107, 120], ["antigenic structure", "OBSERVATION", 132, 151]]], ["Subsequently, based on the crystal structure, McLellan et al. (2013a) were able to stabilize the prefusion F antigen in a trimeric conformation by replacing its transmembrane region with a trimerization domain and by inserting ad hoc mutations to create a novel disulfide bridge and a core structure with improved hydrophobic packing.", [["transmembrane", "ANATOMY", 161, 174], ["disulfide", "CHEMICAL", 262, 271], ["prefusion F antigen", "GENE_OR_GENE_PRODUCT", 97, 116], ["prefusion F antigen", "PROTEIN", 97, 116], ["transmembrane region", "PROTEIN", 161, 181], ["trimerization domain", "PROTEIN", 189, 209], ["disulfide bridge", "PROTEIN", 262, 278], ["a trimeric conformation", "TREATMENT", 120, 143], ["a trimerization domain", "TREATMENT", 187, 209], ["a novel disulfide bridge", "TREATMENT", 254, 278], ["improved hydrophobic packing", "TREATMENT", 305, 333], ["disulfide bridge", "OBSERVATION", 262, 278], ["improved", "OBSERVATION_MODIFIER", 305, 313], ["hydrophobic packing", "OBSERVATION", 314, 333]]], ["This new prefusion antigen was able to elicit much higher levels of RSV-neutralizing activity compared with the postfusion F antigen in mouse and NHP models.", [["prefusion antigen", "GENE_OR_GENE_PRODUCT", 9, 26], ["RSV", "ORGANISM", 68, 71], ["postfusion F antigen", "GENE_OR_GENE_PRODUCT", 112, 132], ["mouse", "ORGANISM", 136, 141], ["NHP", "ORGANISM", 146, 149], ["prefusion antigen", "PROTEIN", 9, 26], ["postfusion F antigen", "PROTEIN", 112, 132], ["mouse", "SPECIES", 136, 141], ["RSV", "SPECIES", 68, 71], ["mouse", "SPECIES", 136, 141], ["This new prefusion antigen", "PROBLEM", 0, 26], ["RSV", "PROBLEM", 68, 71], ["neutralizing activity", "PROBLEM", 72, 93], ["RSV", "OBSERVATION", 68, 71], ["neutralizing activity", "OBSERVATION", 72, 93]]], ["Although polyinosinic:polycytidylic acid adjuvant was used in combination with the engineered F antigen to stimulate an appropriate neutralizing response and no information was provided regarding their potency in the absence of such a strong adjuvant, this work provides an elegant preclinical demonstration of the feasibility of a structure-based vaccine strategy driven by the analysis of the human natural protective immune response and focused on mimicry of a large conformational epitope.", [["polyinosinic:polycytidylic acid", "CHEMICAL", 9, 40], ["polyinosinic:polycytidylic acid", "CHEMICAL", 9, 40], ["polyinosinic:polycytidylic acid", "SIMPLE_CHEMICAL", 9, 40], ["F antigen", "GENE_OR_GENE_PRODUCT", 94, 103], ["human", "ORGANISM", 395, 400], ["F antigen", "PROTEIN", 94, 103], ["human", "SPECIES", 395, 400], ["human", "SPECIES", 395, 400], ["polyinosinic", "PROBLEM", 9, 21], ["polycytidylic acid adjuvant", "TREATMENT", 22, 49], ["the engineered F antigen", "TREATMENT", 79, 103], ["a strong adjuvant", "TREATMENT", 233, 250], ["a structure-based vaccine strategy", "TREATMENT", 330, 364], ["a large conformational epitope", "PROBLEM", 462, 492], ["polycytidylic acid", "OBSERVATION", 22, 40], ["large", "OBSERVATION_MODIFIER", 464, 469], ["conformational epitope", "OBSERVATION", 470, 492]]], ["Indeed, this study provides hope that a vaccine containing a prefusion-stabilized F protein would induce a response protective against RSV infection in humans, and clinical trials are ongoing.Influenza virus ::: Use of protective Abs in structure-based antigen designYet another important area where human immunology is informing the design of novel immunogens is in the search for broadly protective vaccine antigens to protect against influenza (flu), a persistent global public health threat (Lambert and Fauci, 2010).", [["RSV infection", "DISEASE", 135, 148], ["Influenza", "DISEASE", 192, 201], ["influenza", "DISEASE", 437, 446], ["flu", "DISEASE", 448, 451], ["RSV", "ORGANISM", 135, 138], ["humans", "ORGANISM", 152, 158], ["Influenza virus", "ORGANISM", 192, 207], ["human", "ORGANISM", 300, 305], ["prefusion-stabilized F protein", "PROTEIN", 61, 91], ["protective Abs", "PROTEIN", 219, 233], ["RSV", "SPECIES", 135, 138], ["humans", "SPECIES", 152, 158], ["Influenza virus", "SPECIES", 192, 207], ["human", "SPECIES", 300, 305], ["RSV", "SPECIES", 135, 138], ["humans", "SPECIES", 152, 158], ["Influenza virus", "SPECIES", 192, 207], ["human", "SPECIES", 300, 305], ["this study", "TEST", 8, 18], ["a vaccine", "TREATMENT", 38, 47], ["a prefusion-stabilized F protein", "TREATMENT", 59, 91], ["RSV infection in humans", "PROBLEM", 135, 158], ["Influenza virus", "PROBLEM", 192, 207], ["protective Abs in structure", "TREATMENT", 219, 246], ["novel immunogens", "TREATMENT", 344, 360], ["broadly protective vaccine antigens", "TREATMENT", 382, 417], ["influenza", "PROBLEM", 437, 446], ["infection", "OBSERVATION", 139, 148], ["persistent", "OBSERVATION_MODIFIER", 456, 466], ["global", "OBSERVATION_MODIFIER", 467, 473]]], ["Traditional flu vaccines made using HA and neuraminidase antigens purified from egg-grown influenza virus are efficacious when the vaccine antigens are genotypically matched against the circulating strains and subtypes.", [["HA", "GENE_OR_GENE_PRODUCT", 36, 38], ["neuraminidase antigens", "GENE_OR_GENE_PRODUCT", 43, 65], ["egg-grown influenza virus", "ORGANISM", 80, 105], ["HA", "PROTEIN", 36, 38], ["neuraminidase antigens", "PROTEIN", 43, 65], ["vaccine antigens", "PROTEIN", 131, 147], ["influenza virus", "SPECIES", 90, 105], ["influenza virus", "SPECIES", 90, 105], ["Traditional flu vaccines", "TREATMENT", 0, 24], ["HA and neuraminidase antigens", "TREATMENT", 36, 65], ["grown influenza virus", "PROBLEM", 84, 105], ["the vaccine antigens", "TREATMENT", 127, 147], ["the circulating strains", "PROBLEM", 182, 205], ["influenza virus", "OBSERVATION", 90, 105]]], ["However, the frequent occurrence of genetic variation via antigenic drift and reassortment implies that such flu vaccines need to be revised annually to elicit protective responses.", [["genetic variation", "PROBLEM", 36, 53], ["antigenic drift", "PROBLEM", 58, 73], ["reassortment", "TREATMENT", 78, 90], ["such flu vaccines", "TREATMENT", 104, 121], ["antigenic drift", "OBSERVATION", 58, 73]]], ["Indeed, the bulk of the immune response triggered either by the vaccine or by natural infection is against the head of HA, which is highly diverse between distinct strains, and therefore, only minimal cross-protection from one strain to another is typically achieved.", [["head", "ANATOMY", 111, 115], ["infection", "DISEASE", 86, 95], ["head", "ORGANISM_SUBDIVISION", 111, 115], ["HA", "GENE_OR_GENE_PRODUCT", 119, 121], ["the vaccine", "TREATMENT", 60, 71], ["natural infection", "PROBLEM", 78, 95], ["the head of HA", "PROBLEM", 107, 121], ["distinct strains", "PROBLEM", 155, 171], ["immune response", "OBSERVATION", 24, 39], ["infection", "OBSERVATION", 86, 95], ["HA", "OBSERVATION", 119, 121], ["diverse", "OBSERVATION_MODIFIER", 139, 146], ["distinct", "OBSERVATION_MODIFIER", 155, 163], ["strains", "OBSERVATION", 164, 171], ["minimal", "OBSERVATION_MODIFIER", 193, 200]]], ["Consequently, flu vaccine efficiency can be highly variable depending on how much the HA of the circulating flu strains matches the HA in the vaccine strains.", [["HA", "GENE_OR_GENE_PRODUCT", 86, 88], ["flu strains", "ORGANISM", 108, 119], ["HA", "GENE_OR_GENE_PRODUCT", 132, 134], ["flu vaccine efficiency", "TREATMENT", 14, 36], ["the circulating flu strains", "PROBLEM", 92, 119], ["the HA", "PROBLEM", 128, 134], ["the vaccine strains", "TREATMENT", 138, 157]]], ["Moreover, all presently available seasonal flu vaccines are probably unable to prevent infection with a new emerging strain of highly pathogenic flu virus to which the human population has not been previously exposed, such as the H5N1 or H7N9 strains.", [["infection", "DISEASE", 87, 96], ["flu virus", "ORGANISM", 145, 154], ["human", "ORGANISM", 168, 173], ["H7N9 strains", "ORGANISM", 238, 250], ["flu virus", "SPECIES", 145, 154], ["human", "SPECIES", 168, 173], ["flu virus", "SPECIES", 145, 154], ["human", "SPECIES", 168, 173], ["H7N9", "SPECIES", 238, 242], ["seasonal flu vaccines", "TREATMENT", 34, 55], ["infection", "PROBLEM", 87, 96], ["highly pathogenic flu virus", "PROBLEM", 127, 154], ["the H5N1", "PROBLEM", 226, 234], ["H7N9 strains", "PROBLEM", 238, 250], ["infection", "OBSERVATION", 87, 96]]], ["Because the latter circulates among avian populations, there is the risk that zoonosis to humans may trigger a deadly pandemic infection.", [["zoonosis", "DISEASE", 78, 86], ["infection", "DISEASE", 127, 136], ["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["a deadly pandemic infection", "PROBLEM", 109, 136], ["infection", "OBSERVATION", 127, 136]]], ["Therefore, an important goal is the development of a potent and universally protective flu vaccine to generate high titers of bNAbs against influenza virus.", [["influenza virus", "DISEASE", 140, 155], ["bNAbs", "GENE_OR_GENE_PRODUCT", 126, 131], ["influenza virus", "ORGANISM", 140, 155], ["bNAbs", "PROTEIN", 126, 131], ["influenza virus", "SPECIES", 140, 155], ["influenza virus", "SPECIES", 140, 155], ["universally protective flu vaccine", "TREATMENT", 64, 98], ["high titers of bNAbs", "TREATMENT", 111, 131], ["influenza virus", "PROBLEM", 140, 155]]], ["Such a vaccine should ideally induce an immune response against one or more conserved epitopes in the viral proteins to prevent infection or disease from all or nearly all possible circulating strains of the flu virus.", [["infection", "DISEASE", 128, 137], ["flu virus", "ORGANISM", 208, 217], ["viral proteins", "PROTEIN", 102, 116], ["flu virus", "SPECIES", 208, 217], ["a vaccine", "TREATMENT", 5, 14], ["the viral proteins", "PROBLEM", 98, 116], ["infection", "PROBLEM", 128, 137], ["disease", "PROBLEM", 141, 148], ["circulating strains", "PROBLEM", 181, 200], ["the flu virus", "PROBLEM", 204, 217], ["infection", "OBSERVATION", 128, 137], ["flu virus", "OBSERVATION", 208, 217]]], ["The HA stem region is indeed highly conserved among different strains and subtypes of influenza virus, but this region is poorly immunogenic when in the full-length HA protein contained in conventional vaccines.", [["influenza virus", "DISEASE", 86, 101], ["influenza virus", "ORGANISM", 86, 101], ["HA stem region", "DNA", 4, 18], ["HA protein", "PROTEIN", 165, 175], ["influenza virus", "SPECIES", 86, 101], ["influenza virus", "SPECIES", 86, 101], ["The HA stem region", "PROBLEM", 0, 18], ["different strains", "PROBLEM", 52, 69], ["influenza virus", "PROBLEM", 86, 101], ["the full-length HA protein", "TREATMENT", 149, 175], ["conventional vaccines", "TREATMENT", 189, 210], ["HA stem", "ANATOMY", 4, 11], ["influenza virus", "OBSERVATION", 86, 101], ["poorly", "OBSERVATION_MODIFIER", 122, 128], ["immunogenic", "OBSERVATION", 129, 140]]], ["Therefore, conventional flu vaccines are not able to elicit a powerful anti-stem HA Ab response.Influenza virus ::: Use of protective Abs in structure-based antigen designHowever, the appropriateness of the HA stem region as a component in a universal flu vaccine was recently confirmed by the finding that bNAbs against this region of HA can be selected from human subjects after infection or vaccination (Kashyap et al., 2008; Throsby et al., 2008; Ekiert et al., 2009, 2011; Sui et al., 2009; Corti et al., 2011b; Dreyfus et al., 2012).", [["stem region", "ANATOMY", 210, 221], ["Influenza", "DISEASE", 96, 105], ["infection", "DISEASE", 381, 390], ["Influenza virus", "ORGANISM", 96, 111], ["bNAbs", "GENE_OR_GENE_PRODUCT", 307, 312], ["HA", "GENE_OR_GENE_PRODUCT", 336, 338], ["human", "ORGANISM", 360, 365], ["anti-stem HA Ab", "PROTEIN", 71, 86], ["protective Abs", "PROTEIN", 123, 137], ["HA stem region", "DNA", 207, 221], ["bNAbs", "PROTEIN", 307, 312], ["Influenza virus", "SPECIES", 96, 111], ["human", "SPECIES", 360, 365], ["Influenza virus", "SPECIES", 96, 111], ["human", "SPECIES", 360, 365], ["conventional flu vaccines", "TREATMENT", 11, 36], ["Influenza virus", "PROBLEM", 96, 111], ["protective Abs", "TREATMENT", 123, 137], ["the HA stem region", "PROBLEM", 203, 221], ["a universal flu vaccine", "TREATMENT", 240, 263], ["HA", "PROBLEM", 336, 338], ["infection", "PROBLEM", 381, 390], ["HA stem", "ANATOMY", 207, 214]]], ["These observations have driven experimental approaches aimed at improving the immune response against the stem (Hai et al., 2012; Schneemann et al., 2012; Kanekiyo et al., 2013).", [["stem", "CELL", 106, 110], ["experimental approaches", "TREATMENT", 31, 54], ["stem", "ANATOMY", 106, 110]]], ["This aim is complicated because, as for RSV F (see RSV section above), the native HA is a meta-stable membrane glycoprotein that undergoes large conformational changes.", [["membrane", "ANATOMY", 102, 110], ["RSV", "ORGANISM", 40, 43], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["membrane glycoprotein", "PROTEIN", 102, 123], ["RSV", "SPECIES", 40, 43], ["RSV", "SPECIES", 51, 54], ["RSV F", "PROBLEM", 40, 45], ["membrane glycoprotein", "TREATMENT", 102, 123], ["large conformational changes", "PROBLEM", 139, 167], ["membrane glycoprotein", "OBSERVATION", 102, 123], ["large", "OBSERVATION_MODIFIER", 139, 144], ["conformational changes", "OBSERVATION", 145, 167]]], ["To overcome this challenge, Kanekiyo et al. (2013) used a structure-based design to generate a genetic fusion encoding HA from one H1 strain linked to the bacterial protein ferritin.", [["HA", "GENE_OR_GENE_PRODUCT", 119, 121], ["ferritin", "GENE_OR_GENE_PRODUCT", 173, 181], ["HA", "PROTEIN", 119, 121], ["bacterial protein ferritin", "PROTEIN", 155, 181], ["a genetic fusion encoding HA", "PROBLEM", 93, 121], ["one H1 strain", "PROBLEM", 127, 140], ["the bacterial protein ferritin", "TEST", 151, 181], ["bacterial protein ferritin", "OBSERVATION", 155, 181]]], ["Because of the natural oligomerization of ferritin, the HA\u2013ferritin polypeptide spontaneously self-assembled into 24-mer nanoparticles, each displaying eight trimeric H1 subtype HA \u201cspikes\u201d projecting off the ferritin nanoparticle scaffold, oriented such that the immune system could encounter the ordered arrays of HA in a native-like conformation.", [["ferritin", "GENE_OR_GENE_PRODUCT", 42, 50], ["HA\u2013ferritin", "GENE_OR_GENE_PRODUCT", 56, 67], ["24-mer nanoparticles", "SIMPLE_CHEMICAL", 114, 134], ["ferritin", "GENE_OR_GENE_PRODUCT", 209, 217], ["ferritin", "PROTEIN", 42, 50], ["HA\u2013ferritin polypeptide", "PROTEIN", 56, 79], ["the natural oligomerization of ferritin", "PROBLEM", 11, 50], ["the HA\u2013ferritin polypeptide", "TREATMENT", 52, 79], ["eight trimeric H1 subtype HA", "PROBLEM", 152, 180], ["spikes", "PROBLEM", 182, 188], ["the ferritin nanoparticle scaffold", "TREATMENT", 205, 239], ["HA", "PROBLEM", 316, 318]]], ["When tested in preclinical in vivo models, this elegant multivalent immunogen presenting structurally intact HA trimers was effective in eliciting higher titers of NAbs compared with a similarly adjuvanted trivalent inactivated vaccine (TIV) in both mice and ferrets, providing broader coverage against unmatched H1N1 viruses.", [["mice", "ORGANISM", 250, 254], ["ferrets", "ORGANISM", 259, 266], ["H1N1 viruses", "ORGANISM", 313, 325], ["NAbs", "PROTEIN", 164, 168], ["mice", "SPECIES", 250, 254], ["ferrets", "SPECIES", 259, 266], ["TIV", "SPECIES", 237, 240], ["mice", "SPECIES", 250, 254], ["ferrets", "SPECIES", 259, 266], ["H1N1 viruses", "SPECIES", 313, 325], ["this elegant multivalent immunogen", "TREATMENT", 43, 77], ["eliciting higher titers of NAbs", "PROBLEM", 137, 168], ["a similarly adjuvanted trivalent inactivated vaccine", "TREATMENT", 183, 235], ["TIV", "TREATMENT", 237, 240], ["broader coverage", "TREATMENT", 278, 294], ["unmatched H1N1 viruses", "PROBLEM", 303, 325], ["H1N1 viruses", "OBSERVATION", 313, 325]]], ["Analysis of the specificity of the immune response revealed that the NAbs generated by HA\u2013ferritin nanoparticles were directed against both the sensitive receptor binding site in the HA head and the conserved HA stem region, and the latter was responsible for half of the observed heterosubtype neutralizations.", [["HA\u2013ferritin", "CHEMICAL", 87, 98], ["HA\u2013ferritin", "CHEMICAL", 87, 98], ["HA\u2013ferritin nanoparticles", "SIMPLE_CHEMICAL", 87, 112], ["NAbs", "PROTEIN", 69, 73], ["HA head", "PROTEIN", 183, 190], ["conserved HA stem region", "DNA", 199, 223], ["the immune response", "TEST", 31, 50], ["the NAbs", "PROBLEM", 65, 73], ["HA\u2013ferritin nanoparticles", "TREATMENT", 87, 112], ["the observed heterosubtype neutralizations", "PROBLEM", 268, 310], ["head", "ANATOMY", 186, 190], ["HA stem", "ANATOMY", 209, 216]]], ["Although it could not be considered a real universal flu vaccine, this HA nanoparticle\u2013based vaccine proved that a potent and broad neutralizing response against the HA stem region can be induced by the use of an appropriate immunogen.", [["stem region", "ANATOMY", 169, 180], ["HA stem region", "DNA", 166, 180], ["a real universal flu vaccine", "TREATMENT", 36, 64], ["this HA nanoparticle\u2013based vaccine", "TREATMENT", 66, 100], ["a potent and broad neutralizing response", "PROBLEM", 113, 153], ["the HA stem region", "PROBLEM", 162, 180], ["an appropriate immunogen", "TREATMENT", 210, 234]]], ["However, a potent cross-protective response was observed only in the presence of strong adjuvants such as Ribi or MF59.", [["MF59", "CHEMICAL", 114, 118], ["MF59", "CHEMICAL", 114, 118], ["Ribi", "SIMPLE_CHEMICAL", 106, 110], ["MF59", "GENE_OR_GENE_PRODUCT", 114, 118], ["strong adjuvants", "TREATMENT", 81, 97], ["strong", "OBSERVATION_MODIFIER", 81, 87], ["adjuvants", "OBSERVATION", 88, 97]]], ["Such adjuvants may work by improving the development of T follicular helper cells and the germinal center antigen-specific B cell response (Mastelic Gavillet et al., 2015), thus helping the selection of low-abundance B cell clones recognizing poorly immunogenic epitopes such as those of the HA stem region, as experimentally proved for other model antigens (Victora et al., 2010).Influenza virus ::: Use of protective Abs in structure-based antigen designThe identification of human mAbs able to bind conserved epitopes in the HA stem region of several flu strains belonging to different subtypes can be considered the first step toward the discovery of an ideal immunogen for a universal flu vaccine.", [["T follicular helper cells", "ANATOMY", 56, 81], ["germinal center", "ANATOMY", 90, 105], ["B cell", "ANATOMY", 123, 129], ["B cell clones", "ANATOMY", 217, 230], ["stem region", "ANATOMY", 295, 306], ["stem region", "ANATOMY", 531, 542], ["Influenza", "DISEASE", 381, 390], ["T follicular helper cells", "CELL", 56, 81], ["germinal center antigen", "GENE_OR_GENE_PRODUCT", 90, 113], ["B cell", "CELL", 123, 129], ["B cell clones", "CELL", 217, 230], ["Influenza virus", "ORGANISM", 381, 396], ["human", "ORGANISM", 478, 483], ["mAbs", "GENE_OR_GENE_PRODUCT", 484, 488], ["flu strains", "ORGANISM", 554, 565], ["T follicular helper cells", "CELL_TYPE", 56, 81], ["B cell clones", "CELL_LINE", 217, 230], ["protective Abs", "PROTEIN", 408, 422], ["human mAbs", "PROTEIN", 478, 488], ["Influenza virus", "SPECIES", 381, 396], ["human", "SPECIES", 478, 483], ["Influenza virus", "SPECIES", 381, 396], ["human", "SPECIES", 478, 483], ["Such adjuvants", "TREATMENT", 0, 14], ["T follicular helper cells", "PROBLEM", 56, 81], ["the germinal center antigen", "TEST", 86, 113], ["poorly immunogenic epitopes", "PROBLEM", 243, 270], ["Influenza virus", "PROBLEM", 381, 396], ["protective Abs", "TREATMENT", 408, 422], ["human mAbs", "TREATMENT", 478, 488], ["several flu strains", "PROBLEM", 546, 565], ["an ideal immunogen", "TREATMENT", 655, 673], ["a universal flu vaccine", "TREATMENT", 678, 701], ["cell clones", "OBSERVATION", 219, 230], ["HA stem", "ANATOMY", 292, 299]]], ["These Abs are precious tools that can be used both for cocrystal structure studies to precisely identify the neutralizing epitopes in the HA stem region and for binding assays to isolate the most appropriate immunogen to induce a broad protection.", [["Abs", "PROTEIN", 6, 9], ["neutralizing epitopes", "PROTEIN", 109, 130], ["HA stem region", "PROTEIN", 138, 152], ["cocrystal structure studies", "TEST", 55, 82], ["the neutralizing epitopes in the HA stem region", "PROBLEM", 105, 152], ["binding assays", "TEST", 161, 175], ["a broad protection", "TREATMENT", 228, 246], ["neutralizing", "OBSERVATION", 109, 121], ["HA stem", "ANATOMY", 138, 145]]], ["Two different groups have recently taken advantage of such anti\u2013HA stem Abs and the cognate structurally derived epitope mapping information to rationally design and screen a series of novel immunogens, leading to selection of a stable immunogen containing the appropriate conformational epitopes from the HA stem (Impagliazzo et al., 2015; Yassine et al., 2015).", [["anti\u2013HA stem Abs", "PROTEIN", 59, 75], ["conformational epitopes", "PROTEIN", 273, 296], ["such anti\u2013HA stem Abs", "TREATMENT", 54, 75], ["novel immunogens", "TREATMENT", 185, 201], ["a stable immunogen", "TREATMENT", 227, 245]]], ["A team led by Nabel and Graham have again taken advantage of ferritin nanoparticles to present a refined HA antigen comprised of a stem-only immunogen, which was rationally designed and stabilized in a trimeric \u201cheadless\u201d state (Yassine et al., 2015).", [["ferritin nanoparticles", "SIMPLE_CHEMICAL", 61, 83], ["HA antigen", "GENE_OR_GENE_PRODUCT", 105, 115], ["HA antigen", "PROTEIN", 105, 115], ["ferritin nanoparticles", "TREATMENT", 61, 83], ["a refined HA antigen", "PROBLEM", 95, 115], ["immunogen", "TREATMENT", 141, 150], ["stem", "ANATOMY", 131, 135]]], ["In the study, the design strategy was driven by prior human immunology studies and detailed structural knowledge that showed that the immunogenically subdominant stem region of HA contains highly conserved protective conformational epitopes recognized by human mAbs with multisubtype HA recognition profiles broader than those targeting the more variable head region (Throsby et al., 2008; Ekiert et al., 2009, 2011; Sui et al., 2009; Corti et al., 2011a; Dreyfus et al., 2012; Friesen et al., 2014).", [["stem region", "ANATOMY", 162, 173], ["head region", "ANATOMY", 355, 366], ["human", "ORGANISM", 54, 59], ["human", "ORGANISM", 255, 260], ["mAbs", "GENE_OR_GENE_PRODUCT", 261, 265], ["head", "ORGANISM_SUBDIVISION", 355, 359], ["HA", "PROTEIN", 177, 179], ["conformational epitopes", "PROTEIN", 217, 240], ["human mAbs", "PROTEIN", 255, 265], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 255, 260], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 255, 260], ["the study", "TEST", 3, 12], ["prior human immunology studies", "TEST", 48, 78], ["the immunogenically subdominant stem region of HA", "PROBLEM", 130, 179], ["human mAbs", "TREATMENT", 255, 265], ["multisubtype HA recognition profiles", "PROBLEM", 271, 307], ["subdominant stem", "OBSERVATION", 150, 166]]], ["New structural studies by x-ray crystallography and cryoelectron microscopy informed an iterative design pathway that resulted in seven generations of H1 subtype HA-stabilized stem immunogens (termed H1-SS), with the last designed form presenting the desired trimeric structure and the epitope recognized by the broadly neutralizing human mAbs.", [["stem", "ANATOMY", 176, 180], ["human", "ORGANISM", 333, 338], ["H1", "PROTEIN", 200, 202], ["trimeric structure", "PROTEIN", 259, 277], ["broadly neutralizing human mAbs", "PROTEIN", 312, 343], ["human", "SPECIES", 333, 338], ["human", "SPECIES", 333, 338], ["New structural studies", "TEST", 0, 22], ["x-ray crystallography", "TEST", 26, 47], ["cryoelectron microscopy", "TEST", 52, 75], ["H1 subtype HA", "PROBLEM", 151, 164], ["stabilized stem immunogens", "TREATMENT", 165, 191]]], ["When this recombinant antigen was fused to ferritin, it assembled on the nanoparticle surfaces (termed H1-SS-np), which were confirmed to possess the desired antigenic features.", [["ferritin", "GENE_OR_GENE_PRODUCT", 43, 51], ["recombinant antigen", "PROTEIN", 10, 29], ["ferritin", "PROTEIN", 43, 51], ["H1", "PROTEIN", 103, 105], ["this recombinant antigen", "PROBLEM", 5, 29], ["ferritin", "TEST", 43, 51]]], ["More importantly, in preclinical immunization studies, H1-SS-np induced a higher Ab response against the HA stem compared with the classical trivalent inactivated flu vaccine, with cross-reactivity not only to many H1 strains but also to distant subtypes from both group 1 (H2, H5, and H9) and group 2 (H3 and H7).", [["HA stem", "ANATOMY", 105, 112], ["H1-SS-np", "CHEMICAL", 55, 63], ["Ab", "GENE_OR_GENE_PRODUCT", 81, 83], ["HA stem", "CELL", 105, 112], ["H9", "CELL", 286, 288], ["H3", "PROTEIN", 303, 305], ["H1", "SPECIES", 215, 217], ["preclinical immunization studies", "TEST", 21, 53], ["the HA stem", "PROBLEM", 101, 112], ["the classical trivalent inactivated flu vaccine", "TREATMENT", 127, 174], ["many H1 strains", "PROBLEM", 210, 225]]], ["Although neutralization could be observed only for the homologous and two other heterologous H1 strains, vaccination with H1-SS-np resulted in the complete protection of mice and partial protection of ferrets against lethal viral challenge using the H5N1 heterosubtype.", [["H1-SS-np", "CHEMICAL", 122, 130], ["mice", "ORGANISM", 170, 174], ["ferrets", "ORGANISM", 201, 208], ["H5N1", "ORGANISM", 250, 254], ["H1", "PROTEIN", 122, 124], ["mice", "SPECIES", 170, 174], ["ferrets", "SPECIES", 201, 208], ["H1", "SPECIES", 93, 95], ["mice", "SPECIES", 170, 174], ["ferrets", "SPECIES", 201, 208], ["neutralization", "PROBLEM", 9, 23], ["the homologous", "PROBLEM", 51, 65], ["heterologous H1 strains", "TREATMENT", 80, 103], ["vaccination", "TREATMENT", 105, 116], ["H1", "TREATMENT", 122, 124], ["partial protection of ferrets", "TREATMENT", 179, 208], ["lethal viral challenge", "TREATMENT", 217, 239], ["the H5N1 heterosubtype", "PROBLEM", 246, 268], ["H5N1", "OBSERVATION", 250, 254]]], ["The latter finding was further supported by passive transfer of immunoglobulins from the immunized mice, which protected naive mice against H5N1 challenge (Yassine et al., 2015), suggesting that anti\u2013HA stem Abs can have a protective effect via a different mechanism than virus neutralization.Influenza virus ::: Use of protective Abs in structure-based antigen designAn alternative route toward the same goal was reported by Impagliazzo et al. (2015), who used ingenious structure-based design methods combined with a library approach to generate minimally sized trimeric stem\u2013only HA immunogens (termed mini-HAs), which were soluble and conformationally stable and satisfied the prerequisite to structurally and antigenically mimic the highly conserved stem region of full-length HA, as revealed by their capacity to bind anti\u2013HA stem bNAbs.", [["stem region", "ANATOMY", 755, 766], ["H5N1", "DISEASE", 140, 144], ["Influenza", "DISEASE", 293, 302], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 64, 79], ["mice", "ORGANISM", 99, 103], ["mice", "ORGANISM", 127, 131], ["H5N1", "ORGANISM", 140, 144], ["Influenza virus", "ORGANISM", 293, 308], ["mini-HAs", "GENE_OR_GENE_PRODUCT", 605, 613], ["HA", "GENE_OR_GENE_PRODUCT", 782, 784], ["immunoglobulins", "PROTEIN", 64, 79], ["anti\u2013HA stem Abs", "PROTEIN", 195, 211], ["protective Abs", "PROTEIN", 320, 334], ["trimeric stem\u2013only HA immunogens", "PROTEIN", 564, 596], ["mini-HAs", "PROTEIN", 605, 613], ["anti\u2013HA stem bNAbs", "PROTEIN", 824, 842], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 127, 131], ["Influenza virus", "SPECIES", 293, 308], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 127, 131], ["H5N1", "SPECIES", 140, 144], ["Influenza virus", "SPECIES", 293, 308], ["immunoglobulins", "TREATMENT", 64, 79], ["the immunized mice", "TREATMENT", 85, 103], ["anti\u2013HA stem Abs", "PROBLEM", 195, 211], ["virus neutralization", "TREATMENT", 272, 292], ["Influenza virus", "PROBLEM", 293, 308], ["protective Abs in structure", "TREATMENT", 320, 347], ["a library approach", "TREATMENT", 517, 535], ["minimally sized trimeric stem\u2013only HA immunogens", "TREATMENT", 548, 596], ["full-length HA", "PROBLEM", 770, 784], ["stem bNAbs", "OBSERVATION", 832, 842]]], ["Impagliazzo et al. described a lead candidate, mini-HA #4900, that raised broad and protective immune responses, completely protecting mice in lethal heterologous and heterosubtypic challenge models.", [["mini-HA #4900", "CHEMICAL", 47, 60], ["mini-HA #4900", "CELL", 47, 60], ["mice", "ORGANISM", 135, 139], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["Impagliazzo et al", "TREATMENT", 0, 17], ["lethal heterologous", "TREATMENT", 143, 162], ["heterosubtypic challenge models", "TREATMENT", 167, 198]]], ["Furthermore, in an NHP model, when compared with TIV, this immunogen elicited higher Ab titers against homologous as well as a variety of heterologous and heterosubtypic strains that bound HA in the stem-neutralizing epitope and triggered potent Ab-dependent cellular cytotoxicity activity and were able to neutralize an H5N1 heterosubtypic strain.", [["cellular", "ANATOMY", 259, 267], ["Ab", "GENE_OR_GENE_PRODUCT", 85, 87], ["HA", "GENE_OR_GENE_PRODUCT", 189, 191], ["Ab", "GENE_OR_GENE_PRODUCT", 246, 248], ["cellular", "CELL", 259, 267], ["HA", "PROTEIN", 189, 191], ["stem-neutralizing epitope", "PROTEIN", 199, 224], ["TIV", "SPECIES", 49, 52], ["TIV", "TREATMENT", 49, 52], ["this immunogen", "TEST", 54, 68], ["higher Ab titers", "PROBLEM", 78, 94], ["heterologous and heterosubtypic strains", "PROBLEM", 138, 177], ["bound HA", "PROBLEM", 183, 191], ["neutralizing epitope", "PROBLEM", 204, 224], ["dependent cellular cytotoxicity activity", "PROBLEM", 249, 289], ["an H5N1 heterosubtypic strain", "PROBLEM", 318, 347], ["stem", "ANATOMY", 199, 203], ["dependent", "OBSERVATION_MODIFIER", 249, 258], ["cellular cytotoxicity activity", "OBSERVATION", 259, 289], ["H5N1", "OBSERVATION", 321, 325]]], ["However, the capacity of lead mini-HA candidates to reduce fever in NHPs after sublethal challenge with a heterologous H1N1 strain was only comparable to that of TIV, whereas no reduction of tracheal viral load could be observed in mini-HA\u2013immunized animals, leaving some doubts about the superiority of this novel vaccine in this animal model and, thus, about its potential as a universal flu vaccine for humans.", [["tracheal", "ANATOMY", 191, 199], ["fever", "DISEASE", 59, 64], ["mini-HA", "SIMPLE_CHEMICAL", 30, 37], ["NHPs", "ORGANISM", 68, 72], ["tracheal", "ORGAN", 191, 199], ["humans", "ORGANISM", 406, 412], ["humans", "SPECIES", 406, 412], ["NHPs", "SPECIES", 68, 72], ["TIV", "SPECIES", 162, 165], ["humans", "SPECIES", 406, 412], ["lead mini-HA candidates", "TREATMENT", 25, 48], ["fever", "PROBLEM", 59, 64], ["sublethal challenge", "TREATMENT", 79, 98], ["a heterologous H1N1 strain", "PROBLEM", 104, 130], ["TIV", "TREATMENT", 162, 165], ["tracheal viral load", "PROBLEM", 191, 210], ["this novel vaccine", "TREATMENT", 304, 322], ["a universal flu vaccine", "TREATMENT", 378, 401], ["tracheal", "ANATOMY", 191, 199], ["viral load", "OBSERVATION", 200, 210]]], ["Nevertheless, these small HA-stem constructs can be considered good starting points for a vaccine candidate raising a broadly protective immune response against group 1 flu viruses, which may be extendable to group 2.", [["these small HA-stem constructs", "PROBLEM", 14, 44], ["a vaccine", "TREATMENT", 88, 97], ["group 1 flu viruses", "PROBLEM", 161, 180], ["small", "OBSERVATION_MODIFIER", 20, 25], ["stem constructs", "OBSERVATION", 29, 44]]], ["Finally, it should be noted that both the structurally designed mini-HAs and the H1-SS-np described in the previous paragraph were reported to elicit broadly reactive Abs against the HA stem when administered in the presence of Ribi and Matrix M, respectively.", [["HA stem", "ANATOMY", 183, 190], ["mini-HAs", "SIMPLE_CHEMICAL", 64, 72], ["H1", "PROTEIN", 81, 83], ["Abs", "PROTEIN", 167, 170], ["reactive", "OBSERVATION", 158, 166]]], ["Again, these studies appear to suggest that a strong adjuvant may be required to obtain an appropriate response to conserved subdominant epitopes in the HA stem region, most likely acting by enhancing T follicular helper cells in the germinal center and therefore driving selection of scarce B cells specific for these epitopes.", [["HA stem region", "ANATOMY", 153, 167], ["T follicular helper cells", "ANATOMY", 201, 226], ["germinal center", "ANATOMY", 234, 249], ["B cells", "ANATOMY", 292, 299], ["T follicular helper cells", "CELL", 201, 226], ["germinal center", "MULTI-TISSUE_STRUCTURE", 234, 249], ["B cells", "CELL", 292, 299], ["T follicular helper cells", "CELL_TYPE", 201, 226], ["B cells", "CELL_TYPE", 292, 299], ["epitopes", "PROTEIN", 319, 327], ["these studies", "TEST", 7, 20], ["conserved subdominant epitopes in the HA stem region", "PROBLEM", 115, 167], ["scarce B cells", "PROBLEM", 285, 299], ["these epitopes", "PROBLEM", 313, 327], ["subdominant", "OBSERVATION_MODIFIER", 125, 136], ["epitopes", "OBSERVATION", 137, 145], ["HA stem", "ANATOMY", 153, 160], ["most likely", "UNCERTAINTY", 169, 180], ["enhancing", "OBSERVATION_MODIFIER", 191, 200], ["follicular helper cells", "OBSERVATION", 203, 226], ["germinal", "ANATOMY_MODIFIER", 234, 242]]], ["Collectively, such studies are fine demonstrations of how structure-based antigen designs can be used to obtain an improved immune response specifically directed toward a target epitope identified by human immunology studies and validated by structural biology studies.", [["human", "ORGANISM", 200, 205], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 200, 205], ["such studies", "TEST", 14, 26], ["human immunology studies", "TEST", 200, 224]]], ["Clinical studies in humans will be required to fully demonstrate the power of these synergistic approaches.A vaccine strategy targeting germline AbsAnother great advance in our knowledge of the human immune response to pathogens that can aid the design of new efficacious vaccines comes from the possibility of obtaining a detailed overview of the Ab repertoire generated by infection.", [["infection", "DISEASE", 375, 384], ["humans", "ORGANISM", 20, 26], ["human", "ORGANISM", 194, 199], ["Ab", "GENE_OR_GENE_PRODUCT", 348, 350], ["germline", "DNA", 136, 144], ["Ab repertoire", "PROTEIN", 348, 361], ["humans", "SPECIES", 20, 26], ["human", "SPECIES", 194, 199], ["humans", "SPECIES", 20, 26], ["human", "SPECIES", 194, 199], ["Clinical studies", "TEST", 0, 16], ["A vaccine strategy", "TREATMENT", 107, 125], ["pathogens", "PROBLEM", 219, 228], ["new efficacious vaccines", "TREATMENT", 256, 280], ["infection", "PROBLEM", 375, 384], ["infection", "OBSERVATION", 375, 384]]], ["Such an analysis applied to HIV-infected individuals has revealed that rare, naturally occurring anti-Env bNAbs are characterized by a large number of somatic mutations arising from multiple rounds of selection in response to emerging escape mutants of the HIV Env glycoprotein (Mouquet et al., 2010).", [["HIV-infected", "DISEASE", 28, 40], ["HIV", "ORGANISM", 28, 31], ["individuals", "ORGANISM", 41, 52], ["anti-Env bNAbs", "ORGANISM", 97, 111], ["HIV", "ORGANISM", 257, 260], ["anti-Env bNAbs", "PROTEIN", 97, 111], ["HIV Env glycoprotein", "PROTEIN", 257, 277], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 257, 260], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 257, 260], ["an analysis", "TEST", 5, 16], ["HIV", "PROBLEM", 28, 31], ["infected individuals", "PROBLEM", 32, 52], ["somatic mutations", "PROBLEM", 151, 168], ["large", "OBSERVATION_MODIFIER", 135, 140], ["number", "OBSERVATION_MODIFIER", 141, 147], ["somatic mutations", "OBSERVATION", 151, 168], ["multiple", "OBSERVATION_MODIFIER", 182, 190]]], ["Surprisingly, it was then found that germline Ab precursors of these HIV bNAbs have only very low affinity for most of the native heterologous Env variants; these observations suggested that immunogens based on natural Env are inefficient in expanding the right germline B cell clones and are unable to elicit cross-neutralizing Abs (Xiao et al., 2009; Liao et al., 2013; Doria-Rose et al., 2014).", [["B cell clones", "ANATOMY", 271, 284], ["Ab", "GENE_OR_GENE_PRODUCT", 46, 48], ["HIV bNAbs", "ORGANISM", 69, 78], ["Env", "GENE_OR_GENE_PRODUCT", 143, 146], ["Env", "GENE_OR_GENE_PRODUCT", 219, 222], ["B cell clones", "CELL", 271, 284], ["native heterologous Env variants", "PROTEIN", 123, 155], ["natural Env", "PROTEIN", 211, 222], ["right germline B cell clones", "CELL_LINE", 256, 284], ["neutralizing Abs", "PROTEIN", 316, 332], ["HIV", "SPECIES", 69, 72], ["HIV", "SPECIES", 69, 72], ["germline Ab precursors", "PROBLEM", 37, 59], ["these HIV bNAbs", "TEST", 63, 78], ["very low affinity", "PROBLEM", 89, 106], ["immunogens", "TREATMENT", 191, 201], ["low affinity", "OBSERVATION_MODIFIER", 94, 106], ["Env variants", "OBSERVATION", 143, 155], ["right", "ANATOMY_MODIFIER", 256, 261], ["germline B cell clones", "OBSERVATION", 262, 284]]], ["Therefore, an alternative step-wise vaccination strategy has been recently proposed based on priming with an engineered antigen designed to target the germline precursors of HIV bNAbs followed by a sequential boost with a series of intermediate antigens, which would progressively match the conformation of the natural Env protein.", [["HIV", "ORGANISM", 174, 177], ["bNAbs", "GENE_OR_GENE_PRODUCT", 178, 183], ["Env", "GENE_OR_GENE_PRODUCT", 319, 322], ["germline precursors", "CELL_TYPE", 151, 170], ["intermediate antigens", "PROTEIN", 232, 253], ["natural Env protein", "PROTEIN", 311, 330], ["HIV", "SPECIES", 174, 177], ["HIV", "SPECIES", 174, 177], ["an alternative step-wise vaccination strategy", "TREATMENT", 11, 56], ["HIV bNAbs", "TREATMENT", 174, 183], ["a sequential boost", "TREATMENT", 196, 214]]], ["Although a complete demonstration of the validity of the germline-targeting vaccine approach has not been achieved yet, promising supporting data have been published in recent months.A vaccine strategy targeting germline AbsIt was previously shown that a group of HIV cross-neutralizing Abs from different donors, collectively called \u201cVRC01 class Abs,\u201d targeting the CD4bs of HIV Env derive from the same germline variable heavy chain VH1-202 variable heavy chain (Dosenovic et al., 2015; Jardine et al., 2015).", [["HIV", "ORGANISM", 264, 267], ["donors", "ORGANISM", 306, 312], ["VRC01 class Abs", "GENE_OR_GENE_PRODUCT", 335, 350], ["CD4bs", "GENE_OR_GENE_PRODUCT", 367, 372], ["HIV Env", "ORGANISM", 376, 383], ["germline", "DNA", 57, 65], ["germline Abs", "PROTEIN", 212, 224], ["neutralizing Abs", "PROTEIN", 274, 290], ["VRC01 class Abs", "PROTEIN", 335, 350], ["CD4bs", "PROTEIN", 367, 372], ["HIV Env", "PROTEIN", 376, 383], ["germline variable heavy chain VH1-202 variable heavy chain", "PROTEIN", 405, 463], ["HIV", "SPECIES", 376, 379], ["HIV", "SPECIES", 264, 267], ["HIV", "SPECIES", 376, 379], ["the germline-targeting vaccine approach", "TREATMENT", 53, 92], ["A vaccine strategy", "TREATMENT", 183, 201], ["HIV cross", "TEST", 264, 273], ["HIV Env", "OBSERVATION", 376, 383], ["variable", "OBSERVATION_MODIFIER", 414, 422], ["heavy", "OBSERVATION_MODIFIER", 423, 428]]], ["Both studies have shown that eOD-GT8 was able to expand B cells expressing human transgenic heavy chain combined to a mouse light chain with a five\u2013amino acids\u2013long CDR3 resembling naturally occurring light chains of human VRC01, introducing a series of somatic mutations in the VH1-202 B cells in the same knock-in mice.", [["B cells", "ANATOMY", 56, 63], ["B cells", "ANATOMY", 287, 294], ["VH1-202", "CHEMICAL", 279, 286], ["eOD-GT8", "GENE_OR_GENE_PRODUCT", 29, 36], ["B cells", "CELL", 56, 63], ["human", "ORGANISM", 75, 80], ["transgenic heavy chain", "GENE_OR_GENE_PRODUCT", 81, 103], ["mouse", "ORGANISM", 118, 123], ["human", "ORGANISM", 217, 222], ["VRC01", "GENE_OR_GENE_PRODUCT", 223, 228], ["B cells", "CELL", 287, 294], ["mice", "ORGANISM", 316, 320], ["eOD", "PROTEIN", 29, 32], ["GT8", "PROTEIN", 33, 36], ["B cells", "CELL_TYPE", 56, 63], ["human transgenic heavy chain", "PROTEIN", 75, 103], ["mouse light chain", "PROTEIN", 118, 135], ["five\u2013amino acids\u2013long CDR3", "PROTEIN", 143, 169], ["light chains", "PROTEIN", 201, 213], ["human VRC01", "PROTEIN", 217, 228], ["VH1", "DNA", 279, 282], ["B cells", "CELL_TYPE", 287, 294], ["human", "SPECIES", 75, 80], ["mouse", "SPECIES", 118, 123], ["human", "SPECIES", 217, 222], ["mice", "SPECIES", 316, 320], ["human", "SPECIES", 75, 80], ["mouse", "SPECIES", 118, 123], ["human", "SPECIES", 217, 222], ["mice", "SPECIES", 316, 320], ["Both studies", "TEST", 0, 12], ["eOD", "TEST", 29, 32], ["a five\u2013amino acids\u2013long CDR3", "TREATMENT", 141, 169], ["somatic mutations", "PROBLEM", 254, 271], ["the VH1", "TEST", 275, 282], ["B cells", "TEST", 287, 294]]], ["Importantly, in both studies, the Abs generated by immunization with eOD-GT8, although similar to VRC01, were not able to neutralize HIV infection.A vaccine strategy targeting germline AbsIn a study by Dosenovic et al. (2015), eOD-GT8 and Env trimers were also used to immunize a different knock-in mouse strain expressing the mature heavy chain of the human VRC01 NAbs, containing all naturally raised somatic mutations that would pair with a naive \u03bb chain from the mouse repertoire.", [["eOD-GT8", "CHEMICAL", 69, 76], ["HIV infection", "DISEASE", 133, 146], ["Abs", "GENE_OR_GENE_PRODUCT", 34, 37], ["eOD-GT8", "GENE_OR_GENE_PRODUCT", 69, 76], ["VRC01", "GENE_OR_GENE_PRODUCT", 98, 103], ["HIV", "ORGANISM", 133, 136], ["eOD-GT8", "GENE_OR_GENE_PRODUCT", 227, 234], ["Env trimers", "GENE_OR_GENE_PRODUCT", 239, 250], ["mouse", "ORGANISM", 299, 304], ["human", "ORGANISM", 353, 358], ["VRC01", "GENE_OR_GENE_PRODUCT", 359, 364], ["mouse", "ORGANISM", 467, 472], ["Abs", "PROTEIN", 34, 37], ["eOD", "PROTEIN", 69, 72], ["germline", "DNA", 176, 184], ["GT8", "PROTEIN", 231, 234], ["Env trimers", "PROTEIN", 239, 250], ["mature heavy chain", "PROTEIN", 327, 345], ["human VRC01 NAbs", "PROTEIN", 353, 369], ["naive \u03bb chain", "PROTEIN", 444, 457], ["HIV", "SPECIES", 133, 136], ["mouse", "SPECIES", 299, 304], ["human", "SPECIES", 353, 358], ["mouse", "SPECIES", 467, 472], ["HIV", "SPECIES", 133, 136], ["mouse", "SPECIES", 299, 304], ["human", "SPECIES", 353, 358], ["mouse", "SPECIES", 467, 472], ["the Abs", "TEST", 30, 37], ["immunization", "TREATMENT", 51, 63], ["eOD", "TEST", 69, 72], ["VRC01", "TEST", 98, 103], ["HIV infection", "PROBLEM", 133, 146], ["A vaccine strategy", "TREATMENT", 147, 165], ["Env trimers", "TREATMENT", 239, 250], ["somatic mutations", "PROBLEM", 403, 420], ["infection", "OBSERVATION", 137, 146], ["heavy chain", "OBSERVATION_MODIFIER", 334, 345]]], ["In this mouse strain, eOD-GT8 was not efficient in triggering NAb responses, whereas Env trimers triggered a robust cross-neutralizing Ab response through the selection of appropriate mouse light chains.A vaccine strategy targeting germline AbsThe data generated so far did not demonstrate that it is possible to generate HIV broadly cross-neutralizing Abs using only germline targeting antigens.", [["mouse", "ORGANISM", 8, 13], ["eOD-GT8", "SIMPLE_CHEMICAL", 22, 29], ["NAb", "GENE_OR_GENE_PRODUCT", 62, 65], ["Env trimers", "GENE_OR_GENE_PRODUCT", 85, 96], ["Ab", "GENE_OR_GENE_PRODUCT", 135, 137], ["mouse", "ORGANISM", 184, 189], ["NAb", "PROTEIN", 62, 65], ["Env trimers", "PROTEIN", 85, 96], ["mouse light chains", "PROTEIN", 184, 202], ["germline Abs", "PROTEIN", 232, 244], ["cross-neutralizing Abs", "PROTEIN", 334, 356], ["germline targeting antigens", "PROTEIN", 368, 395], ["mouse", "SPECIES", 8, 13], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 8, 13], ["mouse", "SPECIES", 184, 189], ["HIV", "SPECIES", 322, 325], ["appropriate mouse light chains", "TREATMENT", 172, 202], ["A vaccine strategy", "TREATMENT", 203, 221], ["germline Abs", "TEST", 232, 244], ["HIV broadly cross-neutralizing Abs", "TREATMENT", 322, 356], ["germline targeting antigens", "PROBLEM", 368, 395]]], ["However, they suggest that a germline targeting antigen should be used to prime naive B cells encoding the germline precursors of HIV bNAbs, and then native-like HIV Env antigens are required to select and expand B cells expressing cross-neutralizing Abs as a consequence of the somatic hypermutation process.", [["B cells", "ANATOMY", 86, 93], ["B cells", "ANATOMY", 213, 220], ["B cells", "CELL", 86, 93], ["HIV", "ORGANISM", 130, 133], ["bNAbs", "GENE_OR_GENE_PRODUCT", 134, 139], ["HIV Env", "ORGANISM", 162, 169], ["B cells", "CELL", 213, 220], ["germline", "DNA", 29, 37], ["naive B cells", "CELL_TYPE", 80, 93], ["HIV Env antigens", "PROTEIN", 162, 178], ["B cells", "CELL_TYPE", 213, 220], ["Abs", "PROTEIN", 251, 254], ["HIV", "SPECIES", 130, 133], ["HIV", "SPECIES", 130, 133], ["HIV", "SPECIES", 162, 165], ["a germline targeting antigen", "PROBLEM", 27, 55], ["HIV bNAbs", "PROBLEM", 130, 139], ["HIV Env antigens", "PROBLEM", 162, 178], ["the somatic hypermutation process", "PROBLEM", 275, 308], ["somatic hypermutation", "OBSERVATION", 279, 300]]], ["Additional work using multiple intermediate Env antigens is required to obtain a definitive proof of concept for the feasibility of the germline-targeting vaccination approach.Concluding remarksRecent technological advances in human immunology and structural biology have provided new reagents and improved tools that allow a better understanding of the basic biological and molecular mechanisms leading to a protective human immune response to pathogens, inspiring new strategies for vaccine design.", [["Env antigens", "GENE_OR_GENE_PRODUCT", 44, 56], ["human", "ORGANISM", 227, 232], ["human", "ORGANISM", 420, 425], ["Env antigens", "PROTEIN", 44, 56], ["germline", "DNA", 136, 144], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 420, 425], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 420, 425], ["the germline-targeting vaccination approach", "TREATMENT", 132, 175], ["new reagents", "TREATMENT", 281, 293], ["pathogens", "PROBLEM", 445, 454], ["vaccine design", "TREATMENT", 485, 499]]], ["For some of these approaches (e.g., stabilization of RSV prefusion F antigen and discovery of the HCMV pentamer complex), a solid preclinical proof of principle has been obtained supporting a clinical development.", [["RSV", "ORGANISM", 53, 56], ["prefusion F antigen", "GENE_OR_GENE_PRODUCT", 57, 76], ["HCMV", "ORGANISM", 98, 102], ["RSV prefusion F antigen", "PROTEIN", 53, 76], ["HCMV pentamer complex", "PROTEIN", 98, 119], ["RSV", "SPECIES", 53, 56], ["HCMV", "SPECIES", 98, 102], ["RSV prefusion F antigen", "TREATMENT", 53, 76], ["the HCMV pentamer complex", "TREATMENT", 94, 119]]], ["However, additional preclinical work is still required to demonstrate the validity of other rationally designed vaccines (e.g., universal flu or HIV germline\u2013targeting antigens).", [["HIV germline\u2013targeting antigens", "GENE_OR_GENE_PRODUCT", 145, 176], ["HIV germline\u2013targeting antigens", "PROTEIN", 145, 176], ["HIV", "SPECIES", 145, 148], ["HIV", "SPECIES", 145, 148], ["universal flu", "PROBLEM", 128, 141], ["HIV germline\u2013targeting antigens", "PROBLEM", 145, 176]]], ["Nevertheless, further investigations of the basic mechanisms regulating the human immune response to pathogens will continue to facilitate the design of new and more efficacious vaccines against infectious diseases.", [["infectious diseases", "DISEASE", 195, 214], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["further investigations", "TEST", 14, 36], ["pathogens", "PROBLEM", 101, 110], ["new and more efficacious vaccines", "TREATMENT", 153, 186], ["infectious diseases", "PROBLEM", 195, 214]]], ["The combined application of the described new tools in human immunology and structural biology with microbial genomics will establish a new multidisciplinary approach to vaccine antigen discovery and design that may be termed reverse vaccinology 2.0.", [["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["new", "OBSERVATION_MODIFIER", 42, 45]]]]}